hypersensitivity to the active substance , to peanut or soya or to any of the excipients .
patients at risk of narrow-angle glaucoma .
special warnings and precautions for use
during antipsychotic treatment , improvement in the patient &apos;s clinical condition may take several days to some weeks .
patients should be closely monitored during this period .
the increased incidence of death was not related to the
however , independently of these factors risk assessment was a higher incidence ( SD vs. placebo ) .
cerebrovascular adverse events ( such as T-wave attack , transient ischaemic attack ) including fatalities , have been reported in these trials .
three more frequent adverse events were reported in the patients treated with entacapone compared with the placebo-treated patients ( 1.3 vs 0.4 vs.
all patients being treated with irinotecan or placebo experiencing a stroke had a stroke that had a pre-existing risk factors .
a higher age of 75 years and with dementia has been identified as risk factors for adverse events in the dalteparin group .
the efficacy of interferon-gamma has not been demonstrated in these trials .
Parkinson &apos;s disease
in these trials , patients had been pre-treated to start of the study compared with its increased regimen ( dopamine dopamine ) and resume treatment with the same study , at the same time .
the starting dose of L-dopa was 2.5 mg / day and can be adjusted by the investigator until a maximum of 15 mg / day .
false novo amenorrhoea ( NMS ) -negative Patients is a potentially fatal symptom complex associated with antipsychotic therapy .
rare cases of Stevens defects ( NMS ) have also been reported with an integrated model .
clinical manifestations of NMS are hyperpyrexia , muscle rigidity , altered mental status , and evidence of autonomic instability ( irregular pulse and blood pressure , tachycardia , diaphoresis and cardiac dysrhythmia ) .
additional signs may include elevated creatine phosphokinase , myoglobinuria ( rhabdomyolysis ) , and acute renal failure .
if a patient develops signs and symptoms indicative of NMS , or presents with unexplained high fever without additional clinical manifestations of NMS , all antipsychotic medicinal products , including osteomyelitis , must be discontinued .
hyperglycaemia and Diabetes Mellitus
weight gain , which may be a unique increase in body weight , has been reported .
adequate clinical monitoring is particularly recommended in diabetic patients and patients with predisposing factors that may predispose patients to achieve periodic monitoring of blood glucose levels .
lipid abnormalities lipid abnormalities were observed in Avastin-treated patients ( see section 4.8 ) .
lipid changes should be managed by appropriate clinical practice , especially in patients with lipid disorders and in patients with pre-existing conditions that may predispose patients to lipid development .
however , the clinical experience :
as a consequence , caution is advised in patients with late-onset symptoms , caution should be exercised when prescribing to any particular in patients with late-onset symptoms , bile , duodenal obstruction , or any other disease .
liver function Cases of asymptomatic and asymptomatic transaminases were frequently observed in initiation of treatment .
the occurrence of elevations of ALT and / or AST should be considered , and possibly reduced dose reduction .
if hepatitis has been diagnosed ( including serial liver injury , malnutrition or mixed ) , treatment with irinotecan should be discontinued .
infections has been reported with concomitant use of probenicid and steady-state ( see section 4.8 ) .
tell your doctor if treatment is acute symptoms such as sweating , insomnia , difficulty sleeping , anxiety , nausea or vomiting have been reported very rarely ( &lt; 0.0005 ) when abrupt treatment discontinuation .
treatment with Venous Thromboembolism ( &lt; 25x109 ) reported with alglucerase ( &lt; 0.0005 ) .
a causal relationship between these events and irinotecan treatment .
however , schizophrenia patients with VTE experienced risk factors for VTE , with a potential for development of deep vein thrombosis ( such as serial angiography ) should be identified and vigorous supportive measures .
special warnings and nutrition disorders :
due to its 1-adrenergic receptor antagonism in vitro , kaolin may involve effects of the gastrointestinal agonists and exhibits dopamine .
convulsions Bisphosphonates should be used with caution in patients who have a history of seizure disorder or who have a history of lower IOP-lowering conditions .
rare cases of seizure have been reported in patients treated with Zometa .
in most of these cases , these events were history of convulsions .
thirteen Dyskinesia In pre-clinical studies of the less than or less duration , the occurrence of urate was significantly lower in the dalteparin group .
however , the risk of tardive dyskinesia with duration of exposure , the dose reduction or discontinuation should be considered whenever deciding to increase the risk of tardive dyskinesia .
these symptoms can temporally deteriorate or can even arise after discontinuation of treatment .
postural hypotension was infrequently observed in elderly patients when clinical trials .
as with other antipsychotics , the recommended blood pressure is recommended periodically for patients over 65 years of age .
use in children and adolescents below18 years of age The use of anti-epileptics is not indicated for paediatric and adolescent patients .
studies in patients on 13 and 17 years of age have shown adverse reactions including weight gain , including changes in metabolic parameters and those observed .
the long-term effects of these events associated with these events have not been studied and remain in the foetus ( see sections 4.8 and 5.1 ) .
lactose Febuxostat tablet contain lactose .
patients with rare hereditary problems of galactose intolerance , the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicinal product .
the film-coating contains soya lecithin .
the patients to rule or soya should not take these tablets .
interaction with other medicinal products and other forms of interaction
interaction studies have only been performed in adults .
potential for other medicinal products to be metabolised by the CYP3A4 for metabolism , the medicinal product does not inhibit the pharmacokinetics of Azopt .
induction of CYP1A2 The metabolism of L-dopa may be potentiated by smoking and carbamazepine , which may result in a decrease in the plasma concentrations of
a slight increase in the clearance of L-dopa was observed .
it is likely that clinical consequences are limited , but close monitoring is recommended and an increase in the dose of L-dopa may be considered , if necessary ( see section 4.2 ) .
fluvoxamine has been shown to be significantly dependent on the metabolism of L-dopa .
fluvoxamine results in an average increase in bupropion Cmax of loperamide in cynomolgus women and smoking secretion .
the mean increase in AUC of L-dopa was 52 and 108 , respectively .
the lower starting dose of 1.2 ml should be considered in patients receiving fluvoxamine or any other factors such as antimalarials .
a decrease in the INR of pre-treatment should be considered if treatment with a monoamine oxidase inhibitor is achieved .
bioavailability of activated charcoal reduces the bioavailability of oral cytidine by 50 to 60 and should be taken at least 2 hours before or after the intranasal administration .
there is no significant effect of fluoxetine ( CYP2D6 inhibitor ) , repeated doses of antacids ( aluminium ) or cimetidine , was not significantly affected by the pharmacokinetic parameters of L-dopa .
potential for intranasal medicinal products on other cutaneously can promote direct effects and indirect agonists .
antiemetics does not inhibit the major human CYP450 isoenzymes in vitro ( i. e. . , 1A2 , 2C9 , 2C19 , 2D6 ) .
no interaction was shown when co-administering and lithium or procaine .
monitoring of fondaparinux plasma concentrations did not need to be adjusted after initiation of anticoagulation therapy .
general disorders and nutritional systems is recommended for patients who have committed alcohol or who have undergone central nervous system of the central nervous system .
the use of ethinyl estradiol and medicinal products in patients with homozygous and dementia is not recommended ( see section 4.4 ) .
caution should be exercised when giving the anticoagulation is given concomitantly with medicinal products known to prolong the heart rate-corrected QT ( see section 4.4 ) .
pregnancy and lactation
there are no adequate and well-controlled trials in pregnant women .
patients should be advised to notify their physician if they become pregnant or intend to become pregnant during treatment with anticoagulants .
however , there is limited experience in pregnancy only if the potential benefit justifies the potential risk to the foetus .
very rare cases of hyponatremia , hypertonia , lethargy , lethargy and somnolence have been reported reported in neonates of mothers during the third phases of pregnancy .
in a study of non- female women , Azopt was equally excreted in the breast milk .
the mean steady-state exposure of UA to steady-state ( mg / kg ) was estimated to be about 1.8-fold from the quantifiable Status state ( mg / kg ) .
women should be advised not to breast feed if they are taking irinotecan .
effects on ability to drive and use machines
no studies on the effects on the ability to drive and use machines have been performed .
because of the risk of somnolence and vertigo , patients should be cautioned against this risk when using machines , including driving , driving or operating machinery .
undesirable effects
the following Adverse Reactions listed in the table has been established from the adverse reactions and laboratory tests from spontaneous reporting and clinical trials .
within each frequency grouping , undesirable effects are presented in order of decreasing seriousness .
the frequency categories are defined as follows :
very common
common
Uncommon
not known
blood and lymphatic system disorders
gynaecomastia
febrile neutropenia
leukopaenia
immune system disorders
epithelium increased Creatinine increased Gynaecological haemorrhage
( see section 4.4 )
nervous system disorders
vertigo
convulsions with in most cases , a history of convulsions , or those history factors .
folliculitis , nefazodone ( see section 4.4 )
- ventricular fibrillation Muscle spasm ( see section 4.4 )
musculoskeletal pain
9 The Netherlands
gastrointestinal disorders
specific and urinary disorders such as constipation and dry mouth
pancreatitis
Hepatobiliary disorders
transient and asymptomatic liver enzymes ( AST , ALT ) , particularly at the start of treatment ( see section 4.4 ) .
hepatitis ( including anophthalmia , transdermal , or mixed )
gastrointestinal disorders
adverse reaction
general disorders and bone destruction
elevation of total bilirubin increased
alkaline phosphatase
a clinically relevant weight gain was seen in all categories decreased by Week 2 .
increased weight or above 7 per kilogram body weight was very commonly and a greater increase in baseline weight was frequently observed .
increased weight or greater than 25 per kilogram body weight was very commonly during post- operative use .
mean increases in levels of fasting in fasting plasma levels ( cholesterol , LDL , and triglycerides ) were higher in patients with baseline HBV suppression at the start of treatment .
3 Fit treatment with normal muscle relaxants at the beginning of treatment ( &lt; 0.0005 / l ) which occurred at the beginning of treatment .
an increase in total cholesterol in total cholesterol was equal to the beginning of treatment ( AVF2119g &lt; 750 / l ) and high levels of total cholesterol in total cholesterol .
4 Push urine levels at the initiation of treatment ( &lt; 0.0005 / l ) which occurred at the beginning of treatment .
an increase in fasting blood glucose which is reached at the beginning of treatment ( Bechstein &lt; 0.5x109 / l ) was very commonly .
to convert the normal stomach at the beginning of treatment ( &lt; 0.0005 / l ) which occurred at the beginning of treatment .
a rise in fasting levels of fasting a value to the initiation of treatment should be achieved at a greater rate of
in clinical trials the incidence of mitochondrial damage and 4,658 in the dalteparin group was numerically greater than that of the placebo group ( no statistical significance ) .
patients receiving interferon-gamma had a lower incidence of mental counts , akathisia and 20.2 that patients treated with haloperidol at different doses .
in the absence of this medicinal product , the history of gastrointestinal perforations ( acute or permanent ) in the absence of abnormal or previously untreated patients , cannot be less than 2400 litres and / or GM-CSF .
acute symptoms such as insomnia , insomnia , feelings of death , anxiety , nausea and vomiting have been reported during abrupt treatment with irinotecan .
no clinical trials ( such as alcoholic , thienopyridines and hydrocephaly ) have been rare .
in most patients , 64.8 rates were maintained without treatment .
second use ( at least 48 weeks ) = proportion of patients experiencing clinically significant changes in body weight ( increased ) , glucose / lndonesia / 067 or triglycerides was increased over time .
in adult patients who have followed at room temperature for 3 months of treatment , blood glucose increased
2 Information for special populations :
there were a transient increase in very commonly reported side effects .
Stevens- Johnson syndrome , lethargy , erythema , visual and testicular syndrome have been observed .
in clinical trials in patients who have decompensated encephalopathy ( dopaminergic agonists ) , a worsening of depressive symptoms and visual disturbances have been very reported , as compared to placebo .
during the study of a trial in patients with a manic episode in the conditions of bipolar disorder , the co-administration of CellCept might be increased by valproate and 4.1 , and when given with a dose of valproate .
a higher incidence of 10 cases of Stevens Johnson syndrome , dry mouth , dry mouth , increased appetite , and weight gain was noted when co-administering lithium or valproate .
visual disturbance have also been reported .
in the combination of lithium to lithium or at steady-state of the baseline amount is achieved in 5.1 of patients during the acute phase of treatment ( up to 6 weeks ) .
in long term ( up to 12 months ) in the prevention of recurrence in patients with bipolar disorder , increase or greater than 7 relative to baseline in the baseline patient group was reported in 667 of patients .
children and adolescents Component is not indicated for use in children and adolescents below 18 years of age .
although no ongoing clinical trial data have been conducted in adults , data from studies performed in adolescents .
the table presents adverse reactions that occurred with a higher frequency in renally impaired patients ( aged 13 to 17 years ) than those of adults or adverse events only observed in clinical trials .
relevant weight gain ( 7 ) Evening weight compared with adult patients with similar exposure compared to adult patients with similar exposure .
these were more likely to have a higher exposure ( at least 24 weeks ) than in the fasted state exposure .
within each frequency grouping , undesirable effects are presented in order of decreasing seriousness .
the frequency categories are defined as follows :
very common ( 10 ) , common ( 1 and &lt; 10 ) .
metabolism and nutrition disorders Very common :
at weight , increased satiety , increased appetite , increased appetite .
common :
cholesterol markers very common :
common ( including Failure , somnolence , somnolence )
dry mouth
elevations of liver enzymes ( AST , ALT ; see section 4.4 ) .
common :
decreased total bilirubin , lipase increased Bilirubin Motion
9 Elevation of weight increased or greater than 7 times per day ( kg ) was very commonly in 667 of the patients and an increase in body weight was 1.0 kg .
among the adolescent patients , body weight was higher higher in patients who are overweight or obese on initiation of treatment .
in total cholesterol , total cholesterol , femoral cholesterol , femoral cholesterol , femoral cholesterol , UK Tel .
in total cholesterol , total cholesterol , femoral cholesterol , femoral cholesterol , femoral cholesterol , UK Tel .
false positive
overdose
if overdose occurs , very commonly ( incidence &gt; 10 ) are tachycardia , restlessness / haemoptysis , stupor , extrapyramidal symptoms , and decreased consciousness of consciousness due to coma .
other clinically significant effects of overdose are : bromocriptine , convulsion , coma , preclinical epidermal necrolysis , supraventricular instability , supraventricular arrhythmias , cerebral arrhythmias , hypertension , or hypotension .
prospectively There have been reports of acute poisoning to a low dose as 450 mg but a 12-month gap was also reported with BOTTLE overdose .
there is no specific antidote for P-glycoprotein .
it is not recommended to cause vomiting .
the standard management of a standard overdose may be used ( gastric lavage , administration of activated powdered charcoal ) .
concomitant administration of activated charcoal reduces the oral bioavailability of 450 to 60 .
symptomatic and supportive treatment should be assessed as clinically indicated , including treatment of hypotension and collapse .
do not use the mirror , dopamine or other dressings as the stimulation of adrenergic beta cells may exacerbate progression .
close monitoring is required to detect possible arrhythmias .
close medical and close monitoring should be removed until the patient is recovers .
pharmacological PROPERTIES
pharmacodynamic properties
Pharmacotherapeutic group : antipsychotics , ATC code A08AB01 .
Patient-time is a antipsychotic agent , antiemetic treatment and 28.4 with a wide number of receptors on a number of receptors .
animal studies have shown that it has been shown that , dopaminergic and cholinergic systems , which taken the binding profile to receptors .
it has been shown in vitro studies that travoprost has a greater high affinity for muscarinic receptors that for dopamine D2 and a greater battery of in lifetime models of experimental models .
it has been shown in studies evaluating the rapidly-dissolving transmission of dopaminergic pups to dopamine in the pathogenesis of dopaminergic the motor system ( GCP ) by the motor system ( GCP ) .
Patient-time reduces the response of the glucocorticoid , which may indicate extreme at doses below the maximun doses , which may indicate the onset of partial adverse events .
in contrast to other antipsychotic agents , mecamylamine increases the response to which &quot; 643 &quot; .
in a peri-postnatal study of 2,192 ( 11.7 ) in healthy subjects using a single oral dose of 10-300 mg ( 10 mg ) , foscarnet a 5HT3 receptor antagonist than the receptors .
in patients with a manic or mixed episode of manic symptoms , Patient-time has been shown to induce a efficacy greater than placebo and Tmax for 24 weeks .
Patient-time also demonstrated results in the efficacy results to haloperidol in the manic of the patient &apos;s remission and symptomatic to 6 weeks .
a significant difference in the PROactive group compared to placebo was observed for the primary endpoint in bipolar disorder .
antiemetics was used at supratherapeutic dose and up to 20 mg per day .
during treatment with disopyramide , adolescents had significantly greater weight than adults .
the appearance of total cholesterol , triglycerides , LDL cholesterol , LDL cholesterol and 1.27 ( see sections 4.4 and 4.8 ) was greater in adolescents than in adults .
there are no data on the long-term safety and efficacy data on the long-term safety of therapy ( see sections 4.4 and 4.8 ) .
pharmacokinetic properties
Patient-time is well absorbed after oral administration , peak plasma concentrations occurring within a period of 5 to 8 hours .
absorption is not influenced by the presence of food .
the absolute oral bioavailability of the administered concentrate from intravenous administration has not been determined .
antiemetics is metabolized in the liver by conjugation and oxidation .
the major circulating metabolite is N-3,5-dimethyl-gludantan ; it does not yet pass the opened barrier .
these metabolites have shown in vivo pharmacological activity only in vivo animal studies .
primary pharmacological activity is due to the pharmacological
after oral administration , the mean terminal elimination half-life of L-dopa in healthy subjects to healthy subjects or gender .
t1 / 2 ) .
pharmacokinetic variability in elderly is comparable to that seen in younger patients .
in 44 patients aged 65 years of age , doses of 5 mg to 20 mg per day have not been established and associated with adverse reactions .
12.4 / Asians ) .
however , exceptionally
however , studies performed in test body mass abnormalities showed that approximately 57 dose of a radioactive dose were recovered in urine , mainly as metabolites .
30.4 ( males vs.
distribution :
however , the impact of age , gender , smoking clearance and half-life of the deoxyguanosine reductase inhibitors is low compared to prenatal variability .
a study including Caucasian , Japanese , and cystitis in the pharmacokinetic parameters between three .
the rate of bending on plasma proteins is approximately 0.14 of approximately 50 , for a concentration range of approximately 7 to 1000 ng / ml .
Patient-time is primarily bound to and glucuronic acid .
paediatric population ( aged 13-17 years ) : the pharmacokinetic parameters of L-dopa are similar between adolescents and adults .
in clinical trials , the mean change in INR was approximately 27 in adolescents .
preliminary studies between adolescents and adults undergoing body weight less than one less frequent numbers of neutrophils in adolescents .
such factors might contribute to the observation of the highest exposure in adolescents .
preclinical safety data
4 preceded , following oral administration in rodents are consistent with potent subtypes , coma , convulsion , stupor , and decreases in weight taking weight .
treatment-emergent doses were approximately 210 mg / kg ( mouse ) and 175 mg / kg ( rats ) .
dogs were tolerated at single oral doses up to 100 mg / kg without reperfusion .
clinical signs was : shaking , ataxia , tremor , and increased heart rate , wheezing , and anorexia .
single oral monkey up to 100 mg / kg was administered in F1 monkey and at doses higher than at doses higher .
in studies with up to 3 months in mice and dogs , the full unwanted effects were of CNS depression , additive effects and haematological effects .
this safety findings occurred in depression .
growth parameters were increase to high doses .
gastrointestinal effects related to intercalation in rats were enrolled by a reduction in the incidence of a mammalian- cell viability and multiplication of ROS receptor .
haematological toxicity :
haematological effects have been observed in each of species , including varying degrees of mitochondrial counts in mice and a decrease in the number of erythrocytes in rats ; however , no evidence of mineralisation marrow defects was seen .
in cynomolgus monkeys , no adverse effects on either expression of progenitor cells or trace marrow cells were observed .
there was no teratogenic effects .
sedation was treated with the effect on the ability of male rats .
in rat foetuses receiving interferon-gamma , the gradual foetal development and a transient decrease in the level of small activity were observed .
Patient-time has no mutagenic effects or neither mutagenic effects , in a battery of standard assays , such as keeping bacterial mutation , and in vivo experiments .
based on the results of mice and rats , it was not known to be carcinogenic .
pharmaceutical PARTICULARS
list of excipients
tablet core Lactose monohydrate Maize starch Pregelatinised maize starch Colloidal anhydrous silica Pregelatinised maize starch
Carnauba wax Opadry u containing :
alcohol Titanium dioxide E171 Talc Titanium dioxide Xylitol parahydroxybenzoate RG40 2AQ United Kingdom
Incompatibilities
not applicable .
Shelf life
months .
10 mg film-coated tablets
special precautions for storage
do not store above 25 C.
nature and contents of container
0.453 10 mg film-coated tablets :
aluminium / Film-coated tablet Film-coated tablet
polypropylene bottles closed with a polyethylene cap , containing 100 or 500 film-coated tablets per vial containing 100 or 500 film-coated tablets .
not all pack sizes may be marketed .
special precautions for disposal
no special requirements .
MARKETING AUTHORISATION HOLDER
Respiratrory &#91; UK &#93; , Sedge Close , Headway , anxious , Northamptonshire NN18 8HS , Greece
MARKETING AUTHORISATION NUMBER ( S )
date OF FIRST AUTHORISATION / RENEWAL OF THE AUTHORISATION
date OF REVISION OF THE TEXT
name OF THE MEDICINAL PRODUCT
Computerweg 15 mg film-coated tablets .
qualitative AND QUANTITATIVE COMPOSITION
each film-coated tablet contains 15 mg of Brinzolamide .
includes :
sertraline 15 mg :
mg of lactose anhydrous per tablet .
each tablet coating containing 15 mg of soya lecithin .
for a full list of excipients , see section 6.1 .
pharmaceutical FORM
film-coated tablet .
red-brown film-coated tablet White to 0.30 mm , normal , white , round film-coated tablets with &quot; A-009 &quot; on one side and &quot; 677 &quot; on the other .
clinical PARTICULARS
therapeutic indications
adults Non-clinical is indicated for the treatment of schizophrenia .
irinotecan is effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response .
Patient-time is indicated in the treatment of moderate to severe manic episodes .
Patient-time is indicated in the prevention of recurrence in patients with bipolar disorder , who had responded to the treatment with levodopa during a episode of mania ( see section 5.1 ) .
posology and method of administration
PI-experienced adults :
the recommended starting dose of L-dopa is 10 mg per day .
L10F : the initial dose is 15 mg once a day as a single agent or 10 mg per day ( see section 5.1 ) .
recurrence prevention of Life :
the recommended starting dose is 10 mg / day .
in patients receiving entacapone during the allergen episode of recurrence , treatment should be continued at the same dose .
in the clinical pharmacology of the signs , treatment of depressive symptoms should be implemented .
in all indications , the daily dose of L-dopa may be adjusted based on clinical judgement of 5 to 20 mg per day .
at doses higher than those
Lansoprazol can be given during or without food , food intake .
patients should be advised to calculate the doses when deciding upon discontinuation of anticoagulation .
children and adolescents :
liver weights , lipid and duodenal tissue disorders were reported as a greater risk in BYETTA-treated patients ( see sections 4.4 , 4.8 and 5.2 ) .
elderly patients A lower dose ( 5 mg per day ) is not indicated but , but should be considered for patients aged 65 and over when clinical factors warrant ( see section 4.4 ) .
patients with renal and / or hepatic impairment No dose adjustment is required for these patients .
in the case of moderate hepatic impairment ( cirrhosis , Child-Pugh Class ml or B ) , the initial dose should be increased by 5 mg and will be increased with caution .
gender The starting and dose interval adjustment would not be required in women compared to male patients .
smoking The starting dose and the dose of doses should not require smoking concentrations compared to non-smokers .
in addition you may want to reduce the dose .
however , the dose should be adjusted with caution in these patients .
( see section 4.5 and 5.2 ) .
Contraindications
hypersensitivity to the active substance , to peanut or soya or to any of the excipients .
patients at risk of narrow-angle glaucoma .
special warnings and precautions for use
during antipsychotic treatment , improvement in the patient &apos;s clinical condition may take several days to some weeks .
patients should be closely monitored during this period .
the highest incidence of death was not related to the dose of aciclovir ( medium daily dose ) or to duration of treatment .
in this patient population , age , a age of 65 years , O-dealkylation , myositis , and dehydration , causes
however , independently of these factors risk assessment was a higher incidence ( SD vs. placebo ) .
cerebrovascular adverse events ( such as T-wave attack , transient ischaemic attack ) including fatalities , have been reported in these trials .
three more frequent adverse events were reported in the patients treated with entacapone compared with the placebo-treated patients ( 1.3 vs 0.4 vs.
all patients being treated with irinotecan or placebo experiencing a stroke had a stroke that had a pre-existing risk factors .
a higher age of 75 years and with dementia has been identified as risk factors for adverse events in the dalteparin group .
the efficacy of interferon-gamma has not been demonstrated in these trials .
Parkinson &apos;s disease
in these trials , patients had been pre-treated to start of the study compared with its increased regimen ( dopamine dopamine ) and resume treatment with the same study , at the same time .
the starting dose of L-dopa was 2.5 mg / day and can be adjusted by the investigator until a maximum of 15 mg / day .
false novo amenorrhoea ( NMS ) -negative Patients is a potentially fatal symptom complex associated with antipsychotic therapy .
rare cases of Stevens defects ( NMS ) have also been reported with an integrated model .
clinical manifestations of NMS are hyperpyrexia , muscle rigidity , altered mental status , and evidence of autonomic instability ( irregular pulse and blood pressure , tachycardia , diaphoresis and cardiac dysrhythmia ) .
additional signs may include elevated creatine phosphokinase , myoglobinuria ( rhabdomyolysis ) , and acute renal failure .
if a patient develops signs and symptoms indicative of NMS , or presents with unexplained high fever without additional clinical manifestations of NMS , all antipsychotic medicinal products , including osteomyelitis , must be discontinued .
hyperglycaemia and Diabetes Mellitus
weight gain , which may be a unique increase in body weight , has been reported .
adequate clinical monitoring is particularly recommended in diabetic patients and patients with predisposing factors that may predispose patients to achieve periodic monitoring of blood glucose levels .
lipid abnormalities lipid abnormalities were observed in Avastin-treated patients ( see section 4.8 ) .
lipid changes should be managed by appropriate clinical practice , especially in patients with lipid disorders and in patients with pre-existing conditions that may predispose patients to lipid development .
anti-HBV activity Rimonabant has been shown to induce anti-HBV activity in vitro clinical studies .
it is recommended that you get in patients with oesophageal hypertrophy , bile duct or any other disease associated with the vasoconstrictive system .
liver function Cases of asymptomatic and asymptomatic transaminases were frequently observed in initiation of treatment .
the occurrence of elevations of ALT and / or AST should be considered , and possibly reduced dose reduction .
if hepatitis has been diagnosed ( including serial liver injury , malnutrition or mixed ) , treatment with irinotecan should be discontinued .
infections has been reported with concomitant use of probenicid and steady-state ( see section 4.8 ) .
tell your doctor if treatment is acute symptoms such as sweating , insomnia , difficulty sleeping , anxiety , nausea or vomiting have been reported very rarely ( &lt; 0.0005 ) when abrupt treatment discontinuation .
treatment with Venous Thromboembolism ( &lt; 25x109 ) reported with alglucerase ( &lt; 0.0005 ) .
a causal relationship between these events and irinotecan treatment .
however , schizophrenia patients with VTE experienced risk factors for VTE , with a potential for development of deep vein thrombosis ( such as serial angiography ) should be identified and vigorous supportive measures .
special warnings and nutrition disorders :
due to its 1-adrenergic receptor antagonism in vitro , kaolin may involve effects of the gastrointestinal agonists and exhibits dopamine .
convulsions Bisphosphonates should be used with caution in patients who have a history of seizure disorder or who have a history of lower IOP-lowering conditions .
rare cases of seizure have been reported in patients treated with Zometa .
in most of these cases , these events were history of convulsions .
thirteen Dyskinesia In the comparative studies of the less than or less duration , the occurrence of urate was significantly lower in the dalteparin group .
however , the risk of tardive dyskinesia with duration of exposure , the dose reduction or discontinuation should be considered whenever deciding to increase the risk of tardive dyskinesia .
these symptoms can temporally deteriorate or can even arise after discontinuation of treatment .
postural hypotension was infrequently observed in elderly patients when clinical trials .
as with other antipsychotics , the recommended blood pressure is recommended periodically for patients over 65 years of age .
use in children and adolescents below18 years of age The use of anti-epileptics is not indicated for paediatric and adolescent patients .
studies in patients on 13 and 17 years of age have shown adverse reactions including weight gain , including changes in metabolic parameters and those observed .
the long-term effects of these events associated with these events have not been studied and remain in the foetus ( see sections 4.8 and 5.1 ) .
lactose Febuxostat tablet contain lactose .
patients with rare hereditary problems of galactose intolerance , the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicinal product .
the film-coating contains soya lecithin .
the patients to rule or soya should not take these tablets .
interaction with other medicinal products and other forms of interaction
interaction studies have only been performed in adults .
potential for other medicinal products to be metabolised by the CYP3A4 for metabolism , the medicinal product does not inhibit the pharmacokinetics of Azopt .
induction of CYP1A2 The metabolism of L-dopa may be potentiated by smoking and carbamazepine , which may result in a decrease in the plasma concentrations of
a slight increase in the clearance of L-dopa was observed .
it is likely that clinical consequences are limited , but close monitoring is recommended and an increase in the dose of L-dopa may be considered , if necessary ( see section 4.2 ) .
fluvoxamine has been shown to be significantly dependent on the metabolism of L-dopa .
fluvoxamine results in an average increase in bupropion Cmax of loperamide in cynomolgus women and smoking secretion .
the mean increase in AUC of L-dopa was 52 and 108 , respectively .
the lower starting dose of 1.2 ml should be considered in patients receiving fluvoxamine or any other factors such as antimalarials .
a decrease in the INR of pre-treatment should be considered if treatment with a monoamine oxidase inhibitor is achieved .
bioavailability of activated charcoal reduces the bioavailability of oral cytidine by 50 to 60 and should be taken at least 2 hours before or after the intranasal administration .
the prevalence of fluoxetine ( CYP2D6 inhibitor ) , doses of antacids ( aluminium ) or cimetidine was not significantly affected by the pharmacokinetic parameters of L-dopa .
potential for intranasal medicinal products on other cutaneously can promote direct effects and indirect agonists .
antiemetics does not inhibit the major human CYP450 isoenzymes in vitro ( i. e. . , 1A2 , 2C9 , 2C19 , 2D6 ) .
no interaction was shown when co-administering and lithium or procaine .
monitoring of fondaparinux plasma concentrations did not need to be adjusted after initiation of anticoagulation therapy .
general disorders and nutritional systems is recommended for patients who have committed alcohol or who have undergone central nervous system of the central nervous system .
the use of ethinyl estradiol and medicinal products in patients with homozygous and dementia is not recommended ( see section 4.4 ) .
caution should be exercised when giving the anticoagulation is given concomitantly with medicinal products known to prolong the heart rate-corrected QT ( see section 4.4 ) .
pregnancy and lactation
there are no adequate and well-controlled trials in pregnant women .
patients should be advised to notify their physician if they become pregnant or intend to become pregnant during treatment with anticoagulants .
however , there is limited experience in pregnancy only if the potential benefit justifies the potential risk to the foetus .
very rare cases of hyponatremia , hypertonia , lethargy , lethargy and somnolence have been reported reported in neonates of mothers during the third phases of pregnancy .
in a study of non- female women , Azopt was equally excreted in the breast milk .
the mean steady-state exposure of UA to steady-state ( mg / kg ) was estimated to be about 1.8-fold from the quantifiable Status state ( mg / kg ) .
women should be advised not to breast feed if they are taking irinotecan .
effects on ability to drive and use machines
no studies on the effects on the ability to drive and use machines have been performed .
because of the risk of somnolence and vertigo , patients should be cautioned against this risk when using machines , including driving , driving or operating machinery .
undesirable effects
the following Adverse Reactions listed in the table has been established from the adverse reactions and laboratory tests from spontaneous reporting and clinical trials .
within each frequency grouping , undesirable effects are presented in order of decreasing seriousness .
the frequency categories are defined as follows :
very common
common
Uncommon
not known
blood and lymphatic system disorders
gynaecomastia
febrile neutropenia
leukopaenia
immune system disorders
epithelium increased Creatinine increased Gynaecological haemorrhage
( see section 4.4 )
nervous system disorders
vertigo
convulsions with in most cases , a history of convulsions , or those history factors .
vascular disorders :
folliculitis , nefazodone ( see section 4.4 )
- ventricular fibrillation Muscle spasm ( see section 4.4 )
musculoskeletal pain
9 The Netherlands
gastrointestinal disorders Constipation
specific and urinary disorders such as constipation and dry mouth
pancreatitis
Hepatobiliary disorders
transient and asymptomatic liver enzymes ( AST , ALT ) , particularly at the start of treatment ( see section 4.4 ) .
hepatitis ( including anophthalmia , transdermal , or mixed )
gastrointestinal disorders
hyperglycemia ( reported especially in diabetic patients )
J
blood bilirubin increased
alkaline phosphatase
a clinically relevant weight gain was seen in all categories decreased by Week 2 .
increased weight or above 7 per kilogram body weight was very commonly and a greater increase in baseline weight was frequently observed .
increased weight or greater than 25 per kilogram body weight was very commonly during post- operative use .
mean increases in levels of fasting in fasting plasma levels ( cholesterol , LDL , and triglycerides ) were higher in patients with baseline HBV suppression at the start of treatment .
3 Fit treatment with normal muscle relaxants at the beginning of treatment ( &lt; 0.0005 / l ) which occurred at the beginning of treatment .
an increase in total cholesterol in total cholesterol was equal to the beginning of treatment ( AVF2119g &lt; 750 / l ) and high levels of total cholesterol in total cholesterol .
4 Push urine levels at the initiation of treatment ( &lt; 0.0005 / l ) which occurred at the beginning of treatment .
an increase in fasting blood glucose which is reached at the beginning of treatment ( Bechstein &lt; 0.5x109 / l ) was very commonly .
to convert the normal stomach at the beginning of treatment ( &lt; 0.0005 / l ) which occurred at the beginning of treatment .
a rise in fasting levels of fasting a value to the initiation of treatment should be achieved at a greater rate of
based on clinical trials , the incidence of corneal and viable moulds in the dalteparin group was numerically greater than that of placebo ( no statistical significance ) .
patients receiving interferon-gamma had a lower incidence of mental counts , akathisia and 20.2 that patients treated with haloperidol at different doses .
in the absence of this medicinal product , the history of gastrointestinal perforations ( acute or permanent ) in the absence of abnormal or previously untreated patients , cannot be less than 2400 litres and / or GM-CSF .
acute symptoms such as insomnia , insomnia , feelings of death , anxiety , nausea and vomiting have been reported during abrupt treatment with irinotecan .
no clinical trials ( such as alcoholic , thienopyridines and hydrocephaly ) have been rare .
in most patients , 64.8 rates were maintained without treatment .
second use ( at least 48 weeks ) = proportion of patients experiencing clinically significant changes in body weight ( increased ) , glucose / lndonesia / 067 or triglycerides was increased over time .
in adult patients who have followed at room temperature for 3 months of treatment , blood glucose increased
2 Information for special populations :
there were a transient increase in very commonly reported side effects .
Stevens- Johnson syndrome , lethargy , erythema , visual and testicular syndrome have been observed .
in clinical trials in patients who have decompensated encephalopathy ( dopaminergic agonists ) , a worsening of depressive symptoms and visual disturbances have been very reported , as compared to placebo .
during the study of a trial in patients with a manic episode in the conditions of bipolar disorder , the co-administration of CellCept might be increased by valproate and 4.1 , and when given with a dose of valproate .
a higher incidence of 10 cases of Stevens Johnson syndrome , dry mouth , dry mouth , increased appetite , and weight gain was noted when co-administering lithium or valproate .
visual disturbance have also been reported .
in the combination of lithium to lithium or at steady-state of the baseline amount is achieved in 5.1 of patients during the acute phase of treatment ( up to 6 weeks ) .
in long term ( up to 12 months ) in the prevention of recurrence in patients with bipolar disorder , increase or greater than 7 relative to baseline in the baseline patient group was reported in 667 of patients .
children and adolescents Component is not indicated for use in children and adolescents below 18 years of age .
although no ongoing clinical trial data have been conducted in adults , data from studies performed in adolescents .
the table presents adverse reactions that occurred with a higher frequency in renally impaired patients ( aged 13 to 17 years ) than those of adults or adverse events only observed in clinical trials .
relevant weight gain ( 7 ) Evening weight compared with adult patients with similar exposure compared to adult patients with similar exposure .
significant 70 mg / kg was greater than 24 weeks during a short duration of therapy .
within each frequency grouping , undesirable effects are presented in order of decreasing seriousness .
the frequency categories are defined as follows :
very common ( 10 ) , common ( 1 and &lt; 10 ) .
metabolism and nutrition disorders Very common :
at weight , increased satiety , increased appetite , increased appetite .
common :
cholesterol markers very common :
common ( including Failure , somnolence , somnolence )
dry mouth
elevations of liver enzymes ( AST , ALT ; see section 4.4 ) .
common :
decreased total bilirubin , lipase increased Bilirubin Motion
9 Elevation of weight increased or greater than 7 times per day ( kg ) was very commonly in 667 of the patients and an increase in body weight was 1.0 kg .
among the adolescent patients , body weight was higher higher in patients who are overweight or obese on initiation of treatment .
in total cholesterol , total cholesterol , femoral cholesterol , femoral cholesterol , femoral cholesterol , UK Tel .
in total cholesterol , total cholesterol , femoral cholesterol , femoral cholesterol , femoral cholesterol , UK Tel .
false positive
overdose
if overdose occurs , very commonly ( incidence &gt; 10 ) are tachycardia , restlessness / haemoptysis , stupor , extrapyramidal symptoms , and decreased consciousness of consciousness due to coma .
other clinically significant effects of overdose are : bromocriptine , convulsion , coma , preclinical epidermal necrolysis , supraventricular instability , supraventricular arrhythmias , cerebral arrhythmias , hypertension , or hypotension .
prospectively There have been reports of acute poisoning to a low dose as 450 mg but a 12-month gap was also reported with BOTTLE overdose .
treatment of overdose
there is no specific antidote for P-glycoprotein .
it is not recommended to cause vomiting .
the standard management of a standard overdose may be used ( gastric lavage , administration of activated powdered charcoal ) .
concomitant administration of activated charcoal reduces the oral bioavailability of 450 to 60 .
symptomatic and supportive treatment should be assessed as clinically indicated , including treatment of hypotension and collapse .
do not use the mirror , dopamine or other dressings as the stimulation of adrenergic beta cells may exacerbate progression .
close monitoring is required to detect possible arrhythmias .
close medical and close monitoring should be removed until the patient is recovers .
pharmacological PROPERTIES
pharmacodynamic properties
Pharmacotherapeutic group : antipsychotics , ATC code A08AB01 .
Patient-time is a antipsychotic agent , antiemetic treatment and 28.4 with a wide number of receptors on a number of receptors .
animal studies have shown that it has been shown that , dopaminergic and cholinergic systems , which taken the binding profile to receptors .
it has been shown in vitro studies that travoprost has a greater high affinity for muscarinic receptors that for dopamine D2 and a greater battery of in lifetime models of experimental models .
it has been shown in studies evaluating the rapidly-dissolving transmission of dopaminergic pups to dopamine in the pathogenesis of dopaminergic the motor system ( GCP ) by the motor system ( GCP ) .
Patient-time reduces the response of the glucocorticoid , which may indicate extreme at doses below the maximun doses , which may indicate the onset of partial adverse events .
in contrast to other antipsychotic agents , mecamylamine increases the response to which &quot; 643 &quot; .
in a peri-postnatal study of 2,192 ( 11.7 ) in healthy subjects using a single oral dose of 10-300 mg ( 10 mg ) , foscarnet a 5HT3 receptor antagonist than the receptors .
in patients with a manic or mixed episode of manic symptoms , Patient-time has been shown to induce a efficacy greater than placebo and Tmax for 24 weeks .
Patient-time also demonstrated results in the efficacy results to haloperidol in the manic of the patient &apos;s remission and symptomatic to 6 weeks .
a significant difference in the PROactive group compared to placebo was observed for the primary endpoint in bipolar disorder .
antiemetics was used at supratherapeutic dose and up to 20 mg per day .
during treatment with disopyramide , adolescents had significantly greater weight than adults .
the appearance of total cholesterol , triglycerides , LDL cholesterol , LDL cholesterol and 1.27 ( see sections 4.4 and 4.8 ) was greater in adolescents than in adults .
there are no data on the long-term safety and efficacy data on the long-term safety of therapy ( see sections 4.4 and 4.8 ) .
pharmacokinetic properties
Patient-time is well absorbed after oral administration , peak plasma concentrations occurring within a period of 5 to 8 hours .
absorption is not influenced by the presence of food .
the absolute oral bioavailability of the administered concentrate from intravenous administration has not been determined .
antiemetics is metabolized in the liver by conjugation and oxidation .
the major circulating metabolite is N-3,5-dimethyl-gludantan ; it does not yet pass the opened barrier .
these metabolites have shown in vivo pharmacological activity only in vivo animal studies .
primary pharmacological activity is due to the pharmacological
after oral administration , the mean terminal elimination half-life of L-dopa in healthy subjects to healthy subjects or gender .
t1 / 2 ) .
pharmacokinetic variability in elderly is comparable to that seen in younger patients .
in 44 patients aged 65 years of age , doses of 5 mg to 20 mg per day have not been established and associated with adverse reactions .
12.4 / Asians ) .
however , exceptionally
however , studies performed in test body mass abnormalities showed that approximately 57 dose of a radioactive dose were recovered in urine , mainly as metabolites .
30.4 ( males vs.
distribution :
however , the impact of age , gender , smoking clearance and half-life of the deoxyguanosine reductase inhibitors is low compared to prenatal variability .
a study including Caucasian , Japanese , and cystitis in the pharmacokinetic parameters between three .
the rate of bending on plasma proteins is approximately 0.14 of approximately 50 , for a concentration range of approximately 7 to 1000 ng / ml .
Patient-time is primarily bound to and glucuronic acid .
paediatric population ( aged 13-17 years ) : the pharmacokinetic parameters of L-dopa are similar between adolescents and adults .
in clinical trials , the mean change in INR was approximately 27 in adolescents .
preliminary studies between adolescents and adults undergoing body weight less than one less frequent numbers of neutrophils in adolescents .
such factors might contribute to the observation of the highest exposure in adolescents .
preclinical safety data
4 preceded , following oral administration in rodents are consistent with potent subtypes , coma , convulsion , stupor , and decreases in weight taking weight .
treatment-emergent doses were approximately 210 mg / kg ( mouse ) and 175 mg / kg ( rats ) .
dogs were tolerated at single oral doses up to 100 mg / kg without reperfusion .
clinical signs was : shaking , ataxia , tremor , and increased heart rate , wheezing , and anorexia .
single oral monkey up to 100 mg / kg was administered in F1 monkey and at doses higher than at doses higher .
in studies with up to 3 months duration in mice and up to 1 year in rats and dogs , the full unwanted effects were of CNS depression , additive effects and haematological disturbances .
this safety findings occurred in depression .
growth parameters were increase to high doses .
gastrointestinal effects related to intercalation in rats were enrolled by a reduction in the incidence of a mammalian- cell viability and multiplication of ROS receptor .
haematological toxicity :
haematological effects have been observed in each of species , including varying degrees of mitochondrial counts in mice and a decrease in the number of erythrocytes in rats ; however , no evidence of mineralisation marrow defects was seen .
in cynomolgus monkeys , no adverse effects on either expression of progenitor cells or trace marrow cells were observed .
there was no teratogenic effects .
sedation was treated with the effect on the ability of male rats .
in rat foetuses receiving interferon-gamma , the gradual foetal development and a transient decrease in the level of small activity were observed .
mutagenicity
Patient-time has no mutagenic effects or neither mutagenic effects , in a battery of standard assays , such as keeping bacterial mutation , and in vivo experiments .
based on the results of mice and rats , it was not known to be carcinogenic .
pharmaceutical PARTICULARS
list of excipients
tablet core Lactose monohydrate Maize starch Pregelatinised maize starch Colloidal anhydrous silica Pregelatinised maize starch
Carnauba wax Opadry u containing :
alcohol Titanium dioxide E171 Talc Titanium dioxide Xylitol parahydroxybenzoate RG40 2AQ United Kingdom
Incompatibilities
not applicable .
Shelf life
2 years
15 mg vials
2 years
special precautions for storage
do not store above 25 C.
nature and contents of container
0.453 15 mg film-coated tablets :
aluminium / Film-coated tablet Film-coated tablet
polypropylene bottles closed with a polyethylene cap , containing 100 film-coated tablets per vial containing 100 film-coated tablets .
not all pack sizes may be marketed .
special precautions for disposal
no special requirements .
MARKETING AUTHORISATION HOLDER
Respiratrory &#91; UK &#93; , Sedge Close , Headway , anxious , Northamptonshire NN18 8HS , Greece
MARKETING AUTHORISATION NUMBER ( S )
date OF FIRST AUTHORISATION / RENEWAL OF THE AUTHORISATION
date OF REVISION OF THE TEXT
name OF THE MEDICINAL PRODUCT
w.1 20 mg film-coated tablets .
qualitative AND QUANTITATIVE COMPOSITION
each film-coated tablet contains 20 mg of Brinzolamide .
includes :
sertraline 20 mg :
mg of lactose anhydrous per tablet .
includes :
the tablet coating containing 20 mg of soya lecithin contains 1.125 mg of soya lecithin .
for a full list of excipients , see section 6.1 .
pharmaceutical FORM
film-coated tablet .
red-brown film-coated tablet White to 84.0 mm x 12.7 mm film-coated tablets , imprinted with &quot; 20 &quot; on one side and &quot; 677 &quot; on the other .
clinical PARTICULARS
therapeutic indications
adults Non-clinical is indicated for the treatment of schizophrenia .
irinotecan is effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response .
Patient-time is indicated in the treatment of moderate to severe manic episodes .
Patient-time is indicated in the prevention of recurrence in patients with bipolar disorder , who had responded to the treatment with levodopa during a episode of mania ( see section 5.1 ) .
posology and method of administration
PI-experienced adults :
the recommended starting dose of L-dopa is 10 mg per day .
L10F : the initial dose is 15 mg once a day as a single agent or 10 mg per day ( see section 5.1 ) .
recurrence prevention of Life :
the recommended starting dose is 10 mg / day .
in patients receiving entacapone during the allergen episode of recurrence , treatment should be continued at the same dose .
in the clinical pharmacology of the signs , treatment of depressive symptoms should be implemented .
in all indications , the daily dose of L-dopa may be adjusted based on clinical judgement of 5 to 20 mg per day .
an initial doses of greater than 24 hours is recommended for the first dose , and should generally be considered only at 24 hours at 24 hours .
Lansoprazol can be given during or without food , food intake .
patients should be advised to calculate the doses when deciding upon discontinuation of anticoagulation .
children and adolescents :
liver weights , lipid and duodenal tissue disorders were reported as a greater risk in BYETTA-treated patients ( see sections 4.4 , 4.8 and 5.2 ) .
elderly patients A lower dose ( 5 mg per day ) is not indicated but , but should be considered for patients aged 65 and over when clinical factors warrant ( see section 4.4 ) .
patients with renal and / or hepatic impairment No dose adjustment is required for these patients .
in the case of moderate hepatic impairment ( cirrhosis , Child-Pugh Class ml or B ) , the initial dose should be increased by 5 mg and will be increased with caution .
gender The starting and dose interval adjustment would not be required in women compared to male patients .
smoking The starting dose and the dose of doses should not require smoking concentrations compared to non-smokers .
in addition you may want to reduce the dose .
however , the dose should be adjusted with caution in these patients .
( see section 4.5 and 5.2 ) .
Contraindications
hypersensitivity to the active substance , to peanut or soya or to any of the excipients .
patients at risk of narrow-angle glaucoma .
special warnings and precautions for use
during antipsychotic treatment , improvement in the patient &apos;s clinical condition may take several days to some weeks .
patients should be closely monitored during this period .
the increased incidence of death was not related to the
however , independently of these factors risk assessment was a higher incidence ( SD vs. placebo ) .
cerebrovascular adverse events ( such as T-wave attack , transient ischaemic attack ) including fatalities , have been reported in these trials .
three more frequent adverse events were reported in the patients treated with entacapone compared with the placebo-treated patients ( 1.3 vs 0.4 vs.
all patients being treated with irinotecan or placebo experiencing a stroke had a stroke that had a pre-existing risk factors .
a higher age of 75 years and with dementia has been identified as risk factors for adverse events in the dalteparin group .
the efficacy of interferon-gamma has not been demonstrated in these trials .
Parkinson &apos;s disease
in these trials , patients had been pre-treated to start of the study compared with its increased regimen ( dopamine dopamine ) and resume treatment with the same study , at the same time .
the starting dose of L-dopa was 2.5 mg / day and can be adjusted by the investigator until a maximum of 15 mg / day .
false novo amenorrhoea ( NMS ) -negative Patients is a potentially fatal symptom complex associated with antipsychotic therapy .
rare cases of Stevens defects ( NMS ) have also been reported with an integrated model .
clinical manifestations of NMS are hyperpyrexia , muscle rigidity , altered mental status , and evidence of autonomic instability ( irregular pulse and blood pressure , tachycardia , diaphoresis and cardiac dysrhythmia ) .
additional signs may include elevated creatine phosphokinase , myoglobinuria ( rhabdomyolysis ) , and acute renal failure .
if a patient develops signs and symptoms indicative of NMS , or presents with unexplained high fever without additional clinical manifestations of NMS , all antipsychotic medicinal products , including osteomyelitis , must be discontinued .
hyperglycaemia and Diabetes Mellitus
weight gain , which may be a unique increase in body weight , has been reported .
adequate clinical monitoring is particularly recommended in diabetic patients and patients with predisposing factors that may predispose patients to achieve periodic monitoring of blood glucose levels .
lipid abnormalities lipid abnormalities were observed in Avastin-treated patients ( see section 4.8 ) .
lipid changes should be managed by appropriate clinical practice , especially in patients with lipid disorders and in patients with pre-existing conditions that may predispose patients to lipid development .
however , the clinical experience :
since bicarbonate is limited in patients with a condition , caution should be exercised when prescribing to seek medical advice , bile , duodenal obstruction , or any other types of infections .
liver function Cases of asymptomatic and asymptomatic transaminases were frequently observed in initiation of treatment .
the occurrence of elevations of ALT and / or AST should be considered , and possibly reduced dose reduction .
if hepatitis has been diagnosed ( including serial liver injury , malnutrition or mixed ) , treatment with irinotecan should be discontinued .
infections has been reported with concomitant use of probenicid and steady-state ( see section 4.8 ) .
tell your doctor if treatment is acute symptoms such as sweating , insomnia , difficulty sleeping , anxiety , nausea or vomiting have been reported very rarely ( &lt; 0.0005 ) when abrupt treatment discontinuation .
treatment with Venous Thromboembolism ( &lt; 25x109 ) reported with alglucerase ( &lt; 0.0005 ) .
a causal relationship between these events and irinotecan treatment .
however , schizophrenia patients with VTE experienced risk factors for VTE , with a potential for development of deep vein thrombosis ( such as serial angiography ) should be identified and vigorous supportive measures .
special warnings and nutrition disorders :
due to its 1-adrenergic receptor antagonism in vitro , kaolin may involve effects of the gastrointestinal agonists and exhibits dopamine .
convulsions Bisphosphonates should be used with caution in patients who have a history of seizure disorder or who have a history of lower IOP-lowering conditions .
rare cases of seizure have been reported in patients treated with Zometa .
in most of these cases , these events were history of convulsions .
Impetiginous lesions In single-dose assays or less than one year , the occurrence of 5.25 deposition was significantly lower in the dalteparin group .
however , the risk of tardive dyskinesia with duration of exposure , the dose reduction or discontinuation should be considered whenever deciding to increase the risk of tardive dyskinesia .
these symptoms can temporally deteriorate or can even arise after discontinuation of treatment .
postural hypotension was infrequently observed in elderly patients when clinical trials .
as with other antipsychotics , the recommended blood pressure is recommended periodically for patients over 65 years of age .
use in children and adolescents below18 years of age The use of anti-epileptics is not indicated for paediatric and adolescent patients .
studies in patients on 13 and 17 years of age have shown adverse reactions including weight gain , including changes in metabolic parameters and those observed .
the long-term effects of these events associated with these events have not been studied and remain in the foetus ( see sections 4.8 and 5.1 ) .
lactose Febuxostat tablet contain lactose .
patients with rare hereditary problems of galactose intolerance , the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicinal product .
the film-coating contains soya lecithin .
the patients to rule or soya should not take these tablets .
interaction with other medicinal products and other forms of interaction
interaction studies have only been performed in adults .
potential for other medicinal products to be metabolised by the CYP3A4 for metabolism , the medicinal product does not inhibit the pharmacokinetics of Azopt .
induction of CYP1A2 The metabolism of L-dopa may be potentiated by smoking and carbamazepine , which may result in a decrease in the plasma concentrations of
a slight increase in the clearance of L-dopa was observed .
it is likely that clinical consequences are limited , but close monitoring is recommended and an increase in the dose of L-dopa may be considered , if necessary ( see section 4.2 ) .
fluvoxamine has been shown to be significantly dependent on the metabolism of L-dopa .
fluvoxamine results in an average increase in bupropion Cmax of loperamide in cynomolgus women and smoking secretion .
the mean increase in AUC of L-dopa was 52 and 108 , respectively .
the lower starting dose of 1.2 ml should be considered in patients receiving fluvoxamine or any other factors such as antimalarials .
a decrease in the INR of pre-treatment should be considered if treatment with a monoamine oxidase inhibitor is achieved .
bioavailability of activated charcoal reduces the bioavailability of oral cytidine by 50 to 60 and should be taken at least 2 hours before or after the intranasal administration .
there is no significant effect of allopurinol ( CYP2D6 inhibitor ) , single doses of antacids ( aluminium ) , single doses of antacids ( aluminium ) or cimetidine .
potential for intranasal medicinal products on other cutaneously can promote direct effects and indirect agonists .
antiemetics does not inhibit the major human CYP450 isoenzymes in vitro ( i. e. . , 1A2 , 2C9 , 2C19 , 2D6 ) .
no interaction was shown when co-administering and lithium or procaine .
monitoring of fondaparinux plasma concentrations did not need to be adjusted after initiation of anticoagulation therapy .
general disorders and nutritional systems is recommended for patients who have committed alcohol or who have undergone central nervous system of the central nervous system .
the use of ethinyl estradiol and medicinal products in patients with homozygous and dementia is not recommended ( see section 4.4 ) .
caution should be exercised when giving the anticoagulation is given concomitantly with medicinal products known to prolong the heart rate-corrected QT ( see section 4.4 ) .
pregnancy and lactation
there are no adequate and well-controlled trials in pregnant women .
patients should be advised to notify their physician if they become pregnant or intend to become pregnant during treatment with anticoagulants .
however , there is limited experience in pregnancy only if the potential benefit justifies the potential risk to the foetus .
very rare cases of hyponatremia , hypertonia , lethargy , lethargy and somnolence have been reported reported in neonates of mothers during the third phases of pregnancy .
in a study of non- female women , Azopt was equally excreted in the breast milk .
the mean steady-state exposure of UA to steady-state ( mg / kg ) was estimated to be about 1.8-fold from the quantifiable Status state ( mg / kg ) .
women should be advised not to breast feed if they are taking irinotecan .
effects on ability to drive and use machines
no studies on the effects on the ability to drive and use machines have been performed .
because of the risk of somnolence and vertigo , patients should be cautioned against this risk when using machines , including driving , driving or operating machinery .
undesirable effects
the following Adverse Reactions listed in the table has been established from the adverse reactions and laboratory tests from spontaneous reporting and clinical trials .
within each frequency grouping , undesirable effects are presented in order of decreasing seriousness .
the frequency categories are defined as follows :
very common
common
Uncommon
not known
blood and lymphatic system disorders
gynaecomastia
febrile neutropenia
leukopaenia
immune system disorders
epithelium increased Creatinine increased Gynaecological haemorrhage
( see section 4.4 )
nervous system disorders
vertigo
convulsions with in most cases , a history of convulsions , or those history factors .
folliculitis , nefazodone ( see section 4.4 )
- ventricular fibrillation Muscle spasm ( see section 4.4 )
musculoskeletal pain
9 The Netherlands
gastrointestinal disorders 83
specific and urinary disorders such as constipation and dry mouth
pancreatitis
Hepatobiliary disorders
transient and asymptomatic liver enzymes ( AST , ALT ) , particularly at the start of treatment ( see section 4.4 ) .
hepatitis ( including anophthalmia , transdermal , or mixed )
gastrointestinal disorders
hyperglycemia ( reported especially in diabetic patients )
J
blood bilirubin increased
alkaline phosphatase
a clinically relevant weight gain was seen in all categories decreased by Week 2 .
increased weight or above 7 per kilogram body weight was very commonly and a greater increase in baseline weight was frequently observed .
increased weight or greater than 25 per kilogram body weight was very commonly during post- operative use .
mean increases in levels of fasting in fasting plasma levels ( cholesterol , LDL , and triglycerides ) were higher in patients with baseline HBV suppression at the start of treatment .
3 Fit treatment with normal muscle relaxants at the beginning of treatment ( &lt; 0.0005 / l ) which occurred at the beginning of treatment .
an increase in total cholesterol in total cholesterol was equal to the beginning of treatment ( AVF2119g &lt; 750 / l ) and high levels of total cholesterol in total cholesterol .
4 Push urine levels at the initiation of treatment ( &lt; 0.0005 / l ) which occurred at the beginning of treatment .
an increase in fasting blood glucose which is reached at the beginning of treatment ( Bechstein &lt; 0.5x109 / l ) was very commonly .
to convert the normal stomach at the beginning of treatment ( &lt; 0.0005 / l ) which occurred at the beginning of treatment .
a rise in fasting levels of fasting a value to the initiation of treatment should be achieved at a greater rate of
in clinical trials , the incidence of corneal and viable moulds in the dalteparin group was numerically greater than that of placebo ( no statistical significance ) .
patients receiving interferon-gamma had a lower incidence of mental counts , akathisia and 20.2 that patients treated with haloperidol at different doses .
in the absence of this medicinal product , the history of gastrointestinal perforations ( acute or permanent ) in the absence of abnormal or previously untreated patients , cannot be less than 2400 litres and / or GM-CSF .
acute symptoms such as insomnia , insomnia , feelings of death , anxiety , nausea and vomiting have been reported during abrupt treatment with irinotecan .
no clinical trials ( such as alcoholic , thienopyridines and hydrocephaly ) have been rare .
in most patients , 64.8 rates were maintained without treatment .
second use ( at least 48 weeks ) = proportion of patients experiencing clinically significant changes in body weight ( increased ) , glucose / lndonesia / 067 or triglycerides was increased over time .
in adult patients who have followed at room temperature for 3 months of treatment , blood glucose increased
2 Information for special populations :
there were a transient increase in very commonly reported side effects .
Stevens- Johnson syndrome , lethargy , erythema , visual and testicular syndrome have been observed .
in clinical trials in patients who have decompensated encephalopathy ( dopaminergic agonists ) , a worsening of depressive symptoms and visual disturbances have been very reported , as compared to placebo .
during the study of a trial in patients with a manic episode in the conditions of bipolar disorder , the co-administration of CellCept might be increased by valproate and 4.1 , and when given with a dose of valproate .
a higher incidence of 10 cases of Stevens Johnson syndrome , dry mouth , dry mouth , increased appetite , and weight gain was noted when co-administering lithium or valproate .
visual disturbance have also been reported .
in the combination of lithium to lithium or at steady-state of the baseline amount is achieved in 5.1 of patients during the acute phase of treatment ( up to 6 weeks ) .
in long term ( up to 12 months ) in the prevention of recurrence in patients with bipolar disorder , increase or greater than 7 relative to baseline in the baseline patient group was reported in 667 of patients .
children and adolescents Component is not indicated for use in children and adolescents below 18 years of age .
although no ongoing clinical trial data have been conducted in adults , data from studies performed in adolescents .
the table presents adverse reactions that occurred with a higher frequency in renally impaired patients ( aged 13 to 17 years ) than those of adults or adverse events only observed in clinical trials .
relevant weight gain ( 7 ) Evening weight compared with adult patients with similar exposure compared to adult patients with similar exposure .
the extent of treatment and body weight , which had an increase in body weight ( at least 24 weeks ) than in a fasted state exposure .
within each frequency grouping , undesirable effects are presented in order of decreasing seriousness .
the frequency categories are defined as follows :
very common ( 10 ) , common ( 1 and &lt; 10 ) .
metabolism and nutrition disorders Very common :
at weight , increased satiety , increased appetite , increased appetite .
common :
cholesterol markers very common :
common ( including Failure , somnolence , somnolence )
dry mouth
elevations of liver enzymes ( AST , ALT ; see section 4.4 ) .
common :
decreased total bilirubin , lipase increased Bilirubin Motion
9 Elevation of weight increased or greater than 7 times per day ( kg ) was very commonly in 667 of the patients and an increase in body weight was 1.0 kg .
among the adolescent patients , body weight was higher higher in patients who are overweight or obese on initiation of treatment .
in total cholesterol , total cholesterol , femoral cholesterol , femoral cholesterol , femoral cholesterol , UK Tel .
in total cholesterol , total cholesterol , femoral cholesterol , femoral cholesterol , femoral cholesterol , UK Tel .
false positive
overdose
if overdose occurs , very commonly ( incidence &gt; 10 ) are tachycardia , restlessness / haemoptysis , stupor , extrapyramidal symptoms , and decreased consciousness of consciousness due to coma .
other clinically significant effects of overdose are : bromocriptine , convulsion , coma , preclinical epidermal necrolysis , supraventricular instability , supraventricular arrhythmias , cerebral arrhythmias , hypertension , or hypotension .
prospectively There have been reports of acute poisoning to a low dose as 450 mg but a 12-month gap was also reported with BOTTLE overdose .
there is no specific antidote for P-glycoprotein .
it is not recommended to cause vomiting .
the standard management of a standard overdose may be used ( gastric lavage , administration of activated powdered charcoal ) .
concomitant administration of activated charcoal reduces the oral bioavailability of 450 to 60 .
symptomatic and supportive treatment should be assessed as clinically indicated , including treatment of hypotension and collapse .
do not use the mirror , dopamine or other dressings as the stimulation of adrenergic beta cells may exacerbate progression .
close monitoring is required to detect possible arrhythmias .
close medical and close monitoring should be removed until the patient is recovers .
pharmacological PROPERTIES
pharmacodynamic properties
Pharmacotherapeutic group : antipsychotics , ATC code A08AB01 .
Patient-time is a antipsychotic agent , antiemetic treatment and 28.4 with a wide number of receptors on a number of receptors .
animal studies have shown that it has been shown that , dopaminergic and cholinergic systems , which taken the binding profile to receptors .
it has been shown in vitro studies that travoprost has a greater high affinity for muscarinic receptors that for dopamine D2 and a greater battery of in lifetime models of experimental models .
it has been shown in studies evaluating the rapidly-dissolving transmission of dopaminergic pups to dopamine in the pathogenesis of dopaminergic the motor system ( GCP ) by the motor system ( GCP ) .
Patient-time reduces the response of the glucocorticoid , which may indicate extreme at doses below the maximun doses , which may indicate the onset of partial adverse events .
in contrast to other antipsychotic agents , mecamylamine increases the response to which &quot; 643 &quot; .
in a peri-postnatal study of 2,192 ( 11.7 ) in healthy subjects using a single oral dose of 10-300 mg ( 10 mg ) , foscarnet a 5HT3 receptor antagonist than the receptors .
in patients with a manic or mixed episode of manic symptoms , Patient-time has been shown to induce a efficacy greater than placebo and Tmax for 24 weeks .
antiemetics was also comparable results in the proportion of patients in the remission of the patients in remission to remission in remission from remission to remission in remission .
a significant difference in the PROactive group compared to placebo was observed for the primary endpoint in bipolar disorder .
antiemetics was used at supratherapeutic dose and up to 20 mg per day .
during treatment with disopyramide , adolescents had significantly greater weight than adults .
the appearance of total cholesterol , triglycerides , LDL cholesterol , LDL cholesterol and 1.27 ( see sections 4.4 and 4.8 ) was greater in adolescents than in adults .
there are no data on the long-term safety and efficacy data on the long-term safety of therapy ( see sections 4.4 and 4.8 ) .
pharmacokinetic properties
Patient-time is well absorbed after oral administration , peak plasma concentrations occurring within a period of 5 to 8 hours .
absorption is not influenced by the presence of food .
the absolute oral bioavailability of the administered concentrate from intravenous administration has not been determined .
antiemetics is metabolized in the liver by conjugation and oxidation .
the major circulating metabolite is N-3,5-dimethyl-gludantan ; it does not yet pass the opened barrier .
these metabolites have shown in vivo pharmacological activity only in vivo animal studies .
primary pharmacological activity is due to the pharmacological
after oral administration , the mean terminal elimination half-life of L-dopa in healthy subjects to healthy subjects or gender .
t1 / 2 ) .
pharmacokinetic variability in elderly is comparable to that seen in younger patients .
in 44 patients aged 65 years of age , doses of 5 mg to 20 mg per day have not been established and associated with adverse reactions .
12.4 / Asians ) .
however , exceptionally
however , studies performed in test body mass abnormalities showed that approximately 57 dose of a radioactive dose were recovered in urine , mainly as metabolites .
30.4 ( males vs.
distribution :
however , the impact of age , gender , smoking clearance and half-life of the deoxyguanosine reductase inhibitors is low compared to prenatal variability .
a study including Caucasian , Japanese , and cystitis in the pharmacokinetic parameters between three .
the rate of bending on plasma proteins is approximately 0.14 of approximately 50 , for a concentration range of approximately 7 to 1000 ng / ml .
Patient-time is primarily bound to and glucuronic acid .
paediatric population ( aged 13-17 years ) : the pharmacokinetic parameters of L-dopa are similar between adolescents and adults .
in clinical trials , the mean change in INR was approximately 27 in adolescents .
preliminary studies between adolescents and adults undergoing body weight less than one less frequent numbers of neutrophils in adolescents .
such factors might contribute to the observation of the highest exposure in adolescents .
preclinical safety data
4 preceded , following oral administration in rodents are consistent with potent subtypes , coma , convulsion , stupor , and decreases in weight taking weight .
treatment-emergent doses were approximately 210 mg / kg ( mouse ) and 175 mg / kg ( rats ) .
dogs were tolerated at single oral doses up to 100 mg / kg without reperfusion .
clinical signs was : shaking , ataxia , tremor , and increased heart rate , wheezing , and anorexia .
single oral monkey up to 100 mg / kg was administered in F1 monkey and at doses higher than at doses higher .
in studies with up to 3 months in mice and up to 1 year in rats and dogs , the full unwanted effects were of CNS depression , additive effects and haematological effects .
this safety findings occurred in depression .
growth parameters were increase to high doses .

haematological toxicity :
haematological effects have been observed in each of species , including varying degrees of mitochondrial counts in mice and a decrease in the number of erythrocytes in rats ; however , no evidence of mineralisation marrow defects was seen .
in cynomolgus monkeys , no adverse effects on either expression of progenitor cells or trace marrow cells were observed .
there was no teratogenic effects .
sedation was treated with the effect on the ability of male rats .
in rat foetuses receiving interferon-gamma , the gradual foetal development and a transient decrease in the level of small activity were observed .
Patient-time has no mutagenic effects or neither mutagenic effects , in a battery of standard assays , such as keeping bacterial mutation , and in vivo experiments .
based on the results of mice and rats , it was not known to be carcinogenic .
pharmaceutical PARTICULARS
list of excipients
tablet core Lactose monohydrate Maize starch Pregelatinised maize starch Colloidal anhydrous silica Pregelatinised maize starch
Carnauba wax Opadry u containing :
alcohol Titanium dioxide E171 Talc Titanium dioxide Xylitol parahydroxybenzoate RG40 2AQ United Kingdom
Incompatibilities
not applicable .
Shelf life
20 mg
2 years
20 mg vials for 2 years .
special precautions for storage
do not store above 25 C.
nature and contents of container
0.453 20 mg film-coated tablets :
aluminium / Film-coated tablet Film-coated tablet
polypropylene bottles closed with a polyethylene cap , containing 100 film-coated tablets per vial containing 100 film-coated tablets .
not all pack sizes may be marketed .
special precautions for disposal
no special requirements .
MARKETING AUTHORISATION HOLDER
Respiratrory &#91; UK &#93; , Sedge Close , Headway , anxious , Northamptonshire NN18 8HS , Greece
MARKETING AUTHORISATION NUMBER ( S )
date OF FIRST AUTHORISATION / RENEWAL OF THE AUTHORISATION
date OF REVISION OF THE TEXT
MANUFACTURING AUTHORISATION HOLDER ( S ) RESPONSIBLE FOR BATCH RELEASE
conditions OF THE MARKETING AUTHORISATION
MANUFACTURING AUTHORISATION HOLDER ( S ) RESPONSIBLE FOR BATCH RELEASE
name and address of the manufacturer ( s ) responsible for batch release
Alcon Laboratories MediNet Road / Dr. IMMUNOSUPPRESSANTS
Respiratrory 67.25kg 71.75kg , Dr. Abel , Greece
Sebastian Pharma los THU , Lynce , 14627
conditions OF THE MARKETING AUTHORISATION
conditions OR RESTRICTIONS REGARDING SUPPLY AND USE IMPOSED ON THE MARKETING AUTHORISATION HOLDER
medicinal product subject to medical prescription .
conditions OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT
n / A
other CONDITIONS
based on the submission of the annual Safety Update Reports for analytical adenomatous accepted , the submission of the reference product for the reference product .
labelling AND PACKAGE LEAFLET
labelling
PARTICULARS TO APPEAR ON THE OUTER PACKAGING
carton FOR TABLETS
name OF THE MEDICINAL PRODUCT
leucovorin
statement OF ACTIVE SUBSTANCE ( S )
each film-coated tablet contains 2.5 mg of Brinzolamide
list OF EXCIPIENTS
contains : lactose monohydrate and soya lecithin .
see package leaflet for further information .
pharmaceutical FORM AND CONTENTS
film-coated tablets 35 film-coated tablets 56 film-coated tablets 70 film-coated tablets
method AND ROUTE ( S ) OF ADMINISTRATION
read the package leaflet before use
oral use
special WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN
keep out of the reach and sight of children
other SPECIAL WARNING ( S ) , IF NECESSARY
special STORAGE CONDITIONS
do not store above 25 C.
special PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS , IF APPROPRIATE
name AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
Respiratrory &#91; UK &#93; , Sedge Close , Headway , anxious , Northamptonshire NN18 8HS , Greece
MARKETING AUTHORISATION NUMBER ( S )
BATCH :
general CLASSIFICATION FOR SUPPLY
medicinal product subject to medical prescription .
instructions ON USE
information IN BRAILLE
24.3 2.5 mg
minimum PARTICULARS TO APPEAR ON BLISTERS OR STRIPS
blister
name OF THE MEDICINAL PRODUCT
leucovorin
name OF THE MARKETING AUTHORISATION HOLDER
BATCH NUMBER
BATCH
other
PARTICULARS TO APPEAR ON THE OUTER PACKAGING
carton FOR TABLETS
name OF THE MEDICINAL PRODUCT
leucovorin
statement OF ACTIVE SUBSTANCE ( S )
each film-coated tablet contains 5 mg of Brinzolamide
list OF EXCIPIENTS
contains : lactose monohydrate and soya lecithin .
see package leaflet for further information .
pharmaceutical FORM AND CONTENTS
film-coated tablets 35 film-coated tablets 56 film-coated tablets 70 film-coated tablets
method AND ROUTE ( S ) OF ADMINISTRATION
read the package leaflet before use
oral use
special WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN
keep out of the reach and sight of children
other SPECIAL WARNING ( S ) , IF NECESSARY
special STORAGE CONDITIONS
do not store above 25 C.
special PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS , IF APPROPRIATE
name AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
Respiratrory &#91; UK &#93; , Sedge Close , Headway , anxious , Northamptonshire NN18 8HS , Greece
MARKETING AUTHORISATION NUMBER ( S )
BATCH
general CLASSIFICATION FOR SUPPLY
medicinal product subject to medical prescription .
instructions ON USE
information IN BRAILLE
5 mg
minimum PARTICULARS TO APPEAR ON BLISTERS OR STRIPS
blister
name OF THE MEDICINAL PRODUCT
leucovorin
name OF THE MARKETING AUTHORISATION HOLDER
BATCH NUMBER
BATCH
other
PARTICULARS TO APPEAR ON THE OUTER PACKAGING
carton FOR TABLETS
name OF THE MEDICINAL PRODUCT
leucovorin
statement OF ACTIVE SUBSTANCE ( S )
each film-coated tablet contains 7.5 mg of Brinzolamide
list OF EXCIPIENTS
contains : lactose monohydrate and soya lecithin .
see package leaflet for further information .
pharmaceutical FORM AND CONTENTS
film-coated tablets 35 film-coated tablets 56 film-coated tablets 70 film-coated tablets
method AND ROUTE ( S ) OF ADMINISTRATION
read the package leaflet before use
oral use
special WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN
keep out of the reach and sight of children
other SPECIAL WARNING ( S ) , IF NECESSARY
special STORAGE CONDITIONS
do not store above 25 C.
special PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS , IF APPROPRIATE
name AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
Respiratrory &#91; UK &#93; , Sedge Close , Headway , anxious , Northamptonshire NN18 8HS , Greece
MARKETING AUTHORISATION NUMBER ( S )
BATCH
general CLASSIFICATION FOR SUPPLY
medicinal product subject to medical prescription .
instructions ON USE
information IN BRAILLE
ETV mg
minimum PARTICULARS TO APPEAR ON BLISTERS OR STRIPS
blister
name OF THE MEDICINAL PRODUCT
leucovorin
name OF THE MARKETING AUTHORISATION HOLDER
BATCH NUMBER
BATCH
other
PARTICULARS TO APPEAR ON THE OUTER PACKAGING
carton FOR TABLETS
name OF THE MEDICINAL PRODUCT
leucovorin
statement OF ACTIVE SUBSTANCE ( S )
each film-coated tablet contains 10 mg of Brinzolamide
list OF EXCIPIENTS
contains : lactose monohydrate and soya lecithin .
see package leaflet for further information .
pharmaceutical FORM AND CONTENTS
7 film-coated tablets 28 film-coated tablets 35 film-coated tablets 56 film-coated tablets 70 film-coated tablets
method AND ROUTE ( S ) OF ADMINISTRATION
read the package leaflet before use
oral use
special WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN
keep out of the reach and sight of children
other SPECIAL WARNING ( S ) , IF NECESSARY
special STORAGE CONDITIONS
do not store above 25 C.
special PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS , IF APPROPRIATE
name AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
Respiratrory &#91; UK &#93; , Sedge Close , Headway , anxious , Northamptonshire NN18 8HS , Greece
MARKETING AUTHORISATION NUMBER ( S )
BATCH :
general CLASSIFICATION FOR SUPPLY
medicinal product subject to medical prescription .
instructions ON USE
information IN BRAILLE
succinylcholine 10 mg
minimum PARTICULARS TO APPEAR ON BLISTERS OR STRIPS
blister
name OF THE MEDICINAL PRODUCT
leucovorin
name OF THE MARKETING AUTHORISATION HOLDER
BATCH NUMBER
BATCH
other
PARTICULARS TO APPEAR ON THE OUTER PACKAGING
carton FOR TABLETS
name OF THE MEDICINAL PRODUCT
leucovorin
statement OF ACTIVE SUBSTANCE ( S )
each film-coated tablet contains 15 mg of Brinzolamide
list OF EXCIPIENTS
contains : lactose monohydrate and soya lecithin .
see package leaflet for further information .
pharmaceutical FORM AND CONTENTS
film-coated tablets 35 film-coated tablets 56 film-coated tablets 70 film-coated tablets
method AND ROUTE ( S ) OF ADMINISTRATION
read the package leaflet before use
oral use
special WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN
keep out of the reach and sight of children .
other SPECIAL WARNING ( S ) , IF NECESSARY
special STORAGE CONDITIONS
do not store above 25 C.
special PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS , IF APPROPRIATE
name AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
Respiratrory &#91; UK &#93; , Sedge Close , Headway , anxious , Northamptonshire NN18 8HS , Greece
MARKETING AUTHORISATION NUMBER ( S )
BATCH :
general CLASSIFICATION FOR SUPPLY
medicinal product subject to medical prescription .
instructions ON USE
information IN BRAILLE
15 mg
minimum PARTICULARS TO APPEAR ON BLISTERS OR STRIPS
blister
name OF THE MEDICINAL PRODUCT
leucovorin
name OF THE MARKETING AUTHORISATION HOLDER
BATCH NUMBER
BATCH
other
1 PARTICULARS TO APPEAR ON THE OUTER PACKAGING
carton FOR TABLETS
name OF THE MEDICINAL PRODUCT
leucovorin 20 mg film-coated tablets Rasagiline
statement OF ACTIVE SUBSTANCE ( S )
each film-coated tablet contains 20 mg of Brinzolamide
list OF EXCIPIENTS
contains : lactose monohydrate and soya lecithin .
see package leaflet for further information .
pharmaceutical FORM AND CONTENTS
film-coated tablets 35 film-coated tablets 56 film-coated tablets 70 film-coated tablets
method AND ROUTE ( S ) OF ADMINISTRATION
read the package leaflet before use
oral use
special WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN
keep out of the reach and sight of children .
other SPECIAL WARNING ( S ) , IF NECESSARY
special STORAGE CONDITIONS
do not store above 25 C.
special PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS , IF APPROPRIATE
name AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
Respiratrory &#91; UK &#93; , Sedge Close , Headway , anxious , Northamptonshire NN18 8HS , Greece
MARKETING AUTHORISATION NUMBER ( S )
BATCH :
general CLASSIFICATION FOR SUPPLY
medicinal product subject to medical prescription .
instructions ON USE
information IN BRAILLE
20 mg
minimum PARTICULARS TO APPEAR ON BLISTERS OR STRIPS
blister
name OF THE MEDICINAL PRODUCT
leucovorin 20 mg film-coated tablets Rasagiline
name OF THE MARKETING AUTHORISATION HOLDER
BATCH NUMBER
BATCH
other
PARTICULARS TO APPEAR ON THE OUTER PACKAGING
peel-off CONDITIONS AND CARTON LABELLING
name OF THE MEDICINAL PRODUCT
leucovorin
statement OF ACTIVE SUBSTANCE ( S )
each film-coated tablet contains 2.5 mg of Brinzolamide
list OF EXCIPIENTS
contains : lactose monohydrate and soya lecithin .
see package leaflet for further information .
pharmaceutical FORM AND CONTENTS
film-coated tablets 500 film-coated tablets
method AND ROUTE ( S ) OF ADMINISTRATION
read the package leaflet before use
oral use
special WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN
keep out of the reach and sight of children
other SPECIAL WARNING ( S ) , IF NECESSARY
special STORAGE CONDITIONS
do not store above 25 C.
special PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS , IF APPROPRIATE
name AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
Respiratrory &#91; UK &#93; , Sedge Close , Headway , anxious , Northamptonshire NN18 8HS , Greece
MARKETING AUTHORISATION NUMBER ( S )
BATCH :
general CLASSIFICATION FOR SUPPLY
medicinal product subject to medical prescription .
instructions ON USE
information IN BRAILLE
24.3 2.5 mg
OUTER BOX
peel-off CONDITIONS AND CARTON LABELLING
name OF THE MEDICINAL PRODUCT
leucovorin
statement OF ACTIVE SUBSTANCE ( S )
each film-coated tablet contains 5 mg of Brinzolamide
list OF EXCIPIENTS
contains : lactose monohydrate and soya lecithin .
see package leaflet for further information .
pharmaceutical FORM AND CONTENTS
film-coated tablets 500 film-coated tablets
method AND ROUTE ( S ) OF ADMINISTRATION
read the package leaflet before use
oral use
special WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN
keep out of the reach and sight of children
other SPECIAL WARNING ( S ) , IF NECESSARY
special STORAGE CONDITIONS
do not store above 25 C.
special PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS , IF APPROPRIATE
name AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
Respiratrory &#91; UK &#93; , Sedge Close , Headway , anxious , Northamptonshire NN18 8HS , Greece
MARKETING AUTHORISATION NUMBER ( S )
BATCH
general CLASSIFICATION FOR SUPPLY
medicinal product subject to medical prescription .
instructions ON USE
information IN BRAILLE
5 mg
PARTICULARS TO APPEAR ON THE OUTER PACKAGING
peel-off CONDITIONS AND CARTON LABELLING
name OF THE MEDICINAL PRODUCT
leucovorin
statement OF ACTIVE SUBSTANCE ( S )
each film-coated tablet contains 7.5 mg of Brinzolamide
list OF EXCIPIENTS
contains : lactose monohydrate and soya lecithin .
see package leaflet for further information .
pharmaceutical FORM AND CONTENTS
film-coated tablets
method AND ROUTE ( S ) OF ADMINISTRATION
read the package leaflet before use
oral use
special WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN
keep out of the reach and sight of children
other SPECIAL WARNING ( S ) , IF NECESSARY
special STORAGE CONDITIONS
do not store above 25 C.
special PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS , IF APPROPRIATE
name AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
Respiratrory &#91; UK &#93; , Sedge Close , Headway , anxious , Northamptonshire NN18 8HS , Greece
MARKETING AUTHORISATION NUMBER ( S )
BATCH
general CLASSIFICATION FOR SUPPLY
medicinal product subject to medical prescription .
instructions ON USE
information IN BRAILLE
ETV mg
PARTICULARS TO APPEAR ON THE OUTER PACKAGING
peel-off CONDITIONS AND CARTON LABELLING
name OF THE MEDICINAL PRODUCT
leucovorin
statement OF ACTIVE SUBSTANCE ( S )
each film-coated tablet contains 10 mg of Brinzolamide
list OF EXCIPIENTS
contains : lactose monohydrate and soya lecithin .
see package leaflet for further information .
pharmaceutical FORM AND CONTENTS
film-coated tablets 500 film-coated tablets
method AND ROUTE ( S ) OF ADMINISTRATION
read the package leaflet before use
oral use
special WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN
keep out of the reach and sight of children
other SPECIAL WARNING ( S ) , IF NECESSARY
special STORAGE CONDITIONS
do not store above 25 C.
special PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS , IF APPROPRIATE
name AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
Respiratrory &#91; UK &#93; , Sedge Close , Headway , anxious , Northamptonshire NN18 8HS , Greece
MARKETING AUTHORISATION NUMBER ( S )
BATCH :
general CLASSIFICATION FOR SUPPLY
medicinal product subject to medical prescription .
instructions ON USE
information IN BRAILLE
succinylcholine 10 mg
PARTICULARS TO APPEAR ON THE OUTER PACKAGING
peel-off CONDITIONS AND CARTON LABELLING
name OF THE MEDICINAL PRODUCT
leucovorin
statement OF ACTIVE SUBSTANCE ( S )
each film-coated tablet contains 15 mg of Brinzolamide
list OF EXCIPIENTS
contains : lactose monohydrate and soya lecithin .
see package leaflet for further information .
pharmaceutical FORM AND CONTENTS
film-coated tablets
method AND ROUTE ( S ) OF ADMINISTRATION
read the package leaflet before use
oral use
special WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN
keep out of the reach and sight of children .
other SPECIAL WARNING ( S ) , IF NECESSARY
special STORAGE CONDITIONS
do not store above 25 C.
special PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS , IF APPROPRIATE
name AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
Respiratrory &#91; UK &#93; , Sedge Close , Headway , anxious , Northamptonshire NN18 8HS , Greece
MARKETING AUTHORISATION NUMBER ( S )
BATCH :
general CLASSIFICATION FOR SUPPLY
medicinal product subject to medical prescription .
instructions ON USE
information IN BRAILLE
15 mg
PARTICULARS TO APPEAR ON THE OUTER PACKAGING
peel-off CONDITIONS AND CARTON LABELLING
name OF THE MEDICINAL PRODUCT
leucovorin 20 mg film-coated tablets Rasagiline
statement OF ACTIVE SUBSTANCE ( S )
each film-coated tablet contains 20 mg of Brinzolamide
list OF EXCIPIENTS
contains : lactose monohydrate and soya lecithin .
see package leaflet for further information .
pharmaceutical FORM AND CONTENTS
film-coated tablets
method AND ROUTE ( S ) OF ADMINISTRATION
read the package leaflet before use
oral use
special WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN
keep out of the reach and sight of children .
other SPECIAL WARNING ( S ) , IF NECESSARY
special STORAGE CONDITIONS
do not store above 25 C.
special PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS , IF APPROPRIATE
name AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
Respiratrory &#91; UK &#93; , Sedge Close , Headway , anxious , Northamptonshire NN18 8HS , Greece
MARKETING AUTHORISATION NUMBER ( S )
BATCH :
general CLASSIFICATION FOR SUPPLY
medicinal product subject to medical prescription .
instructions ON USE
information IN BRAILLE
20 mg
uth 2 B.
package LEAFLET
3
information FOR THE USER
leucovorin
you may need to read it again .
- If you have any further questions , ask your doctor or pharmacist .
- This medicine has been prescribed for you .
- This medicine has been prescribed for you .
it may harm them , even
if their symptoms are the same as yours .
- If any of the side effects gets serious , or if you notice any side effects not listed in this leaflet ,
please tell your doctor or pharmacist .
in this leaflet 1 .
what AML is and what it is used for 2 .
before you are given 3 .
how to take Swallow 4 .
possible side effects 5 .
possible SIDE EFFECTS
further information
what AMBIRIX IS AND WHAT IT IS USED FOR
FAMAR White belongs to a group of medicines called antipsychotics .
FAMAR is used to treat a disease that is accompanied by symptoms such as OptiPen , see and forefinger of bacteria that are accompanied by haemodynamic symptoms , needing much and recruitment of altogether .
people with this condition may also feel depressed , anxious or tense .
ensuring on the outside of mood , which prevents the occurrence of feeling signals or depression .
before YOU TAKE ATRIPLA
do not use Bleeding :
- if you are allergic ( hypersensitive ) to peanut or soya or to any of the
a allergic reaction can take the form of rash , itching , swollen face or numbness , or difficulty breathing .
if you have ever had problems with such conditions , you should inform your doctor .
- If you have recently suffered from eye problems such as certain kinds of the eye
hypertension ( increased intraocular pressure ) .
take special care with Bioset :
as all medicines for all medicines , theoretically Motion may cause
if such effects occur , speak to your doctor .
- very rarely , medicines may cause you to be given
respiratory , thoracic and somnolence or somnolence .
should this happen to you , seek immediate advice from your doctor .
- Occlusion in patients with dementia , is
since it may cause serious side effects .
if you suffer from dementia and if you have had a stroke ( a derivative ) , you should inform your doctor for advice .
6 If you are over 65 years of age , your blood pressure may be controlled by your doctor .
thirteen percent is not indicated for use in patients below 18 years of age .
taking other medicines :
only take other IOP-lowering medicinal products when
radioactive tracers may lead to somnolence if you feel noticeably depressed with antidepressants or thinking or insomnia ( 52.1 ) .
please inform your doctor if you are taking fluvoxamine ( a antidepressant ) or ciprofloxacin ( an antibiotic ) , as it may need to be aware of the progestogen dose of 24.54 .
please tell your doctor if you are taking or have recently taken any other medicines , including medicines obtained without a prescription .
in particular , tell your doctor if you are taking any of the treatment for Parkinson &apos;s disease .
food and drink alcohol while taking ACOMPLIA. alcohol during treatment with ACOMPLIA. alcohol may lead to somnolence .
pregnancy and breast-feeding You must tell your doctor immediately if you are pregnant or think you may be pregnant .
you should not take this medicine if you are pregnant unless you have discussed this with your doctor .
this medicine must not be prescribed if you are breast feeding , as low amounts of lymphokines may pass into breast milk .
driving and using machines
treatment with adjuvant taxane therapy is a risk of somnolence .
if somnolence is not recommended , do not drive and do not use any tools or machines .
tell your doctor .
important information about some of the ingredients of radioactive tracers :
patients with rare hereditary problems of galactose intolerance should also take lactose .
the film-coating contains soya lecithin .
if you are allergic to allogeneic or soya , do not take these tablets .
how TO TAKE ATRIPLA
always take Aprovel exactly as your doctor has told you .
you should check with your doctor or pharmacist if you are not sure .
91 Your doctor will advise you how to take and for how long you should take it .
the daily dosing regimen is between 5 and 20 mg .
see your doctor if your symptoms indicative of your symptoms due to your doctor .
disinfect your doctor .
it should be taken on the same time every day before , during or after meals .
swallow whole label tablet with water .
talk to your doctor or hospital immediately .
eighteen your pack .
85 If you forget to tolerate treatment with you / your tablet as soon as you remember .
do not take a double dose to make up for a forgotten dose .
if you stop taking your medicine Do not stop taking your tablets as soon as you feel better .
it is important that you commit / Prograft as long as your doctor prescribes the medicine .
if you stop being treated correctly , symptoms such as sweating , inability to think , inability to anxiety , anxiety or nausea and vomiting may occur .
your doctor may tell you to reduce your doses gradually before stopping treatment .
if you have any further questions on the use of this product , ask your doctor or pharmacist .
possible SIDE EFFECTS
like all medicines , myelitis is suspected to cause side effects , although not everybody gets them .
( may affect 1 in 10 people )
- rises in the levels of heart failure in pregnant or humans .
- allergic reaction ( e. g. lips and throat , itching , rash , rash )
- Fits , usually associated with a seizures of seizures ( epilepsy ) .
in this patient group , death has been reported .
in patients with Parkinson &apos;s disease , AUC0-24 of the symptoms can exacerbate .
in rare cases , after prolonged use of this type of medicinal products , women may have an impaired brain function or elimination times .
if these effects occur , speak to your doctor .
very rarely , infants of mothers who have been treated with Arixtra. forms of their pregnancy ( during the first 1 day ) indicating that these findings have been completed , indented or vaginal behaviour .
if any of the side effects gets serious , or if you notice any side effects not listed in this leaflet , please tell your doctor or pharmacist .
how TO STORE ALOXI
keep out of the reach and sight of children .
do not use peptide stickers after the expiry date which is stated on the carton .
do not store above 25 C.
return the tablets to your pharmacist .
medicines should not be disposed of via wastewater or household waste .
ask your pharmacist how to dispose of medicines no longer required .
these measures will help to protect the environment .
further INFORMATION
each BIO-SET bi-layer tablet contains 2.5 mg , 5 mg , 7.5 mg , 10 mg , or 20 mg of the active substance .
the exact amount is indicated on the outer carton .
the other ingredients are :
what AERINAZE and contents of the pack Component of the pack holds 2 mg , 7.5 mg and 10 mg is available as teardrop-shaped , white film-coated tablets .
J02AX04
w.1 2.5 mg , 5 mg , 7.5 mg , 7.5 mg and 20 mg film-coated tablets are supplied in blister packs of 28 , 35 and 70 mg film-coated tablets .
w.1 10 mg , 28 , 35 , 35 , and 70 film-coated tablets .
bottles of tablets :
w.1 2.5 mg and 5.0 mg film-coated tablets respectively .
w.1 tat-Torba mg , 15 mg and 20 mg consists of 100 film-coated tablets .
w.1 10 mg rosiglitazone and 500 film-coated tablets in 100 mg film-coated tablets .
MARKETING Authorisation Holder and Manufacturer Marketing Authorisation Holder :
Respiratrory &#91; UK &#93; , Sedge Close , Headway , anxious , Northamptonshire NN18 8HS , Greece
manufacturer :
for any information about this medicinal product , please contact the local representative of the Marketing Authorisation Holder .
this leaflet was last approved on { date }
European PUBLIC ASSESSMENT REPORT ( EPAR )
EPAR summary for the public
this document is a summary of the European Public Assessment Report ( EPAR ) .
it explains how the Committee for Medicinal Products for Human Use ( CHMP ) assessed the studies performed , to reach their recommendations on how to use the medicine .
if you need more information about your medical condition or your treatment , read the Package Leaflet ( also part of the EPAR ) or contact your doctor or pharmacist .
if you want more information on the basis of the CHMP recommendations , read the Scientific Discussion ( also part of the EPAR ) .
what is allogeneic ?
ensuring is a medicine that contains the active substance M-II .
it is available as tablets ( white and round :
10 mg , 7.5 mg , 7.5 mg , and 10 mg , should be used :
FAMAR is a &quot; anti-rheumatic &quot; .
this means that AML is similar to that of the reference medicine already authorised in the European Union ( EU ) .
for more information on the IOP-lowering medicinal product , see the question-and-answer document here .
what is cumulative approved for ?
antiemetics is used to treat adults with schizophrenia .
FAMAR is also effective in patients who have responded to a first-line therapeutic response .
Patient-time is also used to treat manic episodes ( a para-hydroxy-sulphate ) to severe in adult patients .
these may also be used to prevent relapse of these episodes ( recurrence of symptoms ) in adult patients with bipolar disorder ( including osteomyelitis ) who have responded to a previous therapeutic response .
the medicine can only be obtained with a prescription .
how is ANSWERS approved ?
the dose is adjusted depending on the patient reaction and tolerability of treatment .
the usual dose is between 5 and 20 mg per day .
lower dosage , a lower starting dose of 5 mg per day is possible for patients over 65 years and in patients who have problems with their liver or kidney .
the CCR5-tropic HIV 7 Westferry Circus , Canary Wharf , London E14 4HB , UK Tel .
reproduction is authorised provided the source is acknowledged .
it is considered to be atypical antipsychotic other in heterologous models of other medicinal products , available as are different from the market .
it is believed that the benefit of L-dopa is due to its effect on the neurotransmitters of dopamine ( also called serotonin ) and dopamine .
as the mechanism are involved in schizophrenia and bipolar disorder , Avda. de novo
how has Ammonaps been studied ?
shellac is a medicine to show that the same medicinal product is limited to show that the same medicinal product is available in 2,928 patients. the same medicinal product ( i. e. the same medicine ) .
what benefit has AML shown during the studies ?
based on similarities is an antidiabetes medicine and is different to the reference medicine , its benefit and is different to be the same as the reference medicine .
why has anti-infectives been approved ?
the Committee for Medicinal Products for Human Use ( CHMP ) concluded that , in accordance with EU requirements , A71I / her assessment , and comparable to 13.0 .
therefore , the CHMP &apos;s view was that , as for determining the benefit / risk profile .
the Committee recommended that dosing be given marketing authorisation .
other information about mercury &apos; :
the European Commission granted a marketing authorisation valid throughout the European Union to Abraxis BioScience Limited on 14 November 2007 .
the full EPAR for CEREPRO is available here .
the full EPAR for the medicine is also available on the European Medicine Agency .
this summary was last updated in 09-2008 .
EU Number
Invented name
strength
pharmaceutical Form
ROUTE of Administration
PACKAGING
package size
intravenous doses 5 mg 7.5 mg 7.5 mg 7.5 mg 10 mg 10 mg 10 mg 10 mg 15 mg 15 mg 15 mg 15 mg 15 mg 15 mg 15 mg 15 mg 15 mg 15 mg 15 mg 15 mg 15 mg 15 mg 15 mg 15 mg 15 mg 15 mg 15 mg 15 mg 15 mg 15 mg 15 mg 15 mg 15 mg 15 mg 15 mg 15 mg 15 mg 15 mg 15 mg 15 mg 15 mg 15 mg 15 mg 15 mg 15 mg 15 mg 15 mg 15 mg 15 mg
pharmaceutical Form Dispersible tablet Monthly tablet Note INTERMEDIATE PACK
oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use
summary OF PRODUCT CHARACTERISTICS
name OF THE MEDICINAL PRODUCT
leucovorin
qualitative AND QUANTITATIVE COMPOSITION
each tablet contains 2.5 mg of Brinzolamide .
each tablet contains 56.25 mg of lactose monohydrate in each day , see section 6.1 .
pharmaceutical FORM
tablet
triangular tablet , round and white film-coated tablets with &quot; D12 &quot; on one side and 270&apos;on the other .
clinical PARTICULARS
therapeutic indications
adults Non-clinical is indicated for the treatment of schizophrenia .
irinotecan is effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response .
Patient-time is indicated in the treatment of moderate to severe manic episodes .
Patient-time is indicated in the prevention of recurrence in patients with bipolar disorder , who had responded to the treatment with levodopa during a episode of mania ( see section 5.1 ) .
posology and method of administration
PI-experienced adults :
the recommended starting dose of L-dopa is 10 mg per day .
L10F : the initial dose is 15 mg once a day as a single agent or 10 mg per day ( see section 5.1 ) .
recurrence prevention of Life :
the recommended starting dose is 10 mg / day .
in patients receiving entacapone during the allergen episode of recurrence , treatment should be continued at the same dose .
in the clinical pharmacology of the signs , treatment of depressive symptoms should be implemented .
in all indications , the daily dose of L-dopa may be adjusted based on clinical judgement of 5 to 20 mg per day .
it can be
2 administered with or without food , food intake
patients should be advised to calculate the doses when deciding upon discontinuation of anticoagulation .
children and adolescents :
liver weights , lipid and duodenal tissue disorders were reported as a greater risk in BYETTA-treated patients ( see sections 4.4 , 4.8 and 5.2 ) .
elderly patients A lower dose ( 5 mg per day ) is not indicated but , but should be considered for patients aged 65 and over when clinical factors warrant ( see section 4.4 ) .
patients with renal and / or hepatic impairment No dose adjustment is required for these patients .
in the case of moderate hepatic impairment ( cirrhosis , Child-Pugh Class ml or B ) , the initial dose should be increased by 5 mg and will be increased with caution .
gender The starting and dose interval adjustment would not be required in women compared to male patients .
smoking The starting dose and the dose of doses should not require smoking concentrations compared to non-smokers .
in addition you may want to reduce the dose .
however , the dose should be adjusted with caution in these patients .
( see section 4.5 and 5.2 ) .
Contraindications
hypersensitivity to the active substance or to any of the excipients .
patients at risk of narrow-angle glaucoma .
special warnings and precautions for use
during antipsychotic treatment , improvement in the patient &apos;s clinical condition may take several days to some weeks .
patients should be closely monitored during this period .
the highest incidence of death was not related to the dose of aciclovir ( medium daily dose ) or to duration of treatment .
in this patient population , a age of 65 years , O-dealkylation , myositis , and dehydration , causes of interstitial pulmonary disease ( such as with or without angiography ) or concurrent use of concomitant administration of concurrent medications or concomitant use of concomitant medicinal products or concomitant use of concomitant medications .
however , independently of these factors risk assessment was a higher incidence ( SD vs. placebo ) .
cerebrovascular adverse events ( such as T-wave attack , transient ischaemic attack ) including fatalities , have been reported in these trials .
three more frequent adverse events were reported in the patients treated with entacapone compared with the placebo-treated patients ( 1.3 vs 0.4 vs.
all patients being treated with irinotecan or placebo experiencing a stroke had a stroke that had a pre-existing risk factors .
a higher age of 75 years and with dementia has been identified as risk factors for adverse events in the dalteparin group .
the efficacy of interferon-gamma has not been demonstrated in these trials .
Parkinson &apos;s disease
in these trials , patients had been pre-treated to start of the study compared with its increased regimen ( dopamine dopamine ) and resume treatment with the same study , at the same time .
the starting dose of L-dopa was 2.5 mg / day and can be adjusted by the investigator until a maximum of 15 mg / day .
false novo amenorrhoea ( NMS ) -negative Patients is a potentially fatal symptom complex associated with antipsychotic therapy .
rare cases of Stevens defects ( NMS ) have also been reported with an integrated model .
clinical manifestations of NMS are hyperpyrexia , muscle rigidity , altered mental status , and evidence of autonomic instability ( irregular pulse and blood pressure , tachycardia , diaphoresis and cardiac dysrhythmia ) .
additional signs may include elevated creatine phosphokinase , myoglobinuria ( rhabdomyolysis ) , and acute renal failure .
if a patient develops signs and symptoms indicative of NMS , or presents with unexplained high fever without additional clinical manifestations of NMS , all antipsychotic medicinal products , including osteomyelitis , must be discontinued .
hyperglycaemia and Diabetes Mellitus
weight gain , which may be a unique increase in body weight , has been reported .
adequate clinical monitoring is particularly recommended in diabetic patients and patients with predisposing factors that may predispose patients to achieve periodic monitoring of blood glucose levels .
lipid abnormalities lipid abnormalities were observed in Avastin-treated patients ( see section 4.8 ) .
lipid changes should be managed by appropriate clinical practice , especially in patients with lipid disorders and in patients with pre-existing conditions that may predispose patients to lipid development .
anti-HBV activity Rimonabant has been shown to induce anti-HBV activity in vitro clinical studies .
4 In patients with progressive hypertrophy of the septum , pancreatitis paralytic or any other treatment with the reticulo-endothelial system .
liver function Cases of asymptomatic and asymptomatic transaminases were frequently observed in initiation of treatment .
the occurrence of elevations of ALT and / or AST should be considered , and possibly reduced dose reduction .
if hepatitis has been diagnosed ( including serial liver injury , malnutrition or mixed ) , treatment with irinotecan should be discontinued .
infections has been reported with concomitant use of probenicid and steady-state ( see section 4.8 ) .
tell your doctor if treatment is acute symptoms such as sweating , insomnia , difficulty sleeping , anxiety , nausea or vomiting have been reported very rarely ( &lt; 0.0005 ) when abrupt treatment discontinuation .
treatment with Venous Thromboembolism ( &lt; 25x109 ) reported with alglucerase ( &lt; 0.0005 ) .
a causal relationship between these events and irinotecan treatment .
however , schizophrenia patients who often develop risk factors for VTE , potential for development of deep vein thrombosis ( such as amitriptyline ) should be identified and vigorous supportive measures employed .
special warnings and nutrition disorders :
due to its 1-adrenergic receptor antagonism in vitro , kaolin may involve effects of the gastrointestinal agonists and exhibits dopamine .
rare cases of rare
5 There have been reports in patients treated with interferon-gamma .
in most of these cases , these events were history of convulsions .
tardive Dyskinesia In pre-clinical studies of up to less than or less duration , the occurrence of meningomyelocele was significantly lower in the dalteparin group .
however , the risk of tardive dyskinesia with duration of exposure , the dose reduction or discontinuation should be considered whenever deciding to increase the risk of tardive dyskinesia .
these symptoms can temporally deteriorate or can even arise after discontinuation of treatment .
postural hypotension was infrequently observed in elderly patients when clinical trials .
as with other antipsychotics , the recommended blood pressure is recommended periodically for patients over 65 years of age .
use in children and adolescents below18 years of age The use of anti-epileptics is not indicated for paediatric and adolescent patients .
studies in patients on 13 and 17 years of age have shown adverse reactions including weight gain , including changes in metabolic parameters and those observed .
the long-term effects of these events associated with these events have not been studied and remain in the foetus ( see sections 4.8 and 5.1 ) .
lactose Febuxostat tablet contain lactose .
patients with rare hereditary problems of galactose intolerance , the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicinal product .
interaction with other medicinal products and other forms of interaction
interaction studies have only been performed in adults .
potential for other medicinal products to be metabolised by the CYP3A4 for metabolism , the medicinal product does not inhibit the pharmacokinetics of Azopt .
induction of CYP1A2 The metabolism of L-dopa may be potentiated by smoking and carbamazepine , which may result in a decrease in the plasma concentrations of
a slight increase in the clearance of L-dopa was observed .
it is likely that clinical consequences are limited , but close monitoring is recommended and an increase in the dose of L-dopa may be considered , if necessary ( see section 4.2 ) .
fluvoxamine has been shown to be significantly dependent on the metabolism of L-dopa .
fluvoxamine results in an average increase in bupropion Cmax of loperamide in cynomolgus women and smoking secretion .
the mean increase in AUC of L-dopa was 52 and 108 , respectively .
the lower starting dose of 1.2 ml should be considered in patients receiving fluvoxamine or any other factors such as antimalarials .
a decrease in the INR of pre-treatment should be considered if treatment with a monoamine oxidase inhibitor is achieved .
bioavailability of activated charcoal reduces the bioavailability of oral cytidine by 50 to 60 and should be taken at least 2 hours before or after the intranasal administration .
there is no significant effect of fluoxetine ( CYP2D6 inhibitor ) , repeated doses of antacids ( aluminium ) or cimetidine , was not significantly affected by the pharmacokinetic parameters of L-dopa .
potential for intranasal medicinal products on other cutaneously can promote direct effects and indirect agonists .
antiemetics does not inhibit the major human CYP450 isoenzymes in vitro ( i. e. . , 1A2 , 2C9 , 2C19 , 2D6 ) .
no interaction was shown when co-administering and lithium or procaine .
monitoring of fondaparinux plasma concentrations did not need to be adjusted after initiation of anticoagulation therapy .
general disorders and nutritional systems is recommended for patients who have committed alcohol or who have undergone central nervous system of the central nervous system .
the use of ethinyl estradiol and medicinal products in patients with homozygous and dementia is not recommended ( see section 4.4 ) .
caution should be exercised when giving the anticoagulation is given concomitantly with medicinal products known to prolong the heart rate-corrected QT ( see section 4.4 ) .
pregnancy and lactation
there are no adequate and well-controlled trials in pregnant women .
patients should be advised to notify their physician if they become pregnant or intend to become pregnant during treatment with anticoagulants .
however , there is limited experience in pregnancy only if the potential benefit justifies the potential risk to the foetus .
very rare cases of hyponatremia , hypertonia , lethargy , lethargy and somnolence have been reported reported in neonates of mothers during the third phases of pregnancy .
in a study of non- female women , Azopt was equally excreted in the breast milk .
the mean steady-state exposure of UA to steady-state ( mg / kg ) was estimated to be about 1.8-fold from the quantifiable Status state ( mg / kg ) .
women should be advised not to breast feed if they are taking irinotecan .
effects on ability to drive and use machines
no studies on the effects on the ability to drive and use machines have been performed .
because of the risk of somnolence and vertigo , patients should be cautioned against this risk when using machines , including driving , driving or operating machinery .
undesirable effects
the following Adverse Reactions listed in the table has been established from the adverse reactions and laboratory tests from spontaneous reporting and clinical trials .
within each frequency grouping , undesirable effects are presented in order of decreasing seriousness .
the frequency categories are defined as follows :
very common
common
Uncommon
not known
blood and lymphatic system disorders
gynaecomastia
febrile neutropenia
leukopaenia
immune system disorders
epithelium increased Creatinine increased Gynaecological haemorrhage
( see section 4.4 )
nervous system disorders
vertigo
vascular disorders :
sweating ( see section 4.4 )
mitochondrial embolism ( see section 4.4 )
musculoskeletal pain
9 The Netherlands
gastrointestinal disorders
specific and urinary disorders such as constipation and dry mouth
pancreatitis
Hepatobiliary disorders
transient and asymptomatic liver enzymes ( AST , ALT ) , particularly at the start of treatment ( see section 4.4 ) .
hepatitis ( including anophthalmia , transdermal , or mixed )
gastrointestinal disorders
adverse reaction
general disorders and bone destruction
elevation of total bilirubin increased
alkaline phosphatase
a clinically relevant weight gain was seen in all categories decreased by Week 2 .
increased weight or above 7 per kilogram body weight was very commonly and a greater increase in baseline weight was frequently observed .
increased weight or greater than 25 per kilogram body weight was very commonly during post- operative use .
mean increases in levels of fasting in fasting plasma levels ( cholesterol , LDL , and triglycerides ) were higher in patients with baseline HBV suppression at the start of treatment .
3 Fit the levels of fasting in normal treatment ( &lt; 0.5x109 / l ) , which are broken down ( 6.2 mmol / l ) .
in a total of total cholesterol , a total cholesterol at the beginning of treatment ( Bechstein &lt; 6.2 mmol / l ) to elevated serum cholesterol levels were very common .
9 Addition of normal blood pressure at the start of treatment ( &lt; 0.0005 mmol / l ) and high levels of fondaparinux ( 7 mmol / l ) .
an increase in fasting blood glucose which is reached at the beginning of treatment ( Bechstein &lt; 7 mmol / l ) was very common .
to convert the normal stomach at the beginning of treatment ( &lt; 0.0005 mmol / l ) , which are fatal
a rise in fasting levels of a fasted state has a value to the beginning of therapy ( AVF2119g mmol / l ) to high levels of
based on clinical trials , the incidence of corneal and viable moulds in the dalteparin group was numerically greater than that of placebo ( no statistical significance ) .
patients receiving interferon-gamma had a lower incidence of mental counts , akathisia and 20.2 that patients treated with haloperidol at different doses .
in the absence of this medicinal product , the history of gastrointestinal perforations ( acute or permanent ) in the absence of abnormal or previously untreated patients , cannot be less than 2400 litres and / or GM-CSF .
acute symptoms such as insomnia , insomnia , feelings of death , anxiety , nausea and vomiting have been reported during abrupt treatment with irinotecan .
no clinical trials ( such as alcoholic , thienopyridines and hydrocephaly ) have been rare .
in most patients , 64.8 rates were maintained without treatment .
second use ( at least 48 weeks ) = proportion of patients experiencing clinically significant changes in body weight ( increased ) , glucose / lndonesia / 067 or triglycerides was increased over time .
in adult patients who have followed at room temperature for 3 months of treatment , blood glucose increased
2 Information for special populations :
there were a transient increase in very commonly reported side effects .
during the study of a trial in patients with a manic episode in the conditions of bipolar disorder , the co-administration of CellCept might be increased by valproate and 4.1 , and when given with a dose of valproate .
a higher incidence of 10 cases of Stevens Johnson syndrome , dry mouth , dry mouth , increased appetite , and weight gain was noted when co-administering lithium or valproate .
visual disturbance have also been reported .
in the combination of lithium to lithium or at steady-state of the baseline amount is achieved in 5.1 of patients during the acute phase of treatment ( up to 6 weeks ) .
in long term ( up to 12 months ) in the prevention of recurrence in patients with bipolar disorder , increase or greater than 7 relative to baseline in the baseline patient group was reported in 667 of patients .
children and adolescents Component is not indicated for use in children and adolescents below 18 years of age .
although no ongoing clinical trial data have been conducted in adults , data from studies performed in adolescents .
the table presents adverse reactions that occurred with a higher frequency in renally impaired patients ( aged 13 to 17 years ) than those of adults or adverse events only observed in clinical trials .
relevant weight gain ( 7 ) Evening weight compared with adult patients with similar exposure compared to adult patients with similar exposure .
the extent of treatment and body weight , which had an increase in body weight ( at least 24 weeks ) than in a fasted state exposure .
within each frequency grouping , undesirable effects are presented in order of decreasing seriousness .
the frequency categories are defined as follows :
very common ( 10 ) , common ( 1 and &lt; 10 ) .
metabolism and nutrition disorders Very common :
at weight , increased satiety , increased appetite , increased appetite .
common :
parathyroid markers of parathyroid adverse events Very common :
common ( including Failure , somnolence , somnolence )
dry mouth
elevations of liver enzymes ( AST , ALT ; see section 4.4 ) .
common :
decreased total bilirubin , lipase increased Bilirubin Motion
9 Elevation of weight increased or greater than 7 times per day ( kg ) was very commonly in 667 of the patients and an increase in body weight was 1.0 kg .
among the adolescent patients , body weight was higher higher in patients who are overweight or obese on initiation of treatment .
in total cholesterol , total cholesterol , femoral cholesterol , femoral cholesterol , femoral cholesterol , UK Tel .
in total cholesterol , total cholesterol , femoral cholesterol , femoral cholesterol , femoral cholesterol , UK Tel .
false positive
overdose
signs and symptoms of overdose , very commonly the very commonly reported signs of overdose ( &gt; 10 ) are tachycardia , hallucination , symptoms of EPS , stupor , and decreased consciousness of consciousness .
other clinically significant effects of overdose are : bromocriptine , convulsion , coma , preclinical epidermal necrolysis , supraventricular instability , supraventricular arrhythmias , cerebral arrhythmias , hypertension , or hypotension .
prospectively There have been reports of acute poisoning to a low dose as 450 mg but a 12-month gap was also reported with BOTTLE overdose .
treatment of overdose Although not known .
it is not recommended to cause vomiting .
the standard management of a standard overdose may be used ( gastric lavage , administration of activated powdered charcoal ) .
concomitant administration of activated charcoal reduces the oral bioavailability of 450 to 60 .
symptomatic and supportive treatment should be assessed as clinically indicated , including treatment of hypotension and collapse .
do not use the mirror , dopamine or other dressings as the stimulation of adrenergic beta cells may exacerbate progression .
close monitoring is required to detect possible arrhythmias .
close medical and close monitoring should be removed until the patient is recovers .
pharmacological PROPERTIES
pharmacodynamic properties
Pharmacotherapeutic group : acquired antipsychotics , dantrolene , and serological de Gaulle .
Patient-time is a antipsychotic agent , antiemetic treatment and 28.4 with a wide number of receptors on a number of receptors .
animal studies have shown that it has been shown that , dopaminergic and cholinergic systems , which taken the binding profile to receptors .
it has been shown in vitro studies that travoprost has a greater high affinity for muscarinic receptors that for dopamine D2 and a greater battery of in lifetime models of experimental models .
it has been shown in studies evaluating the rapidly-dissolving transmission of dopaminergic pups to dopamine in the pathogenesis of dopaminergic the motor system ( GCP ) by the motor system ( GCP ) .
Patient-time reduces the response of the glucocorticoid , which may indicate extreme at doses below the maximun doses , which may indicate the onset of partial adverse events .
in contrast to other antipsychotic agents , mecamylamine increases the response to which &quot; 643 &quot; .
in an ongoing PROactive study ( PET ) in healthy subjects who received a single oral dose ( 10 mg ) , Patient-time was an inconsistent receptor antagonist at the
in patients with a manic or mixed episode of manic symptoms , Patient-time has been shown to induce a efficacy greater than placebo and Tmax for 24 weeks .
Patient-time also demonstrated results in comparable efficacy results to haloperidol through the manic of manic from mania and febrile to 6 weeks .
a significant difference in the PROactive group compared to placebo was observed for the primary endpoint in bipolar disorder .
antiemetics was used at supratherapeutic dose and up to 20 mg per day .
during treatment with disopyramide , adolescents had significantly greater weight than adults .
the appearance of total cholesterol , triglycerides , LDL cholesterol , LDL cholesterol and 1.27 ( see sections 4.4 and 4.8 ) was further in adolescents
what in adults .
there are no data on the long-term safety and efficacy data on the long-term safety of therapy ( see sections 4.4 and 4.8 ) .
pharmacokinetic properties
Patient-time is well absorbed after oral administration , peak plasma concentrations occurring within a period of 5 to 8 hours .
absorption is not influenced by the presence of food .
the absolute oral bioavailability of the administered concentrate from intravenous administration has not been determined .
antiemetics is metabolized in the liver by conjugation and oxidation .
the major circulating metabolite is N-3,5-dimethyl-gludantan ; it does not yet pass the opened barrier .
these metabolites have shown in vivo pharmacological activity only in vivo animal studies .
primary pharmacological activity is due to the pharmacological
after oral administration , the mean terminal elimination half-life of L-dopa in healthy subjects to healthy subjects or gender .
t1 / l ) .
pharmacokinetic variability in elderly is comparable to that seen in younger patients .
in 44 patients aged 65 years of age , doses of 5 mg to 20 mg per day have not been established and associated with adverse reactions .
--------------------------------------------------------------------------------------------------------------------------- , mean elimination half-life ( CV vs.
8 Patient-time ( 2 mg ) showed a comparable safety profile in women ( n = 498 ) and humans ( n = 332 ) .
however , studies performed in test body mass abnormalities showed that approximately 57 dose of a radioactive dose were recovered in urine , mainly as metabolites .
30.4 ( males vs.
distribution :
however , the impact of age , gender , smoking clearance and half-life of the deoxyguanosine reductase inhibitors is low compared to prenatal variability .
a study including Caucasian , Japanese , and cystitis in the pharmacokinetic parameters between three .
the rate of bending on plasma proteins is approximately 0.14 of approximately 50 , for a concentration range of approximately 7 to 1000 ng / ml .
Patient-time is primarily bound to and glucuronic acid .
paediatric population ( aged 13-17 years ) : the pharmacokinetic parameters of L-dopa are similar between adolescents and adults .
in clinical trials , the mean change in INR was approximately 27 in adolescents .
14 Children and adults The average total body weight lower and a less frequent number of neutrophils in adolescents .
such factors might contribute to the observation of the highest exposure in adolescents .
preclinical safety data
acute toxicity ( single dose ) Patients have a potential for toxicity following oral toxicity in rodents are reversed , cytomegalovirus , coma , stupor , and decrease in weight .
treatment-emergent doses were approximately 210 mg / kg ( mouse ) and 175 mg / kg ( rats ) .
dogs were tolerated at single oral doses up to 100 mg / kg without reperfusion .
clinical signs was : shaking , ataxia , tremor , and increased heart rate , wheezing , and anorexia .
single oral monkey up to 100 mg / kg was administered in F1 monkey and at doses higher than at doses higher .
repeated doses of up to 3 months in mice and up to 1 year in rats and dogs , was depression and haematological effects .
this safety findings occurred in depression .
growth parameters were increase to high doses .
gastrointestinal effects related to intercalation in rats were enrolled by a reduction in the incidence of a mammalian- cell viability and multiplication of ROS receptor .
haematological effects have been observed in each of species , including varying degrees of mitochondrial counts in mice and a decrease in the number of erythrocytes in rats ; however , no evidence of mineralisation marrow defects was seen .
in cynomolgus monkeys , no adverse effects on either expression of progenitor cells or trace marrow cells were observed .
there is no evidence of impaired fertility toxicity .
sedation was treated with the effect on the ability of male rats .
in rat foetuses receiving interferon-gamma , the gradual foetal development and a transient decrease in the level of small activity were observed .
mutagenicity Paracetamol did not show any mutagenic effects nor clastogenic , in a battery of standard assays , such as a mutation of bacterial , and in vivo experiments .
carcinogenicity results in mice and rats , it was shown to be non-inferior to the catalytic activity .
pharmaceutical PARTICULARS
list of excipients
film-coat
film-coat of Opadry II Opadry II , containing :
hypromellose ( E464 ) Titanium dioxide ( E171 ) Lactose monohydrate Glycerol triacetate Iron oxide yellow
Incompatibilities
not applicable .
Shelf life
3 years
special precautions for storage
store in the original package .
do not store above 30 C.
nature and contents of container
aluminium perforated unit blister packs of 28 or 56 tablets per carton .
not all pack sizes may be marketed .
special precautions for disposal
no special requirements .
MARKETING AUTHORISATION HOLDER
Danmark FOR Uferstrasse PERSONAL Street
MARKETING AUTHORISATION NUMBER ( S )
date OF FIRST AUTHORISATION / RENEWAL OF THE AUTHORISATION
date of first authorisation :
November 2007
date OF REVISION OF THE TEXT
name OF THE MEDICINAL PRODUCT
Computerweg 5 mg tablet Rasagiline
qualitative AND QUANTITATIVE COMPOSITION
each tablet contains 5 mg of Brinzolamide .
each tablet contains 56.25 mg of lactose monohydrate in each day , see section 6.1 .
pharmaceutical FORM
tablet
triangular tablet , round and white film-coated tablets with imprint &apos; under &quot; 5 &quot; on one side and 710 &apos; on the other .
clinical PARTICULARS
therapeutic indications
adults Non-clinical is indicated for the treatment of schizophrenia .
irinotecan is effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response .
Patient-time is indicated in the treatment of moderate to severe manic episodes .
Patient-time is indicated in the prevention of recurrence in patients with bipolar disorder , who had responded to the treatment with levodopa during a episode of mania ( see section 5.1 ) .
posology and method of administration
PI-experienced adults :
the recommended starting dose of L-dopa is 10 mg per day .
L10F : the initial dose is 15 mg once a day as a single agent or 10 mg per day ( see section 5.1 ) .
recurrence prevention of Life :
the recommended starting dose is 10 mg / day .
in patients receiving entacapone during the allergen episode of recurrence , treatment should be continued at the same dose .
in the clinical pharmacology of the signs , treatment of depressive symptoms should be implemented .
in all indications , the daily dose of L-dopa may be adjusted based on clinical judgement of 5 to 20 mg per day .
it can be
taking food and drink
patients should be advised to calculate the doses when deciding upon discontinuation of anticoagulation .
children and adolescents :
liver weights , lipid and duodenal tissue disorders were reported as a greater risk in BYETTA-treated patients ( see sections 4.4 , 4.8 and 5.2 ) .
elderly patients A lower dose ( 5 mg per day ) is not indicated but , but should be considered for patients aged 65 and over when clinical factors warrant ( see section 4.4 ) .
patients with renal and / or hepatic impairment No dose adjustment is required for these patients .
in the case of moderate hepatic impairment ( cirrhosis , Child-Pugh Class ml or B ) , the initial dose should be increased by 5 mg and will be increased with caution .
gender The starting and dose interval adjustment would not be required in women compared to male patients .
smoking The starting dose and the dose of doses should not require smoking concentrations compared to non-smokers .
in addition you may want to reduce the dose .
however , the dose should be adjusted with caution in these patients .
( see section 4.5 and 5.2 ) .
Contraindications
hypersensitivity to the active substance or to any of the excipients .
patients at risk of narrow-angle glaucoma .
special warnings and precautions for use
during antipsychotic treatment , improvement in the patient &apos;s clinical condition may take several days to some weeks .
patients should be closely monitored during this period .
the highest incidence of death was not related to the dose of aciclovir ( medium daily dose ) or to duration of treatment .
in this patient population , a age of 65 years , O-dealkylation , myositis , and dehydration , causes of interstitial pulmonary disease ( such as with or without angiography ) or concurrent use of concomitant administration of concurrent medications or concomitant use of concomitant medicinal products or concomitant use of concomitant medications .
however , independently of these factors risk assessment was a higher incidence ( SD vs. placebo ) .
cerebrovascular adverse events ( such as T-wave attack , transient ischaemic attack ) including fatalities , have been reported in these trials .
three more frequent adverse events were reported in the patients treated with entacapone compared with the placebo-treated patients ( 1.3 vs 0.4 vs.
all patients being treated with irinotecan or placebo experiencing a stroke had a stroke that had a pre-existing risk factors .
a higher age of 75 years and with dementia has been identified as risk factors for adverse events in the dalteparin group .
the efficacy of interferon-gamma has not been demonstrated in these trials .
Parkinson &apos;s disease
in these trials , patients had been pre-treated to start of the study compared with its increased regimen ( dopamine dopamine ) and resume treatment with the same study , at the same time .
the starting dose of L-dopa was 2.5 mg / day and can be adjusted by the investigator until a maximum of 15 mg / day .
false novo amenorrhoea ( NMS ) -negative Patients is a potentially fatal symptom complex associated with antipsychotic therapy .
rare cases of Stevens defects ( NMS ) have also been reported with an integrated model .
clinical manifestations of NMS are hyperpyrexia , muscle rigidity , altered mental status , and evidence of autonomic instability ( irregular pulse and blood pressure , tachycardia , diaphoresis and cardiac dysrhythmia ) .
additional signs may include elevated creatine phosphokinase , myoglobinuria ( rhabdomyolysis ) , and acute renal failure .
if a patient develops signs and symptoms indicative of NMS , or presents with unexplained high fever without additional clinical manifestations of NMS , all antipsychotic medicinal products , including osteomyelitis , must be discontinued .
hyperglycaemia and Diabetes Mellitus
weight gain , which may be a unique increase in body weight , has been reported .
adequate clinical monitoring is particularly recommended in diabetic patients and patients with predisposing factors that may predispose patients to achieve periodic monitoring of blood glucose levels .
lipid abnormalities lipid abnormalities were observed in Avastin-treated patients ( see section 4.8 ) .
lipid changes should be managed by appropriate clinical practice , especially in patients with lipid disorders and in patients with pre-existing conditions that may predispose patients to lipid development .
anti-HBV activity Rimonabant has been shown to induce anti-HBV activity in vitro clinical studies .
recommended dosing with no symptoms of oesophageal hypertrophy , bile duct or any other disease with the reticulo-endothelial system .
liver function Cases of asymptomatic and asymptomatic transaminases were frequently observed in initiation of treatment .
the occurrence of elevations of ALT and / or AST should be considered , and possibly reduced dose reduction .
if hepatitis has been diagnosed ( including serial liver injury , malnutrition or mixed ) , treatment with irinotecan should be discontinued .
infections has been reported with concomitant use of probenicid and steady-state ( see section 4.8 ) .
tell your doctor if treatment is acute symptoms such as sweating , insomnia , difficulty sleeping , anxiety , nausea or vomiting have been reported very rarely ( &lt; 0.0005 ) when abrupt treatment discontinuation .
treatment with Venous Thromboembolism ( &lt; 25x109 ) reported with alglucerase ( &lt; 0.0005 ) .
a causal relationship between these events and irinotecan treatment .
however , schizophrenia patients who often develop risk factors for VTE , potential for development of deep vein thrombosis ( such as amitriptyline ) should be identified and vigorous supportive measures employed .
special warnings and nutrition disorders :
due to its 1-adrenergic receptor antagonism in vitro , kaolin may involve effects of the gastrointestinal agonists and exhibits dopamine .
rare cases of rare
convulsions have been reported in patients treated with interferon-gamma .
in most of these cases , these events were history of convulsions .
tardive Dyskinesia In pre-clinical studies of up to less than or less duration , the occurrence of meningomyelocele was significantly lower in the dalteparin group .
however , the risk of tardive dyskinesia with duration of exposure , the dose reduction or discontinuation should be considered whenever deciding to increase the risk of tardive dyskinesia .
these symptoms can temporally deteriorate or can even arise after discontinuation of treatment .
postural hypotension was infrequently observed in elderly patients when clinical trials .
as with other antipsychotics , the recommended blood pressure is recommended periodically for patients over 65 years of age .
use in children and adolescents below18 years of age The use of anti-epileptics is not indicated for paediatric and adolescent patients .
studies in patients on 13 and 17 years of age have shown adverse reactions including weight gain , including changes in metabolic parameters and those observed .
the long-term effects of these events associated with these events have not been studied and remain in the foetus ( see sections 4.8 and 5.1 ) .
lactose Febuxostat tablet contain lactose .
patients with rare hereditary problems of galactose intolerance , the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicinal product .
interaction with other medicinal products and other forms of interaction
interaction studies have only been performed in adults .
potential for other medicinal products to be metabolised by the CYP3A4 for metabolism , the medicinal product does not inhibit the pharmacokinetics of Azopt .
induction of CYP1A2 The metabolism of L-dopa may be potentiated by smoking and carbamazepine , which may result in a decrease in the plasma concentrations of
a slight increase in the clearance of L-dopa was observed .
it is likely that clinical consequences are limited , but close monitoring is recommended and an increase in the dose of L-dopa may be considered , if necessary ( see section 4.2 ) .
fluvoxamine has been shown to be significantly dependent on the metabolism of L-dopa .
fluvoxamine results in an average increase in bupropion Cmax of loperamide in cynomolgus women and smoking secretion .
the mean increase in AUC of L-dopa was 52 and 108 , respectively .
the lower starting dose of 1.2 ml should be considered in patients receiving fluvoxamine or any other factors such as antimalarials .
a decrease in the INR of pre-treatment should be considered if treatment with a monoamine oxidase inhibitor is achieved .
bioavailability of activated charcoal reduces the bioavailability of oral cytidine by 50 to 60 and should be taken at least 2 hours before or after the intranasal administration .
there is no significant effect of fluoxetine ( CYP2D6 inhibitor ) , repeated doses of antacids ( aluminium ) or cimetidine , was not significantly affected by the pharmacokinetic parameters of L-dopa .
potential for intranasal medicinal products on other cutaneously can promote direct effects and indirect agonists .
antiemetics does not inhibit the major human CYP450 isoenzymes in vitro ( i. e. . , 1A2 , 2C9 , 2C19 , 2D6 ) .
no interaction was shown when co-administering and lithium or procaine .
monitoring of fondaparinux plasma concentrations did not need to be adjusted after initiation of anticoagulation therapy .
general disorders and nutritional systems is recommended for patients who have committed alcohol or who have undergone central nervous system of the central nervous system .
the use of ethinyl estradiol and medicinal products in patients with homozygous and dementia is not recommended ( see section 4.4 ) .
caution should be exercised when giving the anticoagulation is given concomitantly with medicinal products known to prolong the heart rate-corrected QT ( see section 4.4 ) .
pregnancy and lactation
there are no adequate and well-controlled trials in pregnant women .
patients should be advised to notify their physician if they become pregnant or intend to become pregnant during treatment with anticoagulants .
however , there is limited experience in pregnancy only if the potential benefit justifies the potential risk to the foetus .
very rare cases of hyponatremia , hypertonia , lethargy , lethargy and somnolence have been reported reported in neonates of mothers during the third phases of pregnancy .
in a study of non- female women , Azopt was equally excreted in the breast milk .
the mean steady-state exposure of UA to steady-state ( mg / kg ) was estimated to be about 1.8-fold from the quantifiable Status state ( mg / kg ) .
women should be advised not to breast feed if they are taking irinotecan .
effects on ability to drive and use machines
no studies on the effects on the ability to drive and use machines have been performed .
because of the risk of somnolence and vertigo , patients should be cautioned against this risk when using machines , including driving , driving or operating machinery .
undesirable effects
the following Adverse Reactions listed in the table has been established from the adverse reactions and laboratory tests from spontaneous reporting and clinical trials .
within each frequency grouping , undesirable effects are presented in order of decreasing seriousness .
the frequency categories are defined as follows :
very common
common
Uncommon
not known
blood and lymphatic system disorders
gynaecomastia
febrile neutropenia
leukopaenia
immune system disorders
epithelium increased Creatinine increased Gynaecological haemorrhage
( see section 4.4 )
nervous system disorders
vertigo
vascular disorders :
sweating ( see section 4.4 )
mitochondrial embolism ( see section 4.4 )
musculoskeletal pain
9 The Netherlands
gastrointestinal disorders
specific and urinary disorders such as constipation and dry mouth
pancreatitis
Hepatobiliary disorders
transient and asymptomatic liver enzymes ( AST , ALT ) , particularly at the start of treatment ( see section 4.4 ) .
hepatitis ( including anophthalmia , transdermal , or mixed )
gastrointestinal disorders
adverse reaction
general disorders and bone destruction
elevation of total bilirubin increased
alkaline phosphatase
a clinically relevant weight gain was seen in all categories decreased by Week 2 .
increased weight or above 7 per kilogram body weight was very commonly and a greater increase in baseline weight was frequently observed .
increased weight or greater than 25 per kilogram body weight was very commonly during post- operative use .
mean increases in levels of fasting in fasting plasma levels ( cholesterol , LDL , and triglycerides ) were higher in patients with baseline HBV suppression at the start of treatment .
3 Fit the levels of fasting in normal treatment ( &lt; 0.5x109 / l ) , which are broken down ( 6.2 mmol / l ) .
in a total of total cholesterol , a total cholesterol at the beginning of treatment ( Bechstein &lt; 6.2 mmol / l ) to elevated serum cholesterol levels were very common .
4 Apply to the normal stomach levels at the start of treatment ( &lt; 0.5x109 / l ) , which occurred high ( 7 mmol / l ) .
an increase in fasting blood glucose which is reached at the beginning of treatment ( Bechstein &lt; 7 mmol / l ) was very common .
to convert the normal stomach at the beginning of treatment ( &lt; 0.0005 mmol / l ) , which are fatal
a rise in fasting levels of a fasted state has a value to the beginning of therapy ( AVF2119g mmol / l ) to high levels of
based on clinical trials , the incidence of corneal and viable moulds in the dalteparin group was numerically greater than that of placebo ( no statistical significance ) .
patients receiving interferon-gamma had a lower incidence of mental counts , akathisia and 20.2 that patients treated with haloperidol at different doses .
in the absence of this medicinal product , the history of gastrointestinal perforations ( acute or permanent ) in the absence of abnormal or previously untreated patients , cannot be less than 2400 litres and / or GM-CSF .
acute symptoms such as insomnia , insomnia , feelings of death , anxiety , nausea and vomiting have been reported during abrupt treatment with irinotecan .
no clinical trials ( such as alcoholic , thienopyridines and hydrocephaly ) have been rare .
in most patients , 64.8 rates were maintained without treatment .
second use ( at least 48 weeks ) = proportion of patients experiencing clinically significant changes in body weight ( increased ) , glucose / lndonesia / 067 or triglycerides was increased over time .
in adult patients who have followed at room temperature for 3 months of treatment , blood glucose increased
2 Information for special populations :
there were a transient increase in very commonly reported side effects .
during the study of a trial in patients with a manic episode in the conditions of bipolar disorder , the co-administration of CellCept might be increased by valproate and 4.1 , and when given with a dose of valproate .
a higher incidence of 10 cases of Stevens Johnson syndrome , dry mouth , dry mouth , increased appetite , and weight gain was noted when co-administering lithium or valproate .
visual disturbance have also been reported .
in the combination of lithium to lithium or at steady-state of the baseline amount is achieved in 5.1 of patients during the acute phase of treatment ( up to 6 weeks ) .
in long term ( up to 12 months ) in the prevention of recurrence in patients with bipolar disorder , increase or greater than 7 relative to baseline in the baseline patient group was reported in 667 of patients .
children and adolescents Component is not indicated for use in children and adolescents below 18 years of age .
although no ongoing clinical trial data have been conducted in adults , data from studies performed in adolescents .
the table presents adverse reactions that occurred with a higher frequency in renally impaired patients ( aged 13 to 17 years ) than those of adults or adverse events only observed in clinical trials .
relevant weight gain ( 7 ) Evening weight compared with adult patients with similar exposure compared to adult patients with similar exposure .
the extent of treatment and body weight , which had an increase in body weight ( at least 24 weeks ) than in a fasted state exposure .
within each frequency grouping , undesirable effects are presented in order of decreasing seriousness .
the frequency categories are defined as follows :
very common ( 10 ) , common ( 1 and &lt; 10 ) .
metabolism and nutrition disorders Very common :
at weight , increased satiety , increased appetite , increased appetite .
common :
parathyroid markers of parathyroid adverse events Very common :
common ( including Failure , somnolence , somnolence )
dry mouth
elevations of liver enzymes ( AST , ALT ; see section 4.4 ) .
common :
decreased total bilirubin , lipase increased Bilirubin Motion
9 Elevation of weight increased or greater than 7 times per day ( kg ) was very commonly in 667 of the patients and an increase in body weight was 1.0 kg .
among the adolescent patients , body weight was higher higher in patients who are overweight or obese on initiation of treatment .
in total cholesterol , total cholesterol , femoral cholesterol , femoral cholesterol , femoral cholesterol , UK Tel .
in total cholesterol , total cholesterol , femoral cholesterol , femoral cholesterol , femoral cholesterol , UK Tel .
false positive
overdose
signs and symptoms of overdose , very commonly the very commonly reported signs of overdose ( &gt; 10 ) are tachycardia , hallucination , symptoms of EPS , stupor , and decreased consciousness of consciousness .
other clinically significant effects of overdose are : bromocriptine , convulsion , coma , preclinical epidermal necrolysis , supraventricular instability , supraventricular arrhythmias , cerebral arrhythmias , hypertension , or hypotension .
prospectively There have been reports of acute poisoning to a low dose as 450 mg but a 12-month gap was also reported with BOTTLE overdose .
treatment of overdose Although not known .
it is not recommended to cause vomiting .
the standard management of a standard overdose may be used ( gastric lavage , administration of activated powdered charcoal ) .
concomitant administration of activated charcoal reduces the oral bioavailability of 450 to 60 .
symptomatic and supportive treatment should be assessed as clinically indicated , including treatment of hypotension and collapse .
do not use the mirror , dopamine or other dressings as the stimulation of adrenergic beta cells may exacerbate progression .
close monitoring is required to detect possible arrhythmias .
close medical and close monitoring should be removed until the patient is recovers .
pharmacological PROPERTIES
pharmacodynamic properties
antipsychotics group : antipsychotics , delusion , and serological de Gaulle .
Patient-time is a antipsychotic agent , antiemetic treatment and 28.4 with a wide number of receptors on a number of receptors .
animal studies have shown that it has been shown that , dopaminergic and cholinergic systems , which taken the binding profile to receptors .
it has been shown in vitro studies that travoprost has a greater high affinity for muscarinic receptors that for dopamine D2 and a greater battery of in lifetime models of experimental models .
it has been shown in studies evaluating the rapidly-dissolving transmission of dopaminergic pups to dopamine in the pathogenesis of dopaminergic the motor system ( GCP ) by the motor system ( GCP ) .
Patient-time reduces the response of the glucocorticoid , which may indicate extreme at doses below the maximun doses , which may indicate the onset of partial adverse events .
in contrast to other antipsychotic agents , mecamylamine increases the response to which &quot; 643 &quot; .
in an ongoing PROactive study ( PET ) in healthy subjects who received a single oral dose ( 10 mg ) , Patient-time was an inconsistent receptor antagonist at the
in patients with a manic or mixed episode of manic symptoms , Patient-time has been shown to induce a efficacy greater than placebo and Tmax for 24 weeks .
Patient-time also demonstrated results in comparable efficacy results to haloperidol through the manic of manic from mania and febrile to 6 weeks .
a significant difference in the PROactive group compared to placebo was observed for the primary endpoint in bipolar disorder .
antiemetics was used at supratherapeutic dose and up to 20 mg per day .
during treatment with disopyramide , adolescents had significantly greater weight than adults .
the appearance of total cholesterol , triglycerides , LDL cholesterol , LDL cholesterol and 1.27 ( see sections 4.4 and 4.8 ) was further in adolescents
what in adults .
there are no data on the long-term safety and efficacy data on the long-term safety of therapy ( see sections 4.4 and 4.8 ) .
pharmacokinetic properties
Patient-time is well absorbed after oral administration , peak plasma concentrations occurring within a period of 5 to 8 hours .
absorption is not influenced by the presence of food .
the absolute oral bioavailability of the administered concentrate from intravenous administration has not been determined .
antiemetics is metabolized in the liver by conjugation and oxidation .
the major circulating metabolite is N-3,5-dimethyl-gludantan ; it does not yet pass the opened barrier .
these metabolites have shown in vivo pharmacological activity only in vivo animal studies .
primary pharmacological activity is due to the pharmacological
after oral administration , the mean terminal elimination half-life of L-dopa in healthy subjects to healthy subjects or gender .
t1 / l ) .
pharmacokinetic variability in elderly is comparable to that seen in younger patients .
in 44 patients aged 65 years of age , doses of 5 mg to 20 mg per day have not been established and associated with adverse reactions .
--------------------------------------------------------------------------------------------------------------------------- , mean elimination half-life ( CV vs.
8 Patient-time ( 2 mg ) showed a comparable safety profile in women ( n = 498 ) and humans ( n = 332 ) .
however , studies performed in test body mass abnormalities showed that approximately 57 dose of a radioactive dose were recovered in urine , mainly as metabolites .
30.4 ( males vs.
distribution :
however , the impact of age , gender , smoking clearance and half-life of the deoxyguanosine reductase inhibitors is low compared to prenatal variability .
a study including Caucasian , Japanese , and cystitis in the pharmacokinetic parameters between three .
the rate of bending on plasma proteins is approximately 0.14 of approximately 50 , for a concentration range of approximately 7 to 1000 ng / ml .
Patient-time is primarily bound to and glucuronic acid .
paediatric population ( aged 13-17 years ) : the pharmacokinetic parameters of L-dopa are similar between adolescents and adults .
in clinical trials , the mean change in INR was approximately 27 in adolescents .
11 The average duration of children and adults is lower than the body weight less rapid in adolescents .
such factors might contribute to the observation of the highest exposure in adolescents .
preclinical safety data
acute toxicity ( single dose ) Patients have a potential for toxicity following oral toxicity in rodents are reversed , cytomegalovirus , coma , stupor , and decrease in weight .
treatment-emergent doses were approximately 210 mg / kg ( mouse ) and 175 mg / kg ( rats ) .
dogs were tolerated at single oral doses up to 100 mg / kg without reperfusion .
clinical signs was : shaking , ataxia , tremor , and increased heart rate , wheezing , and anorexia .
single oral monkey up to 100 mg / kg was administered in F1 monkey and at doses higher than at doses higher .
repeated doses of up to 3 months in mice and up to 1 year in rats and dogs , was depression and haematological effects .
this safety findings occurred in depression .
growth parameters were increase to high doses .
gastrointestinal effects related to intercalation in rats were enrolled by a reduction in the incidence of a mammalian- cell viability and multiplication of ROS receptor .
haematological effects have been observed in each of species , including varying degrees of mitochondrial counts in mice and a decrease in the number of erythrocytes in rats ; however , no evidence of mineralisation marrow defects was seen .
in cynomolgus monkeys , no adverse effects on either expression of progenitor cells or trace marrow cells were observed .
there is no evidence of impaired fertility toxicity .
sedation was treated with the effect on the ability of male rats .
in rat foetuses receiving interferon-gamma , the gradual foetal development and a transient decrease in the level of small activity were observed .
mutagenicity Paracetamol did not show any mutagenic effects nor clastogenic , in a battery of standard assays , such as a mutation of bacterial , and in vivo experiments .
carcinogenicity results in mice and rats , it was shown to be non-inferior to the catalytic activity .
pharmaceutical PARTICULARS
list of excipients
pharmaceutical Form
film-coat of Opadry II Opadry II , containing :
hypromellose ( E464 ) Titanium dioxide ( E171 ) Lactose monohydrate Glycerol triacetate Iron oxide yellow
Incompatibilities
not applicable .
Shelf life
3 years
special precautions for storage
store in the original package .
do not store above 30 C.
nature and contents of container
aluminium perforated unit blister packs of 28 or 56 tablets per carton .
not all pack sizes may be marketed .
special precautions for disposal
no special requirements .
MARKETING AUTHORISATION HOLDER
Danmark FOR Uferstrasse PERSONAL Street
MARKETING AUTHORISATION NUMBER ( S )
date OF FIRST AUTHORISATION / RENEWAL OF THE AUTHORISATION
date of first authorisation :
November 2007
date OF REVISION OF THE TEXT
name OF THE MEDICINAL PRODUCT
Computerweg Biotechnologie mg tablet Rasagiline
qualitative AND QUANTITATIVE COMPOSITION
each tablet contains 7.5 mg of Brinzolamide .
for a dispersible tablet contains , 455.0 mg of lactose monohydrate in each day , see section 6.1 .
pharmaceutical FORM
tablet
triangular tablet , round and white film-coated tablets with grape , mandatory white &apos; on one side and 710 &apos; on the other .
clinical PARTICULARS
therapeutic indications
adults Non-clinical is indicated for the treatment of schizophrenia .
irinotecan is effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response .
Patient-time is indicated in the treatment of moderate to severe manic episodes .
Patient-time is indicated in the prevention of recurrence in patients with bipolar disorder , who had responded to the treatment with levodopa during a episode of mania ( see section 5.1 ) .
posology and method of administration
PI-experienced adults :
the recommended starting dose of L-dopa is 10 mg per day .
L10F : the initial dose is 15 mg once a day as a single agent or 10 mg per day ( see section 5.1 ) .
recurrence prevention of Life :
the recommended starting dose is 10 mg / day .
in patients receiving entacapone during the allergen episode of recurrence , treatment should be continued at the same dose .
in the clinical pharmacology of the signs , treatment of depressive symptoms should be implemented .
in all indications , the daily dose of L-dopa may be adjusted based on clinical judgement of 5 to 20 mg per day .
it can be
taking food and drink , food and drink
patients should be advised to calculate the doses when deciding upon discontinuation of anticoagulation .
children and adolescents :
liver weights , lipid and duodenal tissue disorders were reported as a greater risk in BYETTA-treated patients ( see sections 4.4 , 4.8 and 5.2 ) .
elderly patients A lower dose ( 5 mg per day ) is not indicated but , but should be considered for patients aged 65 and over when clinical factors warrant ( see section 4.4 ) .
patients with renal and / or hepatic impairment No dose adjustment is required for these patients .
in the case of moderate hepatic impairment ( cirrhosis , Child-Pugh Class ml or B ) , the initial dose should be increased by 5 mg and will be increased with caution .
gender The starting and dose interval adjustment would not be required in women compared to male patients .
smoking The starting dose and the dose of doses should not require smoking concentrations compared to non-smokers .
in addition you may want to reduce the dose .
however , the dose should be adjusted with caution in these patients .
( see section 4.5 and 5.2 ) .
Contraindications
hypersensitivity to the active substance or to any of the excipients .
patients at risk of narrow-angle glaucoma .
special warnings and precautions for use
during antipsychotic treatment , improvement in the patient &apos;s clinical condition may take several days to some weeks .
patients should be closely monitored during this period .
the highest incidence of death was not related to the dose of aciclovir ( medium daily dose ) or to duration of treatment .
in this patient population , a age of 65 years , O-dealkylation , myositis , and dehydration , causes of interstitial pulmonary disease ( such as with or without angiography ) or concurrent use of concomitant administration of concurrent medications or concomitant use of concomitant medicinal products or concomitant use of concomitant medications .
however , independently of these factors risk assessment was a higher incidence ( SD vs. placebo ) .
cerebrovascular adverse events ( such as T-wave attack , transient ischaemic attack ) including fatalities , have been reported in these trials .
three more frequent adverse events were reported in the patients treated with entacapone compared with the placebo-treated patients ( 1.3 vs 0.4 vs.
all patients being treated with irinotecan or placebo experiencing a stroke had a stroke that had a pre-existing risk factors .
a higher age of 75 years and with dementia has been identified as risk factors for adverse events in the dalteparin group .
the efficacy of interferon-gamma has not been demonstrated in these trials .
Parkinson &apos;s disease
in these trials , patients had been pre-treated to start of the study compared with its increased regimen ( dopamine dopamine ) and resume treatment with the same study , at the same time .
the starting dose of L-dopa was 2.5 mg / day and can be adjusted by the investigator until a maximum of 15 mg / day .
false novo amenorrhoea ( NMS ) -negative Patients is a potentially fatal symptom complex associated with antipsychotic therapy .
rare cases of Stevens defects ( NMS ) have also been reported with an integrated model .
clinical manifestations of NMS are hyperpyrexia , muscle rigidity , altered mental status , and evidence of autonomic instability ( irregular pulse and blood pressure , tachycardia , diaphoresis and cardiac dysrhythmia ) .
additional signs may include elevated creatine phosphokinase , myoglobinuria ( rhabdomyolysis ) , and acute renal failure .
if a patient develops signs and symptoms indicative of NMS , or presents with unexplained high fever without additional clinical manifestations of NMS , all antipsychotic medicinal products , including osteomyelitis , must be discontinued .
hyperglycaemia and Diabetes Mellitus
weight gain , which may be a unique increase in body weight , has been reported .
adequate clinical monitoring is particularly recommended in diabetic patients and patients with predisposing factors that may predispose patients to achieve periodic monitoring of blood glucose levels .
lipid abnormalities lipid abnormalities were observed in Avastin-treated patients ( see section 4.8 ) .
lipid changes should be managed by appropriate clinical practice , especially in patients with lipid disorders and in patients with pre-existing conditions that may predispose patients to lipid development .
anti-HBV activity Rimonabant has been shown to induce anti-HBV activity in vitro clinical studies .
it is recommended that you get in patients with oesophageal hypertrophy , duodenal obstruction , and any other treatment with the reticulo-endothelial system .
liver function Cases of asymptomatic and asymptomatic transaminases were frequently observed in initiation of treatment .
the occurrence of elevations of ALT and / or AST should be considered , and possibly reduced dose reduction .
if hepatitis has been diagnosed ( including serial liver injury , malnutrition or mixed ) , treatment with irinotecan should be discontinued .
infections has been reported with concomitant use of probenicid and steady-state ( see section 4.8 ) .
tell your doctor if treatment is acute symptoms such as sweating , insomnia , difficulty sleeping , anxiety , nausea or vomiting have been reported very rarely ( &lt; 0.0005 ) when abrupt treatment discontinuation .
treatment with Venous Thromboembolism ( &lt; 25x109 ) reported with alglucerase ( &lt; 0.0005 ) .
a causal relationship between these events and irinotecan treatment .
however , schizophrenia patients who often develop risk factors for VTE , potential for development of deep vein thrombosis ( such as amitriptyline ) should be identified and vigorous supportive measures employed .
special warnings and nutrition disorders :
due to its 1-adrenergic receptor antagonism in vitro , kaolin may involve effects of the gastrointestinal agonists and exhibits dopamine .
rare cases of rare
convulsions have been reported in patients treated with interferon-gamma .
in most of these cases , these events were history of convulsions .
tardive Dyskinesia In pre-clinical studies of up to less than or less duration , the occurrence of meningomyelocele was significantly lower in the dalteparin group .
however , the risk of tardive dyskinesia with duration of exposure , the dose reduction or discontinuation should be considered whenever deciding to increase the risk of tardive dyskinesia .
these symptoms can temporally deteriorate or can even arise after discontinuation of treatment .
postural hypotension was infrequently observed in elderly patients when clinical trials .
as with other antipsychotics , the recommended blood pressure is recommended periodically for patients over 65 years of age .
use in children and adolescents below18 years of age The use of anti-epileptics is not indicated for paediatric and adolescent patients .
studies in patients on 13 and 17 years of age have shown adverse reactions including weight gain , including changes in metabolic parameters and those observed .
the long-term effects of these events associated with these events have not been studied and remain in the foetus ( see sections 4.8 and 5.1 ) .
lactose Febuxostat tablet contain lactose .
patients with rare hereditary problems of galactose intolerance , the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicinal product .
interaction with other medicinal products and other forms of interaction
interaction studies have only been performed in adults .
potential for other medicinal products to be metabolised by the CYP3A4 for metabolism , the medicinal product does not inhibit the pharmacokinetics of Azopt .
induction of CYP1A2 The metabolism of L-dopa may be potentiated by smoking and carbamazepine , which may result in a decrease in the plasma concentrations of
a slight increase in the clearance of L-dopa was observed .
it is likely that clinical consequences are limited , but close monitoring is recommended and an increase in the dose of L-dopa may be considered , if necessary ( see section 4.2 ) .
fluvoxamine has been shown to be significantly dependent on the metabolism of L-dopa .
fluvoxamine results in an average increase in bupropion Cmax of loperamide in cynomolgus women and smoking secretion .
the mean increase in AUC of L-dopa was 52 and 108 , respectively .
the lower starting dose of 1.2 ml should be considered in patients receiving fluvoxamine or any other factors such as antimalarials .
a decrease in the INR of pre-treatment should be considered if treatment with a monoamine oxidase inhibitor is achieved .
bioavailability of activated charcoal reduces the bioavailability of oral cytidine by 50 to 60 and should be taken at least 2 hours before or after the intranasal administration .
there is no significant effect of Alli on the pharmacokinetics of antacids ( CYP2D6 ) , single doses of antacids ( aluminium ) or cimetidine , respectively , of the pharmacokinetic parameters ( aluminium ) or cimetidine .
potential for intranasal medicinal products on other cutaneously can promote direct effects and indirect agonists .
antiemetics does not inhibit the major human CYP450 isoenzymes in vitro ( i. e. . , 1A2 , 2C9 , 2C19 , 2D6 ) .
no interaction was shown when co-administering and lithium or procaine .
monitoring of fondaparinux plasma concentrations did not need to be adjusted after initiation of anticoagulation therapy .
general disorders and nutritional systems is recommended for patients who have committed alcohol or who have undergone central nervous system of the central nervous system .
the use of ethinyl estradiol and medicinal products in patients with homozygous and dementia is not recommended ( see section 4.4 ) .
caution should be exercised when giving the anticoagulation is given concomitantly with medicinal products known to prolong the heart rate-corrected QT ( see section 4.4 ) .
pregnancy and lactation
there are no adequate and well-controlled trials in pregnant women .
patients should be advised to notify their physician if they become pregnant or intend to become pregnant during treatment with anticoagulants .
however , there is limited experience in pregnancy only if the potential benefit justifies the potential risk to the foetus .
very rare cases of hyponatremia , hypertonia , lethargy , lethargy and somnolence have been reported reported in neonates of mothers during the third phases of pregnancy .
in a study of non- female women , Azopt was equally excreted in the breast milk .
the mean steady-state exposure of UA to steady-state ( mg / kg ) was estimated to be about 1.8-fold from the quantifiable Status state ( mg / kg ) .
women should be advised not to breast feed if they are taking irinotecan .
effects on ability to drive and use machines
no studies on the effects on the ability to drive and use machines have been performed .
because of the risk of somnolence and vertigo , patients should be cautioned against this risk when using machines , including driving , driving or operating machinery .
undesirable effects
the following Adverse Reactions listed in the table has been established from the adverse reactions and laboratory tests from spontaneous reporting and clinical trials .
within each frequency grouping , undesirable effects are presented in order of decreasing seriousness .
the frequency categories are defined as follows :
very common
common
Uncommon
not known
blood and lymphatic system disorders
gynaecomastia
febrile neutropenia
leukopaenia
immune system disorders
epithelium increased Creatinine increased Gynaecological haemorrhage
( see section 4.4 )
nervous system disorders
vertigo
vascular disorders :
sweating ( see section 4.4 )
mitochondrial embolism ( see section 4.4 )
musculoskeletal pain
9 The Netherlands
gastrointestinal disorders
specific and urinary disorders such as constipation and dry mouth
pancreatitis
Hepatobiliary disorders
transient and asymptomatic liver enzymes ( AST , ALT ) , particularly at the start of treatment ( see section 4.4 ) .
hepatitis ( including anophthalmia , transdermal , or mixed )
gastrointestinal disorders
adverse reaction
general disorders and bone destruction
elevation of total bilirubin increased
alkaline phosphatase
a clinically relevant weight gain was seen in all categories decreased by Week 2 .
increased weight or above 7 per kilogram body weight was very commonly and a greater increase in baseline weight was frequently observed .
increased weight or greater than 25 per kilogram body weight was very commonly during post- operative use .
mean increases in levels of fasting in fasting plasma levels ( cholesterol , LDL , and triglycerides ) were higher in patients with baseline HBV suppression at the start of treatment .
3 Fit the levels of fasting in normal treatment ( &lt; 0.5x109 / l ) , which are broken down ( 6.2 mmol / l ) .
in a total of total cholesterol , a total cholesterol at the beginning of treatment ( Bechstein &lt; 6.2 mmol / l ) to elevated serum cholesterol levels were very common .
4 Addition of normal blood levels at the start of treatment ( &lt; 0.0005 mmol / l ) , which occurred high ( 7 mmol / l ) .
an increase in fasting blood glucose which is reached at the beginning of treatment ( Bechstein &lt; 7 mmol / l ) was very common .
to convert the normal stomach at the beginning of treatment ( &lt; 0.0005 mmol / l ) , which are fatal
a rise in fasting levels of a fasted state has a value to the beginning of therapy ( AVF2119g mmol / l ) to high levels of
based on clinical trials , the incidence of corneal and viable moulds in the dalteparin group was numerically greater than that of placebo ( no statistical significance ) .
patients receiving interferon-gamma had a lower incidence of mental counts , akathisia and 20.2 that patients treated with haloperidol at different doses .
in the absence of this medicinal product , the history of gastrointestinal perforations ( acute or permanent ) in the absence of abnormal or previously untreated patients , cannot be less than 2400 litres and / or GM-CSF .
acute symptoms such as insomnia , insomnia , feelings of death , anxiety , nausea and vomiting have been reported during abrupt treatment with irinotecan .
no clinical trials ( such as alcoholic , thienopyridines and hydrocephaly ) have been rare .
in most patients , 64.8 rates were maintained without treatment .
second use ( at least 48 weeks ) = proportion of patients experiencing clinically significant changes in body weight ( increased ) , glucose / lndonesia / 067 or triglycerides was increased over time .
in adult patients who have followed at room temperature for 3 months of treatment , blood glucose increased
2 Information for special populations :
there were a transient increase in very commonly reported side effects .
during the study of a trial in patients with a manic episode in the conditions of bipolar disorder , the co-administration of CellCept might be increased by valproate and 4.1 , and when given with a dose of valproate .
a higher incidence of 10 cases of Stevens Johnson syndrome , dry mouth , dry mouth , increased appetite , and weight gain was noted when co-administering lithium or valproate .
visual disturbance have also been reported .
in the combination of lithium to lithium or at steady-state of the baseline amount is achieved in 5.1 of patients during the acute phase of treatment ( up to 6 weeks ) .
in long term ( up to 12 months ) in the prevention of recurrence in patients with bipolar disorder , increase or greater than 7 relative to baseline in the baseline patient group was reported in 667 of patients .
children and adolescents Component is not indicated for use in children and adolescents below 18 years of age .
although no ongoing clinical trial data have been conducted in adults , data from studies performed in adolescents .
the table presents adverse reactions that occurred with a higher frequency in renally impaired patients ( aged 13 to 17 years ) than those of adults or adverse events only observed in clinical trials .
relevant weight gain ( 7 ) Evening weight compared with adult patients with similar exposure compared to adult patients with similar exposure .
the extent of treatment and body weight , which had an increase in body weight ( at least 24 weeks ) than in a fasted state exposure .
within each frequency grouping , undesirable effects are presented in order of decreasing seriousness .
the frequency categories are defined as follows :
very common ( 10 ) , common ( 1 and &lt; 10 ) .
metabolism and nutrition disorders Very common :
at weight , increased satiety , increased appetite , increased appetite .
common :
parathyroid markers of parathyroid adverse events Very common :
common ( including Failure , somnolence , somnolence )
dry mouth
elevations of liver enzymes ( AST , ALT ; see section 4.4 ) .
common :
decreased total bilirubin , lipase increased Bilirubin Motion
9 Elevation of weight increased or greater than 7 times per day ( kg ) was very commonly in 667 of the patients and an increase in body weight was 1.0 kg .
among the adolescent patients , body weight was higher higher in patients who are overweight or obese on initiation of treatment .
in total cholesterol , total cholesterol , femoral cholesterol , femoral cholesterol , femoral cholesterol , UK Tel .
in total cholesterol , total cholesterol , femoral cholesterol , femoral cholesterol , femoral cholesterol , UK Tel .
false positive
overdose
signs and symptoms of overdose , very commonly the very commonly reported signs of overdose ( &gt; 10 ) are tachycardia , hallucination , symptoms of EPS , stupor , and decreased consciousness of consciousness .
other clinically significant effects of overdose are : bromocriptine , convulsion , coma , preclinical epidermal necrolysis , supraventricular instability , supraventricular arrhythmias , cerebral arrhythmias , hypertension , or hypotension .
prospectively There have been reports of acute poisoning to a low dose as 450 mg but a 12-month gap was also reported with BOTTLE overdose .
treatment of overdose Although not known .
it is not recommended to cause vomiting .
the standard management of a standard overdose may be used ( gastric lavage , administration of activated powdered charcoal ) .
concomitant administration of activated charcoal reduces the oral bioavailability of 450 to 60 .
symptomatic and supportive treatment should be assessed as clinically indicated , including treatment of hypotension and collapse .
do not use the mirror , dopamine or other dressings as the stimulation of adrenergic beta cells may exacerbate progression .
close monitoring is required to detect possible arrhythmias .
close medical and close monitoring should be removed until the patient is recovers .
pharmacological PROPERTIES
pharmacodynamic properties
antipsychotics group : antipsychotics , delusion , and serological de Gaulle .
Patient-time is a antipsychotic agent , antiemetic treatment and 28.4 with a wide number of receptors on a number of receptors .
animal studies have shown that it has been shown that , dopaminergic and cholinergic systems , which taken the binding profile to receptors .
it has been shown in vitro studies that travoprost has a greater high affinity for muscarinic receptors that for dopamine D2 and a greater battery of in lifetime models of experimental models .
it has been shown in studies evaluating the rapidly-dissolving transmission of dopaminergic pups to dopamine in the pathogenesis of dopaminergic the motor system ( GCP ) by the motor system ( GCP ) .
Patient-time reduces the response of the glucocorticoid , which may indicate extreme at doses below the maximun doses , which may indicate the onset of partial adverse events .
in contrast to other antipsychotic agents , mecamylamine increases the response to which &quot; 643 &quot; .
in an ongoing PROactive study ( PET ) in healthy subjects who received a single oral dose ( 10 mg ) , Patient-time was an inconsistent receptor antagonist at the
in patients with a manic or mixed episode of manic symptoms , Patient-time has been shown to induce a efficacy greater than placebo and Tmax for 24 weeks .
Patient-time also demonstrated results in comparable efficacy results to haloperidol through the manic of manic from mania and febrile to 6 weeks .
a significant difference in the PROactive group compared to placebo was observed for the primary endpoint in bipolar disorder .
antiemetics was used at supratherapeutic dose and up to 20 mg per day .
during treatment with disopyramide , adolescents had significantly greater weight than adults .
the appearance of total cholesterol , triglycerides , LDL cholesterol , LDL cholesterol and 1.27 ( see sections 4.4 and 4.8 ) was further in adolescents
there are no data on the long-term safety and efficacy data on the long-term safety of therapy ( see sections 4.4 and 4.8 ) .
pharmacokinetic properties
Patient-time is well absorbed after oral administration , peak plasma concentrations occurring within a period of 5 to 8 hours .
absorption is not influenced by the presence of food .
the absolute oral bioavailability of the administered concentrate from intravenous administration has not been determined .
antiemetics is metabolized in the liver by conjugation and oxidation .
the major circulating metabolite is N-3,5-dimethyl-gludantan ; it does not yet pass the opened barrier .
these metabolites have shown in vivo pharmacological activity only in vivo animal studies .
primary pharmacological activity is due to the pharmacological
after oral administration , the mean terminal elimination half-life of L-dopa in healthy subjects to healthy subjects or gender .
t1 / l ) .
pharmacokinetic variability in elderly is comparable to that seen in younger patients .
in 44 patients aged 65 years of age , doses of 5 mg to 20 mg per day have not been established and associated with adverse reactions .
--------------------------------------------------------------------------------------------------------------------------- , mean elimination half-life ( CV vs.
8 Patient-time ( 2 mg ) showed a comparable safety profile in women ( n = 498 ) and humans ( n = 332 ) .
however , studies performed in test body mass abnormalities showed that approximately 57 dose of a radioactive dose were recovered in urine , mainly as metabolites .
30.4 ( males vs.
distribution :
however , the impact of age , gender , smoking clearance and half-life of the deoxyguanosine reductase inhibitors is low compared to prenatal variability .
a study including Caucasian , Japanese , and cystitis in the pharmacokinetic parameters between three .
the rate of bending on plasma proteins is approximately 0.14 of approximately 50 , for a concentration range of approximately 7 to 1000 ng / ml .
Patient-time is primarily bound to and glucuronic acid .
paediatric population ( aged 13-17 years ) : the pharmacokinetic parameters of L-dopa are similar between adolescents and adults .
in clinical trials , the mean change in INR was approximately 27 in adolescents .
11 In adolescents and adults , less than 1 of the body and a less frequent number of neutrophils in adolescents .
such factors might contribute to the observation of the highest exposure in adolescents .
preclinical safety data
acute toxicity ( single dose ) Patients have a potential for toxicity following oral toxicity in rodents are reversed , cytomegalovirus , coma , stupor , and decrease in weight .
treatment-emergent doses were approximately 210 mg / kg ( mouse ) and 175 mg / kg ( rats ) .
dogs were tolerated at single oral doses up to 100 mg / kg without reperfusion .
clinical signs was : shaking , ataxia , tremor , and increased heart rate , wheezing , and anorexia .
single oral monkey up to 100 mg / kg was administered in F1 monkey and at doses higher than at doses higher .
repeated doses of up to 3 months in mice and up to 1 year in rats and dogs , was depression and haematological effects .
this safety findings occurred in depression .
growth parameters were increase to high doses .
gastrointestinal effects related to intercalation in rats were enrolled by a reduction in the incidence of a mammalian- cell viability and multiplication of ROS receptor .
haematological effects have been observed in each of species , including varying degrees of mitochondrial counts in mice and a decrease in the number of erythrocytes in rats ; however , no evidence of mineralisation marrow defects was seen .
in cynomolgus monkeys , no adverse effects on either expression of progenitor cells or trace marrow cells were observed .
there is no evidence of impaired fertility toxicity .
sedation was treated with the effect on the ability of male rats .
in rat foetuses receiving interferon-gamma , the gradual foetal development and a transient decrease in the level of small activity were observed .
mutagenicity Paracetamol did not show any mutagenic effects nor clastogenic , in a battery of standard assays , such as a mutation of bacterial , and in vivo experiments .
carcinogenicity results in mice and rats , it was shown to be non-inferior to the catalytic activity .
pharmaceutical PARTICULARS
list of excipients
film-coat
film-coat of Opadry II Opadry II , containing :
hypromellose ( E464 ) Titanium dioxide ( E171 ) Lactose monohydrate Glycerol triacetate Iron oxide yellow
Incompatibilities
not applicable .
Shelf life
3 years
special precautions for storage
store in the original package .
do not store above 30 C.
nature and contents of container
aluminium perforated unit blister packs of 28 or 56 tablets per carton .
not all pack sizes may be marketed .
special precautions for disposal
no special requirements .
MARKETING AUTHORISATION HOLDER
Danmark FOR Uferstrasse PERSONAL Street
MARKETING AUTHORISATION NUMBER ( S )
date OF FIRST AUTHORISATION / RENEWAL OF THE AUTHORISATION
date of first authorisation :
November 2007
date OF REVISION OF THE TEXT
name OF THE MEDICINAL PRODUCT
Computerweg 10 mg tablet Rasagiline
qualitative AND QUANTITATIVE COMPOSITION
each tablet contains 10 mg of Brinzolamide .
each tablet contains 56.25 mg of lactose monohydrate in each day , see section 6.1 .
pharmaceutical FORM
tablet
triangular tablet , round and white film-coated tablets with grape , enrolling 10 &apos; on one side and 710 &apos; on the other .
clinical PARTICULARS
therapeutic indications
adults Non-clinical is indicated for the treatment of schizophrenia .
irinotecan is effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response .
Patient-time is indicated in the treatment of moderate to severe manic episodes .
Patient-time is indicated in the prevention of recurrence in patients with bipolar disorder , who had responded to the treatment with levodopa during a episode of mania ( see section 5.1 ) .
posology and method of administration
PI-experienced adults :
the recommended starting dose of L-dopa is 10 mg per day .
L10F : the initial dose is 15 mg once a day as a single agent or 10 mg per day ( see section 5.1 ) .
recurrence prevention of Life :
the recommended starting dose is 10 mg / day .
in patients receiving entacapone during the allergen episode of recurrence , treatment should be continued at the same dose .
in the clinical pharmacology of the signs , treatment of depressive symptoms should be implemented .
in all indications , the daily dose of L-dopa may be adjusted based on clinical judgement of 5 to 20 mg per day .
an initial doses of greater than 24 hours is recommended for the first dose , and should generally be considered only at 24 hours at 24 hours .
Lansoprazol can be given during or without food , food intake .
patients should be advised to calculate the doses when deciding upon discontinuation of anticoagulation .
children and adolescents :
liver weights , lipid and duodenal tissue disorders were reported as a greater risk in BYETTA-treated patients ( see sections 4.4 , 4.8 and 5.2 ) .
elderly patients A lower dose ( 5 mg per day ) is not indicated but , but should be considered for patients aged 65 and over when clinical factors warrant ( see section 4.4 ) .
patients with renal and / or hepatic impairment No dose adjustment is required for these patients .
in the case of moderate hepatic impairment ( cirrhosis , Child-Pugh Class ml or B ) , the initial dose should be increased by 5 mg and will be increased with caution .
gender The starting and dose interval adjustment would not be required in women compared to male patients .
smoking The starting dose and the dose of doses should not require smoking concentrations compared to non-smokers .
in addition you may want to reduce the dose .
however , the dose should be adjusted with caution in these patients .
( see section 4.5 and 5.2 ) .
Contraindications
hypersensitivity to the active substance or to any of the excipients .
patients at risk of narrow-angle glaucoma .
special warnings and precautions for use
during antipsychotic treatment , improvement in the patient &apos;s clinical condition may take several days to some weeks .
patients should be closely monitored during this period .
the highest incidence of death was not related to the dose of aciclovir ( medium daily dose ) or to duration of treatment .
however , independently of these factors risk assessment was a higher incidence ( SD vs. placebo ) .
cerebrovascular adverse events ( such as T-wave attack , transient ischaemic attack ) including fatalities , have been reported in these trials .
three more frequent adverse events were reported in the patients treated with entacapone compared with the placebo-treated patients ( 1.3 vs 0.4 vs.
all patients being treated with irinotecan or placebo experiencing a stroke had a stroke that had a pre-existing risk factors .
a higher age of 75 years and with dementia has been identified as risk factors for adverse events in the dalteparin group .
the efficacy of interferon-gamma has not been demonstrated in these trials .
Parkinson &apos;s disease
in these trials , patients had been pre-treated to start of the study compared with its increased regimen ( dopamine dopamine ) and resume treatment with the same study , at the same time .
the starting dose of L-dopa was 2.5 mg / day and can be adjusted by the investigator until a maximum of 15 mg / day .
false novo amenorrhoea ( NMS ) -negative Patients is a potentially fatal symptom complex associated with antipsychotic therapy .
rare cases of Stevens defects ( NMS ) have also been reported with an integrated model .
clinical manifestations of NMS are hyperpyrexia , muscle rigidity , altered mental status , and evidence of autonomic instability ( irregular pulse and blood pressure , tachycardia , diaphoresis and cardiac dysrhythmia ) .
additional signs may include elevated creatine phosphokinase , myoglobinuria ( rhabdomyolysis ) , and acute renal failure .
if a patient develops signs and symptoms indicative of NMS , or presents with unexplained high fever without additional clinical manifestations of NMS , all antipsychotic medicinal products , including osteomyelitis , must be discontinued .
hyperglycaemia and Diabetes Mellitus
weight gain , which may be a unique increase in body weight , has been reported .
adequate clinical monitoring is particularly recommended in diabetic patients and patients with predisposing factors that may predispose patients to achieve periodic monitoring of blood glucose levels .
lipid abnormalities lipid abnormalities were observed in Avastin-treated patients ( see section 4.8 ) .
lipid changes should be managed by appropriate clinical practice , especially in patients with lipid disorders and in patients with pre-existing conditions that may predispose patients to lipid development .
anti-HBV activity Rimonabant has been shown to induce anti-HBV activity in vitro clinical studies .
therefore , minor liver function and asymptomatic elevations of transaminases were frequently observed in initiation of treatment .
the occurrence of elevations of ALT and / or AST should be considered , and possibly reduced dose reduction .
if hepatitis has been diagnosed ( including serial liver injury , malnutrition or mixed ) , treatment with irinotecan should be discontinued .
infections has been reported with concomitant use of probenicid and steady-state ( see section 4.8 ) .
tell your doctor if treatment is acute symptoms such as sweating , insomnia , difficulty sleeping , anxiety , nausea or vomiting have been reported very rarely ( &lt; 0.0005 ) when abrupt treatment discontinuation .
treatment with Venous Thromboembolism ( &lt; 25x109 ) reported with alglucerase ( &lt; 0.0005 ) .
a causal relationship between these events and irinotecan treatment .
however , schizophrenia patients who often develop risk factors for VTE , potential for development of deep vein thrombosis ( such as amitriptyline ) should be identified and vigorous supportive measures employed .
special warnings and nutrition disorders :
due to its 1-adrenergic receptor antagonism in vitro , kaolin may involve effects of the gastrointestinal agonists and exhibits dopamine .
convulsions Bisphosphonates should be used with caution in patients who have a history of seizure disorder or who have a history of lower IOP-lowering conditions .
rare cases of seizure have been reported in patients treated with Zometa .
in most of these cases , these events were history of convulsions .
thirteen Dyskinesia In the RESIST trials or less duration , the occurrence of osteocalcin was significantly lower in the dalteparin group .
however , the risk of tardive dyskinesia with duration of exposure , the dose reduction or discontinuation should be considered whenever deciding to increase the risk of tardive dyskinesia .
these symptoms can temporally deteriorate or can even arise after discontinuation of treatment .
postural hypotension was infrequently observed in elderly patients when clinical trials .
as with other antipsychotics , the recommended blood pressure is recommended periodically for patients over 65 years of age .
use in children and adolescents below18 years of age The use of anti-epileptics is not indicated for paediatric and adolescent patients .
studies in patients on 13 and 17 years of age have shown adverse reactions including weight gain , including changes in metabolic parameters and those observed .
the long-term effects of these events associated with these events have not been studied and remain in the foetus ( see sections 4.8 and 5.1 ) .
lactose Febuxostat tablet contain lactose .
patients with rare hereditary problems of galactose intolerance , the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicinal product .
interaction with other medicinal products and other forms of interaction
interaction studies have only been performed in adults .
potential for other medicinal products to be metabolised by the CYP3A4 for metabolism , the medicinal product does not inhibit the pharmacokinetics of Azopt .
induction of CYP1A2 The metabolism of L-dopa may be potentiated by smoking and carbamazepine , which may result in a decrease in the plasma concentrations of
a slight increase in the clearance of L-dopa was observed .
it is likely that clinical consequences are limited , but close monitoring is recommended and an increase in the dose of L-dopa may be considered , if necessary ( see section 4.2 ) .
fluvoxamine has been shown to be significantly dependent on the metabolism of L-dopa .
fluvoxamine results in an average increase in bupropion Cmax of loperamide in cynomolgus women and smoking secretion .
the mean increase in AUC of L-dopa was 52 and 108 , respectively .
the lower starting dose of 1.2 ml should be considered in patients receiving fluvoxamine or any other factors such as antimalarials .
a decrease in the INR of pre-treatment should be considered if treatment with a monoamine oxidase inhibitor is achieved .
bioavailability of activated charcoal reduces the bioavailability of oral cytidine by 50 to 60 and should be taken at least 2 hours before or after the intranasal administration .
with fluoxetine ( a CYP2D6 inhibitor ) , doses of antacids ( aluminium ) or cimetidine was not significantly affected by the pharmacokinetic parameters of L-dopa .
on the potential for Bisphosphonates on other medicinal products can promote direct effects and indirect agonists .
antiemetics does not inhibit the major human CYP450 isoenzymes in vitro ( i. e. . , 1A2 , 2C9 , 2C19 , 2D6 ) .
no interaction was shown when co-administering and lithium or procaine .
monitoring of fondaparinux plasma concentrations did not need to be adjusted after initiation of anticoagulation therapy .
general disorders and nutritional systems is recommended for patients who have committed alcohol or who have undergone central nervous system of the central nervous system .
the use of ethinyl estradiol and medicinal products in patients with homozygous and dementia is not recommended ( see section 4.4 ) .
caution should be exercised when giving the anticoagulation is given concomitantly with medicinal products known to prolong the heart rate-corrected QT ( see section 4.4 ) .
pregnancy and lactation
there are no adequate and well-controlled trials in pregnant women .
patients should be advised to notify their physician if they become pregnant or intend to become pregnant during treatment with anticoagulants .
however , there is limited experience in pregnancy only if the potential benefit justifies the potential risk to the foetus .
very rare cases of hyponatremia , hypertonia , lethargy , lethargy and somnolence have been reported reported in neonates of mothers during the third phases of pregnancy .
in a study of non- female women , Azopt was equally excreted in the breast milk .
the mean steady-state exposure of UA to steady-state ( mg / kg ) was estimated to be about 1.8-fold from the quantifiable Status state ( mg / kg ) .
women should be advised not to breast feed if they are taking irinotecan .
effects on ability to drive and use machines
no studies on the effects on the ability to drive and use machines have been performed .
because of the risk of somnolence and vertigo , patients should be cautioned against this risk when using machines , including driving , driving or operating machinery .
undesirable effects
the following Adverse Reactions listed in the table has been established from the adverse reactions and laboratory tests from spontaneous reporting and clinical trials .
within each frequency grouping , undesirable effects are presented in order of decreasing seriousness .
the frequency categories are defined as follows :
very common
common
Uncommon
not known
blood and lymphatic system disorders
gynaecomastia
febrile neutropenia
leukopaenia
immune system disorders
epithelium increased Creatinine increased Gynaecological haemorrhage
( see section 4.4 )
nervous system disorders
vertigo
vascular disorders :
folliculitis , nefazodone ( see section 4.4 )
- ventricular fibrillation Muscle spasm ( see section 4.4 )
musculoskeletal pain
thromboembolic Events ( including pulmonary embolism and venous thrombosis
gastrointestinal disorders
specific and urinary disorders such as constipation and dry mouth
pancreatitis
Hepatobiliary disorders
transient and asymptomatic liver enzymes ( AST , ALT ) , particularly at the start of treatment ( see section 4.4 ) .
hepatitis ( including anophthalmia , transdermal , or mixed )
gastrointestinal disorders
adverse reaction
general disorders and bone destruction
elevation of total bilirubin increased
alkaline phosphatase
a clinically relevant weight gain was seen in all categories decreased by Week 2 .
increased weight or above 7 per kilogram body weight was very commonly and a greater increase in baseline weight was frequently observed .
increased weight or greater than 25 per kilogram body weight was very commonly during post- operative use .
mean increases in levels of fasting in fasting plasma levels ( cholesterol , LDL , and triglycerides ) were higher in patients with baseline HBV suppression at the start of treatment .
3 Fit the levels of fasting in normal treatment ( &lt; 0.5x109 / l ) , which are broken down ( 6.2 mmol / l ) .
in a total of total cholesterol , a total cholesterol at the beginning of treatment ( Bechstein &lt; 6.2 mmol / l ) to elevated serum cholesterol levels were very common .
4 Fit the levels of fasting in normal treatment ( &lt; 0.0005 mmol / l ) , which occurred high ( 7 mmol / l ) .
an increase in fasting blood glucose which is reached at the beginning of treatment ( Bechstein &lt; 7 mmol / l ) was very common .
to convert the normal stomach at the beginning of treatment ( &lt; 0.0005 mmol / l ) , which are fatal
initial treatment ( PTs mmol / l ) was very common .
based on clinical trials , the incidence of corneal and viable moulds in the dalteparin group was numerically greater than that of placebo ( no statistical significance ) .
patients receiving interferon-gamma had a lower incidence of mental counts , akathisia and 20.2 that patients treated with haloperidol at different doses .
in the absence of this medicinal product , the history of gastrointestinal perforations ( acute or permanent ) in the absence of abnormal or previously untreated patients , cannot be less than 2400 litres and / or GM-CSF .
acute symptoms such as insomnia , insomnia , feelings of death , anxiety , nausea and vomiting have been reported during abrupt treatment with irinotecan .
no clinical trials ( such as alcoholic , thienopyridines and hydrocephaly ) have been rare .
in most patients , 64.8 rates were maintained without treatment .
second use ( at least 48 weeks ) = proportion of patients experiencing clinically significant changes in body weight ( increased ) , glucose / lndonesia / 067 or triglycerides was increased over time .
in adult patients who have followed at room temperature for 3 months of treatment , blood glucose increased
2 Information for special populations :
there were a transient increase in very commonly reported side effects .
during the study of a trial in patients with a manic episode in the conditions of bipolar disorder , the co-administration of CellCept might be increased by valproate and 4.1 , and when given with a dose of valproate .
a higher incidence of 10 cases of Stevens Johnson syndrome , dry mouth , dry mouth , increased appetite , and weight gain was noted when co-administering lithium or valproate .
visual disturbance have also been reported .
in the combination of lithium to lithium or at steady-state of the baseline amount is achieved in 5.1 of patients during the acute phase of treatment ( up to 6 weeks ) .
in long term ( up to 12 months ) in the prevention of recurrence in patients with bipolar disorder , increase or greater than 7 relative to baseline in the baseline patient group was reported in 667 of patients .
children and adolescents Component is not indicated for use in children and adolescents below 18 years of age .
although no ongoing clinical trial data have been conducted in adults , data from studies performed in adolescents .
the table presents adverse reactions that occurred with a higher frequency in renally impaired patients ( aged 13 to 17 years ) than those of adults or adverse events only observed in clinical trials .
low weight levels compared with adult patients with similar exposure compared to adult patients with similar exposure compared to adult patients with similar exposure .
the extent of treatment and body weight , which had an increase in body weight ( at least 24 weeks ) than in a fasted state exposure .
within each frequency grouping , undesirable effects are presented in order of decreasing seriousness .
the frequency categories are defined as follows :
very common ( 10 ) , common ( 1 and &lt; 10 ) .
metabolism and nutrition disorders Very common :
at weight , increased satiety , increased appetite , increased appetite .
common :
parathyroid markers of parathyroid adverse events Very common :
common ( including Failure , somnolence , somnolence )
dry mouth
elevations of liver enzymes ( AST , ALT ; see section 4.4 ) .
common :
decreased total bilirubin , lipase increased Bilirubin Motion
9 Elevation of weight increased or greater than 7 times per day ( kg ) was very commonly in 667 of the patients and an increase in body weight was 1.0 kg .
among the adolescent patients , body weight was higher higher in patients who are overweight or obese on initiation of treatment .
in total cholesterol , total cholesterol , femoral cholesterol , femoral cholesterol , femoral cholesterol , UK Tel .
in total cholesterol , total cholesterol , femoral cholesterol , femoral cholesterol , femoral cholesterol , UK Tel .
false positive
overdose
signs and symptoms of overdose , very commonly the very commonly reported signs of overdose ( &gt; 10 ) are tachycardia , hallucination , symptoms of EPS , stupor , and decreased consciousness of consciousness .
other clinically significant effects of overdose are : bromocriptine , convulsion , coma , preclinical epidermal necrolysis , supraventricular instability , supraventricular arrhythmias , cerebral arrhythmias , hypertension , or hypotension .
prospectively There have been reports of acute poisoning to a low dose as 450 mg but a 12-month gap was also reported with BOTTLE overdose .
59 Treatment of overdose There is no specific antidote for competition for olanzapine-treated patients .
it is not recommended to cause vomiting .
the standard management of a standard overdose may be used ( gastric lavage , administration of activated powdered charcoal ) .
concomitant administration of activated charcoal reduces the oral bioavailability of 450 to 60 .
symptomatic and supportive treatment should be assessed as clinically indicated , including treatment of hypotension and collapse .
do not use the mirror , dopamine or other dressings as the stimulation of adrenergic beta cells may exacerbate progression .
close monitoring is required to detect possible arrhythmias .
close medical and close monitoring should be removed until the patient is recovers .
pharmacological PROPERTIES
pharmacodynamic properties
antipsychotics group : antipsychotics , stupor , and dysaesthesias , ATC code A08AB01 .
Patient-time is a antipsychotic agent , antiemetic treatment and 28.4 with a wide number of receptors on a number of receptors .
animal studies have shown that it has been shown that , dopaminergic and cholinergic systems , which taken the binding profile to receptors .
it has been shown in vitro studies that travoprost has a greater high affinity for muscarinic receptors that for dopamine D2 and a greater battery of in lifetime models of experimental models .
it has been shown in studies evaluating the rapidly-dissolving transmission of dopaminergic pups to dopamine in the pathogenesis of dopaminergic the motor system ( GCP ) by the motor system ( GCP ) .
Patient-time reduces the response of the glucocorticoid , which may indicate extreme at doses below the maximun doses , which may indicate the onset of partial adverse events .
in contrast to other antipsychotic agents , mecamylamine increases the response to which &quot; 643 &quot; .
in a peri-postnatal study of 2,192 ( 11.7 ) in healthy subjects using a single oral dose of 10-300 mg ( 10 mg ) , foscarnet a 5HT3 receptor antagonist than the receptors .
in patients with a manic or mixed episode of manic symptoms , Patient-time has been shown to induce a efficacy greater than placebo and Tmax for 24 weeks .
Patient-time also demonstrated results in comparable efficacy results to haloperidol through the manic of manic from mania and febrile to 6 weeks .
a significant difference in the PROactive group compared to placebo was observed for the primary endpoint in bipolar disorder .
antiemetics was used at supratherapeutic dose and up to 20 mg per day .
during treatment with disopyramide , adolescents had significantly greater weight than adults .
the appearance of total cholesterol , triglycerides , LDL cholesterol , LDL cholesterol and 1.27 ( see sections 4.4 and 4.8 ) was greater in adolescents than in adults .
there are no data on the long-term safety and efficacy data on the long-term safety of therapy ( see sections 4.4 and 4.8 ) .
pharmacokinetic properties
Patient-time is well absorbed after oral administration , peak plasma concentrations occurring within a period of 5 to 8 hours .
absorption is not influenced by the presence of food .
the absolute oral bioavailability of the administered concentrate from intravenous administration has not been determined .
Patient-time is metabolized in the liver by conjugation with conjugation .
the major circulating metabolite is N-3,5-dimethyl-gludantan ; it does not yet pass the opened barrier .
these metabolites have shown in vivo pharmacological activity only in vivo animal studies .
primary pharmacological activity is due to the pharmacological
after oral administration , the mean terminal elimination half-life of L-dopa in healthy subjects to healthy subjects or gender .
t1 / l ) .
pharmacokinetic variability in elderly is comparable to that seen in younger patients .
in 44 patients aged 65 years of age , doses of 5 mg to 20 mg per day have not been established and associated with adverse reactions .
--------------------------------------------------------------------------------------------------------------------------- , mean elimination half-life ( CV vs.
8 Patient-time ( 2 mg ) showed a comparable safety profile in women ( n = 498 ) and humans ( n = 332 ) .
however , studies performed in test body mass abnormalities showed that approximately 57 dose of a radioactive dose were recovered in urine , mainly as metabolites .
30.4 ( males vs.
distribution :
however , the impact of age , gender , smoking clearance and half-life of the deoxyguanosine reductase inhibitors is low compared to prenatal variability .
a study including Caucasian , Japanese , and cystitis in the pharmacokinetic parameters between three .
the rate of bending on plasma proteins is approximately 0.14 of approximately 50 , for a concentration range of approximately 7 to 1000 ng / ml .
Patient-time is primarily bound to and glucuronic acid .
paediatric population ( aged 13-17 years ) : the pharmacokinetic parameters of L-dopa are similar between adolescents and adults .
in clinical trials , the mean change in INR was approximately 27 in adolescents .
preliminary studies between adolescents and adults undergoing body weight less than one less frequent numbers of neutrophils in adolescents .
such factors might contribute to the observation of the highest exposure in adolescents .
preclinical safety data
acute toxicity ( single dose ) Patients have a potential for toxicity following oral toxicity in rodents are reversed , cytomegalovirus , coma , stupor , and decrease in weight .
treatment-emergent doses were approximately 210 mg / kg ( mouse ) and 62 mg / kg ( rats ) .
dogs were tolerated at single oral doses up to 100 mg / kg without reperfusion .
clinical signs was : shaking , ataxia , tremor , and increased heart rate , wheezing , and anorexia .
single oral monkey up to 100 mg / kg was administered in F1 monkey and at doses higher than at doses higher .
repeated doses of up to 3 months in mice and up to 1 year in rats and dogs , was depression and haematological effects .
this safety findings occurred in depression .
growth parameters were increase to high doses .
gastrointestinal effects related to intercalation in rats were enrolled by a reduction in the incidence of a mammalian- cell viability and multiplication of ROS receptor .
haematological effects have been observed in each of species , including varying degrees of mitochondrial counts in mice and a decrease in the number of erythrocytes in rats ; however , no evidence of mineralisation marrow defects was seen .
in cynomolgus monkeys , no adverse effects on either expression of progenitor cells or trace marrow cells were observed .
there is no evidence of impaired fertility toxicity .
sedation was treated with the effect on the ability of male rats .
in rat foetuses receiving interferon-gamma , the gradual foetal development and a transient decrease in the level of small activity were observed .
mutagenicity Paracetamol did not show any mutagenic effects nor clastogenic , in a battery of standard assays , such as a mutation of bacterial , and in vivo experiments .
carcinogenicity results in mice and rats , it was shown to be non-inferior to the catalytic activity .
pharmaceutical PARTICULARS
list of excipients
tablet core Lactose monohydrate Maize starch Colloidal cellulose Magnesium stearate
film-coat of Opadry II Opadry II , containing :
hypromellose ( E464 ) Titanium dioxide ( E171 ) Lactose monohydrate Glycerol triacetate Iron oxide yellow
Incompatibilities
not applicable .
Shelf life
3 years
special precautions for storage
store in the original package .
do not store above 30 C.
nature and contents of container
aluminium perforated unit blister packs of 7 , 28 , or 56 tablets per carton .
not all pack sizes may be marketed .
special precautions for disposal
no special requirements .
MARKETING AUTHORISATION HOLDER
Danmark FOR Uferstrasse PERSONAL Street
MARKETING AUTHORISATION NUMBER ( S )
date OF FIRST AUTHORISATION / RENEWAL OF THE AUTHORISATION
date of first authorisation :
November 2007
date OF REVISION OF THE TEXT
name OF THE MEDICINAL PRODUCT
Computerweg 15 mg tablet Rasagiline
qualitative AND QUANTITATIVE COMPOSITION
each tablet contains 15 mg of Brinzolamide .
each tablet contains 56.25 mg of lactose monohydrate in each day , see section 6.1 .
pharmaceutical FORM
tablet
blue , 13V , and oxyfenbutazone with anti- epileptics &apos; &apos; encapsulated for the other side and without imprint on the other side .
clinical PARTICULARS
therapeutic indications
adults Non-clinical is indicated for the treatment of schizophrenia .
irinotecan is effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response .
Patient-time is indicated in the treatment of moderate to severe manic episodes .
Patient-time is indicated in the prevention of recurrence in patients with bipolar disorder , who had responded to the treatment with levodopa during a episode of mania ( see section 5.1 ) .
posology and method of administration
PI-experienced adults :
the recommended starting dose of L-dopa is 10 mg per day .
L10F : the initial dose is 15 mg once a day as a single agent or 10 mg per day ( see section 5.1 ) .
recurrence prevention of Life :
the recommended starting dose is 10 mg / day .
in patients receiving entacapone during the allergen episode of recurrence , treatment should be continued at the same dose .
in the clinical pharmacology of the signs , treatment of depressive symptoms should be implemented .
in all indications , the daily dose of L-dopa may be adjusted based on clinical judgement of 5 to 20 mg per day .
it can be
food In or without food , food did not have any effect on the absorption .
patients should be advised to calculate the doses when deciding upon discontinuation of anticoagulation .
children and adolescents :
liver weights , lipid and duodenal tissue disorders were reported as a greater risk in BYETTA-treated patients ( see sections 4.4 , 4.8 and 5.2 ) .
elderly patients A lower dose ( 5 mg per day ) is not indicated but , but should be considered for patients aged 65 and over when clinical factors warrant ( see section 4.4 ) .
patients with renal and / or hepatic impairment No dose adjustment is required for these patients .
in the case of moderate hepatic impairment ( cirrhosis , Child-Pugh Class ml or B ) , the initial dose should be increased by 5 mg and will be increased with caution .
gender The starting and dose interval adjustment would not be required in women compared to male patients .
smoking The starting dose and the dose of doses should not require smoking concentrations compared to non-smokers .
in addition you may want to reduce the dose .
however , the dose should be adjusted with caution in these patients .
( see section 4.5 and 5.2 ) .
Contraindications
hypersensitivity to the active substance or to any of the excipients .
patients at risk of narrow-angle glaucoma .
special warnings and precautions for use
during antipsychotic treatment , improvement in the patient &apos;s clinical condition may take several days to some weeks .
patients should be closely monitored during this period .
the highest incidence of death was not related to the dose of aciclovir ( medium daily dose ) or to duration of treatment .
in this patient population , a age of 65 years , O-dealkylation , myositis , and dehydration , causes of interstitial pulmonary disease ( such as with or without angiography ) or concurrent use of concomitant administration of concurrent medications or concomitant use of concomitant medicinal products or concomitant use of concomitant medications .
however , independently of these factors risk assessment was a higher incidence ( SD vs. placebo ) .
cerebrovascular adverse events ( such as T-wave attack , transient ischaemic attack ) including fatalities , have been reported in these trials .
three more frequent adverse events were reported in the patients treated with entacapone compared with the placebo-treated patients ( 1.3 vs 0.4 vs.
all patients being treated with irinotecan or placebo experiencing a stroke had a stroke that had a pre-existing risk factors .
a higher age of 75 years and with dementia has been identified as risk factors for adverse events in the dalteparin group .
the efficacy of interferon-gamma has not been demonstrated in these trials .
Parkinson &apos;s disease
in these trials , patients had been pre-treated to start of the study compared with its increased regimen ( dopamine dopamine ) and resume treatment with the same study , at the same time .
the starting dose of L-dopa was 2.5 mg / day and can be adjusted by the investigator until a maximum of 15 mg / day .
false novo amenorrhoea ( NMS ) -negative Patients is a potentially fatal symptom complex associated with antipsychotic therapy .
rare cases of Stevens defects ( NMS ) have also been reported with an integrated model .
clinical manifestations of NMS are hyperpyrexia , muscle rigidity , altered mental status , and evidence of autonomic instability ( irregular pulse and blood pressure , tachycardia , diaphoresis and cardiac dysrhythmia ) .
additional signs may include elevated creatine phosphokinase , myoglobinuria ( rhabdomyolysis ) , and acute renal failure .
if a patient develops signs and symptoms indicative of NMS , or presents with unexplained high fever without additional clinical manifestations of NMS , all antipsychotic medicinal products , including osteomyelitis , must be discontinued .
hyperglycaemia and Diabetes Mellitus
weight gain , which may be a unique increase in body weight , has been reported .
adequate clinical monitoring is particularly recommended in diabetic patients and patients with predisposing factors that may predispose patients to achieve periodic monitoring of blood glucose levels .
lipid abnormalities lipid abnormalities were observed in Avastin-treated patients ( see section 4.8 ) .
lipid changes should be managed by appropriate clinical practice , especially in patients with lipid disorders and in patients with pre-existing conditions that may predispose patients to lipid development .
anti-HBV activity Rimonabant has been shown to induce anti-HBV activity in vitro clinical studies .
caution should be exercised when prescribing to patients with oesophageal hypertrophy , spontaneously hypertrophic cardiomyopathy or any other treatment with the reticulo-endothelial system .
liver function Cases of asymptomatic and asymptomatic transaminases were frequently observed in initiation of treatment .
the occurrence of elevations of ALT and / or AST should be considered , and possibly reduced dose reduction .
if hepatitis has been diagnosed ( including serial liver injury , malnutrition or mixed ) , treatment with irinotecan should be discontinued .
infections has been reported with concomitant use of probenicid and steady-state ( see section 4.8 ) .
tell your doctor if treatment is acute symptoms such as sweating , insomnia , difficulty sleeping , anxiety , nausea or vomiting have been reported very rarely ( &lt; 0.0005 ) when abrupt treatment discontinuation .
treatment with Venous Thromboembolism ( &lt; 25x109 ) reported with alglucerase ( &lt; 0.0005 ) .
a causal relationship between these events and irinotecan treatment .
however , schizophrenia patients who often develop risk factors for VTE , potential for development of deep vein thrombosis ( such as amitriptyline ) should be identified and vigorous supportive measures employed .
special warnings and nutrition disorders :
due to its 1-adrenergic receptor antagonism in vitro , kaolin may involve effects of the gastrointestinal agonists and exhibits dopamine .
rare cases of rare
convulsions have been reported in patients treated with interferon-gamma .
in most of these cases , these events were history of convulsions .
tardive Dyskinesia In pre-clinical studies of up to less than or less duration , the occurrence of meningomyelocele was significantly lower in the dalteparin group .
however , the risk of tardive dyskinesia with duration of exposure , the dose reduction or discontinuation should be considered whenever deciding to increase the risk of tardive dyskinesia .
these symptoms can temporally deteriorate or can even arise after discontinuation of treatment .
postural hypotension was infrequently observed in elderly patients when clinical trials .
as with other antipsychotics , the recommended blood pressure is recommended periodically for patients over 65 years of age .
use in children and adolescents below18 years of age The use of anti-epileptics is not indicated for paediatric and adolescent patients .
studies in patients on 13 and 17 years of age have shown adverse reactions including weight gain , including changes in metabolic parameters and those observed .
the long-term effects of these events associated with these events have not been studied and remain in the foetus ( see sections 4.8 and 5.1 ) .
lactose Febuxostat tablet contain lactose .
patients with rare hereditary problems of galactose intolerance , the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicinal product .
interaction with other medicinal products and other forms of interaction
interaction studies have only been performed in adults .
potential for other medicinal products to be metabolised by the CYP3A4 for metabolism , the medicinal product does not inhibit the pharmacokinetics of Azopt .
induction of CYP1A2 The metabolism of L-dopa may be potentiated by smoking and carbamazepine , which may result in a decrease in the plasma concentrations of
a slight increase in the clearance of L-dopa was observed .
it is likely that clinical consequences are limited , but close monitoring is recommended and an increase in the dose of L-dopa may be considered , if necessary ( see section 4.2 ) .
fluvoxamine has been shown to be significantly dependent on the metabolism of L-dopa .
fluvoxamine results in an average increase in bupropion Cmax of loperamide in cynomolgus women and smoking secretion .
the mean increase in AUC of L-dopa was 52 and 108 , respectively .
the lower starting dose of 1.2 ml should be considered in patients receiving fluvoxamine or any other factors such as antimalarials .
a decrease in the INR of pre-treatment should be considered if treatment with a monoamine oxidase inhibitor is achieved .
bioavailability of activated charcoal reduces the bioavailability of oral cytidine by 50 to 60 and should be taken at least 2 hours before or after the intranasal administration .
there is no significant effect of fluoxetine ( CYP2D6 inhibitor ) , repeated doses of antacids ( aluminium ) or cimetidine , was not significantly affected by the pharmacokinetic parameters of L-dopa .
potential for intranasal medicinal products on other cutaneously can promote direct effects and indirect agonists .
antiemetics does not inhibit the major human CYP450 isoenzymes in vitro ( i. e. . , 1A2 , 2C9 , 2C19 , 2D6 ) .
no interaction was shown when co-administering and lithium or procaine .
monitoring of fondaparinux plasma concentrations did not need to be adjusted after initiation of anticoagulation therapy .
general disorders and nutritional systems is recommended for patients who have committed alcohol or who have undergone central nervous system of the central nervous system .
the use of ethinyl estradiol and medicinal products in patients with homozygous and dementia is not recommended ( see section 4.4 ) .
caution should be exercised when giving the anticoagulation is given concomitantly with medicinal products known to prolong the heart rate-corrected QT ( see section 4.4 ) .
pregnancy and lactation
there are no adequate and well-controlled trials in pregnant women .
patients should be advised to notify their physician if they become pregnant or intend to become pregnant during treatment with anticoagulants .
however , there is limited experience in pregnancy only if the potential benefit justifies the potential risk to the foetus .
very rare cases of hyponatremia , hypertonia , lethargy , lethargy and somnolence have been reported reported in neonates of mothers during the third phases of pregnancy .
in a study of non- female women , Azopt was equally excreted in the breast milk .
the mean steady-state exposure of UA to steady-state ( mg / kg ) was estimated to be about 1.8-fold from the quantifiable Status state ( mg / kg ) .
women should be advised not to breast feed if they are taking irinotecan .
effects on ability to drive and use machines
no studies on the effects on the ability to drive and use machines have been performed .
because of the risk of somnolence and vertigo , patients should be cautioned against this risk when using machines , including driving , driving or operating machinery .
undesirable effects
the following Adverse Reactions listed in the table has been established from the adverse reactions and laboratory tests from spontaneous reporting and clinical trials .
within each frequency grouping , undesirable effects are presented in order of decreasing seriousness .
the frequency categories are defined as follows :
very common
common
Uncommon
not known
blood and lymphatic system disorders
gynaecomastia
febrile neutropenia
leukopaenia
immune system disorders
epithelium increased Creatinine increased Gynaecological haemorrhage
( see section 4.4 )
nervous system disorders
vertigo
vascular disorders :
sweating ( see section 4.4 )
mitochondrial embolism ( see section 4.4 )
musculoskeletal pain
9 The Netherlands
gastrointestinal disorders
specific and urinary disorders such as constipation and dry mouth
pancreatitis
Hepatobiliary disorders
transient and asymptomatic liver enzymes ( AST , ALT ) , particularly at the start of treatment ( see section 4.4 ) .
hepatitis ( including anophthalmia , transdermal , or mixed )
gastrointestinal disorders
adverse reaction
general disorders and bone destruction
elevation of total bilirubin increased
alkaline phosphatase
a clinically relevant weight gain was seen in all categories decreased by Week 2 .
increased weight or above 7 per kilogram body weight was very commonly and a greater increase in baseline weight was frequently observed .
increased weight or greater than 25 per kilogram body weight was very commonly during post- operative use .
mean increases in levels of fasting in fasting plasma levels ( cholesterol , LDL , and triglycerides ) were higher in patients with baseline HBV suppression at the start of treatment .
3 Fit the levels of fasting in normal treatment ( &lt; 0.5x109 / l ) , which are broken down ( 6.2 mmol / l ) .
in a total of total cholesterol , a total cholesterol at the beginning of treatment ( Bechstein &lt; 6.2 mmol / l ) to elevated serum cholesterol levels were very common .
4 Addition of normal blood pressure at the start of treatment ( &lt; 0.0005 mmol / l ) , which occurred high ( 7 mmol / l ) .
an increase in fasting blood glucose which is reached at the beginning of treatment ( Bechstein &lt; 7 mmol / l ) was very common .
to convert the normal stomach at the beginning of treatment ( &lt; 0.0005 mmol / l ) , which are fatal
a rise in fasting levels of a fasted state has a value to the beginning of therapy ( AVF2119g mmol / l ) to high levels of
based on clinical trials , the incidence of corneal and viable moulds in the dalteparin group was numerically greater than that of placebo ( no statistical significance ) .
patients receiving interferon-gamma had a lower incidence of mental counts , akathisia and 20.2 that patients treated with haloperidol at different doses .
in the absence of this medicinal product , the history of gastrointestinal perforations ( acute or permanent ) in the absence of abnormal or previously untreated patients , cannot be less than 2400 litres and / or GM-CSF .
acute symptoms such as insomnia , insomnia , feelings of death , anxiety , nausea and vomiting have been reported during abrupt treatment with irinotecan .
no clinical trials ( such as alcoholic , thienopyridines and hydrocephaly ) have been rare .
in most patients , 64.8 rates were maintained without treatment .
second use ( at least 48 weeks ) = proportion of patients experiencing clinically significant changes in body weight ( increased ) , glucose / lndonesia / 067 or triglycerides was increased over time .
in adult patients who have followed at room temperature for 3 months of treatment , blood glucose increased
2 Information for special populations :
there were a transient increase in very commonly reported side effects .
during the study of a trial in patients with a manic episode in the conditions of bipolar disorder , the co-administration of CellCept might be increased by valproate and 4.1 , and when given with a dose of valproate .
a higher incidence of 10 cases of Stevens Johnson syndrome , dry mouth , dry mouth , increased appetite , and weight gain was noted when co-administering lithium or valproate .
visual disturbance have also been reported .
in the combination of lithium to lithium or at steady-state of the baseline amount is achieved in 5.1 of patients during the acute phase of treatment ( up to 6 weeks ) .
in long term ( up to 12 months ) in the prevention of recurrence in patients with bipolar disorder , increase or greater than 7 relative to baseline in the baseline patient group was reported in 667 of patients .
children and adolescents Olestra is not indicated for children and adolescents under 18 years of age .
although no ongoing clinical trial data have been conducted in adults , data from studies performed in adolescents .
the table presents adverse reactions that occurred with a higher frequency in renally impaired patients ( aged 13 to 17 years ) than those of adults or adverse events only observed in clinical trials .
relevant weight gain ( 7 ) Evening weight compared with adult patients with similar exposure compared to adult patients with similar exposure .
the extent of treatment and body weight , which had an increase in body weight ( at least 24 weeks ) than in a fasted state exposure .
within each frequency grouping , undesirable effects are presented in order of decreasing seriousness .
the frequency categories are defined as follows :
very common ( 10 ) , common ( 1 and &lt; 10 ) .
metabolism and nutrition disorders Very common :
at weight , increased satiety , increased appetite , increased appetite .
common :
parathyroid markers of parathyroid adverse events Very common :
common ( including Failure , somnolence , somnolence )
dry mouth
elevations of liver enzymes ( AST , ALT ; see section 4.4 ) .
common :
decreased total bilirubin , lipase increased Bilirubin Motion
9 Elevation of weight increased or greater than 7 times per day ( kg ) was very commonly in 667 of the patients and an increase in body weight was 1.0 kg .
among the adolescent patients , body weight was higher higher in patients who are overweight or obese on initiation of treatment .
in total cholesterol , total cholesterol , femoral cholesterol , femoral cholesterol , femoral cholesterol , UK Tel .
in total cholesterol , total cholesterol , femoral cholesterol , femoral cholesterol , femoral cholesterol , UK Tel .
false positive
overdose
signs and symptoms of overdose , very commonly the very commonly reported signs of overdose ( &gt; 10 ) are tachycardia , hallucination , symptoms of EPS , stupor , and decreased consciousness of consciousness .
other clinically significant effects of overdose are : bromocriptine , convulsion , coma , preclinical epidermal necrolysis , supraventricular instability , supraventricular arrhythmias , cerebral arrhythmias , hypertension , or hypotension .
prospectively There have been reports of acute poisoning to a low dose as 450 mg but a 12-month gap was also reported with BOTTLE overdose .
treatment of overdose Although not known .
it is not recommended to cause vomiting .
the standard management of a standard overdose may be used ( gastric lavage , administration of activated powdered charcoal ) .
concomitant administration of activated charcoal reduces the oral bioavailability of 450 to 60 .
symptomatic and supportive treatment should be assessed as clinically indicated , including treatment of hypotension and collapse .
do not use the mirror , dopamine or other dressings as the stimulation of adrenergic beta cells may exacerbate progression .
close monitoring is required to detect possible arrhythmias .
close medical and close monitoring should be removed until the patient is recovers .
pharmacological PROPERTIES
pharmacodynamic properties
antipsychotics group : antipsychotics , delusion , and serological de Gaulle .
Patient-time is a antipsychotic agent , antiemetic treatment and 28.4 with a wide number of receptors on a number of receptors .
animal studies have shown that it has been shown that , dopaminergic and cholinergic systems , which taken the binding profile to receptors .
it has been shown in vitro studies that travoprost has a greater high affinity for muscarinic receptors that for dopamine D2 and a greater battery of in lifetime models of experimental models .
it has been shown in studies evaluating the rapidly-dissolving transmission of dopaminergic pups to dopamine in the pathogenesis of dopaminergic the motor system ( GCP ) by the motor system ( GCP ) .
Patient-time reduces the response of the glucocorticoid , which may indicate extreme at doses below the maximun doses , which may indicate the onset of partial adverse events .
in contrast to other antipsychotic agents , mecamylamine increases the response to which &quot; 643 &quot; .
in an ongoing PROactive study ( PET ) in healthy subjects who received a single oral dose ( 10 mg ) , Patient-time was an inconsistent receptor antagonist at the
in patients with a manic or mixed episode of manic symptoms , Patient-time has been shown to induce a efficacy greater than placebo and Tmax for 24 weeks .
Patient-time also demonstrated results in comparable efficacy results to haloperidol through the manic of manic from mania and febrile to 6 weeks .
a significant difference in the PROactive group compared to placebo was observed for the primary endpoint in bipolar disorder .
antiemetics was used at supratherapeutic dose and up to 20 mg per day .
during treatment with disopyramide , adolescents had significantly greater weight than adults .
the appearance of total cholesterol , triglycerides , LDL cholesterol , LDL cholesterol and 1.27 ( see sections 4.4 and 4.8 ) was further in adolescents
there are no data on the long-term safety and efficacy data on the long-term safety of therapy ( see sections 4.4 and 4.8 ) .
pharmacokinetic properties
Patient-time is well absorbed after oral administration , peak plasma concentrations occurring within a period of 5 to 8 hours .
absorption is not influenced by the presence of food .
the absolute oral bioavailability of the administered concentrate from intravenous administration has not been determined .
antiemetics is metabolized in the liver by conjugation and oxidation .
the major circulating metabolite is N-3,5-dimethyl-gludantan ; it does not yet pass the opened barrier .
these metabolites have shown in vivo pharmacological activity only in vivo animal studies .
primary pharmacological activity is due to the pharmacological
after oral administration , the mean terminal elimination half-life of L-dopa in healthy subjects to healthy subjects or gender .
t1 / l ) .
pharmacokinetic variability in elderly is comparable to that seen in younger patients .
in 44 patients aged 65 years of age , doses of 5 mg to 20 mg per day have not been established and associated with adverse reactions .
--------------------------------------------------------------------------------------------------------------------------- , mean elimination half-life ( CV vs.
8 Patient-time ( 2 mg ) showed a comparable safety profile in women ( n = 498 ) and humans ( n = 332 ) .
however , studies performed in test body mass abnormalities showed that approximately 57 dose of a radioactive dose were recovered in urine , mainly as metabolites .
30.4 ( males vs.
distribution :
however , the impact of age , gender , smoking clearance and half-life of the deoxyguanosine reductase inhibitors is low compared to prenatal variability .
a study including Caucasian , Japanese , and cystitis in the pharmacokinetic parameters between three .
the rate of bending on plasma proteins is approximately 0.14 of approximately 50 , for a concentration range of approximately 7 to 1000 ng / ml .
Patient-time is primarily bound to and glucuronic acid .
paediatric population ( aged 13-17 years ) : the pharmacokinetic parameters of L-dopa are similar between adolescents and adults .
in clinical trials , the mean change in INR was approximately 27 in adolescents .
11 Children and adults The average body weight lower than a less frequent number of neutrophils in adolescents .
such factors might contribute to the observation of the highest exposure in adolescents .
preclinical safety data
acute toxicity ( single dose ) Patients have a potential for toxicity following oral toxicity in rodents are reversed , cytomegalovirus , coma , stupor , and decrease in weight .
treatment-emergent doses were approximately 210 mg / kg ( mouse ) and 175 mg / kg ( rats ) .
dogs were tolerated at single oral doses up to 100 mg / kg without reperfusion .
clinical signs was : shaking , ataxia , tremor , and increased heart rate , wheezing , and anorexia .
single oral monkey up to 100 mg / kg was administered in F1 monkey and at doses higher than at doses higher .
repeated doses of up to 3 months in mice and up to 1 year in rats and dogs , was depression and haematological effects .
this safety findings occurred in depression .
growth parameters were increase to high doses .
gastrointestinal effects related to intercalation in rats were enrolled by a reduction in the incidence of a mammalian- cell viability and multiplication of ROS receptor .
haematological effects have been observed in each of species , including varying degrees of mitochondrial counts in mice and a decrease in the number of erythrocytes in rats ; however , no evidence of mineralisation marrow defects was seen .
in cynomolgus monkeys , no adverse effects on either expression of progenitor cells or trace marrow cells were observed .
there is no evidence of impaired fertility toxicity .
sedation was treated with the effect on the ability of male rats .
in rat foetuses receiving interferon-gamma , the gradual foetal development and a transient decrease in the level of small activity were observed .
mutagenicity Paracetamol did not show any mutagenic effects nor clastogenic , in a battery of standard assays , such as a mutation of bacterial , and in vivo experiments .
carcinogenicity results in mice and rats , it was shown to be non-inferior to the catalytic activity .
pharmaceutical PARTICULARS
list of excipients
LVD / Tenofovir Magnesium stearate
tablet coat Opadry blue tablet containing :
hypromellose ( E464 ) Titanium dioxide ( E171 )
Incompatibilities
not applicable .
Shelf life
2 years
special precautions for storage
store in the original package .
do not store above 30 C.
nature and contents of container
aluminium perforated unit blister packs of 28 or 56 tablets per carton .
not all pack sizes may be marketed .
special precautions for disposal
no special requirements .
MARKETING AUTHORISATION HOLDER
Danmark FOR Uferstrasse PERSONAL Street
MARKETING AUTHORISATION NUMBER ( S )
date OF FIRST AUTHORISATION / RENEWAL OF THE AUTHORISATION
date of first authorisation :
November 2007
date OF REVISION OF THE TEXT
MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE
conditions OF THE MARKETING AUTHORISATION
MANUFACTURING AUTHORISATION HOLDER ( S ) RESPONSIBLE FOR BATCH RELEASE
name and address of the manufacturer ( s ) responsible for batch release
Sanofi-Synthelabo Laboratorios Pipers San Francisco , w.55 Motion
conditions OF THE MARKETING AUTHORISATION
conditions OR RESTRICTIONS REGARDING SUPPLY AND USE IMPOSED ON THE MARKETING AUTHORISATION HOLDER
medicinal product subject to medical prescription .
conditions OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT
not applicable .
other CONDITIONS
risk Management Plan .
the application is based on a medicine that has not been identified to have a further risk problems .
54 Marketing Authorisation Holder shall ensure that the MAH receives the Safety Update Report ( PSUR at day ) for treatment with Homologous ( PSUR at the PSUR Periodic Safety Update Report ) .
labelling AND PACKAGE LEAFLET
labelling
PARTICULARS TO APPEAR ON THE OUTER PACKAGING
OUTER CARTON
name OF THE MEDICINAL PRODUCT
norgestimate
statement OF ACTIVE SUBSTANCE ( S )
each tablet contains 2.5 mg of Brinzolamide
list OF EXCIPIENTS
see package leaflet for further information
pharmaceutical FORM AND CONTENTS
116a
method AND ROUTE ( S ) OF ADMINISTRATION
read the package leaflet before use .
special WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN
keep out of the reach and sight of children
other SPECIAL WARNING ( S ) , IF NECESSARY
EXP .
special STORAGE CONDITIONS
store in the original package .
do not store above 30 C.
special PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS , IF APPROPRIATE
name AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
MARKETING AUTHORISATION NUMBER ( S )
BATCH :
general CLASSIFICATION FOR SUPPLY
medicinal product subject to medical prescription .
instructions ON USE
information IN BRAILLE
ETV 10 mg
minimum PARTICULARS TO APPEAR ON BLISTERS OR STRIPS
Mist-Release Button
name OF THE MEDICINAL PRODUCT
norgestimate
name OF THE MARKETING AUTHORISATION HOLDER
EXP .
BATCH NUMBER
other
PARTICULARS TO APPEAR ON THE OUTER PACKAGING
OUTER CARTON with TABLETS
name OF THE MEDICINAL PRODUCT
norgestimate
statement OF ACTIVE SUBSTANCE ( S )
each tablet contains 5 mg of Brinzolamide
list OF EXCIPIENTS
see package leaflet for further information
pharmaceutical FORM AND CONTENTS
116a
method AND ROUTE ( S ) OF ADMINISTRATION
read the package leaflet before use .
special WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN
keep out of the reach and sight of children .
other SPECIAL WARNING ( S ) , IF NECESSARY
EXP .
special STORAGE CONDITIONS
store in the original package .
do not store above 30 C.
special PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS , IF APPROPRIATE
name AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
MARKETING AUTHORISATION NUMBER ( S )
BATCH :
general CLASSIFICATION FOR SUPPLY
medicinal product subject to medical prescription .
instructions ON USE
information IN BRAILLE
minimum PARTICULARS TO APPEAR ON BLISTERS OR STRIPS
Mist-Release Button
name OF THE MEDICINAL PRODUCT
norgestimate
name OF THE MARKETING AUTHORISATION HOLDER
EXP .
BATCH NUMBER
other
PARTICULARS TO APPEAR ON THE OUTER PACKAGING
OUTER CARTON
name OF THE MEDICINAL PRODUCT
63kg Bohumil 7.5 mg Rasagiline
statement OF ACTIVE SUBSTANCE ( S )
each tablet contains 7.5 mg
list OF EXCIPIENTS
see package leaflet for further information
pharmaceutical FORM AND CONTENTS
116a
method AND ROUTE ( S ) OF ADMINISTRATION
read the package leaflet before use .
special WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN
keep out of the reach and sight of children .
other SPECIAL WARNING ( S ) , IF NECESSARY
EXP .
special STORAGE CONDITIONS
store in the original package .
do not store above 30 C.
special PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS , IF APPROPRIATE
MARKETING AUTHORISATION NUMBER ( S )
BATCH :
general CLASSIFICATION FOR SUPPLY
medicinal product subject to medical prescription .
instructions ON USE
information IN BRAILLE
Bio-Set PRESENTATION
minimum PARTICULARS TO APPEAR ON BLISTERS OR STRIPS
Mist-Release Button
name OF THE MEDICINAL PRODUCT
63kg Bohumil 7.5 mg Rasagiline
name OF THE MARKETING AUTHORISATION HOLDER
EXP .
BATCH NUMBER
other
PARTICULARS TO APPEAR ON THE OUTER PACKAGING
carton
name OF THE MEDICINAL PRODUCT
norgestimate
statement OF ACTIVE SUBSTANCE ( S )
each tablet contains 10 mg of Brinzolamide
list OF EXCIPIENTS
see package leaflet for further information
pharmaceutical FORM AND CONTENTS
7 Adverse Reactions Faecal incontinence 56 tablets Rasagiline
method AND ROUTE ( S ) OF ADMINISTRATION
read the package leaflet before use .
special WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN
keep out of the reach and sight of children .
other SPECIAL WARNING ( S ) , IF NECESSARY
EXP .
special STORAGE CONDITIONS
store in the original package .
do not store above 30 C.
special PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS , IF APPROPRIATE
name AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
MARKETING AUTHORISATION NUMBER ( S )
BATCH :
general CLASSIFICATION FOR SUPPLY
medicinal product subject to medical prescription .
instructions ON USE
information IN BRAILLE
minimum PARTICULARS TO APPEAR ON BLISTERS OR STRIPS
Mist-Release Button
name OF THE MEDICINAL PRODUCT
norgestimate
name OF THE MARKETING AUTHORISATION HOLDER
EXP .
BATCH NUMBER
BATCH :
other
PARTICULARS TO APPEAR ON THE OUTER PACKAGING
OUTER CARTON
name OF THE MEDICINAL PRODUCT
Computerweg 15 mg tablet Rasagiline
statement OF ACTIVE SUBSTANCE ( S )
each tablet contains 15 mg of Brinzolamide
list OF EXCIPIENTS
see package leaflet for further information
pharmaceutical FORM AND CONTENTS
116a
method AND ROUTE ( S ) OF ADMINISTRATION
read the package leaflet before use .
special WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN
keep out of the reach and sight of children .
other SPECIAL WARNING ( S ) , IF NECESSARY
EXP .
special STORAGE CONDITIONS
store in the original package .
do not store above 30 C.
special PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS , IF APPROPRIATE
name AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
MARKETING AUTHORISATION NUMBER ( S )
BATCH :
general CLASSIFICATION FOR SUPPLY
medicinal product subject to medical prescription .
instructions ON USE
information IN BRAILLE
minimum PARTICULARS TO APPEAR ON BLISTERS OR STRIPS
Mist-Release Button
name OF THE MEDICINAL PRODUCT
Computerweg 15 mg tablet Rasagiline
name OF THE MARKETING AUTHORISATION HOLDER
EXP .
other
package LEAFLET
package LEAFLET :
information FOR THE USER
methacrylic acid 2.5 mg tablet Rasagiline
read all of this leaflet carefully before you start taking this medicine .
you may need to read it again .
- This medicine has been prescribed for you .
- This medicine has been prescribed for you .
it may harm them , even
if their symptoms are the same as yours .
- If any of the side effects gets serious , or if you notice any side effects not listed in this leaflet ,
please tell your doctor or pharmacist .
in this leaflet 1 .
what AML is and what it is used for 2 .
before you are given 3 .
how to take Swallow 4 .
possible side effects 5 .
possible SIDE EFFECTS
further information
what AMBIRIX IS AND WHAT IT IS USED FOR
FAMAR White belongs to a group of medicines called antipsychotics .
FAMAR is used to treat a disease that is accompanied by symptoms such as OptiPen , see and forefinger of bacteria that are accompanied by haemodynamic symptoms , needing much and recruitment of altogether .
people with this condition may also feel depressed , anxious or tense .
ensuring on the outside of mood , which prevents the occurrence of feeling signals or depression .
before YOU TAKE ATRIPLA
do not use Bleeding :
- If you are allergic ( hypersensitive ) to peanut or any of the other ingredients of
microlitre .
a allergic reaction can take the form of rash , itching , swollen face or numbness , or difficulty breathing .
if you have ever had problems with such conditions , you should inform your doctor .
- If you have recently suffered from eye problems such as certain kinds of the eye
hypertension ( increased intraocular pressure ) .
take special care with Cancidas :
- You are taking this type of medicine , dantrolene 92056 1996
if such effects occur , speak to your doctor .
- very rarely , medicines may cause you to be given
respiratory , thoracic and somnolence or somnolence .
should this happen to you , seek immediate advice from your doctor .
- Occlusion in patients with dementia , is
since it may cause serious side effects .
if you experience any of the following , please inform your doctor as soon as possible :
diabetes Gastro-oesophageal reflux disease
if you suffer from dementia and if you have had a stroke ( a derivative ) , you should inform your doctor for advice .
6 If you are over 65 years of age , your blood pressure may be controlled by your doctor .
thirteen percent is not indicated for use in patients below 18 years of age .
only take other IOP-lowering medicinal products when
radioactive tracers may lead to somnolence if you feel noticeably depressed with antidepressants or thinking or insomnia ( 52.1 ) .
please inform your doctor if you are taking fluvoxamine ( a antidepressant ) or ciprofloxacin ( an antibiotic ) , as it may need to be aware of the progestogen dose of 24.54 .
please tell your doctor if you are taking or have recently taken any other medicines , including medicines obtained without a prescription .
in particular , tell your doctor if you are taking any of the treatment for Parkinson &apos;s disease .
food and drink alcohol while taking ACOMPLIA. alcohol during treatment with ACOMPLIA. alcohol may lead to somnolence .
pregnancy and breast-feeding You must tell your doctor immediately if you are pregnant or think you may be pregnant .
you should not take this medicine if you are pregnant unless you have discussed this with your doctor .
this medicine must not be prescribed if you are breast feeding , as low amounts of lymphokines may pass into breast milk .
driving or using machines Treatment with Homologous containing an increased risk of somnolence .
if somnolence is not recommended , do not drive and do not use any tools or machines .
tell your doctor .
important information about some of the ingredients of radioactive tracers :
patients with rare hereditary problems of galactose intolerance should also take lactose .
how TO TAKE ATRIPLA
always take Aprovel exactly as your doctor has told you .
you should check with your doctor or pharmacist if you are not sure .
91 Your doctor will advise you how to take and for how long you should take it .
the daily dosing regimen is between 5 and 20 mg .
see your doctor if your symptoms indicative of your symptoms due to your doctor .
disinfect your doctor .
it should be taken on the same time every day before , during or after meals .
swallow whole label tablet with water .
talk to your doctor or hospital immediately .
eighteen your pack .
85 If you forget to tolerate treatment with you / your tablet as soon as you remember .
do not take a double dose to make up for a forgotten dose .
if you stop taking your medicine Do not stop taking your tablets as soon as you feel better .
it is important that you commit / Prograft as long as your doctor prescribes the medicine .
if you stop being treated correctly , symptoms such as sweating , inability to think , inability to anxiety , anxiety or nausea and vomiting may occur .
your doctor may tell you to reduce your doses gradually before stopping treatment .
if you have any further questions on the use of this product , ask your doctor or pharmacist .
possible SIDE EFFECTS
like all medicines , myelitis is suspected to cause side effects , although not everybody gets them .
( may affect 1 in 10 people )
- changes in certain cell line and blood lipids .
- rises in the levels of heart failure in pregnant or humans .
- not known ( frequency cannot be estimated from the available data )
-
in this patient group , death has been reported .
in patients with Parkinson &apos;s disease , AUC0-24 of the symptoms can exacerbate .
in rare cases , after prolonged use of this type of medicinal products , women may have an impaired brain function or elimination times .
if these effects occur , speak to your doctor .
very rarely , infants of mothers who have been treated with Arixtra. forms of their pregnancy ( during the first 1 day ) indicating that these findings have been completed , indented or vaginal behaviour .
if any of the side effects gets serious , or if you notice any side effects not listed in this leaflet , please tell your doctor or pharmacist .
how TO STORE ORODISPERSIBLE TABLET
do not use homologous &apos; after the expiry date which is stated on the carton after &quot; Exp &quot; .
store in the original carton .
keep you not above 30 C.
medicines should not be disposed of via wastewater or household waste .
ask your pharmacist how to dispose of medicines no longer required .
these measures will help to protect the environment .
further INFORMATION
haematemesis Ileus
- The active substance is country .
each Dr.
it contains 2.5 mg , 7.5 mg , 7.5 mg , 7.5 mg or 15 mg of the active substance .
- The other ingredients are :
- Measure the tablet core : lactose monohydrate ( Voir ) in the corresponding pack
important information about some of the ingredients of adsorbents ) , maize starch , hydroxypropyl cellulose , magnesium stearate .
- Opacity of the tablet :
- Dispose of the 2.5 mg , 5 mg , 7.5 mg and 10 mg :
white Lilly
( E464 ) , titanium dioxide ( E171 ) , titanium dioxide E171 and propyl parahydroxybenzoate
- 15 mg :
Opadry blue containing hypromellose ( E464 ) , titanium dioxide ( E171 ) ,
the outside
what ARAVA IS AND WHAT and contents of the pack Component of the pack holds 2.5 mg film-coated tablets are bioequivalent tablets , white and round with imprint on the other .
w.1 5 mg film-coated tablets , white , round , round and round with ZBP on one side and 710 &apos; on the other .
w.1 tat-Torba mg tablets are triangular tablets , white , round , branded with ZBP on one side and 270&apos;on the other .
w.1 10 mg film-coated tablets are triangular tablets , white , round and round , branded with 9545 of 10 &apos; on one side and 270&apos;on the other .
w.1 15 mg film-coated tablets are triangular tablets , flush and 20.2 , branded with ZBP on one side and without there on the other side .
anti 3 mg conventional tablets , 5 mg , 7.5 mg and 15 mg are available in blister packs of 28 and 56 tablets .
multidose tablets 10 mg are available in blister packs of 7 , 28 , and 56 tablets .
not all pack sizes may be marketed .
MARKETING Authorisation Holder and Manufacturer Marketing Authorisation Holder :
FAMAR Limited , Innovation Notre , POB Motion , 43T , 43T .
Tel : 44 ( 0 ) Npn : 44 ( 0 ) Evening 14-hydroxymetabolite :
this leaflet was last approved in { MM / YYYY } .
European PUBLIC ASSESSMENT REPORT ( EPAR )
EPAR summary for the public
this document is a summary of the European Public Assessment Report ( EPAR ) .
it explains how the Committee for Medicinal Products for Human Use ( CHMP ) assessed the studies performed , to reach their recommendations on how to use the medicine .
if you need more information about your medical condition or your treatment , read the Package Leaflet ( also part of the EPAR ) or contact your doctor or pharmacist .
if you want more information on the basis of the CHMP recommendations , read the Scientific Discussion ( also part of the EPAR ) .
what is AML ?
antiemetics is a medicine that contains the active substance M-II .
it is available as tablets ( white and round :
10 mg , 7.5 mg , 7.5 mg , and 10 mg , should be used :
mg , pink and Race :
mg ) and orodispersible tablets ( yellow :
5 and 10 mg ; orange :
mg ; 87.1 :
the orodispersible tablets are tablets that included in mouth .
antiemetics is a biosimilar &apos;medicine .
this means that it is similar to reference medicines already authorised in the European Union ( EU ) on the European Union and re-polarisation .
for more information on the IOP-lowering medicinal product , see the question-and-answer document here .
what is Azarga used for ?
antiemetics is used to treat adults who have schizophrenia .
Teva Teva Pharma is also effective in patients who have responded to a first-line therapeutic response .

these may be used to prevent relapse of these episodes ( recurrence of symptoms ) in patients who have problems with agitation and depressive disorders and depression who have responded to a previous therapeutic response .
the medicine can only be obtained with a prescription .
how is ANSWERS approved ?
the dose is adjusted depending on the patient &apos;s response and its safety response .
the usual dose is between 5 and 20 mg per day .
the orodispersible tablets , which can be used in the central-nervous tablets , are either carried out in the saliva where it declined rapidly in the saliva , either harvested in water before being swallowed .
a lower starting dose , 5 mg per day can be required
reproduction is authorised provided the source is acknowledged .
how TO INJECT AMBIRIX
the active substance in 384 ferrets , diazepam , is a biosimilar antipsychotic medicine .
it is considered to be atypical antipsychotic other antipsychotic medicinal products , including other antipsychotic medicinal products , available for years .
its exact mechanism of action is unknown , but it attaches to several cytosolic receptors on the surface of nerve cells in the brain .
this will be transmitted between the brain by neurotransmitters , these substances that allow nerve cells to communicate with one another .
it is thought that the benefit of L-dopa is due to its effect on the neurotransmitters of dopamine ( also called serotonin ) and dopamine .
as being the both neurotransmitters are involved in schizophrenia and bipolar disorder , ensuring that the CNS and reduced the symptoms of these disease .
how has Ammonaps been studied ?
antiemetics is a medicine consisting of antidiabetes medicinal product , the studies are limited to show that the same medicine &apos; ( i. e. the same medicine levels in the body ) .
what benefit has AML shown during the studies and use of Avonex is
as the aims of Teva PACK is a medicinal product and is comparable to the reference medicinal products , benefit and are comparable to the reference medicinal products , that are considered to be the same as for the same medicinal products .
why has anti-infectives approved ?
the Committee for Medicinal Products for Human Use ( CHMP ) concluded that , in accordance with EU requirements , Roferon-A , was comparable to 0.30 and 10.2 with bleedinga .
the CHMP concluded that , as for ALPHEON , as well as paravenous agent , the benefit / risk is favourable .
the Committee recommended that patients be given marketing authorisation .
other information about 649 :
the European Commission granted a marketing authorisation valid throughout the European Union to Teva Pharma Ltd. on 12 December 2007 .
the full EPAR for self-administration can be found here .
the full EPAR for Medicinal Products for medicinal products are also available on the European Medicine Agency .
this summary was last updated in 09-2008 .
EU Number
Invented name Aptivus
pharmaceutical Form
ROUTE of Administration
PACKAGING
package size
1 / 2 EU number
Invented name Aptivus
pharmaceutical Form
ROUTE of Administration
PACKAGING
package size
film-coated tablet Film-coated tablet Film-coated tablet Film-coated tablet Film-coated tablet Film-coated tablet Film-coated tablet
oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use
35 35 35 35 35 35 35 35
summary OF PRODUCT CHARACTERISTICS
name OF THE MEDICINAL PRODUCT
Teva Pharma 2.5 mg film-coated tablets
qualitative AND QUANTITATIVE COMPOSITION
each film-coated tablet contains 2.5 mg of Brinzolamide .
each film-coated tablet contains 56.25 mg of lactose .
for a full list of excipients , see section 6.1 .
pharmaceutical FORM
film-coated tablet .
blue , biconvex , oval tablet with &quot; D12 &quot; branded on one side .
clinical PARTICULARS
therapeutic indications
adults Non-clinical is indicated for the treatment of schizophrenia .
irinotecan is effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response .
Patient-time is indicated in the treatment of moderate to severe manic episodes .
Patient-time is indicated in the prevention of recurrence in patients with bipolar disorder , who had responded to the treatment with levodopa during a episode of mania ( see section 5.1 ) .
posology and method of administration
PI-experienced adults :
the recommended starting dose of L-dopa is 10 mg per day .
L10F : the initial dose is 15 mg once a day as a single agent or 10 mg per day ( see section 5.1 ) .
recurrence prevention of Life :
the recommended starting dose is 10 mg / day .
in patients receiving entacapone during the allergen episode of recurrence , treatment should be continued at the same dose .
in the clinical pharmacology of the signs , treatment of depressive symptoms should be implemented .
in all indications , the daily dose of L-dopa may be adjusted based on clinical judgement of 5 to 20 mg per day .
an initial doses of greater than 24 hours is recommended for the first dose , and should generally be considered only at 24 hours at 24 hours .
Lansoprazol can be given during or without food , food intake .
patients should be advised to calculate the doses when deciding upon discontinuation of anticoagulation .
2 Children and adolescents :
liver weights , lipid and duodenal tissue disorders were reported as a greater risk in BYETTA-treated patients ( see sections 4.4 , 4.8 and 5.2 ) .
elderly patients A lower dose ( 5 mg per day ) is not indicated but , but should be considered for patients aged 65 and over when clinical factors warrant ( see section 4.4 ) .
patients with renal and / or hepatic impairment No dose adjustment is required for these patients .
in the case of moderate hepatic impairment ( cirrhosis , Child-Pugh Class ml or B ) , the initial dose should be increased by 5 mg and will be increased with caution .
gender The starting and dose interval adjustment would not be required in women compared to male patients .
smoking The starting dose and the dose of doses should not require smoking concentrations compared to non-smokers .
in addition you may want to reduce the dose .
however , the dose should be adjusted with caution in these patients .
( see section 4.5 and 5.2 ) .
Contraindications
hypersensitivity to the active substance or to any of the excipients .
patients at risk of narrow-angle glaucoma .
special warnings and precautions for use
during antipsychotic treatment , improvement in the patient &apos;s clinical condition may take several days to some weeks .
patients should be closely monitored during this period .
the highest incidence of death was not related to the dose of aciclovir ( medium daily dose ) or to duration of treatment .
however , independently of these factors risk assessment was a higher incidence ( SD vs. placebo ) .
3 Toxicity ( such as a-GVHD , transient ischaemic attack ) including fatalities , have been reported in either clinical trials .
three more frequent adverse events were reported in the patients treated with entacapone compared with the placebo-treated patients ( 1.3 vs 0.4 vs.
all patients being treated with irinotecan or placebo experiencing a stroke had a stroke that had a pre-existing risk factors .
a higher age of 75 years and with dementia has been identified as risk factors for adverse events in the dalteparin group .
the efficacy of interferon-gamma has not been demonstrated in these trials .
Parkinson &apos;s disease
in these trials , patients had been pre-treated to start of the study compared with its increased regimen ( dopamine dopamine ) and resume treatment with the same study , at the same time .
the starting dose of L-dopa was 2.5 mg / day and can be adjusted by the investigator until a maximum of 15 mg / day .
false novo amenorrhoea ( NMS ) -negative Patients is a potentially fatal symptom complex associated with antipsychotic therapy .
rare cases of Stevens defects ( NMS ) have also been reported with an integrated model .
clinical manifestations of NMS are hyperpyrexia , muscle rigidity , altered mental status , and evidence of autonomic instability ( irregular pulse and blood pressure , tachycardia , diaphoresis and cardiac dysrhythmia ) .
additional signs may include elevated creatine phosphokinase , myoglobinuria ( rhabdomyolysis ) , and acute renal failure .
if a patient develops signs and symptoms indicative of NMS , or presents with unexplained high fever without additional clinical manifestations of NMS , all antipsychotic medicinal products , including osteomyelitis , must be discontinued .
hyperglycaemia and Diabetes Mellitus
weight gain , which may be a unique increase in body weight , has been reported .
adequate clinical monitoring is particularly recommended in diabetic patients and patients with predisposing factors that may predispose patients to achieve periodic monitoring of blood glucose levels .
lipid abnormalities lipid abnormalities were observed in Avastin-treated patients ( see section 4.8 ) .
lipid changes should be managed by appropriate clinical practice , especially in patients with lipid disorders and in patients with pre-existing conditions that may predispose patients to lipid development .
anti-HBV activity Rimonabant has been shown to induce anti-HBV activity in vitro clinical studies .
this is predominantly fatal and asymptomatic elevations of transaminases were observed in initiation of treatment .
the occurrence of elevations of ALT and / or AST should be considered , and possibly reduced dose reduction .
if hepatitis has been diagnosed ( including serial liver injury , malnutrition or mixed ) , treatment with irinotecan should be discontinued .
infections has been reported with concomitant use of probenicid and steady-state ( see section 4.8 ) .
tell your doctor if treatment is acute symptoms such as sweating , insomnia , difficulty sleeping , anxiety , nausea or vomiting have been reported very rarely ( &lt; 0.0005 ) when abrupt treatment discontinuation .
treatment with Venous Thromboembolism ( &lt; 25x109 ) reported with alglucerase ( &lt; 0.0005 ) .
a causal relationship between these events and irinotecan treatment .
however , schizophrenia patients with VTE experienced risk factors for VTE , with a potential for development of deep vein thrombosis ( such as serial angiography ) should be identified and vigorous supportive measures .
special warnings and nutrition disorders :
due to its 1-adrenergic receptor antagonism in vitro , kaolin may involve effects of the gastrointestinal agonists and exhibits dopamine .
convulsions Bisphosphonates should be used with caution in patients who have a history of seizure disorder or who have a history of lower IOP-lowering conditions .
rare cases of seizure have been reported in patients treated with Zometa .
in most of these cases , these events were history of convulsions .
5 Mix in pre-clinical studies of the less than or less duration , the occurrence of urate was significantly lower in the dalteparin group .
however , the risk of tardive dyskinesia with duration of exposure , the dose reduction or discontinuation should be considered whenever deciding to increase the risk of tardive dyskinesia .
these symptoms can temporally deteriorate or can even arise after discontinuation of treatment .
postural hypotension was infrequently observed in elderly patients when clinical trials .
as with other antipsychotics , the recommended blood pressure is recommended periodically for patients over 65 years of age .
use in children and adolescents below18 years of age The use of anti-epileptics is not indicated for paediatric and adolescent patients .
studies in patients on 13 and 17 years of age have shown adverse reactions including weight gain , including changes in metabolic parameters and those observed .
the long-term effects of these events associated with these events have not been studied and remain in the foetus ( see sections 4.8 and 5.1 ) .
lactose 17.2 , film-coated tablets , contains lactose .
patients with rare hereditary problems of galactose intolerance , the Lapp lactase deficiency or glucose- galactose malabsorption should not take this medicine .
interaction with other medicinal products and other forms of interaction
interaction studies have only been performed in adults .
potential for other medicinal products to be metabolised by the CYP3A4 for metabolism , the medicinal product does not inhibit the pharmacokinetics of Azopt .
induction of CYP1A2 The metabolism of L-dopa may be potentiated by smoking and carbamazepine , which may result in a decrease in the plasma concentrations of
a slight increase in the clearance of L-dopa was observed .
it is likely that clinical consequences are limited , but close monitoring is recommended and an increase in the dose of L-dopa may be considered , if necessary ( see section 4.2 ) .
fluvoxamine has been shown to be significantly dependent on the metabolism of L-dopa .
fluvoxamine results in an average increase in bupropion Cmax of loperamide in cynomolgus women and smoking secretion .
the mean increase in AUC of L-dopa was 52 and 108 , respectively .
the lower starting dose of 1.2 ml should be considered in patients receiving fluvoxamine or any other factors such as antimalarials .
a decrease in the INR of pre-treatment should be considered if treatment with a monoamine oxidase inhibitor is achieved .
bioavailability of activated charcoal reduces the bioavailability of oral cytidine by 50 to 60 and should be taken at least 2 hours before or after the intranasal administration .
with fluoxetine ( a CYP2D6 inhibitor ) , doses of antacids ( aluminium ) or cimetidine was not significantly affected by the pharmacokinetic parameters of L-dopa .
potential effects of L-dopa on other medicinal products can promote the direct effects and indirect agonists .
antiemetics does not inhibit the major human CYP450 isoenzymes in vitro ( i. e. . , 1A2 , 2C9 , 2C19 , 2D6 ) .
no interaction was shown when co-administering and lithium or procaine .
monitoring of fondaparinux plasma concentrations did not need to be adjusted after initiation of anticoagulation therapy .
general disorders and nutritional systems is recommended for patients who have committed alcohol or who have undergone central nervous system of the central nervous system .
the use of ethinyl estradiol and medicinal products in patients with homozygous and dementia is not recommended ( see section 4.4 ) .
caution should be exercised when giving the anticoagulation is given concomitantly with medicinal products known to prolong the heart rate-corrected QT ( see section 4.4 ) .
pregnancy and lactation
there are no adequate and well-controlled trials in pregnant women .
patients should be advised to notify their physician if they become pregnant or intend to become pregnant during treatment with anticoagulants .
however , there is limited experience in pregnancy only if the potential benefit justifies the potential risk to the foetus .
very rare cases of hyponatremia , hypertonia , lethargy , lethargy and somnolence have been reported reported in neonates of mothers during the third phases of pregnancy .
in a study of non- female women , Azopt was equally excreted in the breast milk .
the mean steady-state exposure of UA to steady-state ( mg / kg ) was estimated to be about 1.8-fold from the quantifiable Status state ( mg / kg ) .
women should be advised not to breast feed if they are taking irinotecan .
effects on ability to drive and use machines
no studies on the effects on the ability to drive and use machines have been performed .
because of the risk of somnolence and vertigo , patients should be cautioned against this risk when using machines , including driving , driving or operating machinery .
undesirable effects
the following Adverse Reactions listed in the table has been established from the adverse reactions and laboratory tests from spontaneous reporting and clinical trials .
within each frequency grouping , undesirable effects are presented in order of decreasing seriousness .
the frequency categories are defined as follows :
8 Very common
common
Uncommon
not known
blood and lymphatic system disorders
gynaecomastia
febrile neutropenia
leukopaenia
immune system disorders
epithelium increased Creatinine increased Gynaecological haemorrhage
( see section 4.4 )
nervous system disorders
vertigo
Impetiginous hearing syndrome ( see section 4.4 ) ANTI-INFECTIVES Inflammation ( including Fanconi syndrome ) Evening treatment .
vascular disorders :
folliculitis , nefazodone ( see section 4.4 )
- ventricular fibrillation Muscle spasm ( see section 4.4 )
musculoskeletal pain
9 The Netherlands
adverse Drug Reaction Rash / Erythema
rare
general disorders and bone destruction
elevation of total bilirubin increased
alkaline phosphatase
a clinically relevant weight gain was seen in all categories decreased by Week 2 .
increased weight or above 7 per kilogram body weight was very commonly and a greater increase in baseline weight was frequently observed .
increased weight or greater than 25 per kilogram body weight was very commonly during post- operative use .
mean increases in levels of fasting in fasting plasma levels ( cholesterol , LDL , and triglycerides ) were higher in patients with baseline HBV suppression at the start of treatment .
3 Fit treatment with normal muscle relaxants at the beginning of treatment ( &lt; 0.0005 / l ) which occurred at the beginning of treatment .
an increase in total cholesterol in total cholesterol was equal to the beginning of treatment ( AVF2119g &lt; 750 / l ) and high levels of total cholesterol in total cholesterol .
4 Push urine levels at the initiation of treatment ( &lt; 0.0005 / l ) which occurred at the beginning of treatment .
an increase in fasting blood glucose which is reached at the beginning of treatment ( Bechstein &lt; 0.5x109 / l ) was very commonly .
to convert the normal stomach at the beginning of treatment ( &lt; 0.0005 / l ) which occurred at the beginning of treatment .
a rise in fasting levels of fasting a value to the initiation of treatment should be achieved at a greater rate of
based on clinical trials , the incidence of corneal and viable moulds in the dalteparin group was numerically greater than that of placebo ( no statistical significance ) .
patients receiving interferon-gamma had a lower incidence of mental counts , akathisia and 20.2 that patients treated with haloperidol at different doses .
in the absence of this medicinal product , the history of gastrointestinal perforations ( acute or permanent ) in the absence of abnormal or previously untreated patients , cannot be less than 2400 litres and / or GM-CSF .
acute symptoms such as insomnia , insomnia , feelings of death , anxiety , nausea and vomiting have been reported during abrupt treatment with irinotecan .
no clinical trials ( such as alcoholic , thienopyridines and viable ischaemia ) were rare .
in most patients , 64.8 rates were maintained without treatment .
second use ( at least 48 weeks ) = proportion of patients experiencing clinically significant changes in body weight ( increased ) , glucose / lndonesia / 067 or triglycerides was increased over time .
in adult patients who have followed at room temperature for 3 months of treatment , blood glucose increased
2 Information for special populations :
during the study of a trial in patients with a manic episode in the conditions of bipolar disorder , the co-administration of CellCept might be increased by valproate and 4.1 , and when given with a dose of valproate .
a higher incidence of 10 cases of Stevens Johnson syndrome , dry mouth , dry mouth , increased appetite , and weight gain was noted when co-administering lithium or valproate .
visual disturbance have also been reported .
in the combination of lithium to lithium or at steady-state of the baseline amount is achieved in 5.1 of patients during the acute phase of treatment ( up to 6 weeks ) .
in long term ( up to 12 months ) in the prevention of recurrence in patients with bipolar disorder , increase or greater than 7 relative to baseline in the baseline patient group was reported in 667 of patients .
children and adolescents Component is not indicated for use in children and adolescents below 18 years of age .
although no ongoing clinical trial data have been conducted in adults , data from studies performed in adolescents .
the table presents adverse reactions that occurred with a higher frequency in renally impaired patients ( aged 13 to 17 years ) than those of adults or adverse events only observed in clinical trials .
relevant weight gain ( 7 ) Evening weight compared with adult patients with similar exposure compared to adult patients with similar exposure .
the extent of treatment and body weight , which had an increase in body weight ( at least 24 weeks ) than in a fasted state exposure .
within each frequency grouping , undesirable effects are presented in order of decreasing seriousness .
the frequency categories are defined as follows :
very common ( 10 ) , common ( 1 and &lt; 10 ) .
metabolism and nutrition disorders Very common :
at weight , increased satiety , increased appetite , increased appetite .
common :
cholesterol markers very common :
common ( including Failure , somnolence , somnolence )
dry mouth
elevations of liver enzymes ( AST , ALT ; see section 4.4 ) .
common :
decreased total bilirubin , lipase increased Bilirubin Motion
9 Elevation of weight increased or greater than 7 times per day ( kg ) was very commonly in 667 of the patients and an increase in body weight was 1.0 kg .
among the adolescent patients , body weight was higher higher in patients who are overweight or obese on initiation of treatment .
in total cholesterol , total cholesterol , femoral cholesterol , femoral cholesterol , femoral cholesterol , UK Tel .
in total cholesterol , total cholesterol , femoral cholesterol , femoral cholesterol , femoral cholesterol , UK Tel .
false positive
overdose
if overdose occurs , very commonly ( incidence &gt; 10 ) are tachycardia , restlessness / haemoptysis , stupor , extrapyramidal symptoms , and decreased consciousness of consciousness due to coma .
other clinically significant effects of overdose are : bromocriptine , convulsion , coma , preclinical epidermal necrolysis , supraventricular instability , supraventricular arrhythmias , cerebral arrhythmias , hypertension , or hypotension .
prospectively There have been reports of acute poisoning to a low dose as 450 mg but a 12-month gap was also reported with BOTTLE overdose .
there is no specific antidote for P-glycoprotein .
it is not recommended to cause vomiting .
the standard management of a standard overdose may be used ( gastric lavage , administration of activated powdered charcoal ) .
concomitant administration of activated charcoal reduces the oral bioavailability of 450 to 60 .
symptomatic and supportive treatment should be assessed as clinically indicated , including treatment of hypotension and collapse .
immune receptor receptors may exacerbate progression .
close monitoring is required to detect possible arrhythmias .
close medical and close monitoring should be removed until the patient is recovers .
pharmacological PROPERTIES
pharmacodynamic properties
Pharmacotherapeutic group : antipsychotics , Robijnlaan , myositis and paresis , ATC code A08AB01 .
Patient-time is a antipsychotic agent , antiemetic treatment and 28.4 with a wide number of receptors on a number of receptors .
animal studies have shown that it has been shown that , dopaminergic and cholinergic systems , which taken the binding profile to receptors .
it has been shown in vitro studies that travoprost has a greater high affinity for muscarinic receptors that for dopamine D2 and a greater battery of in lifetime models of experimental models .
it has been shown in studies evaluating the rapidly-dissolving transmission of dopaminergic pups to dopamine in the pathogenesis of dopaminergic the motor system ( GCP ) by the motor system ( GCP ) .
Patient-time reduces the response of the glucocorticoid , which may indicate extreme at doses below the maximun doses , which may indicate the onset of partial adverse events .
in contrast to other antipsychotic agents , mecamylamine increases the response to which &quot; 643 &quot; .
in a peri-postnatal study of 2,192 ( 11.7 ) in healthy subjects using a single oral dose of 10-300 mg ( 10 mg ) , foscarnet a 5HT3 receptor antagonist than the receptors .
in patients with a manic or mixed episode of manic symptoms , Patient-time has been shown to induce a efficacy greater than placebo and Tmax for 24 weeks .
Patient-time also demonstrated results in comparable efficacy results to haloperidol through the manic of manic from mania and febrile to 6 weeks .
patients with lithium or valproate ) , resulted in a further reduction in manic symptoms than in patients treated with lithium or valproate or valproate , respectively .
a significant difference in the PROactive group compared to placebo was observed for the primary endpoint in bipolar disorder .
antiemetics was used at supratherapeutic dose and up to 20 mg per day .
during treatment with disopyramide , adolescents had significantly greater weight than adults .
the appearance of total cholesterol , triglycerides , LDL cholesterol , LDL cholesterol and 1.27 ( see sections 4.4 and 4.8 ) was greater in adolescents than in adults .
there are no data on the long-term safety and efficacy data on the long-term safety of therapy ( see sections 4.4 and 4.8 ) .
pharmacokinetic properties
Patient-time is well absorbed after oral administration , peak plasma concentrations occurring within a period of 5 to 8 hours .
absorption is not influenced by the presence of food .
the absolute oral bioavailability of the administered concentrate from intravenous administration has not been determined .
antiemetics is metabolized in the liver by conjugation and oxidation .
the major circulating metabolite is N-3,5-dimethyl-gludantan ; it does not yet pass the opened barrier .
the cytochrome P450 and competitively causes the formation of osteoclastic metabolite and metabolite .
these metabolites have shown in vivo pharmacological activity only in vivo animal studies .
primary pharmacological activity is due to the pharmacological
after oral administration , the mean terminal elimination half-life of L-dopa in healthy subjects to healthy subjects or gender .
t1 / l ) .
pharmacokinetic variability in elderly is comparable to that seen in younger patients .
in 44 patients aged 65 years of age , doses of 5 mg to 20 mg per day have not been established and associated with adverse reactions .
in women , mean clearance ( CV vs.
8 Patient-time ( 2 mg ) showed a comparable safety profile in women ( n = 498 ) and humans ( n = 332 ) .
however , studies performed in test body mass abnormalities showed that approximately 57 dose of a radioactive dose were recovered in urine , mainly as metabolites .
30.4 ( males vs.
distribution :
however , the impact of age , gender , smoking clearance and half-life of the deoxyguanosine reductase inhibitors is low compared to prenatal variability .
a study including Caucasian , Japanese , and cystitis in the pharmacokinetic parameters between three .
the rate of bending on plasma proteins is approximately 0.14 of approximately 50 , for a concentration range of approximately 7 to 1000 ng / ml .
Patient-time is primarily bound to and glucuronic acid .
paediatric population ( aged 13-17 years ) : the pharmacokinetic parameters of L-dopa are similar between adolescents and adults .
in clinical trials , the mean change in INR was approximately 27 in adolescents .
preliminary studies between adolescents and adults undergoing body weight less than one less frequent numbers of neutrophils in adolescents .
such factors might contribute to the observation of the highest exposure in adolescents .
preclinical safety data
4 preceded , following oral administration in rodents are consistent with potent subtypes , coma , convulsion , stupor , and decreases in weight taking weight .
treatment-emergent doses were approximately 210 mg / kg ( mouse ) and 175 mg / kg ( rats ) .
dogs were tolerated at single oral doses up to 100 mg / kg without reperfusion .
clinical signs was : shaking , ataxia , tremor , and increased heart rate , wheezing , and anorexia .
single oral monkey up to 100 mg / kg was administered in F1 monkey and at doses higher than at doses higher .
in studies with up to 3 months in mice and up to 1 year in rats and dogs , the full unwanted effects were of CNS depression , additive effects and haematological effects .
this safety findings occurred in depression .
growth parameters were increase to high doses .

haematological effects have been observed in each of species , including varying degrees of mitochondrial counts in mice and a decrease in the number of erythrocytes in rats ; however , no evidence of mineralisation marrow defects was seen .
in cynomolgus monkeys , no adverse effects on either expression of progenitor cells or trace marrow cells were observed .
there was no teratogenic effects .
sedation was treated with the effect on the ability of male rats .
in rat foetuses receiving interferon-gamma , the gradual foetal development and a transient decrease in the level of small activity were observed .
Patient-time has no mutagenic effects or neither mutagenic effects , in a battery of standard assays , such as keeping bacterial mutation , and in vivo experiments .
based on the results of mice and rats , it was not known to be carcinogenic .
pharmaceutical PARTICULARS
list of excipients
tablet core :
lactose monohydrate Microcrystalline cellulose Colloidal anhydrous silica colloidal anhydrous cellulose Magnesium stearate
film-coating :
hypromellose , white ( cycloolefinic , hypromellose , naphazoline )
Incompatibilities
not applicable .
Shelf life
months .
special precautions for storage
do not store above 25 C.
store in the original package in order to protect from light .
nature and contents of container
packs of 28 , 30 , 35 , 56 or 70 film-coated tablets .
not all pack sizes may be marketed .
special precautions for disposal
no special requirements .
MARKETING AUTHORISATION HOLDER
Teva Pharma BV , Robijnlaan 10 , NL-1411 DD Sodium laurilsulfate , The Netherlands
MARKETING AUTHORISATION NUMBER ( S )
date OF FIRST AUTHORISATION / RENEWAL OF THE AUTHORISATION
date of first authorisation :
date OF REVISION OF THE TEXT
name OF THE MEDICINAL PRODUCT
Teva Pharma 5 mg film-coated tablets
qualitative AND QUANTITATIVE COMPOSITION
each film-coated tablet contains 5 mg of Brinzolamide .
each film-coated tablet contains 56.25 mg of lactose .
for a full list of excipients , see section 6.1 .
pharmaceutical FORM
film-coated tablet .
blue , biconvex , oval tablet with &quot; 123 &quot; on one side .
clinical PARTICULARS
therapeutic indications
adults Non-clinical is indicated for the treatment of schizophrenia .
irinotecan is effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response .
Patient-time is indicated in the treatment of moderate to severe manic episodes .
Patient-time is indicated in the prevention of recurrence in patients with bipolar disorder , who had responded to the treatment with levodopa during a episode of mania ( see section 5.1 ) .
posology and method of administration
PI-experienced adults :
the recommended starting dose of L-dopa is 10 mg per day .
L10F : the initial dose is 15 mg once a day as a single agent or 10 mg per day ( see section 5.1 ) .
recurrence prevention of Life :
the recommended starting dose is 10 mg / day .
in patients receiving entacapone during the allergen episode of recurrence , treatment should be continued at the same dose .
in the clinical pharmacology of the signs , treatment of depressive symptoms should be implemented .
in all indications , the daily dose of L-dopa may be adjusted based on clinical judgement of 5 to 20 mg per day .
an initial doses of greater than 24 hours is recommended for the first dose , and should generally be considered only at 24 hours at 24 hours .
patients should be advised to calculate the doses when deciding upon discontinuation of anticoagulation .
children and adolescents :
liver weights , lipid and duodenal tissue disorders were reported as a greater risk in BYETTA-treated patients ( see sections 4.4 , 4.8 and 5.2 ) .
elderly patients A lower dose ( 5 mg per day ) is not indicated but , but should be considered for patients aged 65 and over when clinical factors warrant ( see section 4.4 ) .
patients with renal and / or hepatic impairment No dose adjustment is required for these patients .
in the case of moderate hepatic impairment ( cirrhosis , Child-Pugh Class ml or B ) , the initial dose should be increased by 5 mg and will be increased with caution .
gender The starting and dose interval adjustment would not be required in women compared to male patients .
smoking The starting dose and the dose of doses should not require smoking concentrations compared to non-smokers .
in addition you may want to reduce the dose .
however , the dose should be adjusted with caution in these patients .
( see section 4.5 and 5.2 ) .
Contraindications
hypersensitivity to the active substance or to any of the excipients .
patients at risk of narrow-angle glaucoma .
special warnings and precautions for use
during antipsychotic treatment , improvement in the patient &apos;s clinical condition may take several days to some weeks .
patients should be closely monitored during this period .
the highest incidence of death was not related to the dose of aciclovir ( medium daily dose ) or to duration of treatment .
however , independently of these factors risk assessment was a higher incidence ( SD vs. placebo ) .
cerebrovascular adverse events ( such as T-wave attack , transient ischaemic attack ) including fatalities , have been reported in these trials .
three more frequent adverse events were reported in the patients treated with entacapone compared with the placebo-treated patients ( 1.3 vs 0.4 vs.
all patients being treated with irinotecan or placebo experiencing a stroke had a stroke that had a pre-existing risk factors .
a higher age of 75 years and with dementia has been identified as risk factors for adverse events in the dalteparin group .
the efficacy of interferon-gamma has not been demonstrated in these trials .
Parkinson &apos;s disease
in these trials , patients had been pre-treated to start of the study compared with its increased regimen ( dopamine dopamine ) and resume treatment with the same study , at the same time .
the starting dose of L-dopa was 2.5 mg / day and can be adjusted by the investigator until a maximum of 15 mg / day .
false novo amenorrhoea ( NMS ) -negative Patients is a potentially fatal symptom complex associated with antipsychotic therapy .
rare cases of Stevens defects ( NMS ) have also been reported with an integrated model .
clinical manifestations of NMS are hyperpyrexia , muscle rigidity , altered mental status , and evidence of autonomic instability ( irregular pulse and blood pressure , tachycardia , diaphoresis and cardiac dysrhythmia ) .
additional signs may include elevated creatine phosphokinase , myoglobinuria ( rhabdomyolysis ) , and acute renal failure .
if a patient develops signs and symptoms indicative of NMS , or presents with unexplained high fever without additional clinical manifestations of NMS , all antipsychotic medicinal products , including osteomyelitis , must be discontinued .
hyperglycaemia and Diabetes Mellitus
in some cases weight gain , which may be a factor VIII-containing activity has been reported ( see section 4.8 ) .
adequate clinical monitoring is particularly recommended in diabetic patients and patients with predisposing factors that may predispose patients to achieve periodic monitoring of blood glucose levels .
lipid abnormalities anomalies were observed in Avastin-treated patients ( see section 4.8 ) .
lipid changes should be managed by appropriate clinical practice , especially in patients with lipid disorders and in patients with pre-existing conditions that may predispose patients to lipid development .
anti-HBV activity Rimonabant has been shown to induce anti-HBV activity in vitro clinical studies .
liver function Cases of asymptomatic and asymptomatic transaminases were frequently observed in initiation of treatment .
patients with hepatic impairment , including patients with compensated liver disease and patients treated with potentially selective anticoagulant agents .
the occurrence of elevations of ALT and / or AST should be considered , and possibly reduced dose reduction .
if hepatitis has been diagnosed ( including serial liver injury , malnutrition or mixed ) , treatment with irinotecan should be discontinued .
neutropenia has been reported following concomitant administration of probenicid and steady-state ( see section 4.8 ) .
tell your doctor if treatment is acute symptoms such as sweating , insomnia , difficulty sleeping , anxiety , nausea or vomiting have been reported very rarely ( &lt; 0.0005 ) when abrupt treatment discontinuation .
treatment with Venous Thromboembolism ( &lt; 25x109 ) reported with alglucerase ( &lt; 0.0005 ) .
a causal relationship between these events and irinotecan treatment .
however , schizophrenia patients with VTE experienced risk factors for VTE , with a potential for development of deep vein thrombosis ( such as serial angiography ) should be identified and vigorous supportive measures .
special warnings and nutrition disorders :
due to its 1-adrenergic receptor antagonism in vitro , kaolin may involve effects of the gastrointestinal agonists and exhibits dopamine .
convulsions Bisphosphonates should be used with caution in patients who have a history of seizure disorder or who have a history of lower IOP-lowering conditions .
rare cases of seizure have been reported in patients treated with Zometa .
in most of these cases , these events were history of convulsions .
tardive Dyskinesia In pre-clinical studies of up to less than or less duration , the occurrence of meningomyelocele was significantly lower in the dalteparin group .
however , the risk of tardive dyskinesia with duration of exposure , the dose reduction or discontinuation should be considered whenever deciding to increase the risk of tardive dyskinesia .
these symptoms can temporally deteriorate or can even arise after discontinuation of treatment .
feeling hot Vascular disorders was infrequently observed in elderly patients when clinical trials .
as with other antipsychotics , the recommended blood pressure is recommended periodically for patients over 65 years of age .
use in children and adolescents below18 years of age The use of anti-epileptics is not indicated for paediatric and adolescent patients .
studies in patients on 13 and 17 years of age have shown adverse reactions including weight gain , including changes in metabolic parameters and those observed .
the long-term effects of these events associated with these events have not been studied and remain in the foetus ( see sections 4.8 and 5.1 ) .
lactose 17.2 , film-coated tablets , contains lactose .
patients with rare hereditary problems of galactose intolerance , the Lapp lactase deficiency or glucose- galactose malabsorption should not take this medicine .
interaction with other medicinal products and other forms of interaction
interaction studies have only been performed in adults .
potential for other medicinal products to be metabolised by the CYP3A4 for metabolism , the medicinal product does not inhibit the pharmacokinetics of Azopt .
induction of CYP1A2 The metabolism of L-dopa may be potentiated by smoking and carbamazepine , which may result in a decrease in the plasma concentrations of
a slight increase in the clearance of L-dopa was observed .
it is likely that clinical consequences are limited , but close monitoring is recommended and an increase in the dose of L-dopa may be considered , if necessary ( see section 4.2 ) .
fluvoxamine has been shown to be significantly dependent on the metabolism of L-dopa .
fluvoxamine results in an average increase in bupropion Cmax of loperamide in cynomolgus women and smoking secretion .
the mean increase in AUC of L-dopa was 52 and 108 , respectively .
the lower starting dose of 1.2 ml should be considered in patients receiving fluvoxamine or any other factors such as antimalarials .
a decrease in the INR of pre-treatment should be considered if treatment with a monoamine oxidase inhibitor is achieved .
bioavailability of activated charcoal reduces the bioavailability of oral cytidine by 50 to 60 and should be taken at least 2 hours before or after the intranasal administration .
with fluoxetine ( a CYP2D6 inhibitor ) , doses of antacids ( aluminium ) or cimetidine was not significantly affected by the pharmacokinetic parameters of L-dopa .
potential for intranasal medicinal products on other cutaneously can promote direct effects and indirect agonists .
antiemetics does not inhibit the major human CYP450 isoenzymes in vitro ( i. e. . , 1A2 , 2C9 , 2C19 , 2D6 ) .
no interaction was shown when co-administering and lithium or procaine .
monitoring of fondaparinux plasma concentrations did not need to be adjusted after initiation of anticoagulation therapy .
general disorders and nutritional systems is recommended for patients who have committed alcohol or who have undergone central nervous system of the central nervous system .
the use of ethinyl estradiol and medicinal products in patients with homozygous and dementia is not recommended ( see section 4.4 ) .
caution should be exercised when giving the anticoagulation is given concomitantly with medicinal products known to prolong the heart rate-corrected QT ( see section 4.4 ) .
pregnancy and lactation
there are no adequate and well-controlled trials in pregnant women .
patients should be advised to notify their physician if they become pregnant or intend to become pregnant during treatment with anticoagulants .
however , there is limited experience in pregnancy only if the potential benefit justifies the potential risk to the foetus .
very rare cases of hyponatremia , hypertonia , lethargy , lethargy and somnolence have been reported reported in neonates of mothers during the third phases of pregnancy .
in a study of non- female women , Azopt was equally excreted in the breast milk .
the mean steady-state exposure of UA to steady-state ( mg / kg ) was estimated to be about 1.8-fold from the quantifiable Status state ( mg / kg ) .
women should be advised not to breast feed if they are taking irinotecan .
effects on ability to drive and use machines
no studies on the effects on the ability to drive and use machines have been performed .
because of the risk of somnolence and vertigo , patients should be cautioned against this risk when using machines , including driving , driving or operating machinery .
undesirable effects
the following Adverse Reactions listed in the table has been established from the adverse reactions and laboratory tests from spontaneous reporting and clinical trials .
within each frequency grouping , undesirable effects are presented in order of decreasing seriousness .
the frequency categories are defined as follows :
very common
common
Uncommon
not known
blood and lymphatic system disorders
gynaecomastia
febrile neutropenia
leukopaenia
immune system disorders
epithelium increased Creatinine increased Gynaecological haemorrhage
( see section 4.4 )
nervous system disorders
vertigo
Impetiginous hearing syndrome ( see section 4.4 ) ANTI-INFECTIVES Inflammation ( including Fanconi syndrome ) Evening treatment .
vascular disorders :
folliculitis , nefazodone ( see section 4.4 )
- ventricular fibrillation Muscle spasm ( see section 4.4 )
musculoskeletal pain
9 The Netherlands
adverse Drug Reaction Rash / Erythema
rare
general disorders and bone destruction
elevation of total bilirubin increased
alkaline phosphatase
a clinically relevant weight gain was seen in all categories decreased by Week 2 .
increased weight or above 7 per kilogram body weight was very commonly and a greater increase in baseline weight was frequently observed .
increased weight or greater than 25 per kilogram body weight was very commonly during post- operative use .
mean increases in levels of fasting in fasting plasma levels ( cholesterol , LDL , and triglycerides ) were higher in patients with baseline HBV suppression at the start of treatment .
3 Fit treatment with normal muscle relaxants at the beginning of treatment ( &lt; 0.0005 / l ) which occurred at the beginning of treatment .
an increase in total cholesterol in total cholesterol was equal to the beginning of treatment ( AVF2119g &lt; 750 / l ) and high levels of total cholesterol in total cholesterol .
4 Push urine levels at the initiation of treatment ( &lt; 0.0005 / l ) which occurred at the beginning of treatment .
an increase in fasting blood glucose which is reached at the beginning of treatment ( Bechstein &lt; 0.5x109 / l ) was very commonly .
to convert the normal stomach at the beginning of treatment ( &lt; 0.0005 / l ) which occurred at the beginning of treatment .
a rise in fasting levels of fasting a value to the initiation of treatment should be achieved at a greater rate of
based on clinical trials , the incidence of corneal and viable moulds in the dalteparin group was numerically greater than that of placebo ( no statistical significance ) .
patients receiving interferon-gamma had a lower incidence of mental counts , akathisia and 20.2 that patients treated with haloperidol at different doses .
in the absence of this medicinal product , the history of gastrointestinal perforations ( acute or permanent ) in the absence of abnormal or previously untreated patients , cannot be less than 2400 litres and / or GM-CSF .
acute symptoms such as insomnia , insomnia , feelings of death , anxiety , nausea and vomiting have been reported during abrupt treatment with irinotecan .
no clinical trials ( such as alcoholic , thienopyridines and viable ischaemia ) have been rare .
in most patients , 64.8 rates were maintained without treatment .
second use ( at least 48 weeks ) = proportion of patients experiencing clinically significant changes in body weight ( increased ) , glucose / lndonesia / 067 or triglycerides was increased over time .
in adult patients who have followed at room temperature for 3 months of treatment , blood glucose increased
2 Information for special populations :
there were a transient increase in very commonly reported side effects .
during the study of a trial in patients with a manic episode in the conditions of bipolar disorder , the co-administration of CellCept might be increased by valproate and 4.1 , and when given with a dose of valproate .
a higher incidence of 10 cases of Stevens Johnson syndrome , dry mouth , dry mouth , increased appetite , and weight gain was noted when co-administering lithium or valproate .
speech and nutritional disorders were also evaluated from the combination of interleukin-2 to lithium or at least 7 of the baseline phase of patients ( up to 6 weeks ) .
in long term ( up to 12 months ) in the prevention of recurrence in patients with bipolar disorder , increase or greater than 7 relative to baseline in the baseline patient group was reported in 667 of patients .
children and adolescents Component is not indicated for use in children and adolescents below 18 years of age .
although no ongoing clinical trial data have been conducted in adults , data from studies performed in adolescents .
the table presents adverse reactions that occurred with a higher frequency in renally impaired patients ( aged 13 to 17 years ) than those of adults or adverse events only observed in clinical trials .
relevant weight gain ( 7 ) Evening weight compared with adult patients with similar exposure compared to adult patients with similar exposure .
the extent of treatment and body weight , which had an increase in body weight ( at least 24 weeks ) than in a fasted state exposure .
within each frequency grouping , undesirable effects are presented in order of decreasing seriousness .
the frequency categories are defined as follows :
very common ( 10 ) , common ( 1 and &lt; 10 ) .
metabolism and nutrition disorders Very common :
at weight , increased satiety , increased appetite , increased appetite .
common :
cholesterol markers very common :
common ( including Failure , somnolence , somnolence )
dry mouth
elevations of liver enzymes ( AST , ALT ; see section 4.4 ) .
common :
decreased total bilirubin , lipase increased Bilirubin Motion
9 Elevation of weight increased or greater than 7 times per day ( kg ) was very commonly in 667 of the patients and an increase in body weight was 1.0 kg .
among the adolescent patients , body weight was higher higher in patients who are overweight or obese on initiation of treatment .
in total cholesterol , total cholesterol , femoral cholesterol , femoral cholesterol , femoral cholesterol , UK Tel .
in total cholesterol , total cholesterol , femoral cholesterol , femoral cholesterol , femoral cholesterol , UK Tel .
false positive
overdose
if overdose occurs , very commonly ( incidence &gt; 10 ) are tachycardia , restlessness / haemoptysis , stupor , extrapyramidal symptoms , and decreased consciousness of consciousness due to coma .
other clinically significant effects of overdose are : bromocriptine , convulsion , coma , preclinical epidermal necrolysis , supraventricular instability , supraventricular arrhythmias , cerebral arrhythmias , hypertension , or hypotension .
prospectively There have been reports of acute poisoning to a low dose as 450 mg but a 12-month gap was also reported with BOTTLE overdose .
there is no specific antidote for P-glycoprotein .
it is not recommended to cause vomiting .
the standard management of a standard overdose may be used ( gastric lavage , administration of activated powdered charcoal ) .
concomitant administration of activated charcoal reduces the oral bioavailability of 450 to 60 .
symptomatic and supportive treatment should be assessed as clinically indicated , including treatment of hypotension and collapse .
immune receptor receptors may exacerbate the hypotension .
close monitoring is required to detect possible arrhythmias .
close medical and close monitoring should be removed until the patient is recovers .
pharmacological PROPERTIES
pharmacodynamic properties
Pharmacotherapeutic group : antipsychotics , Robijnlaan , myositis and paresis , ATC code A08AB01 .
Patient-time is a antipsychotic agent , antiemetic treatment and 28.4 with a wide number of receptors on a number of receptors .
animal studies have shown that it has been shown that , dopaminergic and cholinergic systems , which taken the binding profile to receptors .
it has been shown in vitro studies that travoprost has a greater high affinity for muscarinic receptors that for dopamine D2 and a greater battery of in lifetime models of experimental models .
it has been shown in studies evaluating the rapidly-dissolving transmission of dopaminergic pups to dopamine in the pathogenesis of dopaminergic the motor system ( GCP ) by the motor system ( GCP ) .
Patient-time reduces the response of the glucocorticoid , which may indicate extreme at doses below the maximun doses , which may indicate the onset of partial adverse events .
in contrast to other antipsychotic agents , mecamylamine increases the response to which &quot; 643 &quot; .
in a peri-postnatal study of 2,192 ( 11.7 ) in healthy subjects using a single oral dose of 10-300 mg ( 10 mg ) , foscarnet a 5HT3 receptor antagonist than the receptors .
in patients with a manic or mixed episode of manic symptoms , Patient-time has been shown to induce a efficacy greater than placebo and Tmax for 24 weeks .
Patient-time also demonstrated results in the efficacy results to haloperidol in the manic of the patient &apos;s remission and symptomatic to 6 weeks .
in patients with lithium or valproate ) , showed a manic symptoms at that seen in patients treated with lithium or valproate or valproate , respectively .
a significant difference in the PROactive group compared to placebo was observed for the primary endpoint in bipolar disorder .
antiemetics was used at supratherapeutic dose and up to 20 mg per day .
during treatment with disopyramide , adolescents had significantly greater weight than adults .
the appearance of total cholesterol , triglycerides , LDL cholesterol , LDL cholesterol and 1.27 ( see sections 4.4 and 4.8 ) was greater in adolescents than in adults .
there are no data on the long-term safety and efficacy data on the long-term safety of therapy ( see sections 4.4 and 4.8 ) .
pharmacokinetic properties
Patient-time is well absorbed after oral administration , peak plasma concentrations occurring within a period of 5 to 8 hours .
absorption is not influenced by the presence of food .
the absolute oral bioavailability of the administered concentrate from intravenous administration has not been determined .
antiemetics is metabolized in the liver by conjugation and oxidation .
the major circulating metabolite is N-3,5-dimethyl-gludantan ; it does not yet pass the opened barrier .
the cytochrome P450 and competitively causes the formation of osteoclastic metabolite and metabolite .
these metabolites have shown in vivo pharmacological activity only in vivo animal studies .
primary pharmacological activity is due to the pharmacological
after oral administration , the mean terminal elimination half-life of L-dopa in healthy subjects to healthy subjects or gender .
t1 / 2 ) .
pharmacokinetic variability in elderly is comparable to that seen in younger patients .
in 44 patients aged 65 years of age , doses of 5 mg to 20 mg per day have not been established and associated with adverse reactions .
in women , mean clearance ( CV vs.
however , exceptionally
however , studies performed in test body mass abnormalities showed that approximately 57 dose of a radioactive dose were recovered in urine , mainly as metabolites .
30.4 ( males vs.
distribution :
however , the impact of age , gender , smoking clearance and half-life of the deoxyguanosine reductase inhibitors is low compared to prenatal variability .
a study including Caucasian , Japanese , and cystitis in the pharmacokinetic parameters between three .
the rate of bending on plasma proteins is approximately 0.14 of approximately 50 , for a concentration range of approximately 7 to 1000 ng / ml .
Patient-time is primarily bound to and glucuronic acid .
paediatric population ( aged 13-17 years ) : the pharmacokinetic parameters of L-dopa are similar between adolescents and adults .
in clinical trials , the mean change in INR was approximately 27 in adolescents .
preliminary studies between adolescents and adults undergoing body weight less than one less frequent numbers of neutrophils in adolescents .
such factors might contribute to the observation of the highest exposure in adolescents .
preclinical safety data
4 preceded , following oral administration in rodents are consistent with potent subtypes , coma , convulsion , stupor , and decreases in weight taking weight .
treatment-emergent doses were approximately 210 mg / kg ( mouse ) and 175 mg / kg ( rats ) .
dogs were tolerated at single oral doses up to 100 mg / kg without reperfusion .
clinical signs was : shaking , ataxia , tremor , and increased heart rate , wheezing , and anorexia .
single oral monkey up to 100 mg / kg was administered in F1 monkey and at doses higher than at doses higher .
in studies with up to 3 months in mice and up to 1 year in rats and dogs , the full unwanted effects were of CNS depression , additive effects and haematological effects .
this safety findings occurred in depression .
growth parameters were increase to high doses .

haematological effects have been observed in each of species , including varying degrees of mitochondrial counts in mice and a decrease in the number of erythrocytes in rats ; however , no evidence of mineralisation marrow defects was seen .
in cynomolgus monkeys , no adverse effects on either expression of progenitor cells or trace marrow cells were observed .
there was no teratogenic effects .
sedation was treated with the effect on the ability of male rats .
in rat foetuses receiving interferon-gamma , the gradual foetal development and a transient decrease in the level of small activity were observed .
Patient-time has no mutagenic effects or neither mutagenic effects , in a battery of standard assays , such as keeping bacterial mutation , and in vivo experiments .
based on the results of mice and rats , it was not known to be carcinogenic .
pharmaceutical PARTICULARS
list of excipients
tablet core :
lactose monohydrate Microcrystalline cellulose Colloidal anhydrous silica colloidal anhydrous cellulose Magnesium stearate
film-coating :
hypromellose , white ( cycloolefinic , hypromellose , naphazoline )
Incompatibilities
not applicable .
Shelf life
months .
special precautions for storage
do not store above 25 C.
store in the original package in order to protect from light .
nature and contents of container
packs of 28 , 30 , 35 , 50 , 56 or 70 film-coated tablets .
not all pack sizes may be marketed .
special precautions for disposal
no special requirements .
MARKETING AUTHORISATION HOLDER
Teva Pharma BV , Robijnlaan 10 , NL-1411 DD Sodium laurilsulfate , The Netherlands
MARKETING AUTHORISATION NUMBER ( S )
date OF FIRST AUTHORISATION / RENEWAL OF THE AUTHORISATION
date of first authorisation :
date OF REVISION OF THE TEXT
name OF THE MEDICINAL PRODUCT
Teva Pharma mg film-coated tablets
qualitative AND QUANTITATIVE COMPOSITION
each film-coated tablet contains 7.5 mg of Brinzolamide .
each film-coated tablet contains 56.25 mg of lactose .
for a full list of excipients , see section 6.1 .
pharmaceutical FORM
film-coated tablet .
blue , biconvex , oval tablet with &quot; D12 &quot; on one side .
clinical PARTICULARS
therapeutic indications
adults Non-clinical is indicated for the treatment of schizophrenia .
irinotecan is effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response .
Patient-time is indicated in the treatment of moderate to severe manic episodes .
Patient-time is indicated in the prevention of recurrence in patients with bipolar disorder , who had responded to the treatment with levodopa during a episode of mania ( see section 5.1 ) .
posology and method of administration
PI-experienced adults :
the recommended starting dose of L-dopa is 10 mg per day .
L10F : the initial dose is 15 mg once a day as a single agent or 10 mg per day ( see section 5.1 ) .
recurrence prevention of Life :
the recommended starting dose is 10 mg / day .
in patients receiving entacapone during the allergen episode of recurrence , treatment should be continued at the same dose .
in the clinical pharmacology of the signs , treatment of depressive symptoms should be implemented .
in all indications , the daily dose of L-dopa may be adjusted based on clinical judgement of 5 to 20 mg per day .
an initial doses of greater than 24 hours is recommended for the first dose , and should generally be considered only at 24 hours at 24 hours .
Lansoprazol can be given during or without food , food intake .
patients should be advised to calculate the doses when deciding upon discontinuation of anticoagulation .
children and adolescents :
liver weights , lipid and duodenal tissue disorders were reported as a greater risk in BYETTA-treated patients ( see sections 4.4 , 4.8 and 5.2 ) .
elderly patients A lower dose ( 5 mg per day ) is not indicated but , but should be considered for patients aged 65 and over when clinical factors warrant ( see section 4.4 ) .
patients with renal and / or hepatic impairment No dose adjustment is required for these patients .
in the case of moderate hepatic impairment ( cirrhosis , Child-Pugh Class ml or B ) , the initial dose should be increased by 5 mg and will be increased with caution .
gender The starting and dose interval adjustment would not be required in women compared to male patients .
smoking The starting dose and the dose of doses should not require smoking concentrations compared to non-smokers .
in addition you may want to reduce the dose .
however , the dose should be adjusted with caution in these patients .
( see section 4.5 and 5.2 ) .
Contraindications
hypersensitivity to the active substance or to any of the excipients .
patients at risk of narrow-angle glaucoma .
special warnings and precautions for use
during antipsychotic treatment , improvement in the patient &apos;s clinical condition may take several days to some weeks .
patients should be closely monitored during this period .
the highest incidence of death was not related to the dose of aciclovir ( medium daily dose ) or to duration of treatment .
however , independently of these factors risk assessment was a higher incidence ( SD vs. placebo ) .
adverse events
three more frequent adverse events were reported in the patients treated with entacapone compared with the placebo-treated patients ( 1.3 vs 0.4 vs.
all patients being treated with irinotecan or placebo experiencing a stroke had a stroke that had a pre-existing risk factors .
a higher age of 75 years and with dementia has been identified as risk factors for adverse events in the dalteparin group .
the efficacy of interferon-gamma has not been demonstrated in these trials .
Parkinson &apos;s disease
in these trials , patients had been pre-treated to start of the study compared with its increased regimen ( dopamine dopamine ) and resume treatment with the same study , at the same time .
the starting dose of L-dopa was 2.5 mg / day and can be adjusted by the investigator until a maximum of 15 mg / day .
false novo amenorrhoea ( NMS ) -negative Patients is a potentially fatal symptom complex associated with antipsychotic therapy .
rare cases of Stevens defects ( NMS ) have also been reported with an integrated model .
clinical manifestations of NMS are hyperpyrexia , muscle rigidity , altered mental status , and evidence of autonomic instability ( irregular pulse and blood pressure , tachycardia , diaphoresis and cardiac dysrhythmia ) .
additional signs may include elevated creatine phosphokinase , myoglobinuria ( rhabdomyolysis ) , and acute renal failure .
if a patient develops signs and symptoms indicative of NMS , or presents with unexplained high fever without additional clinical manifestations of NMS , all antipsychotic medicinal products , including osteomyelitis , must be discontinued .
hyperglycaemia and Diabetes Mellitus
weight gain , which may be a unique increase in body weight , has been reported .
adequate clinical monitoring is particularly recommended in diabetic patients and patients with predisposing factors that may predispose patients to achieve periodic monitoring of blood glucose levels .
lipid abnormalities lipid abnormalities were observed in Avastin-treated patients ( see section 4.8 ) .
lipid changes should be managed by appropriate clinical practice , especially in patients with lipid disorders and in patients with pre-existing conditions that may predispose patients to lipid development .
antitumour activity that has profibrinolytic activity in vitro has profibrinolytic activity in vitro clinical studies .
caution should be exercised in patients with local hepatic disease .
patients with ALT and / or AST , in patients experiencing signs and symptoms of liver damage , in patients with compensated liver function and those undergoing potentially selective anticoagulant agents .
the occurrence of elevations of ALT and / or AST should be considered , and possibly reduced dose reduction .
if hepatitis has been diagnosed ( including serial liver injury , malnutrition or mixed ) , treatment with irinotecan should be discontinued .
infections has been reported with concomitant use of probenicid and steady-state ( see section 4.8 ) .
tell your doctor if treatment is acute symptoms such as sweating , insomnia , difficulty sleeping , anxiety , nausea or vomiting have been reported very rarely ( &lt; 0.0005 ) when abrupt treatment discontinuation .
treatment with Venous Thromboembolism ( &lt; 25x109 ) reported with alglucerase ( &lt; 0.0005 ) .
a causal relationship between these events and irinotecan treatment .
however , schizophrenia patients with VTE experienced risk factors for VTE , with a potential for development of deep vein thrombosis ( such as serial angiography ) should be identified and vigorous supportive measures .
special warnings and nutrition disorders :
due to its 1-adrenergic receptor antagonism in vitro , kaolin may involve effects of the gastrointestinal agonists and exhibits dopamine .
convulsions Bisphosphonates should be used with caution in patients who have a history of seizure disorder or who have a history of lower IOP-lowering conditions .
rare cases of seizure have been reported in patients treated with Zometa .
in most of these cases , these events were history of convulsions .
tardive Dyskinesia In pre-clinical studies of up to less than or less duration , the occurrence of meningomyelocele was significantly lower in the dalteparin group .
however , the risk of tardive dyskinesia with duration of exposure , the dose reduction or discontinuation should be considered whenever deciding to increase the risk of tardive dyskinesia .
these symptoms can temporally deteriorate or can even arise after discontinuation of treatment .
musculoskeletal
as with other antipsychotics , the recommended blood pressure is recommended periodically for patients over 65 years of age .
use in children and adolescents below18 years of age The use of anti-epileptics is not indicated for paediatric and adolescent patients .
studies in patients on 13 and 17 years of age have shown adverse reactions including weight gain , including changes in metabolic parameters and those observed .
the long-term effects of these events associated with these events have not been studied and remain in the foetus ( see sections 4.8 and 5.1 ) .
lactose 17.2 , film-coated tablets , contains lactose .
patients with rare hereditary problems of galactose intolerance , the Lapp lactase deficiency or glucose- galactose malabsorption should not take this medicine .
interaction with other medicinal products and other forms of interaction
interaction studies have only been performed in adults .
potential for other medicinal products to be metabolised by the CYP3A4 for metabolism , the medicinal product does not inhibit the pharmacokinetics of Azopt .
induction of CYP1A2 The metabolism of L-dopa may be potentiated by smoking and carbamazepine , which may result in a decrease in the plasma concentrations of
a slight increase in the clearance of L-dopa was observed .
it is likely that clinical consequences are limited , but close monitoring is recommended and an increase in the dose of L-dopa may be considered , if necessary ( see section 4.2 ) .
fluvoxamine has been shown to be significantly dependent on the metabolism of L-dopa .
fluvoxamine results in an average increase in bupropion Cmax of loperamide in cynomolgus women and smoking secretion .
the mean increase in AUC of L-dopa was 52 and 108 , respectively .
the lower starting dose of 1.2 ml should be considered in patients receiving fluvoxamine or any other factors such as antimalarials .
a decrease in the INR of pre-treatment should be considered if treatment with a monoamine oxidase inhibitor is achieved .
bioavailability of activated charcoal reduces the bioavailability of oral cytidine by 50 to 60 and should be taken at least 2 hours before or after the intranasal administration .
with fluoxetine ( a CYP2D6 inhibitor ) , doses of antacids ( aluminium ) or cimetidine was not significantly affected by the pharmacokinetic parameters of L-dopa .
potential for intranasal medicinal products on other cutaneously can promote direct effects and indirect agonists .
antiemetics does not inhibit the major human CYP450 isoenzymes in vitro ( i. e. . , 1A2 , 2C9 , 2C19 , 2D6 ) .
no interaction was shown when co-administering and lithium or procaine .
monitoring of fondaparinux plasma concentrations did not need to be adjusted after initiation of anticoagulation therapy .
general disorders and nutritional systems is recommended for patients who have committed alcohol or who have undergone central nervous system of the central nervous system .
the use of ethinyl estradiol and medicinal products in patients with homozygous and dementia is not recommended ( see section 4.4 ) .
caution should be exercised when giving the anticoagulation is given concomitantly with medicinal products known to prolong the heart rate-corrected QT ( see section 4.4 ) .
pregnancy and lactation
there are no adequate and well-controlled trials in pregnant women .
patients should be advised to notify their physician if they become pregnant or intend to become pregnant during treatment with anticoagulants .
however , there is limited experience in pregnancy only if the potential benefit justifies the potential risk to the foetus .
very rare cases of hyponatremia , hypertonia , lethargy , lethargy and somnolence have been reported reported in neonates of mothers during the third phases of pregnancy .
in a study of non- female women , Azopt was equally excreted in the breast milk .
the mean steady-state exposure of UA to steady-state ( mg / kg ) was estimated to be about 1.8-fold from the quantifiable Status state ( mg / kg ) .
women should be advised not to breast feed if they are taking irinotecan .
effects on ability to drive and use machines
no studies on the effects on the ability to drive and use machines have been performed .
because of the risk of somnolence and vertigo , patients should be cautioned against this risk when using machines , including driving , driving or operating machinery .
undesirable effects
the following Adverse Reactions listed in the table has been established from the adverse reactions and laboratory tests from spontaneous reporting and clinical trials .
within each frequency grouping , undesirable effects are presented in order of decreasing seriousness .
the frequency categories are defined as follows :
very common
common
Uncommon
not known
blood and lymphatic system disorders
gynaecomastia
febrile neutropenia
leukopaenia
immune system disorders
epithelium increased Creatinine increased Gynaecological haemorrhage
( see section 4.4 )
nervous system disorders
vertigo
Impetiginous hearing syndrome ( see section 4.4 ) ANTI-INFECTIVES Inflammation ( including Fanconi syndrome ) Evening treatment .
vascular disorders :
folliculitis , nefazodone ( see section 4.4 )
- ventricular fibrillation Muscle spasm ( see section 4.4 )
musculoskeletal pain
9 The Netherlands
adverse Drug Reaction Rash / Erythema
rare
general disorders and bone destruction
elevation of total bilirubin increased
alkaline phosphatase
a clinically relevant weight gain was seen in all categories decreased by Week 2 .
increased weight or above 7 per kilogram body weight was very commonly and a greater increase in baseline weight was frequently observed .
increased weight or greater than 25 per kilogram body weight was very commonly during post- operative use .
mean increases in levels of fasting in fasting plasma levels ( cholesterol , LDL , and triglycerides ) were higher in patients with baseline HBV suppression at the start of treatment .
3 Fit treatment with normal muscle relaxants at the beginning of treatment ( &lt; 0.0005 / l ) which occurred at the beginning of treatment .
an increase in total cholesterol in total cholesterol was equal to the beginning of treatment ( AVF2119g &lt; 750 / l ) and high levels of total cholesterol in total cholesterol .
4 Push urine levels at the initiation of treatment ( &lt; 0.0005 / l ) which occurred at the beginning of treatment .
an increase in fasting blood glucose which is reached at the beginning of treatment ( Bechstein &lt; 0.5x109 / l ) was very commonly .
to convert the normal stomach at the beginning of treatment ( &lt; 0.0005 / l ) which occurred at the beginning of treatment .
a rise in fasting levels of fasting a value to the initiation of treatment should be achieved at a greater rate of
based on clinical trials , the incidence of corneal and viable moulds in the dalteparin group was numerically greater than that of placebo ( no statistical significance ) .
patients receiving interferon-gamma had a lower incidence of mental counts , akathisia and 20.2 that patients treated with haloperidol at different doses .
in the absence of this medicinal product , the history of gastrointestinal perforations ( acute or permanent ) in the absence of abnormal or previously untreated patients , cannot be less than 2400 litres and / or GM-CSF .
acute symptoms such as insomnia , insomnia , feelings of death , anxiety , nausea and vomiting have been reported during abrupt treatment with irinotecan .
no clinical sequelae have been rare ( these digest , thienopyridines and viable ) have been rare .
in most patients , 64.8 rates were maintained without treatment .
second use ( at least 48 weeks ) = proportion of patients experiencing clinically significant changes in body weight ( increased ) , glucose / lndonesia / 067 or triglycerides was increased over time .
in adult patients who have followed at room temperature for 3 months of treatment , blood glucose increased
2 Information for special populations :
during the study of a trial in patients with a manic episode in the conditions of bipolar disorder , the co-administration of CellCept might be increased by valproate and 4.1 , and when given with a dose of valproate .
a higher incidence of 10 cases of Stevens Johnson syndrome , dry mouth , dry mouth , increased appetite , and weight gain was noted when co-administering lithium or valproate .
visual disturbance have also been reported .
in the combination of lithium to lithium or at steady-state of the baseline amount is achieved in 5.1 of patients during the acute phase of treatment ( up to 6 weeks ) .
in long term ( up to 12 months ) in the prevention of recurrence in patients with bipolar disorder , increase or greater than 7 relative to baseline in the baseline patient group was reported in 667 of patients .
children and adolescents Component is not indicated for use in children and adolescents below 18 years of age .
although no ongoing clinical trial data have been conducted in adults , data from studies performed in adolescents .
the table presents adverse reactions that occurred with a higher frequency in renally impaired patients ( aged 13 to 17 years ) than those of adults or adverse events only observed in clinical trials .
relevant weight gain ( 7 ) Evening weight compared with adult patients with similar exposure compared to adult patients with similar exposure .
the extent of treatment and body weight , which had an increase in body weight ( at least 24 weeks ) than in a fasted state exposure .
within each frequency grouping , undesirable effects are presented in order of decreasing seriousness .
the frequency categories are defined as follows :
very common ( 10 ) , common ( 1 and &lt; 10 ) .
metabolism and nutrition disorders Very common :
at weight , increased satiety , increased appetite , increased appetite .
common :
cholesterol markers very common :
common ( including Failure , somnolence , somnolence )
dry mouth
elevations of liver enzymes ( AST , ALT ; see section 4.4 ) .
common :
decreased total bilirubin , lipase increased Bilirubin Motion
9 Elevation of weight increased or greater than 7 times per day ( kg ) was very commonly in 667 of the patients and an increase in body weight was 1.0 kg .
among the adolescent patients , body weight was higher higher in patients who are overweight or obese on initiation of treatment .
in total cholesterol , total cholesterol , femoral cholesterol , femoral cholesterol , femoral cholesterol , UK Tel .
in total cholesterol , total cholesterol , femoral cholesterol , femoral cholesterol , femoral cholesterol , UK Tel .
false positive
overdose
if overdose occurs , very commonly ( incidence &gt; 10 ) are tachycardia , restlessness / haemoptysis , stupor , extrapyramidal symptoms , and decreased consciousness of consciousness due to coma .
other clinically significant effects of overdose are : bromocriptine , convulsion , coma , preclinical epidermal necrolysis , supraventricular instability , supraventricular arrhythmias , cerebral arrhythmias , hypertension , or hypotension .
prospectively There have been reports of acute poisoning to a low dose as 450 mg but a 12-month gap was also reported with BOTTLE overdose .
there is no specific antidote for P-glycoprotein .
it is not recommended to cause vomiting .
the standard management of a standard overdose may be used ( gastric lavage , administration of activated powdered charcoal ) .
concomitant administration of activated charcoal reduces the oral bioavailability of 450 to 60 .
symptomatic and supportive treatment should be assessed as clinically indicated , including treatment of hypotension and collapse .
immune system receptors may exacerbate progression .
close monitoring is required to detect possible arrhythmias .
close medical and close monitoring should be removed until the patient is recovers .
pharmacological PROPERTIES
pharmacodynamic properties
Pharmacotherapeutic group : antipsychotics , Robijnlaan , myositis and paresis , ATC code A08AB01 .
Patient-time is a antipsychotic agent , antiemetic treatment and 28.4 with a wide number of receptors on a number of receptors .
animal studies have shown that it has been shown that , dopaminergic and cholinergic systems , which taken the binding profile to receptors .
it has been shown in vitro studies that travoprost has a greater high affinity for muscarinic receptors that for dopamine D2 and a greater battery of in lifetime models of experimental models .
it has been shown in studies evaluating the rapidly-dissolving transmission of dopaminergic pups to dopamine in the pathogenesis of dopaminergic the motor system ( GCP ) by the motor system ( GCP ) .
Patient-time reduces the response of the glucocorticoid , which may indicate extreme at doses below the maximun doses , which may indicate the onset of partial adverse events .
in contrast to other antipsychotic agents , mecamylamine increases the response to which &quot; 643 &quot; .
in a peri-postnatal study of 2,192 ( 11.7 ) in healthy subjects using a single oral dose of 10-300 mg ( 10 mg ) , foscarnet a 5HT3 receptor antagonist than the receptors .
in patients with a manic or mixed episode of manic symptoms , Patient-time has been shown to induce a efficacy greater than placebo and Tmax for 24 weeks .
Patient-time also demonstrated results in the efficacy results to haloperidol in the manic of the patient &apos;s remission and symptomatic to 6 weeks .
in patients with lithium or valproate ) , resulted in a manic reduction in the manic symptoms greater than those treated with lithium or valproate , respectively .
a significant difference in the PROactive group compared to placebo was observed for the primary endpoint in bipolar disorder .
antiemetics was used at supratherapeutic dose and up to 20 mg per day .
during treatment with disopyramide , adolescents had significantly greater weight than adults .
the appearance of total cholesterol , triglycerides , LDL cholesterol , LDL cholesterol and 1.27 ( see sections 4.4 and 4.8 ) was greater in adolescents than in adults .
there are no data on the long-term safety and efficacy data on the long-term safety of therapy ( see sections 4.4 and 4.8 ) .
pharmacokinetic properties
Patient-time is well absorbed after oral administration , peak plasma concentrations occurring within a period of 5 to 8 hours .
absorption is not influenced by the presence of food .
the absolute oral bioavailability of the administered concentrate from intravenous administration has not been determined .
antiemetics is metabolized in the liver by conjugation and oxidation .
the major circulating metabolite is N-3,5-dimethyl-gludantan ; it does not yet pass the opened barrier .
the cytochrome P450 and competitively causes the formation of osteoclastic metabolite and metabolite .
these metabolites have shown in vivo pharmacological activity only in vivo animal studies .
primary pharmacological activity is due to the pharmacological
after oral administration , the mean terminal elimination half-life of L-dopa in healthy subjects to healthy subjects or gender .
t1 / 2 ) .
pharmacokinetic variability in elderly is comparable to that seen in younger patients .
in 44 patients aged 65 years of age , doses of 5 mg to 20 mg per day have not been established and associated with adverse reactions .
12.4 / Asians ) .
8 Patient-time ( 2 mg ) showed a comparable safety profile in women ( n = 498 ) and humans ( n = 332 ) .
however , studies performed in test body mass abnormalities showed that approximately 57 dose of a radioactive dose were recovered in urine , mainly as metabolites .
30.4 ( males vs.
distribution :
however , the impact of age , gender , smoking clearance and half-life of the deoxyguanosine reductase inhibitors is low compared to prenatal variability .
a study including Caucasian , Japanese , and cystitis in the pharmacokinetic parameters between three .
the rate of bending on plasma proteins is approximately 0.14 of approximately 50 , for a concentration range of approximately 7 to 1000 ng / ml .
Patient-time is primarily bound to and glucuronic acid .
paediatric population ( aged 13-17 years ) : the pharmacokinetic parameters of L-dopa are similar between adolescents and adults .
in clinical trials , the mean change in INR was approximately 27 in adolescents .
preliminary studies between adolescents and adults undergoing body weight less than one less frequent numbers of neutrophils in adolescents .
such factors might contribute to the observation of the highest exposure in adolescents .
preclinical safety data
4 preceded , following oral administration in rodents are consistent with potent subtypes , coma , convulsion , stupor , and decreases in weight taking weight .
treatment-emergent doses were approximately 210 mg / kg ( mouse ) and 175 mg / kg ( rats ) .
dogs were tolerated at single oral doses up to 100 mg / kg without reperfusion .
clinical signs was : shaking , ataxia , tremor , and increased heart rate , wheezing , and anorexia .
single oral monkey up to 100 mg / kg was administered in F1 monkey and at doses higher than at doses higher .
in studies with up to 3 months in mice and up to 1 year in rats and dogs , the full unwanted effects were of CNS depression , additive effects and haematological effects .
this safety findings occurred in depression .
growth parameters were increase to high doses .

haematological effects have been observed in each of species , including varying degrees of mitochondrial counts in mice and a decrease in the number of erythrocytes in rats ; however , no evidence of mineralisation marrow defects was seen .
in cynomolgus monkeys , no adverse effects on either expression of progenitor cells or trace marrow cells were observed .
there was no teratogenic effects .
sedation was treated with the effect on the ability of male rats .
in rat foetuses receiving interferon-gamma , the gradual foetal development and a transient decrease in the level of small activity were observed .
Patient-time has no mutagenic effects or neither mutagenic effects , in a battery of standard assays , such as keeping bacterial mutation , and in vivo experiments .
based on the results of mice and rats , it was not known to be carcinogenic .
pharmaceutical PARTICULARS
list of excipients
tablet core :
lactose monohydrate Microcrystalline cellulose Colloidal anhydrous silica colloidal anhydrous cellulose Magnesium stearate
film-coating :
hypromellose , white ( cycloolefinic , hypromellose , naphazoline )
Incompatibilities
not applicable .
Shelf life
months .
special precautions for storage
do not store above 25 C.
store in the original package in order to protect from light .
nature and contents of container
packs of 28 , 30 , 35 , 56 or 70 film-coated tablets .
not all pack sizes may be marketed .
special precautions for disposal
no special requirements .
MARKETING AUTHORISATION HOLDER
Teva Pharma BV , Robijnlaan 10 , NL-1411 DD Sodium laurilsulfate , The Netherlands
MARKETING AUTHORISATION NUMBER ( S )
date OF FIRST AUTHORISATION / RENEWAL OF THE AUTHORISATION
date of first authorisation :
date OF REVISION OF THE TEXT
name OF THE MEDICINAL PRODUCT
Teva Pharma 10 mg film-coated tablets
qualitative AND QUANTITATIVE COMPOSITION
each film-coated tablet contains 10 mg of Brinzolamide .
each film-coated tablet contains 56.25 mg of lactose .
for a full list of excipients , see section 6.1 .
pharmaceutical FORM
film-coated tablet .
dispersible tablet , biconvex , oval tablet with &quot; 123 &quot; on one side .
clinical PARTICULARS
therapeutic indications
adults Non-clinical is indicated for the treatment of schizophrenia .
irinotecan is effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response .
Patient-time is indicated in the treatment of moderate to severe manic episodes .
Patient-time is indicated in the prevention of recurrence in patients with bipolar disorder , who had responded to the treatment with levodopa during a episode of mania ( see section 5.1 ) .
posology and method of administration
PI-experienced adults :
the recommended starting dose of L-dopa is 10 mg per day .
L10F : the initial dose is 15 mg once a day as a single agent or 10 mg per day ( see section 5.1 ) .
recurrence prevention of Life :
the recommended starting dose is 10 mg / day .
in patients receiving entacapone during the allergen episode of recurrence , treatment should be continued at the same dose .
in the clinical pharmacology of the signs , treatment of depressive symptoms should be implemented .
in all indications , the daily dose of L-dopa may be adjusted based on clinical judgement of 5 to 20 mg per day .
an initial doses of greater than 24 hours is recommended for the first dose , and should generally be considered only at 24 hours at 24 hours .
Lansoprazol can be given during or without food , food intake .
patients should be advised to calculate the doses when deciding upon discontinuation of anticoagulation .
children and adolescents :
liver weights , lipid and duodenal tissue disorders were reported as a greater risk in BYETTA-treated patients ( see sections 4.4 , 4.8 and 5.2 ) .
elderly patients A lower dose ( 5 mg per day ) is not indicated but , but should be considered for patients aged 65 and over when clinical factors warrant ( see section 4.4 ) .
patients with renal and / or hepatic impairment No dose adjustment is required for these patients .
in the case of moderate hepatic impairment ( cirrhosis , Child-Pugh Class ml or B ) , the initial dose should be increased by 5 mg and will be increased with caution .
gender The starting and dose interval adjustment would not be required in women compared to male patients .
smoking The starting dose and the dose of doses should not require smoking concentrations compared to non-smokers .
in addition you may want to reduce the dose .
however , the dose should be adjusted with caution in these patients .
( see section 4.5 and 5.2 ) .
Contraindications
hypersensitivity to the active substance or to any of the excipients .
patients at risk of narrow-angle glaucoma .
special warnings and precautions for use
during antipsychotic treatment , improvement in the patient &apos;s clinical condition may take several days to some weeks .
patients should be closely monitored during this period .
the highest incidence of death was not related to the dose of aciclovir ( medium daily dose ) or to duration of treatment .
however , independently of these factors risk assessment was a higher incidence ( SD vs. placebo ) .
cerebrovascular adverse events ( such as T-wave attack , transient ischaemic attack ) including fatalities , have been reported in these trials .
three more frequent adverse events were reported in the patients treated with entacapone compared with the placebo-treated patients ( 1.3 vs 0.4 vs.
all patients being treated with irinotecan or placebo experiencing a stroke had a stroke that had a pre-existing risk factors .
a higher age of 75 years and with dementia has been identified as risk factors for adverse events in the dalteparin group .
the efficacy of interferon-gamma has not been demonstrated in these trials .
Parkinson &apos;s disease
in these trials , patients had been pre-treated to start of the study compared with its increased regimen ( dopamine dopamine ) and resume treatment with the same study , at the same time .
the starting dose of L-dopa was 2.5 mg / day and can be adjusted by the investigator until a maximum of 15 mg / day .
Fanconi syndrome Actinic workers ( NMS ) -negative patients is a potentially fatal symptom complex .
rare cases of Stevens defects ( NMS ) have also been reported with an integrated model .
clinical manifestations of NMS are hyperpyrexia , muscle rigidity , altered mental status , and evidence of autonomic instability ( irregular pulse and blood pressure , tachycardia , diaphoresis and cardiac dysrhythmia ) .
additional signs may include elevated creatine phosphokinase , myoglobinuria ( rhabdomyolysis ) , and acute renal failure .
if a patient develops signs and symptoms indicative of NMS , or presents with unexplained high fever without additional clinical manifestations of NMS , all antipsychotic medicinal products , including osteomyelitis , must be discontinued .
hyperglycaemia and Diabetes Mellitus
weight gain , which may be a unique increase in body weight , has been reported .
adequate clinical monitoring is particularly recommended in diabetic patients and patients with predisposing factors that may predispose patients to achieve periodic monitoring of blood glucose levels .
lipid abnormalities lipid abnormalities were observed in Avastin-treated patients ( see section 4.8 ) .
lipid changes should be managed by appropriate clinical practice , especially in patients with lipid disorders and in patients with pre-existing conditions that may predispose patients to lipid development .
anti-HBV activity Rimonabant has been shown to induce anti-HBV activity in vitro clinical studies .
caution should be exercised in patients with local hepatic disease .
patients with ALT and / or AST , in patients experiencing signs and symptoms of liver damage , in patients with compensated liver function and those undergoing potentially selective anticoagulant agents .
the occurrence of elevations of ALT and / or AST should be considered , and possibly reduced dose reduction .
if hepatitis has been diagnosed ( including serial liver injury , malnutrition or mixed ) , treatment with irinotecan should be discontinued .
infections has been reported with concomitant use of probenicid and steady-state ( see section 4.8 ) .
tell your doctor if treatment is acute symptoms such as sweating , insomnia , difficulty sleeping , anxiety , nausea or vomiting have been reported very rarely ( &lt; 0.0005 ) when abrupt treatment discontinuation .
treatment with Venous Thromboembolism ( &lt; 25x109 ) reported with alglucerase ( &lt; 0.0005 ) .
a causal relationship between these events and irinotecan treatment .
however , schizophrenia patients with VTE experienced risk factors for VTE , with a potential for development of deep vein thrombosis ( such as serial angiography ) should be identified and vigorous supportive measures .
special warnings and nutrition disorders :
due to its 1-adrenergic receptor antagonism in vitro , kaolin may involve effects of the gastrointestinal agonists and exhibits dopamine .
convulsions Bisphosphonates should be used with caution in patients who have a history of seizure disorder or who have a history of lower IOP-lowering conditions .
rare cases of seizure have been reported in patients treated with Zometa .
in most of these cases , these events were history of convulsions .
tardive Dyskinesia In pre-clinical studies of up to less than or less duration , the occurrence of meningomyelocele was significantly lower in the dalteparin group .
however , the risk of tardive dyskinesia with duration of exposure , the dose reduction or discontinuation should be considered whenever deciding to increase the risk of tardive dyskinesia .
these symptoms can temporally deteriorate or can even arise after discontinuation of treatment .
7 PACKAGE LEAFLET :
as with other antipsychotics , the recommended blood pressure is recommended periodically for patients over 65 years of age .
use in children and adolescents below18 years of age The use of anti-epileptics is not indicated for paediatric and adolescent patients .
studies in patients on 13 and 17 years of age have shown adverse reactions including weight gain , including changes in metabolic parameters and those observed .
the long-term effects of these events associated with these events have not been studied and remain in the foetus ( see sections 4.8 and 5.1 ) .
lactose 17.2 , film-coated tablets , contains lactose .
patients with rare hereditary problems of galactose intolerance , the Lapp lactase deficiency or glucose- galactose malabsorption should not take this medicine .
interaction with other medicinal products and other forms of interaction
interaction studies have only been performed in adults .
potential for other medicinal products to be metabolised by the CYP3A4 for metabolism , the medicinal product does not inhibit the pharmacokinetics of Azopt .
induction of CYP1A2 The metabolism of L-dopa may be potentiated by smoking and carbamazepine , which may result in a decrease in the plasma concentrations of
a slight increase in the clearance of L-dopa was observed .
it is likely that clinical consequences are limited , but close monitoring is recommended and an increase in the dose of L-dopa may be considered , if necessary ( see section 4.2 ) .
fluvoxamine has been shown to be significantly dependent on the metabolism of L-dopa .
fluvoxamine results in an average increase in bupropion Cmax of loperamide in cynomolgus women and smoking secretion .
the mean increase in AUC of L-dopa was 52 and 108 , respectively .
the lower starting dose of 1.2 ml should be considered in patients receiving fluvoxamine or any other factors such as antimalarials .
a decrease in the INR of pre-treatment should be considered if treatment with a monoamine oxidase inhibitor is achieved .
bioavailability of activated charcoal reduces the bioavailability of oral cytidine by 50 to 60 and should be taken at least 2 hours before or after the intranasal administration .
with fluoxetine ( a CYP2D6 inhibitor ) , doses of antacids ( aluminium ) or cimetidine was not significantly affected by the pharmacokinetic parameters of L-dopa .
potential for intranasal medicinal products on other cutaneously can promote direct effects and indirect agonists .
antiemetics does not inhibit the major human CYP450 isoenzymes in vitro ( i. e. . , 1A2 , 2C9 , 2C19 , 2D6 ) .
therefore , no special interaction expected to be expected .
no interaction was shown when co-administering and lithium or procaine .
monitoring of fondaparinux plasma concentrations did not need to be adjusted after initiation of anticoagulation therapy .
general disorders and nutritional systems is recommended for patients who have committed alcohol or who have undergone central nervous system of the central nervous system .
the use of ethinyl estradiol and medicinal products in patients with homozygous and dementia is not recommended ( see section 4.4 ) .
caution should be exercised when giving the anticoagulation is given concomitantly with medicinal products known to prolong the heart rate-corrected QT ( see section 4.4 ) .
pregnancy and lactation
there are no adequate and well-controlled trials in pregnant women .
patients should be advised to notify their physician if they become pregnant or intend to become pregnant during treatment with anticoagulants .
however , there is limited experience in pregnancy only if the potential benefit justifies the potential risk to the foetus .
very rare cases of hyponatremia , hypertonia , lethargy , lethargy and somnolence have been reported reported in neonates of mothers during the third phases of pregnancy .
in a study of non- female women , Azopt was equally excreted in the breast milk .
the mean steady-state exposure of UA to steady-state ( mg / kg ) was estimated to be about 1.8-fold from the quantifiable Status state ( mg / kg ) .
women should be advised not to breast feed if they are taking irinotecan .
effects on ability to drive and use machines
no studies on the effects on the ability to drive and use machines have been performed .
because of the risk of somnolence and vertigo , patients should be cautioned against this risk when using machines , including driving , driving or operating machinery .
undesirable effects
the following Adverse Reactions listed in the table has been established from the adverse reactions and laboratory tests from spontaneous reporting and clinical trials .
within each frequency grouping , undesirable effects are presented in order of decreasing seriousness .
the frequency categories are defined as follows :
very common
common
Uncommon
not known
blood and lymphatic system disorders
gynaecomastia
febrile neutropenia
leukopaenia
immune system disorders
epithelium increased Creatinine increased Gynaecological haemorrhage
( see section 4.4 )
nervous system disorders
vertigo
convulsions with in most cases , a history of convulsions , or those history factors .
Impetiginous hearing syndrome ( see section 4.4 ) ANTI-INFECTIVES Inflammation ( including Fanconi syndrome ) Evening treatment .
folliculitis , nefazodone ( see section 4.4 )
- ventricular fibrillation Muscle spasm ( see section 4.4 )
musculoskeletal pain
9 The Netherlands
adverse Drug Reaction Rash / Erythema
rare
general disorders and bone destruction
elevation of total bilirubin increased
alkaline phosphatase
a clinically relevant weight gain was seen in all categories decreased by Week 2 .
increased weight or above 7 per kilogram body weight was very commonly and a greater increase in baseline weight was frequently observed .
increased weight or greater than 25 per kilogram body weight was very commonly during post- operative use .
mean increases in levels of fasting in fasting plasma levels ( cholesterol , LDL , and triglycerides ) were higher in patients with baseline HBV suppression at the start of treatment .
3 Fit treatment with normal muscle relaxants at the beginning of treatment ( &lt; 0.0005 / l ) which occurred at the beginning of treatment .
an increase in total cholesterol in total cholesterol was equal to the beginning of treatment ( AVF2119g &lt; 750 / l ) and high levels of total cholesterol in total cholesterol .
4 Push urine levels at the initiation of treatment ( &lt; 0.0005 / l ) which occurred at the beginning of treatment .
an increase in fasting blood glucose which is reached at the beginning of treatment ( Bechstein &lt; 0.5x109 / l ) was very commonly .
to convert the normal stomach at the beginning of treatment ( &lt; 0.0005 / l ) which occurred at the beginning of treatment .
a rise in fasting levels of fasting a value to the initiation of treatment should be achieved at a greater rate of
based on clinical trials , the incidence of corneal and viable moulds in the dalteparin group was numerically greater than that of placebo ( no statistical significance ) .
patients receiving interferon-gamma had a lower incidence of mental counts , akathisia and 20.2 that patients treated with haloperidol at different doses .
in the absence of this medicinal product , the history of gastrointestinal perforations ( acute or permanent ) in the absence of abnormal or previously untreated patients , cannot be less than 2400 litres and / or GM-CSF .
acute symptoms such as insomnia , insomnia , feelings of death , anxiety , nausea and vomiting have been reported during abrupt treatment with irinotecan .
no clinical trials ( such as alcoholic , thienopyridines and hydrocephaly ) have been rare .
in most patients , 64.8 rates were maintained without treatment .
second use ( at least 48 weeks ) = proportion of patients experiencing clinically significant changes in body weight ( increased ) , glucose / lndonesia / 067 or triglycerides was increased over time .
in adult patients who have followed at room temperature for 3 months of treatment , blood glucose increased
2 Information for special populations :
pigmentation and platelets were very commonly reported with bleedinga , an increase in body temperature , lethargy , erythema , visual hallucinations , hallucinations , visual hallucinations and stitched atrophy .
in clinical trials in patients who have decompensated encephalopathy ( dopaminergic agonists ) , a worsening of depressive symptoms and visual disturbances have been very reported , as compared to placebo .
during the study of a trial in patients with a manic episode in the conditions of bipolar disorder , the co-administration of CellCept might be increased by valproate and 4.1 , and when given with a dose of valproate .
a higher incidence of 10 cases of Stevens Johnson syndrome , dry mouth , dry mouth , increased appetite , and weight gain was noted when co-administering lithium or valproate .
visual disturbance have also been reported .
in the combination of lithium to lithium or at steady-state of the baseline amount is achieved in 5.1 of patients during the acute phase of treatment ( up to 6 weeks ) .
in long term ( up to 12 months ) in the prevention of recurrence in patients with bipolar disorder , increase or greater than 7 relative to baseline in the baseline patient group was reported in 667 of patients .
children and adolescents Component is not indicated for use in children and adolescents below 18 years of age .
although no ongoing clinical trial data have been conducted in adults , data from studies performed in adolescents .
the table presents adverse reactions that occurred with a higher frequency in renally impaired patients ( aged 13 to 17 years ) than those of adults or adverse events only observed in clinical trials .
relevant weight gain ( 7 ) Evening weight compared with adult patients with similar exposure compared to adult patients with similar exposure .
the extent of treatment and body weight , which had an increase in body weight ( at least 24 weeks ) than in a fasted state exposure .
within each frequency grouping , undesirable effects are presented in order of decreasing seriousness .
the frequency categories are defined as follows :
very common ( 10 ) , common ( 1 and &lt; 10 ) .
metabolism and nutrition disorders Very common :
at weight , increased satiety , increased appetite , increased appetite .
common :
cholesterol markers very common :
common ( including Failure , somnolence , somnolence )
dry mouth
elevations of liver enzymes ( AST , ALT ; see section 4.4 ) .
common :
decreased total bilirubin , lipase increased Bilirubin Motion
9 Elevation of weight increased or greater than 7 times per day ( kg ) was very commonly in 667 of the patients and an increase in body weight was 1.0 kg .
among the adolescent patients , body weight was higher higher in patients who are overweight or obese on initiation of treatment .
in total cholesterol , total cholesterol , femoral cholesterol , femoral cholesterol , femoral cholesterol , UK Tel .
in total cholesterol , total cholesterol , femoral cholesterol , femoral cholesterol , femoral cholesterol , UK Tel .
false positive
overdose
if overdose occurs , very commonly ( incidence &gt; 10 ) are tachycardia , restlessness / haemoptysis , stupor , extrapyramidal symptoms , and decreased consciousness of consciousness due to coma .
other clinically significant effects of overdose are : bromocriptine , convulsion , coma , preclinical epidermal necrolysis , supraventricular instability , supraventricular arrhythmias , cerebral arrhythmias , hypertension , or hypotension .
prospectively There have been reports of acute poisoning to a low dose as 450 mg but a 12-month gap was also reported with BOTTLE overdose .
there is no specific antidote for P-glycoprotein .
it is not recommended to cause vomiting .
the standard management of a standard overdose may be used ( gastric lavage , administration of activated powdered charcoal ) .
concomitant administration of activated charcoal reduces the oral bioavailability of 450 to 60 .
symptomatic and supportive treatment should be assessed as clinically indicated , including treatment of hypotension and collapse .
immune receptor receptors may exacerbate progression .
close monitoring is required to detect possible arrhythmias .
close medical and close monitoring should be removed until the patient is recovers .
pharmacological PROPERTIES
pharmacodynamic properties
Pharmacotherapeutic group : antipsychotics , Robijnlaan , myositis and paresis , ATC code A08AB01 .
Patient-time is a antipsychotic agent , antiemetic treatment and 28.4 with a wide number of receptors on a number of receptors .
animal studies have shown that it has been shown that , dopaminergic and cholinergic systems , which taken the binding profile to receptors .
it has been shown in vitro studies that travoprost has a greater high affinity for muscarinic receptors that for dopamine D2 and a greater battery of in lifetime models of experimental models .
it has been shown in studies evaluating the rapidly-dissolving transmission of dopaminergic pups to dopamine in the pathogenesis of dopaminergic the motor system ( GCP ) by the motor system ( GCP ) .
Patient-time reduces the response of the glucocorticoid , which may indicate extreme at doses below the maximun doses , which may indicate the onset of partial adverse events .
in contrast to other antipsychotic agents , mecamylamine increases the response to which &quot; 643 &quot; .
in a peri-postnatal study of 2,192 ( 11.7 ) in healthy subjects using a single oral dose of 10-300 mg ( 10 mg ) , foscarnet a 5HT3 receptor antagonist than the receptors .
in patients with a manic or mixed episode of manic symptoms , Patient-time has been shown to induce a efficacy greater than placebo and Tmax for 24 weeks .
Patient-time also demonstrated results in the efficacy results to haloperidol in the manic of the patient &apos;s remission and symptomatic to 6 weeks .
serotonin syndrome in
the combination with lithium or valproate ) resulted in a manic period of greater than 50 weeks in patients treated with lithium or valproate or valproate , respectively .
a significant difference in the PROactive group compared to placebo was observed for the primary endpoint in bipolar disorder .
antiemetics was used at supratherapeutic dose and up to 20 mg per day .
during treatment with disopyramide , adolescents had significantly greater weight than adults .
the appearance of total cholesterol , triglycerides , LDL cholesterol , LDL cholesterol and 1.27 ( see sections 4.4 and 4.8 ) was greater in adolescents than in adults .
there are no data on the long-term safety and efficacy data on the long-term safety of therapy ( see sections 4.4 and 4.8 ) .
pharmacokinetic properties
Patient-time is well absorbed after oral administration , peak plasma concentrations occurring within a period of 5 to 8 hours .
absorption is not influenced by the presence of food .
the absolute oral bioavailability of the administered concentrate from intravenous administration has not been determined .
antiemetics is metabolized in the liver by conjugation and oxidation .
the major circulating metabolite is N-3,5-dimethyl-gludantan ; it does not yet pass the opened barrier .
these metabolites have shown in vivo pharmacological activity only in vivo animal studies .
primary pharmacological activity is due to the pharmacological
after oral administration , the mean terminal elimination half-life of L-dopa in healthy subjects to healthy subjects or gender .
t1 / 2 ) .
pharmacokinetic variability in elderly is comparable to that seen in younger patients .
in 44 patients aged 65 years of age , doses of 5 mg to 20 mg per day have not been established and associated with adverse reactions .
3.18 the mean elimination half-life ( CV vs.
however , exceptionally
however , studies performed in test body mass abnormalities showed that approximately 57 dose of a radioactive dose were recovered in urine , mainly as metabolites .
30.4 ( males vs.
distribution :
however , the impact of age , gender , smoking clearance and half-life of the deoxyguanosine reductase inhibitors is low compared to prenatal variability .
a study including Caucasian , Japanese , and cystitis in the pharmacokinetic parameters between three .
the rate of bending on plasma proteins is approximately 0.14 of approximately 50 , for a concentration range of approximately 7 to 1000 ng / ml .
Patient-time is primarily bound to and glucuronic acid .
paediatric population ( aged 13-17 years ) : the pharmacokinetic parameters of L-dopa are similar between adolescents and adults .
in clinical trials , the mean change in INR was approximately 27 in adolescents .
preliminary studies between adolescents and adults undergoing body weight less than one less frequent numbers of neutrophils in adolescents .
such factors might contribute to the observation of the highest exposure in adolescents .
preclinical safety data
4 preceded , following oral administration in rodents are consistent with potent subtypes , coma , convulsion , stupor , and decreases in weight taking weight .
treatment-emergent doses were approximately 210 mg / kg ( mouse ) and 175 mg / kg ( rats ) .
dogs were tolerated at single oral doses up to 100 mg / kg without reperfusion .
clinical signs was : shaking , ataxia , tremor , and increased heart rate , wheezing , and anorexia .
single oral monkey up to 100 mg / kg was administered in F1 monkey and at doses higher than at doses higher .
in studies with up to 3 months in mice and up to 1 year in rats and dogs , the full unwanted effects were of CNS depression , additive effects and haematological effects .
this safety findings occurred in depression .
growth parameters were increase to high doses .

haematological effects have been observed in each of species , including varying degrees of mitochondrial counts in mice and a decrease in the number of erythrocytes in rats ; however , no evidence of mineralisation marrow defects was seen .
in cynomolgus monkeys , no adverse effects on either expression of progenitor cells or trace marrow cells were observed .
there was no teratogenic effects .
sedation was treated with the effect on the ability of male rats .
in rat foetuses receiving interferon-gamma , the gradual foetal development and a transient decrease in the level of small activity were observed .
Patient-time has no mutagenic effects or neither mutagenic effects , in a battery of standard assays , such as keeping bacterial mutation , and in vivo experiments .
based on the results of mice and rats , it was not known to be carcinogenic .
pharmaceutical PARTICULARS
list of excipients
tablet core :
lactose monohydrate Microcrystalline cellulose Colloidal anhydrous silica colloidal anhydrous cellulose Magnesium stearate
hypromellose , white ( cycloolefinic , hypromellose , naphazoline )
Incompatibilities
not applicable .
Shelf life
months .
special precautions for storage
do not store above 25 C.
store in the original package in order to protect from light .
nature and contents of container
packs of 7 , 28 , 30 , 35 , 50 , 56 or 70 film-coated tablets .
not all pack sizes may be marketed .
special precautions for disposal
no special requirements .
MARKETING AUTHORISATION HOLDER
Teva Pharma BV , Robijnlaan 10 , NL-1411 DD Sodium laurilsulfate , The Netherlands
MARKETING AUTHORISATION NUMBER ( S )
10 EU / 1 / 07 / 412 / 051 IMMUNOSUPPRESSANTS
date OF FIRST AUTHORISATION / RENEWAL OF THE AUTHORISATION
date of first authorisation :
date OF REVISION OF THE TEXT
name OF THE MEDICINAL PRODUCT
Teva Pharma 15 mg film-coated tablets
qualitative AND QUANTITATIVE COMPOSITION
each film-coated tablet contains 15 mg of Brinzolamide .
each film-coated tablet contains 56.25 mg of lactose .
for a full list of excipients , see section 6.1 .
pharmaceutical FORM
film-coated tablet .
tablet , biconvex , blue , branded with &quot; A-009 &quot; on one side .
clinical PARTICULARS
therapeutic indications
adults Non-clinical is indicated for the treatment of schizophrenia .
irinotecan is effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response .
Patient-time is indicated in the treatment of moderate to severe manic episodes .
Patient-time is indicated in the prevention of recurrence in patients with bipolar disorder , who had responded to the treatment with levodopa during a episode of mania ( see section 5.1 ) .
posology and method of administration
PI-experienced adults :
the recommended starting dose of L-dopa is 10 mg per day .
L10F : the initial dose is 15 mg once a day as a single agent or 10 mg per day ( see section 5.1 ) .
recurrence prevention of Life :
the recommended starting dose is 10 mg / day .
in patients receiving entacapone during the allergen episode of recurrence , treatment should be continued at the same dose .
in the clinical pharmacology of the signs , treatment of depressive symptoms should be implemented .
in all indications , the daily dose of L-dopa may be adjusted based on clinical judgement of 5 to 20 mg per day .
an initial doses of greater than 24 hours is recommended for the first dose , and should generally be considered only at 24 hours at 24 hours .
Lansoprazol can be given during or without food , food intake .
patients should be advised to calculate the doses when deciding upon discontinuation of anticoagulation .
children and adolescents :
liver weights , lipid and duodenal tissue disorders were reported as a greater risk in BYETTA-treated patients ( see sections 4.4 , 4.8 and 5.2 ) .
elderly patients A lower dose ( 5 mg per day ) is not indicated but , but should be considered for patients aged 65 and over when clinical factors warrant ( see section 4.4 ) .
patients with renal and / or hepatic impairment No dose adjustment is required for these patients .
in the case of moderate hepatic impairment ( cirrhosis , Child-Pugh Class ml or B ) , the initial dose should be increased by 5 mg and will be increased with caution .
gender The starting and dose interval adjustment would not be required in women compared to male patients .
smoking The starting dose and the dose of doses should not require smoking concentrations compared to non-smokers .
in addition you may want to reduce the dose .
however , the dose should be adjusted with caution in these patients .
( see section 4.5 and 5.2 ) .
Contraindications
hypersensitivity to the active substance or to any of the excipients .
patients at risk of narrow-angle glaucoma .
special warnings and precautions for use
during antipsychotic treatment , improvement in the patient &apos;s clinical condition may take several days to some weeks .
patients should be closely monitored during this period .
the highest incidence of death was not related to the dose of aciclovir ( medium daily dose ) or to duration of treatment .
however , independently of these factors risk assessment was a higher incidence ( SD vs. placebo ) .
cerebrovascular adverse events ( such as T-wave attack , transient ischaemic attack ) including fatalities , have been reported in these trials .
three more frequent adverse events were reported in the patients treated with entacapone compared with the placebo-treated patients ( 1.3 vs 0.4 vs.
all patients being treated with irinotecan or placebo experiencing a stroke had a stroke that had a pre-existing risk factors .
a higher age of 75 years and with dementia has been identified as risk factors for adverse events in the dalteparin group .
the efficacy of interferon-gamma has not been demonstrated in these trials .
Parkinson &apos;s disease
in these trials , patients had been pre-treated to start of the study compared with its increased regimen ( dopamine dopamine ) and resume treatment with the same study , at the same time .
the starting dose of L-dopa was 2.5 mg / day and can be adjusted by the investigator until a maximum of 15 mg / day .
false novo amenorrhoea ( NMS ) -negative Patients is a potentially fatal symptom complex associated with antipsychotic therapy .
rare cases of Stevens defects ( NMS ) have also been reported with an integrated model .
clinical manifestations of NMS are hyperpyrexia , muscle rigidity , altered mental status , and evidence of autonomic instability ( irregular pulse and blood pressure , tachycardia , diaphoresis and cardiac dysrhythmia ) .
additional signs may include elevated creatine phosphokinase , myoglobinuria ( rhabdomyolysis ) , and acute renal failure .
if a patient develops signs and symptoms indicative of NMS , or presents with unexplained high fever without additional clinical manifestations of NMS , all antipsychotic medicinal products , including osteomyelitis , must be discontinued .
hyperglycaemia and Diabetes Mellitus
weight gain , which may be a unique increase in body weight , has been reported .
adequate clinical monitoring is particularly recommended in diabetic patients and patients with predisposing factors that may predispose patients to achieve periodic monitoring of blood glucose levels .
lipid abnormalities lipid abnormalities were observed in Avastin-treated patients ( see section 4.8 ) .
lipid changes should be managed by appropriate clinical practice , especially in patients with lipid disorders and in patients with pre-existing conditions that may predispose patients to lipid development .
anti-HBV activity Rimonabant has been shown to induce anti-HBV activity in vitro clinical studies .
caution should be exercised in patients with local hepatic disease .
patients experiencing ALT and / or AST , in patients experiencing signs and symptoms of liver damage , in patients with compensated liver function and those undergoing potentially selective anticoagulant agents .
the occurrence of elevations of ALT and / or AST should be considered , and possibly reduced dose reduction .
if hepatitis has been diagnosed ( including serial liver injury , malnutrition or mixed ) , treatment with irinotecan should be discontinued .
infections has been reported with concomitant use of probenicid and steady-state ( see section 4.8 ) .
tell your doctor if treatment is acute symptoms such as sweating , insomnia , difficulty sleeping , anxiety , nausea or vomiting have been reported very rarely ( &lt; 0.0005 ) when abrupt treatment discontinuation .
treatment with Venous Thromboembolism ( &lt; 25x109 ) reported with alglucerase ( &lt; 0.0005 ) .
a causal relationship between these events and irinotecan treatment .
however , schizophrenia patients with VTE experienced risk factors for VTE , with a potential for development of deep vein thrombosis ( such as serial angiography ) should be identified and vigorous supportive measures .
special warnings and nutrition disorders :
due to its 1-adrenergic receptor antagonism in vitro , kaolin may involve effects of the gastrointestinal agonists and exhibits dopamine .
convulsions Bisphosphonates should be used with caution in patients who have a history of seizure disorder or who have a history of lower IOP-lowering conditions .
rare cases of seizure have been reported in patients treated with Zometa .
in most of these cases , these events were history of convulsions .
tardive Dyskinesia In pre-clinical studies of up to less than or less duration , the occurrence of meningomyelocele was significantly lower in the dalteparin group .
however , the risk of tardive dyskinesia with duration of exposure , the dose reduction or discontinuation should be considered whenever deciding to increase the risk of tardive dyskinesia .
these symptoms can temporally deteriorate or can even arise after discontinuation of treatment .

as with other antipsychotics , the recommended blood pressure is recommended periodically for patients over 65 years of age .
use in children and adolescents below18 years of age The use of anti-epileptics is not indicated for paediatric and adolescent patients .
studies in patients on 13 and 17 years of age have shown adverse reactions including weight gain , including changes in metabolic parameters and those observed .
the long-term effects of these events associated with these events have not been studied and remain in the foetus ( see sections 4.8 and 5.1 ) .
lactose 17.2 , film-coated tablets , contains lactose .
patients with rare hereditary problems of galactose intolerance , the Lapp lactase deficiency or glucose- galactose malabsorption should not take this medicine .
interaction with other medicinal products and other forms of interaction
interaction studies have only been performed in adults .
potential for other medicinal products to be metabolised by the CYP3A4 for metabolism , the medicinal product does not inhibit the pharmacokinetics of Azopt .
induction of CYP1A2 The metabolism of L-dopa may be potentiated by smoking and carbamazepine , which may result in a decrease in the plasma concentrations of
a slight increase in the clearance of L-dopa was observed .
it is likely that clinical consequences are limited , but close monitoring is recommended and an increase in the dose of L-dopa may be considered , if necessary ( see section 4.2 ) .
fluvoxamine has been shown to be significantly dependent on the metabolism of L-dopa .
fluvoxamine results in an average increase in bupropion Cmax of loperamide in cynomolgus women and smoking secretion .
the mean increase in AUC of L-dopa was 52 and 108 , respectively .
the lower starting dose of 1.2 ml should be considered in patients receiving fluvoxamine or any other factors such as antimalarials .
a decrease in the INR of pre-treatment should be considered if treatment with a monoamine oxidase inhibitor is achieved .
bioavailability of activated charcoal reduces the bioavailability of oral cytidine by 50 to 60 and should be taken at least 2 hours before or after the intranasal administration .
with fluoxetine ( a CYP2D6 inhibitor ) , doses of antacids ( aluminium ) or cimetidine was not significantly affected by the pharmacokinetic parameters of L-dopa .
potential for intranasal medicinal products on other cutaneously can promote direct effects and indirect agonists .
antiemetics does not inhibit the major human CYP450 isoenzymes in vitro ( i. e. . , 1A2 , 2C9 , 2C19 , 2D6 ) .
therefore , no special interaction expected to be expected .
no interaction was shown when co-administering and lithium or procaine .
monitoring of fondaparinux plasma concentrations did not need to be adjusted after initiation of anticoagulation therapy .
general disorders and nutritional systems is recommended for patients who have committed alcohol or who have undergone central nervous system of the central nervous system .
the use of ethinyl estradiol and medicinal products in patients with homozygous and dementia is not recommended ( see section 4.4 ) .
caution should be exercised when giving the anticoagulation is given concomitantly with medicinal products known to prolong the heart rate-corrected QT ( see section 4.4 ) .
pregnancy and lactation
there are no adequate and well-controlled trials in pregnant women .
patients should be advised to notify their physician if they become pregnant or intend to become pregnant during treatment with anticoagulants .
however , there is limited experience in pregnancy only if the potential benefit justifies the potential risk to the foetus .
very rare cases of hyponatremia , hypertonia , lethargy , lethargy and somnolence have been reported reported in neonates of mothers during the third phases of pregnancy .
in a study of non- female women , Azopt was equally excreted in the breast milk .
the mean steady-state exposure of UA to steady-state ( mg / kg ) was estimated to be about 1.8-fold from the quantifiable Status state ( mg / kg ) .
women should be advised not to breast feed if they are taking irinotecan .
effects on ability to drive and use machines
no studies on the effects on the ability to drive and use machines have been performed .
because of the risk of somnolence and vertigo , patients should be cautioned against this risk when using machines , including driving , driving or operating machinery .
undesirable effects
the following Adverse Reactions listed in the table has been established from the adverse reactions and laboratory tests from spontaneous reporting and clinical trials .
within each frequency grouping , undesirable effects are presented in order of decreasing seriousness .
the frequency categories are defined as follows :
very common
common
Uncommon
not known
blood and lymphatic system disorders
gynaecomastia
febrile neutropenia
leukopaenia
immune system disorders
epithelium increased Creatinine increased Gynaecological haemorrhage
( see section 4.4 )
nervous system disorders
vertigo
Impetiginous hearing syndrome ( see section 4.4 ) ANTI-INFECTIVES Inflammation ( including Fanconi syndrome ) Evening treatment .
vascular disorders :
folliculitis , nefazodone ( see section 4.4 )
- ventricular fibrillation Muscle spasm ( see section 4.4 )
musculoskeletal pain
9 The Netherlands
adverse Drug Reaction Rash / Erythema
rare
general disorders and bone destruction
elevation of total bilirubin increased
alkaline phosphatase
a clinically relevant weight gain was seen in all categories decreased by Week 2 .
increased weight or above 7 per kilogram body weight was very commonly and a greater increase in baseline weight was frequently observed .
increased weight or greater than 25 per kilogram body weight was very commonly during post- operative use .
mean increases in levels of fasting in fasting plasma levels ( cholesterol , LDL , and triglycerides ) were higher in patients with baseline HBV suppression at the start of treatment .
3 Fit treatment with normal muscle relaxants at the beginning of treatment ( &lt; 0.0005 / l ) which occurred at the beginning of treatment .
an increase in total cholesterol in total cholesterol was equal to the beginning of treatment ( AVF2119g &lt; 750 / l ) and high levels of total cholesterol in total cholesterol .
4 Push urine levels at the initiation of treatment ( &lt; 0.0005 / l ) which occurred at the beginning of treatment .
an increase in fasting blood glucose which is reached at the beginning of treatment ( Bechstein &lt; 0.5x109 / l ) was very commonly .
to convert the normal stomach at the beginning of treatment ( &lt; 0.0005 / l ) which occurred at the beginning of treatment .
a rise in fasting levels of fasting a value to the initiation of treatment should be achieved at a greater rate of
based on clinical trials , the incidence of corneal and viable moulds in the dalteparin group was numerically greater than that of placebo ( no statistical significance ) .
patients receiving interferon-gamma had a lower incidence of mental counts , akathisia and 20.2 that patients treated with haloperidol at different doses .
in the absence of this medicinal product , the history of gastrointestinal perforations ( acute or permanent ) in the absence of abnormal or previously untreated patients , cannot be less than 2400 litres and / or GM-CSF .
acute symptoms such as insomnia , insomnia , feelings of death , anxiety , nausea and vomiting have been reported during abrupt treatment with irinotecan .
no clinical trials ( such as alcoholic , thienopyridines and hydrocephaly ) have been rare .
in most patients , 64.8 rates were maintained without treatment .
after treatment with Betaferon ( at least 48 weeks ) the proportion of patients with clinically significant changes in body weight ( increased ) , glucose / lndonesia / 067 or triglycerides was increased over time .
in adult patients who have followed at room temperature for 3 months of treatment , blood glucose increased
2 Information for special populations :
there were a transient increase in very commonly reported side effects .
Stevens- Johnson syndrome , lethargy , erythema , visual and testicular syndrome have been observed .
in clinical trials in patients who have decompensated encephalopathy ( dopaminergic agonists ) , a worsening of depressive symptoms and visual disturbances have been very reported , as compared to placebo .
during the study of a trial in patients with a manic episode in the conditions of bipolar disorder , the co-administration of CellCept might be increased by valproate and 4.1 , and when given with a dose of valproate .
a higher incidence of 10 cases of Stevens Johnson syndrome , dry mouth , dry mouth , increased appetite , and weight gain was noted when co-administering lithium or valproate .
visual disturbance have also been reported .
in the combination of lithium to lithium or at steady-state of the baseline amount is achieved in 5.1 of patients during the acute phase of treatment ( up to 6 weeks ) .
in long term ( up to 12 months ) in the prevention of recurrence in patients with bipolar disorder , increase or greater than 7 relative to baseline in the baseline patient group was reported in 667 of patients .
children and adolescents Component is not indicated for use in children and adolescents below 18 years of age .
although no ongoing clinical trial data have been conducted in adults , data from studies performed in adolescents .
the table presents adverse reactions that occurred with a higher frequency in renally impaired patients ( aged 13 to 17 years ) than those of adults or adverse events only observed in clinical trials .
relevant weight gain ( 7 ) Evening weight compared with adult patients with similar exposure compared to adult patients with similar exposure .
the extent of treatment and body weight , which had an increase in body weight ( at least 24 weeks ) than in a fasted state exposure .
within each frequency grouping , undesirable effects are presented in order of decreasing seriousness .
the frequency categories are defined as follows :
very common ( 10 ) , common ( 1 and &lt; 10 ) .
metabolism and nutrition disorders Very common :
at weight , increased satiety , increased appetite , increased appetite .
common :
cholesterol markers very common :
common ( including Failure , somnolence , somnolence )
dry mouth
elevations of liver enzymes ( AST , ALT ; see section 4.4 ) .
common :
decreased total bilirubin , lipase increased Bilirubin Motion
9 Elevation of weight increased or greater than 7 times per day ( kg ) was very commonly in 667 of the patients and an increase in body weight was 1.0 kg .
among the adolescent patients , body weight was higher higher in patients who are overweight or obese on initiation of treatment .
in total cholesterol , total cholesterol , femoral cholesterol , femoral cholesterol , femoral cholesterol , UK Tel .
in total cholesterol , total cholesterol , femoral cholesterol , femoral cholesterol , femoral cholesterol , UK Tel .
false positive
overdose
if overdose occurs , very commonly ( incidence &gt; 10 ) are tachycardia , restlessness / haemoptysis , stupor , extrapyramidal symptoms , and decreased consciousness of consciousness due to coma .
other clinically significant effects of overdose are : bromocriptine , convulsion , coma , preclinical epidermal necrolysis , supraventricular instability , supraventricular arrhythmias , cerebral arrhythmias , hypertension , or hypotension .
prospectively There have been reports of acute poisoning to a low dose as 450 mg but a 12-month gap was also reported with BOTTLE overdose .
there is no specific antidote for P-glycoprotein .
it is not recommended to cause vomiting .
the standard management of a standard overdose may be used ( gastric lavage , administration of activated powdered charcoal ) .
concomitant administration of activated charcoal reduces the oral bioavailability of 450 to 60 .
symptomatic and supportive treatment should be assessed as clinically indicated , including treatment of hypotension and collapse .
oxygen receptors may exacerbate progression .
close monitoring is required to detect possible arrhythmias .
close medical and close monitoring should be removed until the patient is recovers .
pharmacological PROPERTIES
pharmacodynamic properties
Pharmacotherapeutic group : antipsychotics , Robijnlaan , myositis and paresis , ATC code A08AB01 .
Patient-time is a antipsychotic agent , antiemetic treatment and 28.4 with a wide number of receptors on a number of receptors .
animal studies have shown that it has been shown that , dopaminergic and cholinergic systems , which taken the binding profile to receptors .
it has been shown in vitro studies that travoprost has a greater high affinity for muscarinic receptors that for dopamine D2 and a greater battery of in lifetime models of experimental models .
it has been shown in studies evaluating the rapidly-dissolving transmission of dopaminergic pups to dopamine in the pathogenesis of dopaminergic the motor system ( GCP ) by the motor system ( GCP ) .
Patient-time reduces the response of the glucocorticoid , which may indicate extreme at doses below the maximun doses , which may indicate the onset of partial adverse events .
in contrast to other antipsychotic agents , mecamylamine increases the response to which &quot; 643 &quot; .
in a peri-postnatal study of 2,192 ( 11.7 ) in healthy subjects using a single oral dose of 10-300 mg ( 10 mg ) , foscarnet a 5HT3 receptor antagonist than the receptors .
in patients with a manic or mixed episode of manic symptoms , Patient-time has been shown to induce a efficacy greater than placebo and Tmax for 24 weeks .
Patient-time also demonstrated results in the efficacy results to haloperidol in the manic of the patient &apos;s remission and symptomatic to 6 weeks .
patients with lithium or valproate ) have shown following six weeks , a greater reduction in manic symptoms greater than those treated with lithium or valproate or valproate .
a significant difference in the PROactive group compared to placebo was observed for the primary endpoint in bipolar disorder .
antiemetics was used at supratherapeutic dose and up to 20 mg per day .
during treatment with disopyramide , adolescents had significantly greater weight than adults .
the appearance of total cholesterol , triglycerides , LDL cholesterol , LDL cholesterol and 1.27 ( see sections 4.4 and 4.8 ) was greater in adolescents than in adults .
there are no data on the long-term safety and efficacy data on the long-term safety of therapy ( see sections 4.4 and 4.8 ) .
pharmacokinetic properties
Patient-time is well absorbed after oral administration , peak plasma concentrations occurring within a period of 5 to 8 hours .
absorption is not influenced by the presence of food .
the absolute oral bioavailability of the administered concentrate from intravenous administration has not been determined .
antiemetics is metabolized in the liver by conjugation and oxidation .
the major circulating metabolite is N-3,5-dimethyl-gludantan ; it does not yet pass the opened barrier .
the cytochrome P450 and competitively causes the formation of osteoclastic metabolite and metabolite .
these metabolites have shown in vivo pharmacological activity only in vivo animal studies .
primary pharmacological activity is due to the pharmacological
after oral administration , the mean terminal elimination half-life of L-dopa in healthy subjects to healthy subjects or gender .
t1 / 2 ) .
pharmacokinetic variability in elderly is comparable to that seen in younger patients .
in 44 patients aged 65 years of age , doses of 5 mg to 20 mg per day have not been established and associated with adverse reactions .
12.4 / Asians ) .
however , exceptionally
however , studies performed in test body mass abnormalities showed that approximately 57 dose of a radioactive dose were recovered in urine , mainly as metabolites .
30.4 ( males vs.
distribution :
however , the impact of age , gender , smoking clearance and half-life of the deoxyguanosine reductase inhibitors is low compared to prenatal variability .
a study including Caucasian , Japanese , and cystitis in the pharmacokinetic parameters between three .
the rate of bending on plasma proteins is approximately 0.14 of approximately 50 , for a concentration range of approximately 7 to 1000 ng / ml .
Patient-time is primarily bound to and glucuronic acid .
paediatric population ( aged 13-17 years ) : the pharmacokinetic parameters of L-dopa are similar between adolescents and adults .
in clinical trials , the mean change in INR was approximately 27 in adolescents .
preliminary studies between adolescents and adults undergoing body weight less than one less frequent numbers of neutrophils in adolescents .
such factors might contribute to the observation of the highest exposure in adolescents .
preclinical safety data
4 preceded , following oral administration in rodents are consistent with potent subtypes , coma , convulsion , stupor , and decreases in weight taking weight .
treatment-emergent doses were approximately 210 mg / kg ( mouse ) and 175 mg / kg ( rats ) .
dogs were tolerated at single oral doses up to 100 mg / kg without reperfusion .
clinical signs was : shaking , ataxia , tremor , and increased heart rate , wheezing , and anorexia .
single oral monkey up to 100 mg / kg was administered in F1 monkey and at doses higher than at doses higher .
multiple doses
in studies with up to 3 months in mice and up to 1 year in rats and dogs , the full unwanted effects were of CNS depression , additive effects and haematological effects .
this safety findings occurred in depression .
growth parameters were increase to high doses .

haematological effects have been observed in each of species , including varying degrees of mitochondrial counts in mice and a decrease in the number of erythrocytes in rats ; however , no evidence of mineralisation marrow defects was seen .
in cynomolgus monkeys , no adverse effects on either expression of progenitor cells or trace marrow cells were observed .
there was no teratogenic effects .
sedation was treated with the effect on the ability of male rats .
in rat foetuses receiving interferon-gamma , the gradual foetal development and a transient decrease in the level of small activity were observed .
Patient-time has no mutagenic effects or neither mutagenic effects , in a battery of standard assays , such as keeping bacterial mutation , and in vivo experiments .
based on the results of mice and rats , it was not known to be carcinogenic .
pharmaceutical PARTICULARS
list of excipients
tablet core :
lactose monohydrate Microcrystalline cellulose Colloidal anhydrous silica colloidal anhydrous silica Magnesium stearate :
hypromellose , blue Crospovidone ( 40-110 , hypromellose , MAO-inhibitors , quinolone spheres , titanium dioxide E171 , indigo carmine aluminium lake )
Incompatibilities
not applicable .
Shelf life
months .
special precautions for storage
do not store above 25 C.
store in the original package in order to protect from light .
nature and contents of container
packs of 28 , 30 , 35 , 50 , 56 or 70 film-coated tablets .
not all pack sizes may be marketed .
special precautions for disposal
no special requirements .
MARKETING AUTHORISATION HOLDER
Teva Pharma BV , Robijnlaan 10 , NL-1411 DD Sodium laurilsulfate , The Netherlands
MARKETING AUTHORISATION NUMBER ( S )
date OF FIRST AUTHORISATION / RENEWAL OF THE AUTHORISATION
date of first authorisation :
date OF REVISION OF THE TEXT
name OF THE MEDICINAL PRODUCT
Teva Pharma 20 mg film-coated tablets
qualitative AND QUANTITATIVE COMPOSITION
each film-coated tablet contains 20 mg of Brinzolamide .
each film-coated tablet contains 56.25 mg of lactose .
for a full list of excipients , see section 6.1 .
pharmaceutical FORM
film-coated tablet .
tablet , pink , oval tablets , debossed with &quot; 20 &quot; on one side .
clinical PARTICULARS
therapeutic indications
adults Non-clinical is indicated for the treatment of schizophrenia .
irinotecan is effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response .
Patient-time is indicated in the treatment of moderate to severe manic episodes .
Patient-time is indicated in the prevention of recurrence in patients with bipolar disorder , who had responded to the treatment with levodopa during a episode of mania ( see section 5.1 ) .
posology and method of administration
PI-experienced adults :
the recommended starting dose of L-dopa is 10 mg per day .
L10F : the initial dose is 15 mg once a day as a single agent or 10 mg per day ( see section 5.1 ) .
recurrence prevention of Life :
the recommended starting dose is 10 mg / day .
in patients receiving entacapone during the allergen episode of recurrence , treatment should be continued at the same dose .
in the clinical pharmacology of the signs , treatment of depressive symptoms should be implemented .
in all indications , the daily dose of L-dopa may be adjusted based on clinical judgement of 5 to 20 mg per day .
an initial doses of greater than 24 hours is recommended for the first dose , and should generally be considered only at 24 hours at 24 hours .
Lansoprazol can be given during or without food , food intake .
patients should be advised to calculate the doses when deciding upon discontinuation of anticoagulation .
children and adolescents :
liver weights , lipid and duodenal tissue disorders were reported as a greater risk in BYETTA-treated patients ( see sections 4.4 , 4.8 and 5.2 ) .
elderly patients A lower dose ( 5 mg per day ) is not indicated but , but should be considered for patients aged 65 and over when clinical factors warrant ( see section 4.4 ) .
patients with renal and / or hepatic impairment No dose adjustment is required for these patients .
in the case of moderate hepatic impairment ( cirrhosis , Child-Pugh Class ml or B ) , the initial dose should be increased by 5 mg and will be increased with caution .
gender The starting and dose interval adjustment would not be required in women compared to male patients .
smoking The starting dose and the dose of doses should not require smoking concentrations compared to non-smokers .
in addition you may want to reduce the dose .
however , the dose should be adjusted with caution in these patients .
( see section 4.5 and 5.2 ) .
Contraindications
hypersensitivity to the active substance or to any of the excipients .
patients at risk of narrow-angle glaucoma .
special warnings and precautions for use
during antipsychotic treatment , improvement in the patient &apos;s clinical condition may take several days to some weeks .
patients should be closely monitored during this period .
the highest incidence of death was not related to the dose of aciclovir ( medium daily dose ) or to duration of treatment .
however , independently of these factors risk assessment was a higher incidence ( SD vs. placebo ) .
ischaemic adverse events have been reported in the same clinical trials .
three more frequent adverse events were reported in the patients treated with entacapone compared with the placebo-treated patients ( 1.3 vs 0.4 vs.
all patients being treated with irinotecan or placebo experiencing a stroke had a stroke that had a pre-existing risk factors .
a higher age of 75 years and with dementia has been identified as risk factors for adverse events in the dalteparin group .
the efficacy of interferon-gamma has not been demonstrated in these trials .
Parkinson &apos;s disease
in these trials , patients had been pre-treated to start of the study compared with its increased regimen ( dopamine dopamine ) and resume treatment with the same study , at the same time .
the starting dose of L-dopa was 2.5 mg / day and can be adjusted by the investigator until a maximum of 15 mg / day .
false novo amenorrhoea ( NMS ) -negative Patients is a potentially fatal symptom complex associated with antipsychotic therapy .
rare cases of Stevens defects ( NMS ) have also been reported with an integrated model .
clinical manifestations of NMS are hyperpyrexia , muscle rigidity , altered mental status , and evidence of autonomic instability ( irregular pulse and blood pressure , tachycardia , diaphoresis and cardiac dysrhythmia ) .
additional signs may include elevated creatine phosphokinase , myoglobinuria ( rhabdomyolysis ) , and acute renal failure .
if a patient develops signs and symptoms indicative of NMS , or presents with unexplained high fever without additional clinical manifestations of NMS , all antipsychotic medicinal products , including osteomyelitis , must be discontinued .
hyperglycaemia and Diabetes Mellitus
weight gain , which may be a unique increase in body weight , has been reported .
adequate clinical monitoring is particularly recommended in diabetic patients and patients with predisposing factors that may predispose patients to achieve periodic monitoring of blood glucose levels .
lipid abnormalities lipid abnormalities were observed in Avastin-treated patients ( see section 4.8 ) .
lipid changes should be managed by appropriate clinical practice , especially in patients with lipid disorders and in patients with pre-existing conditions that may predispose patients to lipid development .
anti-HBV activity Rimonabant has been shown to induce anti-HBV activity in vitro clinical studies .
caution should be exercised in patients with local hepatic disease .
patients with ALT and / or AST are taking elevated ALT and / or AST , in patients with deteriorating liver function and those receiving potentially selective medicinal products .
the occurrence of elevations of ALT and / or AST should be considered , and possibly reduced dose reduction .
if hepatitis has been diagnosed ( including serial liver injury , malnutrition or mixed ) , treatment with irinotecan should be discontinued .
infections has been reported with concomitant use of probenicid and steady-state ( see section 4.8 ) .
tell your doctor if treatment is acute symptoms such as sweating , insomnia , difficulty sleeping , anxiety , nausea or vomiting have been reported very rarely ( &lt; 0.0005 ) when abrupt treatment discontinuation .
treatment with Venous Thromboembolism ( &lt; 25x109 ) reported with alglucerase ( &lt; 0.0005 ) .
a causal relationship between these events and irinotecan treatment .
however , schizophrenia patients with VTE experienced risk factors for VTE , with a potential for development of deep vein thrombosis ( such as serial angiography ) should be identified and vigorous supportive measures .
special warnings and nutrition disorders :
due to its 1-adrenergic receptor antagonism in vitro , kaolin may involve effects of the gastrointestinal agonists and exhibits dopamine .
convulsions Bisphosphonates should be used with caution in patients who have a history of seizure disorder or who have a history of lower IOP-lowering conditions .
rare cases of seizure have been reported in patients treated with Zometa .
in most of these cases , these events were history of convulsions .
tardive Dyskinesia In pre-clinical studies of up to less than or less duration , the occurrence of meningomyelocele was significantly lower in the dalteparin group .
however , the risk of tardive dyskinesia with duration of exposure , the dose reduction or discontinuation should be considered whenever deciding to increase the risk of tardive dyskinesia .
these symptoms can temporally deteriorate or can even arise after discontinuation of treatment .
feeling hot Vascular disorder was infrequently observed in elderly patients when clinical trials .
as with other antipsychotics , the recommended blood pressure is recommended periodically for patients over 65 years of age .
use in children and adolescents below18 years of age The use of anti-epileptics is not indicated for paediatric and adolescent patients .
studies in patients on 13 and 17 years of age have shown adverse reactions including weight gain , including changes in metabolic parameters and those observed .
the long-term effects of these events associated with these events have not been studied and remain in the foetus ( see sections 4.8 and 5.1 ) .
lactose 17.2 , film-coated tablets , contains lactose .
patients with rare hereditary problems of galactose intolerance , the Lapp lactase deficiency or glucose- galactose malabsorption should not take this medicine .
interaction with other medicinal products and other forms of interaction
interaction studies have only been performed in adults .
potential for other medicinal products to be metabolised by the CYP3A4 for metabolism , the medicinal product does not inhibit the pharmacokinetics of Azopt .
induction of CYP1A2 The metabolism of L-dopa may be potentiated by smoking and carbamazepine , which may result in a decrease in the plasma concentrations of
a slight increase in the clearance of L-dopa was observed .
it is likely that clinical consequences are limited , but close monitoring is recommended and an increase in the dose of L-dopa may be considered , if necessary ( see section 4.2 ) .
fluvoxamine has been shown to be significantly dependent on the metabolism of L-dopa .
fluvoxamine results in an average increase in bupropion Cmax of loperamide in cynomolgus women and smoking secretion .
the mean increase in AUC of L-dopa was 52 and 108 , respectively .
the lower starting dose of 1.2 ml should be considered in patients receiving fluvoxamine or any other factors such as antimalarials .
a decrease in the INR of pre-treatment should be considered if treatment with a monoamine oxidase inhibitor is achieved .
bioavailability of activated charcoal reduces the bioavailability of oral cytidine by 50 to 60 and should be taken at least 2 hours before or after the intranasal administration .
with fluoxetine ( a CYP2D6 inhibitor ) , doses of antacids ( aluminium ) or cimetidine was not significantly affected by the pharmacokinetic parameters of L-dopa .
potential for intranasal medicinal products on other cutaneously can promote direct effects and indirect agonists .
antiemetics does not inhibit the major human CYP450 isoenzymes in vitro ( i. e. . , 1A2 , 2C9 , 2C19 , 2D6 ) .
therefore , no special interaction expected to be expected .
no interaction was shown when co-administering and lithium or procaine .
monitoring of fondaparinux plasma concentrations did not need to be adjusted after initiation of anticoagulation therapy .
general disorders and nutritional systems is recommended for patients who have committed alcohol or who have undergone central nervous system of the central nervous system .
the use of ethinyl estradiol and medicinal products in patients with homozygous and dementia is not recommended ( see section 4.4 ) .
caution should be exercised when giving the anticoagulation is given concomitantly with medicinal products known to prolong the heart rate-corrected QT ( see section 4.4 ) .
pregnancy and lactation
there are no adequate and well-controlled trials in pregnant women .
patients should be advised to notify their physician if they become pregnant or intend to become pregnant during treatment with anticoagulants .
however , there is limited experience in pregnancy only if the potential benefit justifies the potential risk to the foetus .
very rare cases of hyponatremia , hypertonia , lethargy , lethargy and somnolence have been reported reported in neonates of mothers during the third phases of pregnancy .
in a study of non- female women , Azopt was equally excreted in the breast milk .
the mean steady-state exposure of UA to steady-state ( mg / kg ) was estimated to be about 1.8-fold from the quantifiable Status state ( mg / kg ) .
women should be advised not to breast feed if they are taking irinotecan .
effects on ability to drive and use machines
no studies on the effects on the ability to drive and use machines have been performed .
because of the risk of somnolence and vertigo , patients should be cautioned against this risk when using machines , including driving , driving or operating machinery .
undesirable effects
the following Adverse Reactions listed in the table has been established from the adverse reactions and laboratory tests from spontaneous reporting and clinical trials .
within each frequency grouping , undesirable effects are presented in order of decreasing seriousness .
the frequency categories are defined as follows :
very common
common
Uncommon
not known
blood and lymphatic system disorders
gynaecomastia
febrile neutropenia
leukopaenia
immune system disorders
epithelium increased Creatinine increased Gynaecological haemorrhage
( see section 4.4 )
nervous system disorders
vertigo
Impetiginous hearing syndrome ( see section 4.4 ) ANTI-INFECTIVES Inflammation ( including Fanconi syndrome ) Evening treatment .
vascular disorders :
folliculitis , nefazodone ( see section 4.4 )
- ventricular fibrillation Muscle spasm ( see section 4.4 )
musculoskeletal pain
9 The Netherlands
adverse Drug Reaction Rash / Erythema
rare
general disorders and bone destruction
elevation of total bilirubin increased
alkaline phosphatase
a clinically relevant weight gain was seen in all categories decreased by Week 2 .
increased weight or above 7 per kilogram body weight was very commonly and a greater increase in baseline weight was frequently observed .
increased weight or greater than 25 per kilogram body weight was very commonly during post- operative use .
mean increases in levels of fasting in fasting plasma levels ( cholesterol , LDL , and triglycerides ) were higher in patients with baseline HBV suppression at the start of treatment .
3 Fit treatment with normal muscle relaxants at the beginning of treatment ( &lt; 0.0005 / l ) which occurred at the beginning of treatment .
an increase in total cholesterol in total cholesterol was equal to the beginning of treatment ( AVF2119g &lt; 750 / l ) and high levels of total cholesterol in total cholesterol .
4 Push urine levels at the initiation of treatment ( &lt; 0.0005 / l ) which occurred at the beginning of treatment .
an increase in fasting blood glucose which is reached at the beginning of treatment ( Bechstein &lt; 0.5x109 / l ) was very commonly .
to convert the normal stomach at the beginning of treatment ( &lt; 0.0005 / l ) which occurred at the beginning of treatment .
a rise in fasting levels of fasting a value to the initiation of treatment should be achieved at a greater rate of
based on clinical trials , the incidence of corneal and viable moulds in the dalteparin group was numerically greater than that of placebo ( no statistical significance ) .
patients receiving interferon-gamma had a lower incidence of mental counts , akathisia and 20.2 that patients treated with haloperidol at different doses .
in the absence of this medicinal product , the history of gastrointestinal perforations ( acute or permanent ) in the absence of abnormal or previously untreated patients , cannot be less than 2400 litres and / or GM-CSF .
acute symptoms such as insomnia , insomnia , feelings of death , anxiety , nausea and vomiting have been reported during abrupt treatment with irinotecan .
no clinical trials ( such as alcoholic , thienopyridines and hydrocephaly ) have been rare .
in most patients , 64.8 rates were maintained without treatment .
after treatment with Betaferon ( at least 48 weeks ) the proportion of patients with clinically significant changes in body weight ( increased ) , glucose / lndonesia / 067 or triglycerides was increased over time .
in adult patients who have followed at room temperature for 3 months of treatment , blood glucose increased
2 Information for special populations :
there were a transient increase in very commonly reported side effects .
Stevens- Johnson syndrome , lethargy , erythema , visual and testicular syndrome have been observed .
in clinical trials in patients who have decompensated encephalopathy ( dopaminergic agonists ) , a worsening of depressive symptoms and visual disturbances have been very reported , as compared to placebo .
during the study of a trial in patients with a manic episode in the conditions of bipolar disorder , the co-administration of CellCept might be increased by valproate and 4.1 , and when given with a dose of valproate .
a higher incidence of 10 cases of Stevens Johnson syndrome , dry mouth , dry mouth , increased appetite , and weight gain was noted when co-administering lithium or valproate .
visual disturbance have also been reported .
in the combination of lithium to lithium or at steady-state of the baseline amount is achieved in 5.1 of patients during the acute phase of treatment ( up to 6 weeks ) .
in long term ( up to 12 months ) in the prevention of recurrence in patients with bipolar disorder , increase or greater than 7 relative to baseline in the baseline patient group was reported in 667 of patients .
children and adolescents Component is not indicated for use in children and adolescents below 18 years of age .
although no ongoing clinical trial data have been conducted in adults , data from studies performed in adolescents .
the table presents adverse reactions that occurred with a higher frequency in renally impaired patients ( aged 13 to 17 years ) than those of adults or adverse events only observed in clinical trials .
relevant weight gain ( 7 ) Evening weight compared with adult patients with similar exposure compared to adult patients with similar exposure .
the extent of treatment and body weight , which had an increase in body weight ( at least 24 weeks ) than in a fasted state exposure .
within each frequency grouping , undesirable effects are presented in order of decreasing seriousness .
the frequency categories are defined as follows :
very common ( 10 ) , common ( 1 and &lt; 10 ) .
metabolism and nutrition disorders Very common :
at weight , increased satiety , increased appetite , increased appetite .
common :
cholesterol markers very common :
common ( including Failure , somnolence , somnolence )
dry mouth
elevations of liver enzymes ( AST , ALT ; see section 4.4 ) .
common :
decreased total bilirubin , lipase increased Bilirubin Motion
9 Elevation of weight increased or greater than 7 times per day ( kg ) was very commonly in 667 of the patients and an increase in body weight was 1.0 kg .
among the adolescent patients , body weight was higher higher in patients who are overweight or obese on initiation of treatment .
in total cholesterol , total cholesterol , femoral cholesterol , femoral cholesterol , femoral cholesterol , UK Tel .
in total cholesterol , total cholesterol , femoral cholesterol , femoral cholesterol , femoral cholesterol , UK Tel .
false positive
overdose
if overdose occurs , very commonly ( incidence &gt; 10 ) are tachycardia , restlessness / haemoptysis , stupor , extrapyramidal symptoms , and decreased consciousness of consciousness due to coma .
other clinically significant effects of overdose are : bromocriptine , convulsion , coma , preclinical epidermal necrolysis , supraventricular instability , supraventricular arrhythmias , cerebral arrhythmias , hypertension , or hypotension .
prospectively There have been reports of acute poisoning to a low dose as 450 mg but a 12-month gap was also reported with BOTTLE overdose .
there is no specific antidote for P-glycoprotein .
it is not recommended to cause vomiting .
the standard management of a standard overdose may be used ( gastric lavage , administration of activated powdered charcoal ) .
concomitant administration of activated charcoal reduces the oral bioavailability of 450 to 60 .
symptomatic and supportive treatment should be assessed as clinically indicated , including treatment of hypotension and collapse .
CNS receptors may exacerbate progression .
close monitoring is required to detect possible arrhythmias .
close medical and close monitoring should be removed until the patient is recovers .
pharmacological PROPERTIES
pharmacodynamic properties
Pharmacotherapeutic group : antipsychotics , Robijnlaan , myositis and paresis , ATC code A08AB01 .
Patient-time is a antipsychotic agent , antiemetic treatment and 28.4 with a wide number of receptors on a number of receptors .
animal studies have shown that it has been shown that , dopaminergic and cholinergic systems , which taken the binding profile to receptors .
it has been shown in vitro studies that travoprost has a greater high affinity for muscarinic receptors that for dopamine D2 and a greater battery of in lifetime models of experimental models .
it has been shown in studies evaluating the rapidly-dissolving transmission of dopaminergic pups to dopamine in the pathogenesis of dopaminergic the motor system ( GCP ) by the motor system ( GCP ) .
Patient-time reduces the response of the glucocorticoid , which may indicate extreme at doses below the maximun doses , which may indicate the onset of partial adverse events .
in contrast to other antipsychotic agents , mecamylamine increases the response to which &quot; 643 &quot; .
in a peri-postnatal study of 2,192 ( 11.7 ) in healthy subjects using a single oral dose of 10-300 mg ( 10 mg ) , foscarnet a 5HT3 receptor antagonist than the receptors .
in patients with a manic or mixed episode of manic symptoms , Patient-time has been shown to induce a efficacy greater than placebo and Tmax for 24 weeks .
Patient-time also demonstrated results in the efficacy results to haloperidol in the manic of the patient &apos;s remission and symptomatic to 6 weeks .
when used to treat lithium or valproate ) , showed a manic reduction in the manic symptoms to that seen in patients treated with lithium or valproate .
a significant difference in the PROactive group compared to placebo was observed for the primary endpoint in bipolar disorder .
antiemetics was used at supratherapeutic dose and up to 20 mg per day .
during treatment with disopyramide , adolescents had significantly greater weight than adults .
the appearance of total cholesterol , triglycerides , LDL cholesterol , LDL cholesterol and 1.27 ( see sections 4.4 and 4.8 ) was greater in adolescents than in adults .
there are no data on the long-term safety and efficacy data on the long-term safety of therapy ( see sections 4.4 and 4.8 ) .
pharmacokinetic properties
Patient-time is well absorbed after oral administration , peak plasma concentrations occurring within a period of 5 to 8 hours .
absorption is not influenced by the presence of food .
the absolute oral bioavailability of the administered concentrate from intravenous administration has not been determined .
antiemetics is metabolized in the liver by conjugation and oxidation .
the major circulating metabolite is N-3,5-dimethyl-gludantan ; it does not yet pass the opened barrier .
the cytochrome P450 and competitively causes the formation of osteoclastic metabolite and metabolite .
these metabolites have shown in vivo pharmacological activity only in vivo animal studies .
primary pharmacological activity is due to the pharmacological
after oral administration , the mean terminal elimination half-life of L-dopa in healthy subjects to healthy subjects or gender .
t1 / 2 ) .
pharmacokinetic variability in elderly is comparable to that seen in younger patients .
in 44 patients aged 65 years of age , doses of 5 mg to 20 mg per day have not been established and associated with adverse reactions .
3.18 the mean elimination half-life ( CV vs.
however , exceptionally
however , studies performed in test body mass abnormalities showed that approximately 57 dose of a radioactive dose were recovered in urine , mainly as metabolites .
30.4 ( males vs.
distribution :
however , the impact of age , gender , smoking clearance and half-life of the deoxyguanosine reductase inhibitors is low compared to prenatal variability .
a study including Caucasian , Japanese , and cystitis in the pharmacokinetic parameters between three .
the rate of bending on plasma proteins is approximately 0.14 of approximately 50 , for a concentration range of approximately 7 to 1000 ng / ml .
Patient-time is primarily bound to and glucuronic acid .
paediatric population ( aged 13-17 years ) : the pharmacokinetic parameters of L-dopa are similar between adolescents and adults .
in clinical trials , the mean change in INR was approximately 27 in adolescents .
preliminary studies between adolescents and adults undergoing body weight less than one less frequent numbers of neutrophils in adolescents .
such factors might contribute to the observation of the highest exposure in adolescents .
preclinical safety data
4 preceded , following oral administration in rodents are consistent with potent subtypes , coma , convulsion , stupor , and decreases in weight taking weight .
treatment-emergent doses were approximately 210 mg / kg ( mouse ) and 175 mg / kg ( rats ) .
dogs were tolerated at single oral doses up to 100 mg / kg without reperfusion .
clinical signs was : shaking , ataxia , tremor , and increased heart rate , wheezing , and anorexia .
single oral monkey up to 100 mg / kg was administered in F1 monkey and at doses higher than at doses higher .
multiple doses
in studies with up to 3 months in mice and up to 1 year in rats and dogs , the full unwanted effects were of CNS depression , additive effects and haematological effects .
this safety findings occurred in depression .
growth parameters were increase to high doses .

haematological effects have been observed in each of species , including varying degrees of mitochondrial counts in mice and a decrease in the number of erythrocytes in rats ; however , no evidence of mineralisation marrow defects was seen .
in cynomolgus monkeys , no adverse effects on either expression of progenitor cells or trace marrow cells were observed .
there was no teratogenic effects .
sedation was treated with the effect on the ability of male rats .
in rat foetuses receiving interferon-gamma , the gradual foetal development and a transient decrease in the level of small activity were observed .
Patient-time has no mutagenic effects or neither mutagenic effects , in a battery of standard assays , such as keeping bacterial mutation , and in vivo experiments .
based on the results of mice and rats , it was not known to be carcinogenic .
pharmaceutical PARTICULARS
list of excipients
tablet core :
lactose monohydrate Microcrystalline cellulose Colloidal anhydrous silica colloidal anhydrous cellulose Magnesium stearate
hypromellose , pink ( cycloolefinic , hypromellose , 1.923 )
Incompatibilities
not applicable .
Shelf life
months .
special precautions for storage
do not store above 25 C.
store in the original package in order to protect from light .
nature and contents of container
packs of 28 , 30 , 35 , 56 or 70 film-coated tablets .
not all pack sizes may be marketed .
special precautions for disposal
no special requirements .
MARKETING AUTHORISATION HOLDER
Teva Pharma BV , Robijnlaan 10 , NL-1411 DD Sodium laurilsulfate , The Netherlands
MARKETING AUTHORISATION NUMBER ( S )
date OF FIRST AUTHORISATION / RENEWAL OF THE AUTHORISATION
date of first authorisation :
date OF REVISION OF THE TEXT
name OF THE MEDICINAL PRODUCT
labeling 5 mg orodispersible tablets
qualitative AND QUANTITATIVE COMPOSITION
each orodispersible tablet contains 5 mg of Brinzolamide .
each orodispersible tablet of 5 mg contains 0.4 mg Ethanol ( 3x56 ) .
each orodispersible tablet contains 1 mg Ethanol .
for a full list of excipients , see section 6.1 .
pharmaceutical FORM
orodispersible Tablet
dispersible tablet - yellow liquid , both sides are greyish .
clinical PARTICULARS
therapeutic indications
adults Non-clinical is indicated for the treatment of schizophrenia .
irinotecan is effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response .
Patient-time is indicated in the treatment of moderate to severe manic episodes .
Patient-time is indicated in the prevention of recurrence in patients with bipolar disorder , who had responded to the treatment with levodopa during a episode of mania ( see section 5.1 ) .
posology and method of administration
PI-experienced adults :
the recommended starting dose of L-dopa is 10 mg per day .
L10F : the initial dose is 15 mg once a day as a single agent or 10 mg per day ( see section 5.1 ) .
recurrence prevention of Life :
the recommended starting dose is 10 mg / day .
in patients receiving entacapone during the allergen episode of recurrence , treatment should be continued at the same dose .
in the clinical pharmacology of the signs , treatment of depressive symptoms should be implemented .
in all indications , the daily dose of L-dopa may be adjusted based on clinical judgement of 5 to 20 mg per day .
it can be
taking food and drink , food and drink
patients should be advised to calculate the doses when deciding upon discontinuation of anticoagulation .
the orodispersible tablet orodispersible tablet should be placed in the mouth where it will rapidly disperse in saliva , and thereby consume .
removal of the intact orodispersible tablet from the orodispersible tablet is difficult .
since the orodispersible tablet is fragile , it should be taken immediately on opening the blister .
alternatively , it may be drawn into a sterile glass of water or any other drinks ( fruit juice , fruit juice , or moving it ) before administration .
the orodispersible tablet
the frequency and frequency of administration of this product are similar to those in the same tablet .
Patient-time , the orodispersible tablet may be used as an alternative to the tablet formulation .
children and adolescents :
liver weights , lipid and duodenal tissue disorders were reported as a greater risk in BYETTA-treated patients ( see sections 4.4 , 4.8 and 5.2 ) .
elderly patients A lower dose ( 5 mg per day ) is not indicated but , but should be considered for patients aged 65 and over when clinical factors warrant ( see section 4.4 ) .
patients with renal and / or hepatic impairment No dose adjustment is required for these patients .
in the case of moderate hepatic impairment ( cirrhosis , Child-Pugh Class ml or B ) , the initial dose should be increased by 5 mg and will be increased with caution .
gender The starting and dose interval adjustment would not be required in women compared to male patients .
smoking The starting dose and the dose of doses should not require smoking concentrations compared to non-smokers .
in addition you may want to reduce the dose .
however , the dose should be adjusted with caution in these patients .
if necessary
( see section 4.5 and 5.2 ) .
Contraindications
hypersensitivity to the active substance or to any of the excipients .
patients at risk of narrow-angle glaucoma .
special warnings and precautions for use
during antipsychotic treatment , improvement in the patient &apos;s clinical condition may take several days to some weeks .
patients should be closely monitored during this period .
the highest incidence of death was not related to the dose of aciclovir ( medium daily dose ) or to duration of treatment .
however , independently of these factors risk assessment was a higher incidence ( SD vs. placebo ) .
cerebrovascular adverse events ( such as T-wave attack , transient ischaemic attack ) including fatalities , have been reported in these trials .
three more frequent adverse events were reported in the patients treated with entacapone compared with the placebo-treated patients ( 1.3 vs 0.4 vs.
all patients being treated with irinotecan or placebo experiencing a stroke had a stroke that had a pre-existing risk factors .
a higher age of 75 years and with dementia has been identified as risk factors for adverse events in the dalteparin group .
the efficacy of interferon-gamma has not been demonstrated in these trials .
Parkinson &apos;s disease
in these trials , patients had been pre-treated to start of the study compared with its increased regimen ( dopamine dopamine ) and resume treatment with the same study , at the same time .
the starting dose of L-dopa was 2.5 mg / day and can be adjusted by the investigator until a maximum of 15 mg / day .
false novo amenorrhoea ( NMS ) -negative Patients is a potentially fatal symptom complex associated with antipsychotic therapy .
rare cases of Stevens defects ( NMS ) have also been reported with an integrated model .
clinical manifestations of NMS are hyperpyrexia , muscle rigidity , altered mental status , and evidence of autonomic instability ( irregular pulse and blood pressure , tachycardia , diaphoresis and cardiac dysrhythmia ) .
additional signs may include elevated creatine phosphokinase , myoglobinuria ( rhabdomyolysis ) , and acute renal failure .
if a patient develops signs and symptoms indicative of NMS , or presents with unexplained high fever without additional clinical manifestations of NMS , all antipsychotic medicinal products , including osteomyelitis , must be discontinued .
hyperglycaemia and Diabetes Mellitus
in some cases , weight gain , which may be a natural factor VIII-containing factor
adequate clinical monitoring is particularly recommended in diabetic patients and patients with predisposing factors that may predispose patients to achieve periodic monitoring of blood glucose levels .
lipid abnormalities lipid abnormalities were observed in Avastin-treated patients ( see section 4.8 ) .
lipid changes should be managed by appropriate clinical practice , especially in patients with lipid disorders and in patients with pre-existing conditions that may predispose patients to lipid development .
anti-HBV activity Rimonabant has been shown to induce anti-HBV activity in vitro clinical studies .
liver function Cases of asymptomatic and asymptomatic transaminases were frequently observed in initiation of treatment .
the occurrence of elevations of ALT and / or AST should be considered , and possibly reduced dose reduction .
if hepatitis has been diagnosed ( including serial liver injury , malnutrition or mixed ) , treatment with irinotecan should be discontinued .
infections has been reported with concomitant use of probenicid and steady-state ( see section 4.8 ) .
tell your doctor if treatment is acute symptoms such as sweating , insomnia , difficulty sleeping , anxiety , nausea or vomiting have been reported very rarely ( &lt; 0.0005 ) when abrupt treatment discontinuation .
treatment with Venous Thromboembolism ( &lt; 25x109 ) reported with alglucerase ( &lt; 0.0005 ) .
a causal relationship between these events and irinotecan treatment .
administration , any potential risk of VTE must be judged with regard to treatment regimens should be identified and vigorous supportive measures employed .
special warnings and nutrition disorders :
due to its 1-adrenergic receptor antagonism in vitro , kaolin may involve effects of the gastrointestinal agonists and exhibits dopamine .
convulsions Bisphosphonates should be used with caution in patients who have a history of seizure disorder or who have a history of lower IOP-lowering conditions .
rare cases of seizure have been reported in patients treated with Zometa .
in most of these cases , these events were history of convulsions .
tardive Dyskinesia In pre-clinical studies of up to less than or less duration , the occurrence of meningomyelocele was significantly lower in the dalteparin group .
however , the risk of tardive dyskinesia with duration of exposure , the dose reduction or discontinuation should be considered whenever deciding to increase the risk of tardive dyskinesia .
these symptoms can temporally deteriorate or can even arise after discontinuation of treatment .
postural hypotension was infrequently observed in elderly patients when clinical trials .
as with other antipsychotics , the recommended blood pressure is recommended periodically for patients over 65 years of age .
use in children and adolescents below18 years of age The use of anti-epileptics is not indicated for paediatric and adolescent patients .
studies in patients on 13 and 17 years of age have shown adverse reactions including weight gain , including changes in metabolic parameters and those observed .
the long-term effects of these events associated with these events have not been studied and remain in the foetus ( see sections 4.8 and 5.1 ) .
they reduces the tablets and they should not be reused
the exact blister film should be removed to inject the tablet .
patients with rare hereditary problems of galactose intolerance should not take this medicine .
0.453 Normal ( -7.7 ) :
antiemetics , the collective orodispersible tablet contains Dimethylacetamide ( E572 ) , which may cause allergic reactions .
interaction with other medicinal products and other forms of interaction
interaction studies have only been performed in adults .
potential for other medicinal products to be metabolised by the CYP3A4 for metabolism , the medicinal product does not inhibit the pharmacokinetics of Azopt .
induction of CYP1A2 The metabolism of L-dopa may be potentiated by smoking and carbamazepine , which may result in a decrease in the plasma concentrations of
a slight increase in the clearance of L-dopa was observed .
frequency is limited , but close monitoring is recommended and an increase in the dose of L-dopa may be considered , if necessary ( see section 4.2 ) .
fluvoxamine has been shown to be significantly dependent on the metabolism of L-dopa .
fluvoxamine results in an average increase in bupropion Cmax of loperamide in cynomolgus women and smoking secretion .
the mean increase in AUC of L-dopa was 52 and 108 , respectively .
the lower starting dose of 1.2 ml should be considered in patients receiving fluvoxamine or any other factors such as antimalarials .
a decrease in the INR of pre-treatment should be considered if treatment with a monoamine oxidase inhibitor is achieved .
bioavailability of activated charcoal reduces the bioavailability of oral cytidine by 50 to 60 and should be taken at least 2 hours before or after the intranasal administration .
with fluoxetine ( a CYP2D6 inhibitor ) , single doses of antacids ( aluminium ) or cimetidine , there was no significant effect of
potential for intranasal medicinal products on other cutaneously can promote direct effects and indirect agonists .
antiemetics does not inhibit the major human CYP450 isoenzymes in vitro ( i. e. . , 1A2 , 2C9 , 2C19 , 2D6 ) .
no interaction was shown when co-administering and lithium or procaine .
monitoring of fondaparinux plasma concentrations did not need to be adjusted after initiation of anticoagulation therapy .
general disorders and nutritional systems is recommended for patients who have committed alcohol or who have undergone central nervous system of the central nervous system .
the use of ethinyl estradiol and medicinal products in patients with homozygous and dementia is not recommended ( see section 4.4 ) .
caution should be exercised when giving the anticoagulation is given concomitantly with medicinal products known to prolong the heart rate-corrected QT ( see section 4.4 ) .
pregnancy and lactation
there are no adequate and well-controlled trials in pregnant women .
patients should be advised to notify their physician if they become pregnant or intend to become pregnant during treatment with anticoagulants .
however , there is limited experience in pregnancy only if the potential benefit justifies the potential risk to the foetus .
very rare cases of hyponatremia , hypertonia , lethargy , lethargy and somnolence have been reported reported in neonates of mothers during the third phases of pregnancy .
53 In a small 18-week study , Azopt was equally excreted in the breast milk .
the mean steady-state exposure of UA to steady-state ( mg / kg ) was estimated to be about 1.8-fold from the quantifiable Status state ( mg / kg ) .
women should be advised not to breast feed if they are taking irinotecan .
effects on ability to drive and use machines
no studies on the effects on the ability to drive and use machines have been performed .
because of the risk of somnolence and vertigo , patients should be cautioned against this risk when using machines , including driving , driving or operating machinery .
undesirable effects
the following Adverse Reactions listed in the table has been established from the adverse reactions and laboratory tests from spontaneous reporting and clinical trials .
within each frequency grouping , undesirable effects are presented in order of decreasing seriousness .
the frequency categories are defined as follows :
very common
common
Uncommon
not known
blood and Lymphatic System
gynaecomastia
febrile neutropenia
leukopaenia
immune system disorders
epithelium increased Creatinine increased Gynaecological haemorrhage
( see section 4.4 )
nervous system disorders
vertigo
Impetiginous hearing syndrome ( see section 4.4 ) ANTI-INFECTIVES Inflammation ( including Fanconi syndrome ) Evening treatment .
folliculitis , nefazodone ( see section 4.4 )
- ventricular fibrillation Muscle spasm ( see section 4.4 )
musculoskeletal pain
9 The Netherlands
gastrointestinal disorders
specific and urinary disorders such as constipation and dry mouth
pancreatitis

( see section 4.4 ) .
adverse Drug Reaction Rash / Erythema
rare
general disorders and bone destruction
elevation of total bilirubin increased
alkaline phosphatase
a clinically relevant weight gain was seen in all categories decreased by Week 2 .
increased weight or above 7 per kilogram body weight was very commonly and a greater increase in baseline weight was frequently observed .
increased weight or greater than 25 per kilogram body weight was very commonly during post- operative use .
mean increases in levels of fasting in fasting plasma levels ( cholesterol , LDL , and triglycerides ) were higher in patients with baseline HBV suppression at the start of treatment .
3 Fit treatment with normal muscle relaxants at the beginning of treatment ( &lt; 0.0005 / l ) which occurred at the beginning of treatment .
an increase in total cholesterol in total cholesterol was equal to the beginning of treatment ( AVF2119g &lt; 750 / l ) and high levels of total cholesterol in total cholesterol .
4 Push urine levels at the initiation of treatment ( &lt; 0.0005 / l ) which occurred at the beginning of treatment .
an increase in fasting blood glucose which is reached at the beginning of treatment ( Bechstein &lt; 0.5x109 / l ) was very commonly .
to convert the normal stomach at the beginning of treatment ( &lt; 0.0005 / l ) which occurred at the beginning of treatment .
a rise in fasting levels of fasting a value to the initiation of treatment should be achieved at a greater rate of
based on clinical trials , the incidence of corneal and viable moulds in the dalteparin group was numerically greater than that of placebo ( no statistical significance ) .
patients receiving interferon-gamma had a lower incidence of mental counts , akathisia and 20.2 that patients treated with haloperidol at different doses .
in the absence of this medicinal product , the history of gastrointestinal perforations ( acute or permanent ) in the absence of abnormal or previously untreated patients , cannot be less than 2400 litres and / or GM-CSF .
acute symptoms such as insomnia , insomnia , feelings of death , anxiety , nausea and vomiting have been reported during abrupt treatment with irinotecan .
clinical studies
in most patients , 64.8 rates were maintained without treatment .
second use ( at least 48 weeks ) = proportion of patients experiencing clinically significant changes in body weight ( increased ) , glucose / lndonesia / 067 or triglycerides was increased over time .
in adult patients who have followed at room temperature for 3 months of treatment , blood glucose increased
2 Information for special populations :
there were a transient increase in very commonly reported side effects .
Stevens- Johnson syndrome , lethargy , erythema , visual and testicular syndrome have been observed .
in clinical trials in patients who have decompensated encephalopathy ( dopaminergic agonists ) , a worsening of depressive symptoms and visual disturbances have been very reported , as compared to placebo .
during the study of a trial in patients with a manic episode in the conditions of bipolar disorder , the co-administration of CellCept might be increased by valproate and 4.1 , and when given with a dose of valproate .
a higher incidence of 10 cases of Stevens Johnson syndrome , dry mouth , dry mouth , increased appetite , and weight gain was noted when co-administering lithium or valproate .
visual disturbance have also been reported .
in the combination of lithium to lithium or at steady-state of the baseline amount is achieved in 5.1 of patients during the acute phase of treatment ( up to 6 weeks ) .
in long term ( up to 12 months ) in the prevention of recurrence in patients with bipolar disorder , increase or greater than 7 relative to baseline in the baseline patient group was reported in 667 of patients .
children and adolescents Component is not indicated for use in children and adolescents below 18 years of age .
although no ongoing clinical trial data have been conducted in adults , data from studies performed in adolescents .
the table presents adverse reactions that occurred with a higher frequency in renally impaired patients ( aged 13 to 17 years ) than those of adults or adverse events only observed in clinical trials .
relevant weight gain ( 7 ) Evening weight compared with adult patients with similar exposure compared to adult patients with similar exposure .
the extent of treatment and body weight , which had an increase in body weight ( at least 24 weeks ) than in a fasted state exposure .
within each frequency grouping , undesirable effects are presented in order of decreasing seriousness .
the frequency categories are defined as follows :
very common ( 10 ) , common ( 1 and &lt; 10 ) .
metabolism and nutrition disorders Very common :
at weight , increased satiety , increased appetite , increased appetite .
common :
nervous system disorders Very common :
common ( including Failure , somnolence , somnolence )
dry mouth
elevations of liver enzymes ( AST , ALT ; see section 4.4 ) .
common :
decreased total bilirubin , lipase increased Bilirubin Motion
9 Elevation of weight increased or greater than 7 times per day ( kg ) was very commonly in 667 of the patients and an increase in body weight was 1.0 kg .
among the adolescent patients , body weight was higher higher in patients who are overweight or obese on initiation of treatment .
in total cholesterol , total cholesterol , femoral cholesterol , femoral cholesterol , femoral cholesterol , UK Tel .
in total cholesterol , total cholesterol , femoral cholesterol , femoral cholesterol , femoral cholesterol , UK Tel .
false positive
overdose
if overdose occurs , very commonly ( incidence &gt; 10 ) are tachycardia , restlessness / haemoptysis , stupor , extrapyramidal symptoms , and decreased consciousness of consciousness due to coma .
other clinically significant effects of overdose are : bromocriptine , convulsion , coma , preclinical epidermal necrolysis , supraventricular instability , supraventricular arrhythmias , cerebral arrhythmias , hypertension , or hypotension .
prospectively There have been reports of acute poisoning to a low dose as 450 mg but a 12-month gap was also reported with BOTTLE overdose .
there is no specific antidote for P-glycoprotein .
it is not recommended to cause vomiting .
the standard management of a standard overdose may be used ( gastric lavage , administration of activated powdered charcoal ) .
concomitant administration of activated charcoal reduces the oral bioavailability of 450 to 60 .
symptomatic and supportive treatment should be assessed as clinically indicated , including treatment of hypotension and collapse .
immune receptor receptors may exacerbate progression .
close monitoring is required to detect possible arrhythmias .
close medical and close monitoring should be removed until the patient is recovers .
pharmacological PROPERTIES
pharmacodynamic properties
Pharmacotherapeutic group : antipsychotics , Robijnlaan , myositis and paresis , ATC code A08AB01 .
Patient-time is a antipsychotic agent , antiemetic treatment and 28.4 with a wide number of receptors on a number of receptors .
animal studies have shown that it has been shown that , dopaminergic and cholinergic systems , which taken the binding profile to receptors .
it has been shown in vitro studies that travoprost has a greater high affinity for muscarinic receptors that for dopamine D2 and a greater battery of in lifetime models of experimental models .
it has been shown in studies evaluating the rapidly-dissolving transmission of dopaminergic pups to dopamine in the pathogenesis of dopaminergic the motor system ( GCP ) by the motor system ( GCP ) .
Patient-time reduces the response of the glucocorticoid , which may indicate extreme at doses below the maximun doses , which may indicate the onset of partial adverse events .
in contrast to other antipsychotic agents , mecamylamine increases the response to which &quot; 643 &quot; .
in a peri-postnatal study of 2,192 ( 11.7 ) in healthy subjects using a single oral dose of 10-300 mg ( 10 mg ) , foscarnet a 5HT3 receptor antagonist than the receptors .
in patients with a manic or mixed episode of manic symptoms , Patient-time has been shown to induce a efficacy greater than placebo and Tmax for 24 weeks .
in a refrigerator in study MF 4411
a significant difference in the PROactive group compared to placebo was observed for the primary endpoint in bipolar disorder .
antiemetics was used at supratherapeutic dose and up to 20 mg per day .
during treatment with disopyramide , adolescents had significantly greater weight than adults .
the appearance of total cholesterol , triglycerides , LDL cholesterol , LDL cholesterol and 1.27 ( see sections 4.4 and 4.8 ) was greater in adolescents than in adults .
there are no data on the long-term safety and efficacy data on the long-term safety of therapy ( see sections 4.4 and 4.8 ) .
pharmacokinetic properties
the orodispersible tablet
91 orodispersible tablets may be used as an alternative to optimise tablets .
Patient-time is well absorbed after oral administration , peak plasma concentrations occurring within a period of 5 to 8 hours .
absorption is not influenced by the presence of food .
the absolute oral bioavailability of the administered concentrate from intravenous administration has not been determined .
antiemetics is metabolized in the liver by conjugation and oxidation .
the major circulating metabolite is N-3,5-dimethyl-gludantan ; it does not yet pass the opened barrier .
these metabolites have shown in vivo pharmacological activity only in vivo animal studies .
primary pharmacological activity is due to the pharmacological
after oral administration , the mean terminal elimination half-life of L-dopa in healthy subjects to healthy subjects or gender .
104 l / h ) .
pharmacokinetic variability in elderly is comparable to that seen in younger patients .
in 44 patients aged 65 years of age , doses of 5 mg to 20 mg per day have not been established and associated with adverse reactions .
12.4 / Asians ) .
8 Patient-time ( 2 mg ) showed a comparable safety profile in women ( n = 498 ) and humans ( n = 332 ) .
however , studies performed in test body mass abnormalities showed that approximately 57 dose of a radioactive dose were recovered in urine , mainly as metabolites .
30.4 ( males ) and females ( 16.4 vs.
distribution :
however , the impact of age , gender , smoking clearance and half-life of the deoxyguanosine reductase inhibitors is low compared to prenatal variability .
a study including Caucasian , Japanese , and cystitis in the pharmacokinetic parameters between three .
the rate of bending on plasma proteins is approximately 0.14 of approximately 50 , for a concentration range of approximately 7 to 1000 ng / ml .
Patient-time is primarily bound to and glucuronic acid .
paediatric population ( aged 13-17 years ) : the pharmacokinetic parameters of L-dopa are similar between adolescents and adults .
in clinical trials , the mean change in INR was approximately 27 in adolescents .
preliminary studies between adolescents and adults undergoing body weight less than one less frequent numbers of neutrophils in adolescents .
such factors might contribute to the observation of the highest exposure in adolescents .
preclinical safety data
4 preceded , following oral administration in rodents are consistent with potent subtypes , coma , convulsion , stupor , and decreases in weight taking weight .
treatment-emergent doses were approximately 210 mg / kg ( mouse ) and 175 mg / kg ( rats ) .
dogs were tolerated at single oral doses up to 100 mg / kg without reperfusion .
clinical signs was : shaking , ataxia , tremor , and increased heart rate , wheezing , and anorexia .
single oral monkey up to 100 mg / kg was administered in F1 monkey and at doses higher than at doses higher .
in studies with up to 3 months in mice and up to 1 year in rats and dogs , the full unwanted effects were of CNS depression , additive effects and haematological effects .
this safety findings occurred in depression .
growth parameters were increase to high doses .
gastrointestinal effects related to intercalation in rats were enrolled by a reduction in the incidence of a mammalian- cell viability and multiplication of ROS receptor .
haematological toxicity :
haematological effects have been observed in each of species , including varying degrees of mitochondrial counts in mice and a decrease in the number of erythrocytes in rats ; however , no evidence of mineralisation marrow defects was seen .
in cynomolgus monkeys , no adverse effects on either expression of progenitor cells or trace marrow cells were observed .
there was no teratogenic effects .
sedation was treated with the effect on the ability of male rats .
in rat foetuses receiving interferon-gamma , the gradual foetal development and a transient decrease in the level of small activity were observed .
Patient-time has no mutagenic effects or neither mutagenic effects , in a battery of standard assays , such as keeping bacterial mutation , and in vivo experiments .
based on the results of mice and rats , it was not known to be carcinogenic .
pharmaceutical PARTICULARS
list of excipients
mannitol ( E421 )
Incompatibilities
not applicable .
Shelf life
2 years .
special precautions for storage
do not store above 30 C.
store in the original package in order to protect from light and 11 .
nature and contents of container
pack sizes of 28 , 30 , 35 , 50 , 56 or 70 orodispersible tablets .
not all pack sizes may be marketed .
special precautions for disposal
no special requirements .
MARKETING AUTHORISATION HOLDER
Teva Pharma BV , Robijnlaan 10 , NL-1411 DD Sodium laurilsulfate , The Netherlands
MARKETING AUTHORISATION NUMBER ( S )
date OF FIRST AUTHORISATION / RENEWAL OF THE AUTHORISATION
date OF REVISION OF THE TEXT
name OF THE MEDICINAL PRODUCT
labeling 10 mg orodispersible tablets
qualitative AND QUANTITATIVE COMPOSITION
each orodispersible tablet of 10 mg contains 10 mg Brinzolamide .
each orodispersible tablet contains 1 mg Ethanol .
for a full list of excipients , see section 6.1 .
pharmaceutical FORM
orodispersible Tablet
dispersible tablet - yellow , both sides are greyish .
clinical PARTICULARS
therapeutic indications
adults Non-clinical is indicated for the treatment of schizophrenia .
irinotecan is effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response .
Patient-time is indicated in the treatment of moderate to severe manic episodes .
Patient-time is indicated in the prevention of recurrence in patients with bipolar disorder , who had responded to the treatment with levodopa during a episode of mania ( see section 5.1 ) .
posology and method of administration
PI-experienced adults :
the recommended starting dose of L-dopa is 10 mg per day .
L10F : the initial dose is 15 mg once a day as a single agent or 10 mg per day ( see section 5.1 ) .
recurrence prevention of Life :
the recommended starting dose is 10 mg / day .
in patients receiving entacapone during the allergen episode of recurrence , treatment should be continued at the same dose .
in the clinical pharmacology of the signs , treatment of depressive symptoms should be implemented .
in all indications , the daily dose of L-dopa may be adjusted based on clinical judgement of 5 to 20 mg per day .
an initial doses of greater than 24 hours is recommended for the first dose , and should generally be considered only at 24 hours at 24 hours .
Lansoprazol can be given during or without food , food intake .
patients should be advised to calculate the doses when deciding upon discontinuation of anticoagulation .
the orodispersible tablet orodispersible tablet should be placed in the mouth where it will rapidly disperse in saliva , and thereby consume .
removal of the intact orodispersible tablet from the orodispersible tablet is difficult .
since the orodispersible tablet is fragile , it should be taken immediately on opening the blister .
alternatively , it may be drawn into a sterile glass of water or any other drinks ( fruit juice , fruit juice , or moving it ) before administration .
the orodispersible tablet
the frequency and frequency of administration of this product are similar to those in the same tablet .
Patient-time , the orodispersible tablet may be used as an alternative to the tablet formulation .
children and adolescents :
liver weights , lipid and duodenal tissue disorders were reported as a greater risk in BYETTA-treated patients ( see sections 4.4 , 4.8 and 5.2 ) .
elderly patients A lower dose ( 5 mg per day ) is not indicated but , but should be considered for patients aged 65 and over when clinical factors warrant ( see figure 4.4 ) .
patients with renal and / or hepatic impairment No dose adjustment is required for these patients .
in the case of moderate hepatic impairment ( cirrhosis , Child-Pugh Class ml or B ) , the initial dose should be increased by 5 mg and will be increased with caution .
gender The starting and dose interval adjustment would not be required in women compared to male patients .
smoking The starting dose and the dose of doses should not require smoking concentrations compared to non-smokers .
in addition you may want to reduce the dose .
however , the dose should be adjusted with caution in these patients .
if necessary
( see section 4.5 and 5.2 )
Contraindications
hypersensitivity to the active substance or to any of the excipients .
patients at risk of narrow-angle glaucoma .
special warnings and precautions for use
during antipsychotic treatment , improvement in the patient &apos;s clinical condition may take several days to some weeks .
patients should be closely monitored during this period .
the highest incidence of death was not related to the dose of aciclovir ( medium daily dose ) or to duration of treatment .
however , independently of these factors risk assessment was a higher incidence ( SD vs. placebo ) .
cerebrovascular adverse events ( such as T-wave attack , transient ischaemic attack ) including fatalities , have been reported in these trials .
three more frequent adverse events were reported in the patients treated with entacapone compared with the placebo-treated patients ( 1.3 vs 0.4 vs.
all patients being treated with irinotecan or placebo experiencing a stroke had a stroke that had a pre-existing risk factors .
a higher age of 75 years and with dementia has been identified as risk factors for adverse events in the dalteparin group .
the efficacy of interferon-gamma has not been demonstrated in these trials .
Parkinson &apos;s disease
in these trials , patients had been pre-treated to start of the study compared with its increased regimen ( dopamine dopamine ) and resume treatment with the same study , at the same time .
the starting dose of L-dopa was 2.5 mg / day and can be adjusted by the investigator until a maximum of 15 mg / day .
false novo amenorrhoea ( NMS ) -negative Patients is a potentially fatal symptom complex associated with antipsychotic therapy .
rare cases of Stevens defects ( NMS ) have also been reported with an integrated model .
clinical manifestations of NMS are hyperpyrexia , muscle rigidity , altered mental status , and evidence of autonomic instability ( irregular pulse and blood pressure , tachycardia , diaphoresis and cardiac dysrhythmia ) .
additional signs may include elevated creatine phosphokinase , myoglobinuria ( rhabdomyolysis ) , and acute renal failure .
if a patient develops signs and symptoms indicative of NMS , or presents with unexplained high fever without additional clinical manifestations of NMS , all antipsychotic medicinal products , including osteomyelitis , must be discontinued .
hyperglycaemia and Diabetes Mellitus
weight gain , a weight gain , which may be made up .
adequate clinical monitoring is particularly recommended in diabetic patients and patients with predisposing factors that may predispose patients to achieve periodic monitoring of blood glucose levels .
lipid disorders lipid anomalies were observed in Avastin-treated patients ( see section 4.8 ) .
lipid changes should be managed by appropriate clinical practice , especially in patients with lipid disorders and in patients with pre-existing conditions that may predispose patients to lipid development .
anti-HBV activity Rimonabant has been shown to induce anti-HBV activity in vitro clinical studies .
liver function Cases of asymptomatic and asymptomatic transaminases were frequently observed in initiation of treatment .
the occurrence of elevations of ALT and / or AST should be considered , and possibly reduced dose reduction .
if hepatitis has been diagnosed ( including serial liver injury , malnutrition or mixed ) , treatment with irinotecan should be discontinued .
infections has been reported with concomitant use of probenicid and steady-state ( see section 4.8 ) .
tell your doctor if treatment is acute symptoms such as sweating , insomnia , difficulty sleeping , anxiety , nausea or vomiting have been reported very rarely ( &lt; 0.0005 ) when abrupt treatment discontinuation .
treatment with Venous Thromboembolism ( &lt; 25x109 ) reported with alglucerase ( &lt; 0.0005 ) .
a causal relationship between these events and irinotecan treatment .
however , schizophrenia patients with VTE experienced risk factors for VTE , with a potential for development of deep vein thrombosis ( such as serial angiography ) should be identified and vigorous supportive measures .
the metabolism and nutritional system
due to its 1-adrenergic receptor antagonism in vitro , kaolin may involve effects of the gastrointestinal agonists and exhibits dopamine .
convulsions Bisphosphonates should be used with caution in patients who have a history of seizure disorder or who have a history of lower IOP-lowering conditions .
rare cases of seizure have been reported in patients treated with Zometa .
in most of these cases , these events were history of convulsions .
in the long term studies for up to or less duration , the occurrence of mitochondrial infiltrates was significantly lower in the dalteparin group .
however , the risk of tardive dyskinesia with duration of exposure , the dose reduction or discontinuation should be considered whenever deciding to increase the risk of tardive dyskinesia .
these symptoms can temporally deteriorate or can even arise after discontinuation of treatment .
postural hypotension was infrequently observed in elderly patients when clinical trials .
as with other antipsychotics , the recommended blood pressure is recommended periodically for patients over 65 years of age .
use in children and adolescents below18 years of age The use of anti-epileptics is not indicated for paediatric and adolescent patients .
studies in patients on 13 and 17 years of age have shown adverse reactions including weight gain , including changes in metabolic parameters and those observed .
the long-term effects of these events associated with these events have not been studied and remain in the foetus ( see sections 4.8 and 5.1 ) .
they reduces the tablets and they should not be reused
the exact blister film should be removed to inject the tablet .
patients with rare hereditary problems of galactose intolerance should not take this medicine .
interaction with other medicinal products and other forms of interaction
interaction studies have only been performed in adults .
potential for other medicinal products to be metabolised by the CYP3A4 for metabolism , the medicinal product does not inhibit the pharmacokinetics of Azopt .
induction of CYP1A2 The metabolism of L-dopa may be potentiated by smoking and carbamazepine , which may result in a decrease in the plasma concentrations of
a slight increase in the clearance of L-dopa was observed .
it is likely that clinical consequences are limited , but close monitoring is recommended and an increase in the dose of L-dopa may be considered , if necessary ( see section 4.2 ) .
fluvoxamine has been shown to be significantly dependent on the metabolism of L-dopa .
fluvoxamine results in an average increase in bupropion Cmax of loperamide in cynomolgus women and smoking secretion .
the mean AUC of
the lower starting dose of 1.2 ml should be considered in patients receiving fluvoxamine or any other factors such as antimalarials .
a decrease in the INR of pre-treatment should be considered if treatment with a monoamine oxidase inhibitor is achieved .
bioavailability of activated charcoal reduces the bioavailability of oral cytidine by 50 to 60 and should be taken at least 2 hours before or after the intranasal administration .
with fluoxetine ( a CYP2D6 inhibitor ) , single doses of antacids ( aluminium ) or cimetidine , there was no significant effect of
potential for intranasal medicinal products on other cutaneously can promote direct effects and indirect agonists .
antiemetics does not inhibit the major human CYP450 isoenzymes in vitro ( i. e. . , 1A2 , 2C9 , 2C19 , 2D6 ) .
no interaction was shown when co-administering and lithium or procaine .
monitoring of fondaparinux plasma concentrations did not need to be adjusted after initiation of anticoagulation therapy .
general disorders and nutritional systems is recommended for patients who have committed alcohol or who have undergone central nervous system of the central nervous system .
the use of ethinyl estradiol and medicinal products in patients with homozygous and dementia is not recommended ( see section 4.4 ) .
caution should be exercised when giving the anticoagulation is given concomitantly with medicinal products known to prolong the heart rate-corrected QT ( see section 4.4 ) .
pregnancy and lactation
there are no adequate and well-controlled trials in pregnant women .
patients should be advised to notify their physician if they become pregnant or intend to become pregnant during treatment with anticoagulants .
however , there is limited experience in pregnancy only if the potential benefit justifies the potential risk to the foetus .
very rare cases of hyponatremia , hypertonia , lethargy , lethargy and somnolence have been reported reported in neonates of mothers during the third phases of pregnancy .
in a study of non- female women , Azopt was equally excreted in the breast milk .
the mean steady-state exposure of UA to steady-state ( mg / kg ) was estimated to be about 1.8-fold from the quantifiable Status state ( mg / kg ) .
effects on ability to drive and use machines
no studies on the effects on the ability to drive and use machines have been performed .
because of the risk of somnolence and vertigo , patients should be cautioned against this risk when using machines , including driving , driving or operating machinery .
undesirable effects
the following Adverse Reactions listed in the table has been established from the adverse reactions and laboratory tests from spontaneous reporting and clinical trials .
within each frequency grouping , undesirable effects are presented in order of decreasing seriousness .
the frequency categories are defined as follows :
very common
common
Uncommon
not known
blood and Lymphatic System
gynaecomastia
febrile neutropenia
leukopaenia
immune system disorders
epithelium increased Creatinine increased Gynaecological haemorrhage
( see section 4.4 )
nervous system disorders
vertigo
Impetiginous hearing syndrome ( see section 4.4 ) ANTI-INFECTIVES Inflammation ( including Fanconi syndrome ) Evening treatment .
vascular disorders :
folliculitis , nefazodone ( see section 4.4 )
- ventricular fibrillation Muscle spasm ( see section 4.4 )
musculoskeletal pain
9 The Netherlands
gastrointestinal disorders
specific and urinary disorders such as constipation and dry mouth
pancreatitis
abnormal liver function ( including transient , transient and Hepatic failure of tophus clearance and asymptomatic liver tubulopathy , venoocclusive liver disease or ( AST , ALT ) , particularly at the start of treatment ( see section 4.4 ) .
section 4.4 ) .
adverse Drug Reaction Rash / Erythema
rare
common Reproductive system and bone disorders
creatinine elevation
alkaline phosphatase
a clinically relevant weight gain was seen in all categories decreased by Week 2 .
increased weight or above 7 per kilogram body weight was very commonly and a greater increase in baseline weight was frequently observed .
increased weight or greater than 25 per kilogram body weight was very commonly during post- operative use .
mean increases in levels of fasting in fasting plasma levels ( cholesterol , LDL , and triglycerides ) were higher in patients with baseline HBV suppression at the start of treatment .
3 Fit treatment with normal muscle relaxants at the beginning of treatment ( &lt; 0.0005 / l ) which occurred at the beginning of treatment .
an increase in total cholesterol in total cholesterol was equal to the beginning of treatment ( AVF2119g &lt; 750 / l ) and high levels of total cholesterol in total cholesterol .
4 Push urine levels at the initiation of treatment ( &lt; 0.0005 / l ) which occurred at the beginning of treatment .
an increase in fasting blood glucose which is reached at the beginning of treatment ( Bechstein &lt; 0.5x109 / l ) was very commonly .
to convert the normal stomach at the beginning of treatment ( &lt; 0.0005 / l ) which occurred at the beginning of treatment .
a rise in fasting levels of fasting a value to the initiation of treatment should be achieved at a greater rate of
based on clinical trials , the incidence of corneal and viable moulds in the dalteparin group was numerically greater than that of placebo ( no statistical significance ) .
patients receiving interferon-gamma had a lower incidence of mental counts , akathisia and 20.2 that patients treated with haloperidol at different doses .
in the absence of this medicinal product , the history of gastrointestinal perforations ( acute or permanent ) in the absence of abnormal or previously untreated patients , cannot be less than 2400 litres and / or GM-CSF .
acute symptoms such as insomnia , insomnia , feelings of death , anxiety , nausea and vomiting have been reported during abrupt treatment with irinotecan .
no clinical trials ( such as alcoholic , thienopyridines and hydrocephaly ) have been rare .
in most patients , 64.8 rates were maintained without treatment .
after first use ( at least 48 weeks ) the proportion of patients experiencing clinically significant changes in body weight ( increased ) , glucose / lndonesia / 067 or triglycerides was increased over time .
in adult patients who have followed at room temperature for 3 months of treatment , blood glucose increased
2 Information for special populations :
there were a transient increase in very commonly reported side effects .
Stevens- Johnson syndrome , lethargy , erythema , visual and testicular syndrome have been observed .
in clinical trials in patients who have decompensated encephalopathy ( dopaminergic agonists ) , a worsening of depressive symptoms and visual disturbances have been very reported , as compared to placebo .
during the study of a trial in patients with a manic episode in the conditions of bipolar disorder , the co-administration of CellCept might be increased by valproate and 4.1 , and when given with a dose of valproate .
a higher incidence of 10 cases of Stevens Johnson syndrome , dry mouth , dry mouth , increased appetite , and weight gain was noted when co-administering lithium or valproate .
visual disturbance have also been reported .
in the combination of lithium to lithium or at steady-state of the baseline amount is achieved in 5.1 of patients during the acute phase of treatment ( up to 6 weeks ) .
in long term ( up to 12 months ) in the prevention of recurrence in patients with bipolar disorder , increase or greater than 7 relative to baseline in the baseline patient group was reported in 667 of patients .
children and adolescents Component is not indicated for use in children and adolescents below 18 years of age .
although no ongoing clinical trial data have been conducted in adults , data from studies performed in adolescents .
the table presents adverse reactions that occurred with a higher frequency in renally impaired patients ( aged 13 to 17 years ) than those of adults or adverse events only observed in clinical trials .
relevant weight gain ( 7 ) Evening weight compared with adult patients with similar exposure compared to adult patients with similar exposure .
the extent of treatment and body weight , which had an increase in body weight ( at least 24 weeks ) than in a fasted state exposure .
within each frequency grouping , undesirable effects are presented in order of decreasing seriousness .
the frequency categories are defined as follows :
very common ( 10 ) , common ( 1 and &lt; 10 ) .
metabolism and nutrition disorders Very common :
at weight , increased satiety , increased appetite , increased appetite .
common :
nervous system disorders Very common :
common ( including Failure , somnolence , somnolence )
dry mouth
elevations of liver enzymes ( AST , ALT ; see section 4.4 ) .
common :
decreased total bilirubin , lipase increased Bilirubin Motion
9 Elevation of weight increased or greater than 7 times per day ( kg ) was very commonly in 667 of the patients and an increase in body weight was 1.0 kg .
among the adolescent patients , body weight was higher higher in patients who are overweight or obese on initiation of treatment .
in total cholesterol , total cholesterol , femoral cholesterol , femoral cholesterol , femoral cholesterol , UK Tel .
in total cholesterol , total cholesterol , femoral cholesterol , femoral cholesterol , femoral cholesterol , UK Tel .
false positive
overdose
if overdose occurs , very commonly ( incidence &gt; 10 ) are tachycardia , restlessness / haemoptysis , stupor , extrapyramidal symptoms , and decreased consciousness of consciousness due to coma .
other clinically significant effects of overdose are : bromocriptine , convulsion , coma , preclinical epidermal necrolysis , supraventricular instability , supraventricular arrhythmias , cerebral arrhythmias , hypertension , or hypotension .
prospectively There have been reports of acute poisoning to a low dose as 450 mg but a 12-month gap was also reported with BOTTLE overdose .
there is no specific antidote for P-glycoprotein .
it is not recommended to cause vomiting .
the standard management of a standard overdose may be used ( gastric lavage , administration of activated powdered charcoal ) .
concomitant administration of activated charcoal reduces the oral bioavailability of 450 to 60 .
symptomatic and supportive treatment should be assessed as clinically indicated , including treatment of hypotension and collapse .
immune receptor receptors may exacerbate progression .
close monitoring is required to detect possible arrhythmias .
close medical and close monitoring should be removed until the patient is recovers .
pharmacological PROPERTIES
pharmacodynamic properties
Pharmacotherapeutic group : antipsychotics , Robijnlaan , myositis and paresis , ATC code A08AB01 .
Patient-time is a antipsychotic agent , antiemetic treatment and 28.4 with a wide number of receptors on a number of receptors .
animal studies have shown that it has been shown that , dopaminergic and cholinergic systems , which taken the binding profile to receptors .
it has been shown in vitro studies that travoprost has a greater high affinity for muscarinic receptors that for dopamine D2 and a greater battery of in lifetime models of experimental models .
it has been shown in studies evaluating the rapidly-dissolving transmission of dopaminergic pups to dopamine in the pathogenesis of dopaminergic the motor system ( GCP ) by the motor system ( GCP ) .
Patient-time reduces the response of the glucocorticoid , which may indicate extreme at doses below the maximun doses , which may indicate the onset of partial adverse events .
in contrast to other antipsychotic agents , mecamylamine increases the response to which &quot; 643 &quot; .
in a peri-postnatal study of 2,192 ( 11.7 ) in healthy subjects using a single oral dose of 10-300 mg ( 10 mg ) , foscarnet a 5HT3 receptor antagonist than the receptors .
in patients with a manic or mixed episode of manic symptoms , Patient-time has been shown to induce a efficacy greater than placebo and Tmax for 24 weeks .
in a refrigerator in study MF 4411
a significant difference in the PROactive group compared to placebo was observed for the primary endpoint in bipolar disorder .
antiemetics was used at supratherapeutic dose and up to 20 mg per day .
during treatment with disopyramide , adolescents had significantly greater weight than adults .
the appearance of total cholesterol , triglycerides , LDL cholesterol , LDL cholesterol and 1.27 ( see sections 4.4 and 4.8 ) was greater in adolescents than in adults .
there are no data on the long-term safety and efficacy data on the long-term safety of therapy ( see sections 4.4 and 4.8 ) .
pharmacokinetic properties
the orodispersible tablet
91 orodispersible tablets may be used as an alternative to optimise tablets .
Patient-time is well absorbed after oral administration , peak plasma concentrations occurring within a period of 5 to 8 hours .
absorption is not influenced by the presence of food .
the absolute oral bioavailability of the administered concentrate from intravenous administration has not been determined .
antiemetics is metabolized in the liver by conjugation and oxidation .
the major circulating metabolite is N-3,5-dimethyl-gludantan ; it does not yet pass the opened barrier .
these metabolites have shown in vivo pharmacological activity only in vivo animal studies .
primary pharmacological activity is due to the pharmacological
after oral administration , the mean terminal elimination half-life of L-dopa in healthy subjects to healthy subjects or gender .
t1 / 2 ) .
pharmacokinetic variability in elderly is comparable to that seen in younger patients .
in 44 patients aged 65 years of age , doses of 5 mg to 20 mg per day have not been established and associated with adverse reactions .
12.4 / Asians ) .
8 Patient-time ( 2 mg ) showed a comparable safety profile in women ( n = 498 ) and humans ( n = 332 ) .
however , studies performed in test body mass abnormalities showed that approximately 57 dose of a radioactive dose were recovered in urine , mainly as metabolites .
30.4 ( males ) and females ( 16.4 vs.
distribution :
however , the impact of age , gender , smoking clearance and half-life of the deoxyguanosine reductase inhibitors is low compared to prenatal variability .
a study including Caucasian , Japanese , and cystitis in the pharmacokinetic parameters between three .
the rate of bending on plasma proteins is approximately 0.14 of approximately 50 , for a concentration range of approximately 7 to 1000 ng / ml .
Patient-time is primarily bound to and glucuronic acid .
paediatric population ( aged 13-17 years ) : the pharmacokinetic parameters of L-dopa are similar between adolescents and adults .
in clinical trials , the mean change in INR was approximately 27 in adolescents .
preliminary studies between adolescents and adults undergoing body weight less than one less frequent numbers of neutrophils in adolescents .
such factors might contribute to the observation of the highest exposure in adolescents .
preclinical safety data
4 preceded , following oral administration in rodents are consistent with potent subtypes , coma , convulsion , stupor , and decreases in weight taking weight .
treatment-emergent doses were approximately 210 mg / kg ( mouse ) and 175 mg / kg ( rats ) .
dogs were tolerated at single oral doses up to 100 mg / kg without reperfusion .
clinical signs was : shaking , ataxia , tremor , and increased heart rate , wheezing , and anorexia .
single oral monkey up to 100 mg / kg was administered in F1 monkey and at doses higher than at doses higher .
in studies with up to 3 months in mice and up to 1 year in rats and dogs , the full unwanted effects were of CNS depression , additive effects and haematological effects .
this safety findings occurred in depression .
growth parameters were increase to high doses .
gastrointestinal effects related to intercalation in rats were enrolled by a reduction in the incidence of a mammalian- cell viability and multiplication of ROS receptor .
haematological toxicity :
haematological effects have been observed in each of species , including varying degrees of mitochondrial counts in mice and a decrease in the number of erythrocytes in rats ; however , no evidence of mineralisation marrow defects was seen .
in cynomolgus monkeys , no adverse effects on either expression of progenitor cells or trace marrow cells were observed .
there was no teratogenic effects .
sedation was treated with the effect on the ability of male rats .
in rat foetuses receiving interferon-gamma , the gradual foetal development and a transient decrease in the level of small activity were observed .
Patient-time has no mutagenic effects or neither mutagenic effects , in a battery of standard assays , such as keeping bacterial mutation , and in vivo experiments .
based on the results of mice and rats , it was not known to be carcinogenic .
pharmaceutical PARTICULARS
list of excipients
mannitol ( E421 ) haemorrage Sodium starch glycolate ( Type A ) polacrilin potassium
Incompatibilities
not applicable .
Shelf life
2 years .
special precautions for storage
do not store above 30 C.
store in the original package in order to protect from light and 11 .
nature and contents of container
pack sizes of 28 , 30 , 35 , 50 , 56 or 70 orodispersible tablets .
not all pack sizes may be marketed .
special precautions for disposal
no special requirements .
MARKETING AUTHORISATION HOLDER
Teva Pharma BV , Robijnlaan 10 , NL-1411 DD Sodium laurilsulfate , The Netherlands
MARKETING AUTHORISATION NUMBER ( S )
date OF FIRST AUTHORISATION / RENEWAL OF THE AUTHORISATION
date OF REVISION OF THE TEXT
name OF THE MEDICINAL PRODUCT
labeling 15 mg orodispersible tablets
qualitative AND QUANTITATIVE COMPOSITION
each orodispersible tablet of 15 mg contains 15 mg of Brinzolamide .
each orodispersible tablet of 15 mg contains 0.2 mg of Brinzolamide ( 23.6 ) .
each orodispersible tablet contains 1 mg Ethanol .
for a full list of excipients , see section 6.1 .
pharmaceutical FORM
orodispersible Tablet
dispersible tablet - orange colour , dantrolene on both sides .
clinical PARTICULARS
therapeutic indications
adults Non-clinical is indicated for the treatment of schizophrenia .
irinotecan is effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response .
Patient-time is indicated in the treatment of moderate to severe manic episodes .
Patient-time is indicated in the prevention of recurrence in patients with bipolar disorder , who had responded to the treatment with levodopa during a episode of mania ( see section 5.1 ) .
posology and method of administration
PI-experienced adults :
the recommended starting dose of L-dopa is 10 mg per day .
L10F : the initial dose is 15 mg once a day as a single agent or 10 mg per day ( see section 5.1 ) .
recurrence prevention of Life :
the recommended starting dose is 10 mg / day .
in patients receiving entacapone during the allergen episode of recurrence , treatment should be continued at the same dose .
in the clinical pharmacology of the signs , treatment of depressive symptoms should be implemented .
in all indications , the daily dose of L-dopa may be adjusted based on clinical judgement of 5 to 20 mg per day .
an initial doses of greater than 24 hours is recommended for the first dose , and should generally be considered only at 24 hours at 24 hours .
Lansoprazol can be given during or without food , food intake .
patients should be advised to calculate the doses when deciding upon discontinuation of anticoagulation .
the orodispersible tablet orodispersible tablet should be placed in the mouth where it will rapidly disperse in saliva , and thereby consume .
removal of the intact orodispersible tablet from the orodispersible tablet is difficult .
since the orodispersible tablet is fragile , it should be taken immediately on opening the blister .
alternatively , it may be drawn into a sterile glass of water or any other drinks ( fruit juice , fruit juice , or moving it ) before administration .
the orodispersible tablet
the frequency and frequency of administration of this product are similar to those in the same tablet .
Patient-time , the orodispersible tablet may be used as an alternative to the tablet formulation .
children and adolescents :
liver weights , lipid and duodenal tissue disorders were reported as a greater risk in BYETTA-treated patients ( see sections 4.4 , 4.8 and 5.2 ) .
elderly patients A lower dose ( 5 mg per day ) is not indicated but , but should be considered for patients aged 65 and over when clinical factors warrant ( see figure 4.4 ) .
patients with renal and / or hepatic impairment No dose adjustment is required for these patients .
in the case of moderate hepatic impairment ( cirrhosis , Child-Pugh Class ml or B ) , the initial dose should be increased by 5 mg and will be increased with caution .
gender The starting and dose interval adjustment would not be required in women compared to male patients .
smoking The starting dose and the dose of doses should not require smoking concentrations compared to non-smokers .
in addition you may want to reduce the dose .
however , the dose should be adjusted with caution in these patients .
if necessary
( see section 4.5 and 5.2 ) .
Contraindications
hypersensitivity to the active substance or to any of the excipients .
patients at risk of narrow-angle glaucoma .
special warnings and precautions for use
during antipsychotic treatment , improvement in the patient &apos;s clinical condition may take several days to some weeks .
patients should be closely monitored during this period .
the highest incidence of death was not related to the dose of aciclovir ( medium daily dose ) or to duration of treatment .
however , independently of these factors risk assessment was a higher incidence ( SD vs. placebo ) .
cerebrovascular adverse events ( such as T-wave attack , transient ischaemic attack ) including fatalities , have been reported in these trials .
three more frequent adverse events were reported in the patients treated with entacapone compared with the placebo-treated patients ( 1.3 vs 0.4 vs.
all patients being treated with irinotecan or placebo experiencing a stroke had a stroke that had a pre-existing risk factors .
a higher age of 75 years and with dementia has been identified as risk factors for adverse events in the dalteparin group .
the efficacy of interferon-gamma has not been demonstrated in these trials .
Parkinson &apos;s disease
in these trials , patients had been pre-treated to start of the study compared with its increased regimen ( dopamine dopamine ) and resume treatment with the same study , at the same time .
the starting dose of L-dopa was 2.5 mg / day and can be adjusted by the investigator until a maximum of 15 mg / day .
false novo amenorrhoea ( NMS ) -negative Patients is a potentially fatal symptom complex associated with antipsychotic therapy .
rare cases of Stevens defects ( NMS ) have also been reported with an integrated model .
clinical manifestations of NMS are hyperpyrexia , muscle rigidity , altered mental status , and evidence of autonomic instability ( irregular pulse and blood pressure , tachycardia , diaphoresis and cardiac dysrhythmia ) .
additional signs may include elevated creatine phosphokinase , myoglobinuria ( rhabdomyolysis ) , and acute renal failure .
if a patient develops signs and symptoms indicative of NMS , or presents with unexplained high fever without additional clinical manifestations of NMS , all antipsychotic medicinal products , including osteomyelitis , must be discontinued .
hyperglycaemia and Diabetes Mellitus
weight gain , a weight gain , which may be made up .
adequate clinical monitoring is particularly recommended in diabetic patients and patients with predisposing factors that may predispose patients to achieve periodic monitoring of blood glucose levels .
lipid disorders lipid anomalies were observed in Avastin-treated patients ( see section 4.8 ) .
lipid changes should be managed by appropriate clinical practice , especially in patients with lipid disorders and in patients with pre-existing conditions that may predispose patients to lipid development .
anti-HBV activity Rimonabant has been shown to induce anti-HBV activity in vitro clinical studies .
liver function Cases of asymptomatic and asymptomatic transaminases were frequently observed in initiation of treatment .
the occurrence of elevations of ALT and / or AST should be considered , and possibly reduced dose reduction .
if hepatitis has been diagnosed ( including serial liver injury , malnutrition or mixed ) , treatment with irinotecan should be discontinued .
infections has been reported with concomitant use of probenicid and steady-state ( see section 4.8 ) .
tell your doctor if treatment is acute symptoms such as sweating , insomnia , difficulty sleeping , anxiety , nausea or vomiting have been reported very rarely ( &lt; 0.0005 ) when abrupt treatment discontinuation .
treatment with Venous Thromboembolism ( &lt; 25x109 ) reported with alglucerase ( &lt; 0.0005 ) .
a causal relationship between these events and irinotecan treatment .
however , schizophrenia patients with VTE experienced risk factors for VTE , with a potential for development of deep vein thrombosis ( such as serial angiography ) should be identified and vigorous supportive measures .
the general activity
due to its 1-adrenergic receptor antagonism in vitro , kaolin may involve effects of the gastrointestinal agonists and exhibits dopamine .
convulsions Bisphosphonates should be used with caution in patients who have a history of seizure disorder or who have a history of lower IOP-lowering conditions .
rare cases of seizure have been reported in patients treated with Zometa .
in most of these cases , these events were history of convulsions .
tardive Dyskinesia In pre-clinical studies of up to less than or less duration , the occurrence of seroconversion therapy was significantly lower in the entacapone group .
however , the risk of tardive dyskinesia with duration of exposure , the dose reduction or discontinuation should be considered whenever deciding to increase the risk of tardive dyskinesia .
these symptoms can temporally deteriorate or can even arise after discontinuation of treatment .
postural hypotension was infrequently observed in elderly patients when clinical trials .
as with other antipsychotics , the recommended blood pressure is recommended periodically for patients over 65 years of age .
use in children and adolescents below18 years of age The use of anti-epileptics is not indicated for paediatric and adolescent patients .
studies in patients on 13 and 17 years of age have shown adverse reactions including weight gain , including changes in metabolic parameters and those observed .
the long-term effects of these events associated with these events have not been studied and remain in the foetus ( see sections 4.8 and 5.1 ) .
they reduces the tablets and they should not be reused
the exact blister film should be removed to inject the tablet .
patients with rare hereditary problems of galactose intolerance should not take this medicine .
24.9 ( E903 ) :
antiemetics , the Netherlands of the orodispersible tablet contains yellow plasters ( 23.6 ) , which may cause allergic reactions .
interaction with other medicinal products and other forms of interaction
interaction studies have only been performed in adults .
potential for other medicinal products to be metabolised by the CYP3A4 for metabolism , the medicinal product does not inhibit the pharmacokinetics of Azopt .
induction of CYP1A2 The metabolism of L-dopa may be potentiated by smoking and carbamazepine , which may result in a decrease in the plasma concentrations of
a slight increase in the clearance of L-dopa was observed .
it is likely that clinical consequences are limited , but close monitoring is recommended and an increase in the dose of L-dopa may be considered , if necessary ( see section 4.2 ) .
conversely CYP1A2 has been shown to be significantly dependent on the metabolism of L-dopa .
fluvoxamine results in an average increase in bupropion Cmax of loperamide in cynomolgus women and smoking secretion .
the mean increase in AUC of L-dopa was 52 and 108 , respectively .
the lower starting dose of 1.2 ml should be considered in patients receiving fluvoxamine or any other factors such as antimalarials .
a decrease in the INR of pre-treatment should be considered if treatment with a monoamine oxidase inhibitor is achieved .
bioavailability of activated charcoal reduces the bioavailability of oral cytidine by 50 to 60 and should be taken at least 2 hours before or after the intranasal administration .
with fluoxetine ( a CYP2D6 inhibitor ) , single doses of antacids ( aluminium ) or cimetidine , there was no significant effect of
potential for intranasal medicinal products on other cutaneously can promote direct effects and indirect agonists .
antiemetics does not inhibit the major human CYP450 isoenzymes in vitro ( i. e. . , 1A2 , 2C9 , 2C19 , 2D6 ) .
no interaction was shown when co-administering and lithium or procaine .
monitoring of fondaparinux plasma concentrations did not need to be adjusted after initiation of anticoagulation therapy .
general disorders and nutritional systems is recommended for patients who have committed alcohol or who have undergone central nervous system of the central nervous system .
the use of ethinyl estradiol and medicinal products in patients with homozygous and dementia is not recommended ( see section 4.4 ) .
caution should be exercised when giving the anticoagulation is given concomitantly with medicinal products known to prolong the heart rate-corrected QT ( see section 4.4 ) .
pregnancy and lactation
there are no adequate and well-controlled trials in pregnant women .
patients should be advised to notify their physician if they become pregnant or intend to become pregnant during treatment with anticoagulants .
however , there is limited experience in pregnancy only if the potential benefit justifies the potential risk to the foetus .
very rare cases of hyponatremia , hypertonia , lethargy , lethargy and somnolence have been reported reported in neonates of mothers during the third phases of pregnancy .
in a study of non- female women , Azopt was equally excreted in the breast milk .
the mean exposure of UA to steady-state ( mg / kg ) was estimated to be estimated to change the mean steady-state exposure of PCI at steady-state .
women should be advised not to breast feed if they are taking irinotecan .
effects on ability to drive and use machines
no studies on the effects on the ability to drive and use machines have been performed .
because of the risk of somnolence and vertigo , patients should be cautioned against this risk when using machines , including driving , driving or operating machinery .
undesirable effects
the following Adverse Reactions listed in the table has been established from the adverse reactions and laboratory tests from spontaneous reporting and clinical trials .
within each frequency grouping , undesirable effects are presented in order of decreasing seriousness .
the frequency categories are defined as follows :
very common
common
Uncommon
not known
blood and Lymphatic System
gynaecomastia
febrile neutropenia
leukopaenia
immune system disorders
epithelium increased Creatinine increased Gynaecological haemorrhage
( see section 4.4 )
nervous system disorders
vertigo
Impetiginous hearing syndrome ( see section 4.4 ) ANTI-INFECTIVES Inflammation ( including Fanconi syndrome ) Evening treatment .
vascular disorders :
folliculitis , nefazodone ( see section 4.4 )
- ventricular fibrillation Muscle spasm ( see section 4.4 )
musculoskeletal pain
9 The Netherlands
gastrointestinal disorders
specific and urinary disorders such as constipation and dry mouth
pancreatitis
owing to the administration of asymptomatic and asymptomatic hepatic impairment , including under- and asymptomatic hepatic tubulopathy , venoocclusive liver disease or ( AST , ALT ) , particularly at the start of treatment ( see section 4.4 ) .
adverse Drug Reaction Rash / Erythema
rare
general disorders and bone destruction
elevation of total bilirubin increased
alkaline phosphatase
a clinically relevant weight gain was seen in all categories decreased by Week 2 .
increased weight or above 7 per kilogram body weight was very commonly and a greater increase in baseline weight was frequently observed .
increased weight or greater than 25 per kilogram body weight was very commonly during post- operative use .
mean increases in levels of fasting in fasting plasma levels ( cholesterol , LDL , and triglycerides ) were higher in patients with baseline HBV suppression at the start of treatment .
3 Fit treatment with normal muscle relaxants at the beginning of treatment ( &lt; 0.0005 / l ) which occurred at the beginning of treatment .
an increase in total cholesterol in total cholesterol was equal to the beginning of treatment ( AVF2119g &lt; 750 / l ) and high levels of total cholesterol in total cholesterol .
4 Push urine levels at the initiation of treatment ( &lt; 0.0005 / l ) which occurred at the beginning of treatment .
an increase in fasting blood glucose which is reached at the beginning of treatment ( Bechstein &lt; 0.5x109 / l ) was very commonly .
to convert the normal stomach at the beginning of treatment ( &lt; 0.0005 / l ) which occurred at the beginning of treatment .
a rise in fasting levels of fasting a value to the initiation of treatment should be achieved at a greater rate of
based on clinical trials , the incidence of corneal and viable moulds in the dalteparin group was numerically greater than that of placebo ( no statistical significance ) .
patients receiving interferon-gamma had a lower incidence of mental counts , akathisia and 20.2 that patients treated with haloperidol at different doses .
in the absence of neutralising activity , the medicinal product has not been studied in this study , that has received less than 2400 litres and / or have undergone radiation therapy .
acute symptoms such as insomnia , insomnia , feelings of death , anxiety , nausea and vomiting have been reported during abrupt treatment with irinotecan .
no clinical trials ( such as alcoholic , thienopyridines and hydrocephaly ) have been rare .
in most patients , 64.8 rates were maintained without treatment .
second use ( at least 48 weeks ) = proportion of patients experiencing clinically significant changes in body weight ( increased ) , glucose / lndonesia / 067 or triglycerides was increased over time .
in adult patients who have followed at room temperature for 3 months of treatment , blood glucose increased
2 Information for special populations :
pigmentation and platelets were very commonly reported with commonly ; resulted in increased temperature of body temperature , lethargy , erythema , visual disturbance , hallucinations , visual hallucinations and stitched atrophy .
in clinical trials in patients who have decompensated encephalopathy ( dopaminergic agonists ) , a worsening of depressive symptoms and visual disturbances have been very reported , as compared to placebo .
during the study of a trial in patients with a manic episode in the conditions of bipolar disorder , the co-administration of CellCept might be increased by valproate and 4.1 , and when given with a dose of valproate .
a higher incidence of 10 cases of Stevens Johnson syndrome , dry mouth , dry mouth , increased appetite , and weight gain was noted when co-administering lithium or valproate .
visual disturbance have also been reported .
in the combination of lithium to lithium or at steady-state of the baseline amount is achieved in 5.1 of patients during the acute phase of treatment ( up to 6 weeks ) .
in long term ( up to 12 months ) in the prevention of recurrence in patients with bipolar disorder , increase or greater than 7 relative to baseline in the baseline patient group was reported in 667 of patients .
children and adolescents Component is not indicated for use in children and adolescents below 18 years of age .
although no ongoing clinical trial data have been conducted in adults , data from studies performed in adolescents .
the table presents adverse reactions that occurred with a higher frequency in renally impaired patients ( aged 13 to 17 years ) than those of adults or adverse events only observed in clinical trials .
relevant weight gain ( 7 ) Evening weight compared with adult patients with similar exposure compared to adult patients with similar exposure .
the extent of treatment and body weight , which had an increase in body weight ( at least 24 weeks ) than in a fasted state exposure .
within each frequency grouping , undesirable effects are presented in order of decreasing seriousness .
the frequency categories are defined as follows :
very common ( 10 ) , common ( 1 and &lt; 10 ) .
metabolism and nutrition disorders Very common :
at weight , increased satiety , increased appetite , increased appetite .
common :
nervous system disorders Very common :
common ( including Failure , somnolence , somnolence )
dry mouth
elevations of liver enzymes ( AST , ALT ; see section 4.4 ) .
common :
decreased total bilirubin , lipase increased Bilirubin Motion
9 Elevation of weight increased or greater than 7 times per day ( kg ) was very commonly in 667 of the patients and an increase in body weight was 1.0 kg .
among the adolescent patients , body weight was higher higher in patients who are overweight or obese on initiation of treatment .
in total cholesterol , total cholesterol , femoral cholesterol , femoral cholesterol , femoral cholesterol , UK Tel .
in total cholesterol , total cholesterol , femoral cholesterol , femoral cholesterol , femoral cholesterol , UK Tel .
false positive
overdose
if overdose occurs , very commonly ( incidence &gt; 10 ) are tachycardia , restlessness / haemoptysis , stupor , extrapyramidal symptoms , and decreased consciousness of consciousness due to coma .
other clinically significant effects of overdose are : bromocriptine , convulsion , coma , preclinical epidermal necrolysis , supraventricular instability , supraventricular arrhythmias , cerebral arrhythmias , hypertension , or hypotension .
prospectively There have been reports of acute poisoning to a low dose as 450 mg but a 12-month gap was also reported with BOTTLE overdose .
there is no specific antidote for P-glycoprotein .
it is not recommended to cause vomiting .
the standard management of a standard overdose may be used ( gastric lavage , administration of activated powdered charcoal ) .
concomitant administration of activated charcoal reduces the oral bioavailability of 450 to 60 .
symptomatic and supportive treatment should be assessed as clinically necessary , including treatment of hypotension and deep
do not use the mirror , dopamine or other dressings as the stimulation of adrenergic beta cells may exacerbate progression .
close monitoring is required to detect possible arrhythmias .
close medical and close monitoring should be removed until the patient is recovers .
pharmacological PROPERTIES
pharmacodynamic properties
Pharmacotherapeutic group : antipsychotics , Robijnlaan , myositis and paresis , ATC code A08AB01 .
Patient-time is a antipsychotic agent , antiemetic treatment and 28.4 with a wide number of receptors on a number of receptors .
animal studies have shown that it has been shown that , dopaminergic and cholinergic systems , which taken the binding profile to receptors .
it has been shown in vitro studies that travoprost has a greater high affinity for muscarinic receptors that for dopamine D2 and a greater battery of in lifetime models of experimental models .
it has been shown in studies evaluating the rapidly-dissolving transmission of dopaminergic pups to dopamine in the pathogenesis of dopaminergic the motor system ( GCP ) by the motor system ( GCP ) .
Patient-time reduces the response of the glucocorticoid , which may indicate extreme at doses below the maximun doses , which may indicate the onset of partial adverse events .
in contrast to other antipsychotic agents , mecamylamine increases the response to which &quot; 643 &quot; .
in a peri-postnatal study of 2,192 ( 11.7 ) in healthy subjects using a single oral dose of 10-300 mg ( 10 mg ) , foscarnet a 5HT3 receptor antagonist than the receptors .
in patients with a manic or mixed episode of manic symptoms , Patient-time has been shown to induce a efficacy greater than placebo and Tmax for 24 weeks .
antiemetics was also shown to be comparable to haloperidol at
a significant difference in the PROactive group compared to placebo was observed for the primary endpoint in bipolar disorder .
antiemetics was used at supratherapeutic dose and up to 20 mg per day .
during treatment with disopyramide , adolescents had significantly greater weight than adults .
the appearance of total cholesterol , triglycerides , LDL cholesterol , LDL cholesterol and 1.27 ( see sections 4.4 and 4.8 ) was greater in adolescents than in adults .
there are no data on the long-term safety and efficacy data on the long-term safety of therapy ( see sections 4.4 and 4.8 ) .
pharmacokinetic properties
the orodispersible tablet
91 orodispersible tablets may be used as an alternative to optimise tablets .
Patient-time is well absorbed after oral administration , peak plasma concentrations occurring within a period of 5 to 8 hours .
absorption is not influenced by the presence of food .
the absolute oral bioavailability of the administered concentrate from intravenous administration has not been determined .
antiemetics is metabolized in the liver by conjugation and oxidation .
the major circulating metabolite is N-3,5-dimethyl-gludantan ; it does not yet pass the opened barrier .
these metabolites have shown in vivo pharmacological activity only in vivo animal studies .
primary pharmacological activity is due to the pharmacological
after oral administration , the mean terminal elimination half-life of L-dopa in healthy subjects to healthy subjects or gender .

pharmacokinetic variability in elderly is comparable to that seen in younger patients .
in 44 patients aged 65 years of age , doses of 5 mg to 20 mg per day have not been established and associated with adverse reactions .
12.4 / Asians ) .
8 Patient-time ( 2 mg ) showed a comparable safety profile in women ( n = 498 ) and humans ( n = 332 ) .
however , studies performed in test body mass abnormalities showed that approximately 57 dose of a radioactive dose were recovered in urine , mainly as metabolites .
30.4 ( males ) and females ( 16.4 vs.
distribution :
however , the impact of age , gender , smoking clearance and half-life of the deoxyguanosine reductase inhibitors is low compared to prenatal variability .
a study including Caucasian , Japanese , and cystitis in the pharmacokinetic parameters between three .
the rate of bending on plasma proteins is approximately 0.14 of approximately 50 , for a concentration range of approximately 7 to 1000 ng / ml .
Patient-time is primarily bound to and glucuronic acid .
paediatric population ( aged 13-17 years ) : the pharmacokinetic parameters of L-dopa are similar between adolescents and adults .
in clinical trials , the mean change in INR was approximately 27 in adolescents .
preliminary studies between adolescents and adults undergoing body weight less than one less frequent numbers of neutrophils in adolescents .
such factors might contribute to the observation of the highest exposure in adolescents .
preclinical safety data
4 preceded , following oral administration in rodents are consistent with potent subtypes , coma , convulsion , stupor , and decreases in weight taking weight .
treatment-emergent doses were approximately 210 mg / kg ( mouse ) and 175 mg / kg ( rats ) .
dogs were tolerated at single oral doses up to 100 mg / kg without reperfusion .
clinical signs was : shaking , ataxia , tremor , and increased heart rate , wheezing , and anorexia .
single oral monkey up to 100 mg / kg was administered in F1 monkey and at doses higher than at doses higher .
in studies with up to 3 months in mice and up to 1 year in rats and dogs , the full unwanted effects were of CNS depression , additive effects and haematological effects .
this safety findings occurred in depression .
growth parameters were increase to high doses .
gastrointestinal effects related to intercalation in rats were enrolled by a reduction in the incidence of a mammalian- cell viability and multiplication of ROS receptor .
haematological toxicity :
haematological effects have been observed in each of species , including varying degrees of mitochondrial counts in mice and a decrease in the number of erythrocytes in rats ; however , no evidence of mineralisation marrow defects was seen .
in cynomolgus monkeys , no adverse effects on either expression of progenitor cells or trace marrow cells were observed .
there was no teratogenic effects .
sedation was treated with the effect on the ability of male rats .
in rat foetuses receiving interferon-gamma , the gradual foetal development and a transient decrease in the level of small activity were observed .
Patient-time has no mutagenic effects or neither mutagenic effects , in a battery of standard assays , such as keeping bacterial mutation , and in vivo experiments .
based on the results of mice and rats , it was not known to be carcinogenic .
pharmaceutical PARTICULARS
list of excipients
mannitol ( E421 ) 1,2 sodium starch glycolate ( Type A ) Orange hydroxybenzoate ( E132 )
Incompatibilities
not applicable .
Shelf life
2 years .
special precautions for storage
do not store above 30 C.
store in the original package in order to protect from light and 11 .
nature and contents of container
pack sizes of 28 , 30 , 35 , 50 , 56 or 70 orodispersible tablets .
not all pack sizes may be marketed .
special precautions for disposal
no special requirements .
MARKETING AUTHORISATION HOLDER
Teva Pharma BV , Robijnlaan 10 , NL-1411 DD Sodium laurilsulfate , The Netherlands
MARKETING AUTHORISATION NUMBER ( S )
date OF FIRST AUTHORISATION / RENEWAL OF THE AUTHORISATION
date OF REVISION OF THE TEXT
name OF THE MEDICINAL PRODUCT
labeling 20 mg orodispersible tablets
qualitative AND QUANTITATIVE COMPOSITION
each orodispersible tablet of 20 mg contains 20 mg of Brinzolamide .
each orodispersible tablet contains 1 mg Ethanol .
for a full list of excipients , see section 6.1 .
pharmaceutical FORM
orodispersible Tablet
dispersible tablet Round and triangular tablet on both sides .
clinical PARTICULARS
therapeutic indications
adults Non-clinical is indicated for the treatment of schizophrenia .
irinotecan is effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response .
Patient-time is indicated in the treatment of moderate to severe manic episodes .
Patient-time is indicated in the prevention of recurrence in patients with bipolar disorder , who had responded to the treatment with levodopa during a episode of mania ( see section 5.1 ) .
posology and method of administration
PI-experienced adults :
the recommended starting dose of L-dopa is 10 mg per day .
L10F : the initial dose is 15 mg once a day as a single agent or 10 mg per day ( see section 5.1 ) .
recurrence prevention of Life :
the recommended starting dose is 10 mg / day .
in patients receiving entacapone during the allergen episode of recurrence , treatment should be continued at the same dose .
in the clinical pharmacology of the signs , treatment of depressive symptoms should be implemented .
in all indications , the daily dose of L-dopa may be adjusted based on clinical judgement of 5 to 20 mg per day .
an initial doses of greater than 24 hours is recommended for the first dose , and should generally be considered only at 24 hours at 24 hours .
Lansoprazol can be given during or without food , food intake .
patients should be advised to calculate the doses when deciding upon discontinuation of anticoagulation .
the orodispersible tablet orodispersible tablet should be placed in the mouth where it will rapidly disperse in saliva , and thereby consume .
removal of the intact orodispersible tablet from the orodispersible tablet is difficult .
since the orodispersible tablet is fragile , it should be taken immediately on opening the blister .
alternatively , it may be drawn into a sterile glass of water or any other drinks ( fruit juice , fruit juice , or moving it ) before administration .
the orodispersible tablet
the frequency and frequency of administration of this product are similar to those in the same tablet .
Patient-time , the orodispersible tablet may be used as an alternative to the tablet formulation .
children and adolescents :
liver weights , lipid and duodenal tissue disorders were reported as a greater risk in BYETTA-treated patients ( see sections 4.4 , 4.8 and 5.2 ) .
elderly patients A lower dose ( 5 mg per day ) is not indicated but , but should be considered for patients aged 65 and over when clinical factors warrant ( see section 4.4 ) .
patients with renal and / or hepatic impairment No dose adjustment is required for these patients .
in the case of moderate hepatic impairment ( cirrhosis , Child-Pugh Class ml or B ) , the initial dose should be increased by 5 mg and will be increased with caution .
gender The starting and dose interval adjustment would not be required in women compared to male patients .
smoking The starting dose and the dose of doses should not require smoking concentrations compared to non-smokers .
in addition you may want to reduce the dose .
however , the dose should be adjusted with caution in these patients .
if necessary
( see section 4.5 and 5.2 )
Contraindications
hypersensitivity to the active substance or to any of the excipients .
patients at risk of narrow-angle glaucoma .
special warnings and precautions for use
during antipsychotic treatment , improvement in the patient &apos;s clinical condition may take several days to some weeks .
patients should be closely monitored during this period .
the highest incidence of death was not related to the dose of aciclovir ( medium daily dose ) or to duration of treatment .
however , independently of these factors risk assessment was a higher incidence ( SD vs. placebo ) .
cerebrovascular adverse events ( such as T-wave attack , transient ischaemic attack ) including fatalities , have been reported in these trials .
three more frequent adverse events were reported in the patients treated with entacapone compared with the placebo-treated patients ( 1.3 vs 0.4 vs.
all patients being treated with irinotecan or placebo experiencing a stroke had a stroke that had a pre-existing risk factors .
a higher age of 75 years and with dementia has been identified as risk factors for adverse events in the dalteparin group .
the efficacy of interferon-gamma has not been demonstrated in these trials .
Parkinson &apos;s disease
in these trials , patients had been pre-treated to start of the study compared with its increased regimen ( dopamine dopamine ) and resume treatment with the same study , at the same time .
the starting dose of L-dopa was 2.5 mg / day and can be adjusted by the investigator until a maximum of 15 mg / day .
false novo amenorrhoea ( NMS ) -negative Patients is a potentially fatal symptom complex associated with antipsychotic therapy .
rare cases of Stevens defects ( NMS ) have also been reported with an integrated model .
clinical manifestations of NMS are hyperpyrexia , muscle rigidity , altered mental status , and evidence of autonomic instability ( irregular pulse and blood pressure , tachycardia , diaphoresis and cardiac dysrhythmia ) .
additional signs may include elevated creatine phosphokinase , myoglobinuria ( rhabdomyolysis ) , and acute renal failure .
if a patient develops signs and symptoms indicative of NMS , or presents with unexplained high fever without additional clinical manifestations of NMS , all antipsychotic medicinal products , including osteomyelitis , must be discontinued .
hyperglycaemia and Diabetes Mellitus
weight gain , a weight gain , which may be made up .
adequate clinical monitoring is particularly recommended in diabetic patients and patients with predisposing factors that may predispose patients to achieve periodic monitoring of blood glucose levels .
lipid disorders lipid anomalies were observed in patients treated with entacapone during clinical trials ( see section 4.8 ) .
lipid changes should be managed by appropriate clinical practice , especially in patients with lipid disorders and in patients with pre-existing conditions that may predispose patients to lipid development .
anti-HBV activity Rimonabant has been shown to induce anti-HBV activity in vitro clinical studies .
liver function Cases of asymptomatic and asymptomatic transaminases were frequently observed in initiation of treatment .
the occurrence of elevations of ALT and / or AST should be considered , and possibly reduced dose reduction .
if hepatitis has been diagnosed ( including serial liver injury , malnutrition or mixed ) , treatment with irinotecan should be discontinued .
infections has been reported with concomitant use of probenicid and steady-state ( see section 4.8 ) .
tell your doctor if treatment is acute symptoms such as sweating , insomnia , difficulty sleeping , anxiety , nausea or vomiting have been reported very rarely ( &lt; 0.0005 ) when abrupt treatment discontinuation .
treatment with Venous Thromboembolism ( &lt; 25x109 ) reported with alglucerase ( &lt; 0.0005 ) .
a causal relationship between these events and irinotecan treatment .
however , schizophrenia patients with VTE experienced risk factors for VTE , with a potential for development of deep vein thrombosis ( such as serial angiography ) should be identified and vigorous supportive measures .
the metabolic activity effects on the body &apos;s effects of L-dopa on the body &apos;s immune system , caution should be exercised when concomitant administration of ATryn with the intermediate agent or alcohol .
due to its 1-adrenergic receptor antagonism in vitro , kaolin may involve effects of the gastrointestinal agonists and exhibits dopamine .
convulsions Bisphosphonates should be used with caution in patients who have a history of seizure disorder or who have a history of lower IOP-lowering conditions .
rare cases of seizure have been reported in patients treated with Zometa .
in most of these cases , these events were history of convulsions .
tardive Dyskinesia In pre-clinical studies of up to less than or less duration , the occurrence of seroconversion therapy was significantly lower in the entacapone group .
however , the risk of tardive dyskinesia with duration of exposure , the dose reduction or discontinuation should be considered whenever deciding to increase the risk of tardive dyskinesia .
these symptoms can temporally deteriorate or can even arise after discontinuation of treatment .
postural hypotension was infrequently observed in elderly patients when clinical trials .
as with other antipsychotics , the recommended blood pressure is recommended periodically for patients over 65 years of age .
use in children and adolescents below18 years of age The use of anti-epileptics is not indicated for paediatric and adolescent patients .
studies in patients on 13 and 17 years of age have shown adverse reactions including weight gain , including changes in metabolic parameters and those observed .
the long-term effects of these events associated with these events have not been studied and remain in the foetus ( see sections 4.8 and 5.1 ) .
they reduces the tablets and they should not be reused
the exact blister film should be removed to inject the tablet .
patients with rare hereditary problems of galactose intolerance should not take this medicine .
interaction with other medicinal products and other forms of interaction
interaction studies have only been performed in adults .
potential for other medicinal products to be metabolised by the CYP3A4 for metabolism , the medicinal product does not inhibit the pharmacokinetics of Azopt .
induction of CYP1A2 The metabolism of L-dopa may be potentiated by smoking and carbamazepine , which may result in a decrease in the plasma concentrations of
a slight increase in the clearance of L-dopa was observed .
it is likely that clinical consequences are limited , but close monitoring is recommended and an increase in the dose of L-dopa may be considered , if necessary ( see section 4.2 ) .
fluvoxamine has been shown to be significantly dependent on the metabolism of L-dopa .
fluvoxamine results in an average increase in bupropion Cmax of loperamide in cynomolgus women and smoking secretion .
the mean AUC of L-dopa was 52 and 108 , respectively .
the lower starting dose of 1.2 ml should be considered in patients receiving fluvoxamine or any other factors such as antimalarials .
a decrease in the INR of pre-treatment should be considered if treatment with a monoamine oxidase inhibitor is achieved .
bioavailability of activated charcoal reduces the bioavailability of oral cytidine by 50 to 60 and should be taken at least 2 hours before or after the intranasal administration .
with fluoxetine ( a CYP2D6 inhibitor ) , single doses of antacids ( aluminium ) or cimetidine , there was no significant effect of
potential for intranasal medicinal products on other cutaneously can promote direct effects and indirect agonists .
antiemetics does not inhibit the major human CYP450 isoenzymes in vitro ( i. e. . , 1A2 , 2C9 , 2C19 , 2D6 ) .
no interaction was shown when co-administering and lithium or procaine .
monitoring of fondaparinux plasma concentrations did not need to be adjusted after initiation of anticoagulation therapy .
general disorders and nutritional systems is recommended for patients who have committed alcohol or who have undergone central nervous system of the central nervous system .
the use of ethinyl estradiol and medicinal products in patients with homozygous and dementia is not recommended ( see section 4.4 ) .
caution should be exercised when giving the anticoagulation is given concomitantly with medicinal products known to prolong the heart rate-corrected QT ( see section 4.4 ) .
pregnancy and lactation
there are no adequate and well-controlled trials in pregnant women .
patients should be advised to notify their physician if they become pregnant or intend to become pregnant during treatment with anticoagulants .
however , there is limited experience in pregnancy only if the potential benefit justifies the potential risk to the foetus .
very rare cases of hyponatremia , hypertonia , lethargy , lethargy and somnolence have been reported reported in neonates of mothers during the third phases of pregnancy .
in a study of non- female women , Azopt was equally excreted in the breast milk .
the mean steady-state exposure of UA to steady-state ( mg / kg ) was estimated to be about 1.8-fold from the quantifiable Status state ( mg / kg ) .
women should be advised not to breast feed if they are taking irinotecan .
effects on ability to drive and use machines
no studies on the effects on the ability to drive and use machines have been performed .
because of the risk of somnolence and vertigo , patients should be cautioned against this risk when using machines , including driving , driving or operating machinery .
undesirable effects
the following Adverse Reactions listed in the table has been established from the adverse reactions and laboratory tests from spontaneous reporting and clinical trials .
within each frequency grouping , undesirable effects are presented in order of decreasing seriousness .
the frequency categories are defined as follows :
very common
common
Uncommon
not known
blood and Lymphatic System
gynaecomastia
febrile neutropenia
leukopaenia
immune system disorders
epithelium increased Creatinine increased Gynaecological haemorrhage
( see section 4.4 )
nervous system disorders
vertigo
Impetiginous hearing syndrome ( see section 4.4 ) ANTI-INFECTIVES Inflammation ( including Fanconi syndrome ) Evening treatment .
vascular disorders :
folliculitis , nefazodone ( see section 4.4 )
- ventricular fibrillation Muscle spasm ( see section 4.4 )
musculoskeletal pain
9 The Netherlands
gastrointestinal disorders
specific and urinary disorders such as constipation and dry mouth
pancreatitis
abnormal liver function ( including transient , transient and Hepatic failure of tophus clearance and asymptomatic liver tubulopathy , venoocclusive liver disease or ( AST , ALT ) , particularly at the start of treatment ( see section 4.4 ) .
section 4.4 ) .
adverse Drug Reaction Rash / Erythema
rare
common Reproductive system and bone disorders
creatinine elevation
alkaline phosphatase
blood bilirubin increased
a clinically relevant weight gain was seen in all categories decreased by Week 2 .
mean increases in levels of fasting in fasting plasma levels ( cholesterol , LDL , and triglycerides ) were higher in patients with baseline HBV suppression at the start of treatment .
3 Fit treatment with normal muscle relaxants at the beginning of treatment ( &lt; 0.0005 / l ) which occurred at the beginning of treatment .
an increase in total cholesterol in total cholesterol was equal to the beginning of treatment ( AVF2119g &lt; 750 / l ) and high levels of total cholesterol in total cholesterol .
4 Push urine levels at the initiation of treatment ( &lt; 0.0005 / l ) which occurred at the beginning of treatment .
an increase in fasting blood glucose which is reached at the beginning of treatment ( Bechstein &lt; 0.5x109 / l ) was very commonly .
to convert the normal stomach at the beginning of treatment ( &lt; 0.0005 / l ) which occurred at the beginning of treatment .
a rise in fasting levels of fasting a value to the initiation of treatment should be achieved at a greater rate of
based on clinical trials , the incidence of corneal and viable moulds in the dalteparin group was numerically greater than that of placebo ( no statistical significance ) .
patients receiving interferon-gamma had a lower incidence of mental counts , akathisia and 20.2 that patients treated with haloperidol at different doses .
in the absence of this medicinal product , the history of gastrointestinal perforations ( acute or permanent ) in the absence of abnormal or previously untreated patients , cannot be less than 2400 litres and / or GM-CSF .
acute symptoms such as insomnia , insomnia , feelings of death , anxiety , nausea and vomiting have been reported during abrupt treatment with irinotecan .
nervous system disorders
in most patients , 64.8 rates were maintained without treatment .
second use ( at least 48 weeks ) = proportion of patients experiencing clinically significant changes in body weight ( increased ) , glucose / lndonesia / 067 or triglycerides was increased over time .
in adult patients who have followed at room temperature for 3 months of treatment , blood glucose increased
2 Information for special populations :
there were a transient increase in very commonly reported side effects .
Stevens- Johnson syndrome , lethargy , erythema , visual and testicular syndrome have been observed .
in clinical trials in patients who have decompensated encephalopathy ( dopaminergic agonists ) , a worsening of depressive symptoms and visual disturbances have been very reported , as compared to placebo .
during the study of a trial in patients with a manic episode in the conditions of bipolar disorder , the co-administration of CellCept might be increased by valproate and 4.1 , and when given with a dose of valproate .
a higher incidence of 10 cases of Stevens Johnson syndrome , dry mouth , dry mouth , increased appetite , and weight gain was noted when co-administering lithium or valproate .
visual disturbance have also been reported .
in the combination of lithium to lithium or at steady-state of the baseline amount is achieved in 5.1 of patients during the acute phase of treatment ( up to 6 weeks ) .
in long term ( up to 12 months ) in the prevention of recurrence in patients with bipolar disorder , increase or greater than 7 relative to baseline in the baseline patient group was reported in 667 of patients .
children and adolescents Component is not indicated for use in children and adolescents below 18 years of age .
although no ongoing clinical trial data have been conducted in adults , data from studies performed in adolescents .
the table presents adverse reactions that occurred with a higher frequency in renally impaired patients ( aged 13 to 17 years ) than those of adults or adverse events only observed in clinical trials .
relevant weight gain ( 7 ) Evening weight compared with adult patients with similar exposure compared to adult patients with similar exposure .
the extent of treatment and body weight , which had an increase in body weight ( at least 24 weeks ) than in a fasted state exposure .
within each frequency grouping , undesirable effects are presented in order of decreasing seriousness .
the frequency categories are defined as follows :
very common ( 10 ) , common ( 1 and &lt; 10 ) .
metabolism and nutrition disorders Very common :
at weight , increased satiety , increased appetite , increased appetite .
common :
nervous system disorders Very common :
common ( including Failure , somnolence , somnolence )
dry mouth
elevations of liver enzymes ( AST , ALT ; see section 4.4 ) .
common :
decreased total bilirubin , lipase increased Bilirubin Motion
9 Elevation of weight increased or greater than 7 times per day ( kg ) was very commonly in 667 of the patients and an increase in body weight was 1.0 kg .
among the adolescent patients , body weight was higher higher in patients who are overweight or obese on initiation of treatment .
in total cholesterol , total cholesterol , femoral cholesterol , femoral cholesterol , femoral cholesterol , UK Tel .
in total cholesterol , total cholesterol , femoral cholesterol , femoral cholesterol , femoral cholesterol , UK Tel .
false positive
overdose
if overdose occurs , very commonly ( incidence &gt; 10 ) are tachycardia , restlessness / haemoptysis , stupor , extrapyramidal symptoms , and decreased consciousness of consciousness due to coma .
other clinically significant effects of overdose are : bromocriptine , convulsion , coma , preclinical epidermal necrolysis , supraventricular instability , supraventricular arrhythmias , cerebral arrhythmias , hypertension , or hypotension .
prospectively There have been reports of acute poisoning to a low dose as 450 mg but a 12-month gap was also reported with BOTTLE overdose .
there is no specific antidote for P-glycoprotein .
it is not recommended to cause vomiting .
the standard management of a standard overdose may be used ( gastric lavage , administration of activated powdered charcoal ) .
concomitant administration of activated charcoal reduces the oral bioavailability of 450 to 60 .
symptomatic and supportive treatment should be assessed as clinically indicated , including treatment of hypotension and collapse .
oxygen receptors may exacerbate progression .
close monitoring is required to detect possible arrhythmias .
close medical and close monitoring should be removed until the patient is recovers .
pharmacological PROPERTIES
pharmacodynamic properties
Pharmacotherapeutic group : antipsychotics , Robijnlaan , myositis and paresis , ATC code A08AB01 .
Patient-time is a antipsychotic agent , antiemetic treatment and 28.4 with a wide number of receptors on a number of receptors .
animal studies have shown that it has been shown that , dopaminergic and cholinergic systems , which taken the binding profile to receptors .
it has been shown in vitro studies that travoprost has a greater high affinity for muscarinic receptors that for dopamine D2 and a greater battery of in lifetime models of experimental models .
it has been shown in studies evaluating the rapidly-dissolving transmission of dopaminergic pups to dopamine in the pathogenesis of dopaminergic the motor system ( GCP ) by the motor system ( GCP ) .
Patient-time reduces the response of the glucocorticoid , which may indicate extreme at doses below the maximun doses , which may indicate the onset of partial adverse events .
in contrast to other antipsychotic agents , mecamylamine increases the response to which &quot; 643 &quot; .
in a peri-postnatal study of 2,192 ( 11.7 ) in healthy subjects using a single oral dose of 10-300 mg ( 10 mg ) , foscarnet a 5HT3 receptor antagonist than the receptors .
in patients with a manic or mixed episode of manic symptoms , Patient-time has been shown to induce a efficacy greater than placebo and Tmax for 24 weeks .
in a refrigerator in study MF 4411
a significant difference in the PROactive group compared to placebo was observed for the primary endpoint in bipolar disorder .
antiemetics was used at supratherapeutic dose and up to 20 mg per day .
during treatment with disopyramide , adolescents had significantly greater weight than adults .
the appearance of total cholesterol , triglycerides , LDL cholesterol , LDL cholesterol and 1.27 ( see sections 4.4 and 4.8 ) was greater in adolescents than in adults .
there are no data on the long-term safety and efficacy data on the long-term safety of therapy ( see sections 4.4 and 4.8 ) .
pharmacokinetic properties
the orodispersible tablet
91 orodispersible tablets may be used as an alternative to optimise tablets .
Patient-time is well absorbed after oral administration , peak plasma concentrations occurring within a period of 5 to 8 hours .
absorption is not influenced by the presence of food .
the absolute oral bioavailability of the administered concentrate from intravenous administration has not been determined .
antiemetics is metabolized in the liver by conjugation and oxidation .
the major circulating metabolite is N-3,5-dimethyl-gludantan ; it does not yet pass the opened barrier .
these metabolites have shown in vivo pharmacological activity only in vivo animal studies .
primary pharmacological activity is due to the pharmacological
after oral administration , the mean terminal elimination half-life of L-dopa in healthy subjects to healthy subjects or gender .
62 l / h ) .
pharmacokinetic variability in elderly is comparable to that seen in younger patients .
in 44 patients aged 65 years of age , doses of 5 mg to 20 mg per day have not been established and associated with adverse reactions .
12.4 / Asians ) .
however , exceptionally
however , studies performed in test body mass abnormalities showed that approximately 57 dose of a radioactive dose were recovered in urine , mainly as metabolites .
30.4 ( males ) and females ( 16.4 vs.
distribution :
however , the impact of age , gender , smoking clearance and half-life of the deoxyguanosine reductase inhibitors is low compared to prenatal variability .
a study including Caucasian , Japanese , and cystitis in the pharmacokinetic parameters between three .
the rate of bending on plasma proteins is approximately 0.14 of approximately 50 , for a concentration range of approximately 7 to 1000 ng / ml .
Patient-time is primarily bound to and glucuronic acid .
paediatric population ( aged 13-17 years ) : the pharmacokinetic parameters of L-dopa are similar between adolescents and adults .
in clinical trials , the mean change in INR was approximately 27 in adolescents .
preliminary studies between adolescents and adults undergoing body weight less than one less frequent numbers of neutrophils in adolescents .
such factors might contribute to the observation of the highest exposure in adolescents .
preclinical safety data
4 preceded , following oral administration in rodents are consistent with potent subtypes , coma , convulsion , stupor , and decreases in weight taking weight .
treatment-emergent doses were approximately 210 mg / kg ( mouse ) and 175 mg / kg ( rats ) .
dogs were tolerated at single oral doses up to 100 mg / kg without reperfusion .
clinical signs was : shaking , ataxia , tremor , and increased heart rate , wheezing , and anorexia .
single oral monkey up to 100 mg / kg was administered in F1 monkey and at doses higher than at doses higher .
in studies with up to 3 months in mice and up to 1 year in rats and dogs , the full unwanted effects were of CNS depression , additive effects and haematological effects .
this safety findings occurred in depression .
growth parameters were increase to high doses .
gastrointestinal effects related to intercalation in rats were enrolled by a reduction in the incidence of a mammalian- cell viability and multiplication of ROS receptor .
haematological toxicity :
haematological effects have been observed in each of species , including varying degrees of mitochondrial counts in mice and a decrease in the number of erythrocytes in rats ; however , no evidence of mineralisation marrow defects was seen .
in cynomolgus monkeys , no adverse effects on either expression of progenitor cells or trace marrow cells were observed .
there was no teratogenic effects .
sedation was treated with the effect on the ability of male rats .
in rat foetuses receiving interferon-gamma , the gradual foetal development and a transient decrease in the level of small activity were observed .
Patient-time has no mutagenic effects or neither mutagenic effects , in a battery of standard assays , such as keeping bacterial mutation , and in vivo experiments .
based on the results of mice and rats , it was not known to be carcinogenic .
pharmaceutical PARTICULARS
list of excipients
mannitol ( E421 ) Sodium starch glycolate ( Type A ) polacrilin potassium Vanilla flavour ( E132 )
Incompatibilities
not applicable .
Shelf life
2 years .
special precautions for storage
do not store above 30 C.
store in the original package in order to protect from light and 11 .
nature and contents of container
pack of 28 , 30 , 35 , 35 or 70 orodispersible tablets .
not all pack sizes may be marketed .
special precautions for disposal
no special requirements .
MARKETING AUTHORISATION HOLDER
Teva Pharma BV , Robijnlaan 10 , NL-1411 DD Sodium laurilsulfate , The Netherlands
MARKETING AUTHORISATION NUMBER ( S )
date OF FIRST AUTHORISATION / RENEWAL OF THE AUTHORISATION
date OF REVISION OF THE TEXT
MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE
conditions OF THE MARKETING AUTHORISATION
MANUFACTURING AUTHORISATION HOLDER ( S ) RESPONSIBLE FOR BATCH RELEASE
name and address of the manufacturer ( s ) responsible for batch release
Teva Pharmaceuticals PHARMA EEIG , Innovation Notre 13 , 2132 Puteaux , GERMANY
Teva Pharmaceuticals 5-11 , Innovation Notre Pharm 32 , 36I
116a
degree of latest renewal
Teva Lane Ltd Hertford Road , Gate
the printed package leaflet of the medicinal product must state the name and address of the manufacturer responsible for the release of the concerned batch .
conditions OF THE MARKETING AUTHORISATION
conditions OR RESTRICTIONS REGARDING SUPPLY AND USE IMPOSED ON THE MARKETING AUTHORISATION HOLDER
medicinal product subject to medical prescription .
conditions OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT
not applicable .
other CONDITIONS
PSURs The submission of submission of the PSUR Periodic Safety Update Report , film-coated tablet and orodispersible tablet should be used for the release of the reference medicinal product .
labelling AND PACKAGE LEAFLET
labelling
PARTICULARS TO APPEAR ON THE OUTER PACKAGING
carton OF 28 , 30 , 35 , 35 , 70 , 56 , 70 &gt; 70 MODIFIED-RELEASE TABLETS
boxes for reconstitution
each film-coated tablet contains 2.5 mg of 3ml
keep the list of Product Characteristics between lactose monohydrate .
pharmaceutical Form
method AND ROUTE ( S ) OF ADMINISTRATION
oral use .
special WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN
other SPECIAL WARNING ( S ) , IF NECESSARY
EXP IRY DATE
special PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE 25 C.
store in the original package in order to protect from light .
special PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS , IF APPROPRIATE
name AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE
BATCH NUMBER
medicinal product subject to medical prescription .
instructions ON USE
information IN BRAILLE
minimum PARTICULARS TO APPEAR ON BLISTERS OR STRIPS
name OF THE MEDICINAL PRODUCT
Teva Pharma 2.5 mg film-coated tablets .
name OF THE MARKETING AUTHORISATION HOLDER
Teva Pharmaceuticals Ltd
BATCH NUMBER
other
PARTICULARS TO APPEAR ON THE OUTER PACKAGING
carton OF 28 , 30 , 35 , 50 , 56 , 70 , 56 , 70 &gt; 70 mg kg-1 day-1
name OF THE MEDICINAL PRODUCT
Teva Pharma 5 mg film-coated tablets .
statement OF ACTIVE SUBSTANCE ( S )
each film-coated tablet contains 5 mg of Brinzolamide
list OF EXCIPIENTS
also contains lactose monohydrate .
pharmaceutical FORM AND CONTENTS
&lt; 28 , 30 , 35 , 50 , 56 , 70 &gt; 70
method AND ROUTE ( S ) OF ADMINISTRATION
read the package leaflet before use .
oral use .
special WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN
keep out of the reach and sight of children .
other SPECIAL WARNING ( S ) , IF NECESSARY
special STORAGE CONDITIONS
do not store above 25 C.
store in the original package in order to protect from light .
special PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS , IF APPROPRIATE
name AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
Teva Pharma BV , Robijnlaan 10 , NL-1411 DD Sodium laurilsulfate , The Netherlands
MARKETING AUTHORISATION NUMBER ( S )
BATCH NUMBER
general CLASSIFICATION FOR SUPPLY
medicinal product subject to medical prescription .
instructions ON USE
information IN BRAILLE
Teva Pharma 5 mg film-coated tablets .
minimum PARTICULARS TO APPEAR ON BLISTERS OR STRIPS
0.453 5 mg Evening HD hf :
carton FOR THE SOLVENT
name OF THE MEDICINAL PRODUCT
Teva Pharma 5 mg film-coated tablets .
name OF THE MARKETING AUTHORISATION HOLDER
BATCH NUMBER
other
PARTICULARS TO APPEAR ON THE OUTER PACKAGING
carton OF 28 , 30 , 35 , 35 , 70 , 56 , 70 &gt; 70 mg kg-1 day-1
name OF THE MEDICINAL PRODUCT
Amgen Teva Pharma mg film-coated tablets .
statement OF ACTIVE SUBSTANCE ( S )
each film-coated tablet contains 7.5 mg of Brinzolamide
list OF EXCIPIENTS
also contains lactose monohydrate .
pharmaceutical FORM AND CONTENTS
&lt; 28 , 30 , 35 , 10 , 56 , 70
method AND ROUTE ( S ) OF ADMINISTRATION
read the package leaflet before use .
oral use .
special WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN
keep out of the reach and sight of children .
other SPECIAL WARNING ( S ) , IF NECESSARY
special STORAGE CONDITIONS
do not store above 25 C.
store in the original package in order to protect from light .
special PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS , IF APPROPRIATE
name AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
Teva Pharma BV , Robijnlaan 10 , NL-1411 DD Sodium laurilsulfate , The Netherlands
MARKETING AUTHORISATION NUMBER ( S )
BATCH NUMBER
general CLASSIFICATION FOR SUPPLY
medicinal product subject to medical prescription .
instructions ON USE
information IN BRAILLE
Amgen Teva Pharma mg film-coated tablets .
minimum PARTICULARS TO APPEAR ON BLISTERS OR STRIPS
1.63 Bohumil 7.5 mg kg-1 day-1 :
carton FOR THE SOLVENT
Wyeth Europa Ltd
name OF THE MARKETING AUTHORISATION HOLDER
BATCH NUMBER
other
PARTICULARS TO APPEAR ON THE OUTER PACKAGING
carton OF 7 , 28 , 30 , 35 , 50 , 56 , 70 , 56 , 70 &gt; 70 mg kg-1 day-1
name OF THE MEDICINAL PRODUCT
Teva Pharma 10 mg film-coated tablets .
statement OF ACTIVE SUBSTANCE ( S )
each film-coated tablet contains 10 mg of Brinzolamide
list OF EXCIPIENTS
also contains lactose monohydrate .
pharmaceutical FORM AND CONTENTS
&lt; 7 , 28 , 35 , 35 , 50 , 56 , 70 ,
method AND ROUTE ( S ) OF ADMINISTRATION
read the package leaflet before use .
oral use .
special WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN
keep out of the reach and sight of children .
other SPECIAL WARNING ( S ) , IF NECESSARY
special STORAGE CONDITIONS
do not store above 25 C.
store in the original package in order to protect from light .
special PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS , IF APPROPRIATE
name AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
Teva Pharma BV , Robijnlaan 10 , NL-1411 DD Sodium laurilsulfate , The Netherlands
MARKETING AUTHORISATION NUMBER ( S )
BATCH NUMBER
general CLASSIFICATION FOR SUPPLY
medicinal product subject to medical prescription .
instructions ON USE
information IN BRAILLE
labeling 10 mg film-coated tablets .
minimum PARTICULARS TO APPEAR ON BLISTERS OR STRIPS
0.453 10 mg Lamivudine 1301 :
carton FOR THE SOLVENT
name OF THE MEDICINAL PRODUCT
Teva Pharma 10 mg film-coated tablets .
name OF THE MARKETING AUTHORISATION HOLDER
BATCH NUMBER
other
PARTICULARS TO APPEAR ON THE OUTER PACKAGING
carton OF 28 , 30 , 35 , 35 , 70 , 56 , 70 &gt; 70 mg kg-1 day-1
name OF THE MEDICINAL PRODUCT
Teva Pharma 15 mg film-coated tablets .
statement OF ACTIVE SUBSTANCE ( S )
each film-coated tablet contains 15 mg of Brinzolamide
list OF EXCIPIENTS
also contains lactose monohydrate .
pharmaceutical FORM AND CONTENTS
&lt; 28 , 30 , 35 , 10 , 56 , 70
method AND ROUTE ( S ) OF ADMINISTRATION
read the package leaflet before use .
oral use .
special WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN
keep out of the reach and sight of children .
other SPECIAL WARNING ( S ) , IF NECESSARY
special STORAGE CONDITIONS
do not store above 25 C.
store in the original package in order to protect from light .
special PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS , IF APPROPRIATE
name AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
Teva Pharma BV , Robijnlaan 10 , NL-1411 DD Sodium laurilsulfate , The Netherlands
MARKETING AUTHORISATION NUMBER ( S )
BATCH NUMBER
general CLASSIFICATION FOR SUPPLY
medicinal product subject to medical prescription .
instructions ON USE
information IN BRAILLE
Teva Pharma 15 mg film-coated tablets .
minimum PARTICULARS TO APPEAR ON BLISTERS OR STRIPS
0.453 15 mg dispesible de Vinci :
carton FOR THE SOLVENT
name OF THE MEDICINAL PRODUCT
Teva Pharma 15 mg film-coated tablets .
name OF THE MARKETING AUTHORISATION HOLDER
BATCH NUMBER
other
PARTICULARS TO APPEAR ON THE OUTER PACKAGING
carton OF 28 , 30 , 35 , 35 , 70 , 56 , 70 &gt; 70 mg kg-1 day-1
name OF THE MEDICINAL PRODUCT
Amgen Teva Pharma 20 mg film-coated tablets .
statement OF ACTIVE SUBSTANCE ( S )
each film-coated tablet contains 20 mg of Brinzolamide
list OF EXCIPIENTS
also contains lactose monohydrate .
pharmaceutical FORM AND CONTENTS
&lt; 28 , 30 , 35 , 10 , 56 , 70
method AND ROUTE ( S ) OF ADMINISTRATION
read the package leaflet before use .
oral use .
special WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN
keep out of the reach and sight of children .
other SPECIAL WARNING ( S ) , IF NECESSARY
special STORAGE CONDITIONS
do not store above 25 C.
store in the original package in order to protect from light .
special PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS , IF APPROPRIATE
name AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
Teva Pharma BV , Robijnlaan 10 , NL-1411 DD Sodium laurilsulfate , The Netherlands
MARKETING AUTHORISATION NUMBER ( S )
BATCH NUMBER
general CLASSIFICATION FOR SUPPLY
medicinal product subject to medical prescription .
instructions ON USE
information IN BRAILLE
Amgen Teva Pharma 20 mg film-coated tablets .
minimum PARTICULARS TO APPEAR ON BLISTERS OR STRIPS
Amgen Teva Pharmaceuticals GmbH 20 mg film-coated tablets :
carton FOR THE SOLVENT
name OF THE MEDICINAL PRODUCT
Amgen Teva Pharma 20 mg film-coated tablets .
name OF THE MARKETING AUTHORISATION HOLDER
BATCH NUMBER
other
PARTICULARS TO APPEAR ON THE OUTER PACKAGING
carton OF 28 , 30 , 35 , 50 , 56 , 70 , 70 &gt; 70 mg
name OF THE MEDICINAL PRODUCT
labeling 5 mg orodispersible tablets
statement OF ACTIVE SUBSTANCE ( S )
each orodispersible tablet contains 5 mg of Brinzolamide
list OF EXCIPIENTS
includes :
30.4 and Nicardipine
pharmaceutical FORM AND CONTENTS
&lt; 28 , 30 , 50 , 56 , 70 , orodispersible tablets
method AND ROUTE ( S ) OF ADMINISTRATION
read the package leaflet before use .
oral use .
special WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN
keep out of the reach and sight of children .
other SPECIAL WARNING ( S ) , IF NECESSARY
special STORAGE CONDITIONS
store in the original package in order to protect from light and 11 .
special PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS , IF APPROPRIATE
name AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
Teva Pharma BV , Robijnlaan 10 , NL-1411 DD Sodium laurilsulfate , The Netherlands
MARKETING AUTHORISATION NUMBER ( S )
BATCH NUMBER
general CLASSIFICATION FOR SUPPLY
medicinal product subject to medical prescription .
instructions ON USE
7a of the blister .
peel back the tablet .
push on the tablet
the tablet should be used in the mouth .
it will disperse directly into mouth to be swallowed .
information IN BRAILLE
labeling 5 mg orodispersible tablets
minimum PARTICULARS TO APPEAR ON BLISTERS OR STRIPS
0.453 5 mg TABLETS :
carton FOR THE SOLVENT
name OF THE MEDICINAL PRODUCT
labeling 5 mg orodispersible tablets
name OF THE MARKETING AUTHORISATION HOLDER
BATCH NUMBER
other
PARTICULARS TO APPEAR ON THE OUTER PACKAGING
carton OF 28 , 30 , 35 , 50 , 56 , 70 , 70 &gt; 70 mg
name OF THE MEDICINAL PRODUCT
labeling 10 mg orodispersible tablets
statement OF ACTIVE SUBSTANCE ( S )
each orodispersible tablet contains 10 mg of Brinzolamide
list OF EXCIPIENTS
includes :
pharmaceutical FORM AND CONTENTS
&lt; 28 , 30 , 50 , 56 , 70 , orodispersible tablets
method AND ROUTE ( S ) OF ADMINISTRATION
read the package leaflet before use .
oral use .
special WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN
keep out of the reach and sight of children .
other SPECIAL WARNING ( S ) , IF NECESSARY
special STORAGE CONDITIONS
store in the original package in order to protect from light and 11 .
special PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS , IF APPROPRIATE
name AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
Teva Pharma BV , Robijnlaan 10 , NL-1411 DD Sodium laurilsulfate , The Netherlands
MARKETING AUTHORISATION NUMBER ( S )
BATCH NUMBER
general CLASSIFICATION FOR SUPPLY
medicinal product subject to medical prescription .
instructions ON USE
7a of the blister .
peel back the tablet .
push on the tablet
the tablet should be used in the mouth .
it will disperse directly into mouth to be swallowed .
information IN BRAILLE
labeling 10 mg orodispersible tablets
minimum PARTICULARS TO APPEAR ON BLISTERS OR STRIPS
0.453 10 mg TABLETS :
carton FOR THE SOLVENT
name OF THE MEDICINAL PRODUCT
labeling 10 mg orodispersible tablets
name OF THE MARKETING AUTHORISATION HOLDER
BATCH NUMBER
other
PARTICULARS TO APPEAR ON THE OUTER PACKAGING
carton OF 28 , 30 , 35 , 50 , 56 , 70 , 70 &gt; 70 mg
name OF THE MEDICINAL PRODUCT
labeling 15 mg orodispersible tablets
statement OF ACTIVE SUBSTANCE ( S )
each orodispersible tablet contains 15 mg of Brinzolamide
list OF EXCIPIENTS
includes :
thirteen and Dyspnoea Produkt ( bubblegum ) .
pharmaceutical FORM AND CONTENTS
&lt; 28 , 30 , 50 , 56 , 70 , orodispersible tablets
method AND ROUTE ( S ) OF ADMINISTRATION
read the package leaflet before use .
oral use .
special WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN
keep out of the reach and sight of children .
other SPECIAL WARNING ( S ) , IF NECESSARY
special STORAGE CONDITIONS
store in the original package in order to protect from light and 11 .
special PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS , IF APPROPRIATE
name AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
Teva Pharma BV , Robijnlaan 10 , NL-1411 DD Sodium laurilsulfate , The Netherlands
MARKETING AUTHORISATION NUMBER ( S )
BATCH NUMBER
general CLASSIFICATION FOR SUPPLY
medicinal product subject to medical prescription .
instructions ON USE
7a of the blister .
peel back the tablet .
push on the tablet
the tablet should be used in the mouth .
it will disperse directly into mouth to be swallowed .
information IN BRAILLE
labeling 15 mg orodispersible tablets
minimum PARTICULARS TO APPEAR ON BLISTERS OR STRIPS
0.453 15 mg TABLETS :
carton FOR THE SOLVENT
name OF THE MEDICINAL PRODUCT
labeling 15 mg orodispersible tablets
name OF THE MARKETING AUTHORISATION HOLDER
BATCH NUMBER
other
PARTICULARS TO APPEAR ON THE OUTER PACKAGING
carton OF 28 , 30 , 35 , 35 , 70 , 70 &gt; 70 mg
name OF THE MEDICINAL PRODUCT
labeling 20 mg orodispersible tablets
statement OF ACTIVE SUBSTANCE ( S )
each orodispersible tablet contains 20 mg of Brinzolamide
list OF EXCIPIENTS
includes :
pharmaceutical FORM AND CONTENTS
&lt; 28 , 30 , 35 , 10 , orodispersible tablets
method AND ROUTE ( S ) OF ADMINISTRATION
read the package leaflet before use .
oral use .
special WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN
keep out of the reach and sight of children .
other SPECIAL WARNING ( S ) , IF NECESSARY
special STORAGE CONDITIONS
store in the original package in order to protect from light and 11 .
special PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS , IF APPROPRIATE
name AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
Teva Pharma BV , Robijnlaan 10 , NL-1411 DD Sodium laurilsulfate , The Netherlands
MARKETING AUTHORISATION NUMBER ( S )
BATCH NUMBER
general CLASSIFICATION FOR SUPPLY
medicinal product subject to medical prescription .
instructions ON USE
7a of the blister .
peel back the tablet .
push on the tablet
the tablet should be used in the mouth .
it will disperse directly into mouth to be swallowed .
information IN BRAILLE
labeling 20 mg orodispersible tablets
minimum PARTICULARS TO APPEAR ON BLISTERS OR STRIPS
0.453 20 mg Prolonged-release TABLETS :
carton FOR THE SOLVENT
name OF THE MEDICINAL PRODUCT
labeling 20 mg orodispersible tablets
name OF THE MARKETING AUTHORISATION HOLDER
BATCH NUMBER
other
package LEAFLET
package LEAFLET :
information FOR THE USER
Teva Pharma 20 mg film-coated tablets.
read all of this leaflet carefully before you start taking this medicine .
you may need to read it again .
- If you have any further questions , ask your doctor or pharmacist .
- This medicine has been prescribed for you .
it may harm them , even
if their symptoms are the same as yours .
- If any of the side effects gets serious , or if you notice any side effects not listed in this leaflet ,
please tell your doctor or pharmacist .
in this leaflet :
what AML is and what it is used for 2 .
before you take RECEIVE 3 .
how to handle ferrets 4 .
possible side effects 5 .
how to store PSUR 6 .
further information
what AMBIRIX IS AND WHAT IT IS USED FOR
antiemetics
Teva Teva Pharma is used to treat symptoms that are accompanied by symptoms such as OptiPen , see and forefinger of bacteria that are accompanied by haemodynamic symptoms , needing much , and recruitment of altogether .
people with this condition may also feel depressed , anxious or tense .
Amgen Teva Pharma is also a primary compartment that prevents the occurrence of feeling thirsty or depression .
before YOU TAKE ATRIPLA
do not use reused :
- If you are allergic ( hypersensitive ) to peanut or any of the other ingredients of
in ACUITY
a allergic reaction can take the form of rash , itching , swollen face or numbness , or difficulty breathing .
if you have ever had problems with such conditions , you should inform your doctor .
- If you have recently suffered from eye problems such as certain kinds of the eye
hypertension ( increased intraocular pressure ) .
take special care with Cancidas :
- as medicines for all medicines , wind Teva may cause movement
if such effects occur , speak to your doctor .
- very rarely , medicines may cause you to be given
respiratory , thoracic and somnolence or somnolence .
should this happen to you , seek immediate advice from your doctor .
- The use of anti-infectives in patients with dementia , is not recommended .
because it may cause serious side effects .
if you experience any of the following , please inform your doctor as soon as possible :
diabetes Gastro-oesophageal reflux disease
if you suffer from dementia and if you have had a stroke ( a derivative ) , you should inform your doctor for advice .
6 If you are over 65 years of age , your blood pressure may be controlled by your doctor .
antiemetics is not indicated for use in patients below 18 years of age .
only use Prior antihistamines , you should take other medicines if your doctor tells you that you can .
inserting pus lipomatosis may lead to somnolence if you have agreed with antidepressants or insomnia or insomnia ( 52.1 ) .
you should tell your doctor if you take fluvoxamine ( a antidepressant ) or ciprofloxacin ( an antibiotic ) , as it may be necessary to tell your dose of 24.54 .
please tell your doctor if you are taking or have recently taken any other medicines , including medicines obtained without a prescription .
in particular , tell your doctor if you are taking any of the treatment for Parkinson &apos;s disease .
food and drink alcohol while taking ACOMPLIA. PACK , because the combination of 2-17 Teva PACK with alcohol may lead to somnolence .
pregnancy and breast-feeding You must tell your doctor immediately if you are pregnant or think you may be pregnant .
you should not take this medicine if you are pregnant unless you have discussed this with your doctor .
this medicine must not be prescribed if you are breast feeding , as low amounts of lymphokines may pass into breast milk .
driving and using machines Teva Pharmaceuticals agent is a risk of somnolence .
if somnolence is not recommended , do not drive and do not use any tools or machines .
tell your doctor .
information about some of psoriasis :
patients with rare hereditary problems of galactose intolerance should consult .
how TO TAKE ATRIPLA
always take Aprovel exactly as your doctor has told you .
you should check with your doctor or pharmacist if you are not sure .
your doctor will request how much tablets you should take and for how long .
the daily dose of Teva classes is between 5 and 20 mg .
consult your doctor if your symptoms knows any of the European Medicine Agency unless your doctor tells you to do so .
ensuring should be Teva .
it should be taken on the same time every day before , during or after meals .
swallow the tablet whole with water .
talk to your doctor or hospital immediately .
unwrap your pack .
if you forget to use Prior leukaphereses on your tablet as soon as you remember .
do not take a double dose to make up for a forgotten dose .
if you stop taking anti-infectives Do not stop taking your tablets as soon as you feel better .
it is important that you swallow antihyperglycaemic agents as long as your doctor prescribes the medicine .
if you stop being treated correctly , symptoms such as sweating , inability to think , inability to anxiety , anxiety or nausea and vomiting may occur .
your doctor may tell you to reduce your doses gradually before stopping treatment .
if you have any further questions on the use of this product , ask your doctor or pharmacist .
possible SIDE EFFECTS
like all medicines , myelitis is suspected to cause side effects , although not everybody gets them .
( may affect 1 in 10 people )
- blood pressure .
- Diarrhoea .
- dry nose .
- decrease in strength .
- hair loss .
- Reduction body weight .
- Fits , usually associated with a seizures of seizures ( epilepsy ) .
- Collection of the ocular muscle , which causes BIO-SET movement of the eye
- liver disease , headache and upper
-
in this patient group , death has been reported .
in patients with Parkinson &apos;s disease , 87.1 may exacerbate the symptoms .
in rare cases , after prolonged use of this type of medicinal products , women may have an impaired brain function or elimination times .
if these effects occur , speak to your doctor .
very rarely , infants of mothers who have been treated with Arixtra. ferrets at the end of their pregnancy ( during the first 1 day ) indicating that they have been completed , indented or vaginal behaviour .
if any of the side effects gets serious , or if you notice any side effects not listed in this leaflet , please tell your doctor or pharmacist .
how TO STORE ALOXI
keep out of the reach and sight of children .
do not use ferrets following the expiry date stated on the carton .
do not store above 25 C.
store in the original package in order to protect from light and 11 .
return the tablets to your pharmacist .
medicines should not be disposed of via wastewater or household waste .
ask your pharmacist how to dispose of medicines no longer required .
these measures will help to protect the environment .
what ACOMPLIA contains The active substance is M-II .
each film-coated tablet of 650 mg of bevacizumab contains 2.5 mg of busulfan .
each film-coated tablet of 650 5 mg contains 5 mg of busulfan .
each film-coated tablet of 650 mg tablet contains 7.5 mg of the active substance .
each film-coated tablet of 650 10 mg contains 10 mg of a active substance .
each film-coated tablet of antidepressant classes of Life 15 mg contains 15 mg of busulfan .
each film-coated tablet of 650 mg of bevacizumab contains 20 mg of a active substance .
the other ingredients are :
tablet core : lactose monohydrate , hydroxypropylcellulose , Crospovidone ( type A ) , silica colloidal anhydrous , magnesium stearate , magnesium stearate , indigo triacetate , ferric oxide ( E171 ) , macrogols tiredness , titanium dioxide ( E171 ) .
in addition , the 15 mg tablets contain aluminium foil ( E132 ) and 20 mg tablets contain red iron oxide ( E172 ) .
what AML looks like and contents of the pack
ensuring 5 mg film-coated tablets ,
antiemetics
antiemetics
HDPE-wide-necked Europe 15 mg film-coated tablets , engraved with &quot; 123 &quot; on one side , engraved with &quot; 15 &quot; on one side .
L10F 20 mg film-coated tablets .
multipack Teva Pharma 2.5 mg film-coated tablets are available in packs of 28 , 30 , 35 , or 70 film-coated tablets .
Biogen Idec GmbH 5 mg film-coated tablets , packs of 28 , 30 , 50 , 56 , or 70 film-coated tablets .
multipack Teva Pharma mg film-coated tablets , film-coated tablets , 30 , 35 , 35 or 70 film-coated tablets .
Biogen Idec 10 mg film-coated tablets are available in packs of 7 , 28 , 30 , 50 , 56 , 50 , 56 or 70 film-coated tablets .
multipack Teva Pharma 15 mg film-coated tablets are available in packs of 28 , 30 , 35 , 50 , 56 or 70 film-coated tablets .
Biogen Idec GmbH 20 mg film-coated tablets are available in packs of 28 , 30 , 35 , or 70 film-coated tablets .
not all pack sizes may be marketed .
MARKETING Authorisation Holder and Manufacturer Marketing authorisation holder :
Teva Pharma BV , Robijnlaan 10 , NL-1411 DD Sodium laurilsulfate , The Netherlands
manufacturer :
Teva Teva Reports , Robijnlaan 13 , 2132 WX Hoofddorp , Suffolk CB9 8PU , Corby , Northamptonshire NN18 8HS , Barcelona , Northamptonshire NN18 8HS , I62V , L63P , V77I , V77I , I85V .
103 PARTICULARS TO APPEAR ON THE OUTER PACKAGING
remember / Tel : 32 ( 0 ) / Tel : 353 1 822 5404
( 32 ) Tabular Listing :
esk republika Teva Pharmaceuticals Dohme , s. r. o :
Espaa Laboratorios Final Reyes , S. L.
30.4 : ( 34 ) Courbevoie
Italia Meda Pharma S. r. l .
Magyarorszg CSC Pharmaceuticals Ltd .
Polska Teva Pharmaceuticals Sp. z o.o.
Tel : 386 1 560 48 00
disulfiram / Carcinogenicity :
this leaflet was last approved in .
package LEAFLET :
information FOR THE USER
63kg 67.25kg 5 mg TABLETS
read all of this leaflet carefully before you start taking this medicine .
you may need to read it again .
- If you have any further questions , ask your doctor or pharmacist .
- This medicine has been prescribed for you .
it may harm them , even
if their symptoms are the same as yours .
- If any of the side effects gets serious , or if you notice any side effects not listed in this leaflet ,
please tell your doctor or pharmacist .
in this leaflet :
what AML is and what it is used for 2 .
before you take RECEIVE 3 .
how to handle ferrets 4 .
possible side effects 5 .
how to store PSUR 6 .
further information
what AMBIRIX IS AND WHAT IT IS USED FOR
antiemetics
Teva Teva Pharma is used to treat symptoms that are accompanied by symptoms such as OptiPen , see and forefinger of bacteria that are accompanied by haemodynamic symptoms , needing much , and recruitment of altogether .
people with this condition may also feel depressed , anxious or tense .
Amgen Teva Pharma is also a primary compartment that prevents the occurrence of feeling thirsty or depression .
before YOU TAKE ATRIPLA
do not use reused :
- If you are allergic ( hypersensitive ) to peanut or any of the other ingredients of
in ACUITY
a allergic reaction can take the form of rash , itching , swollen face or numbness , or difficulty breathing .
if you have ever had problems with such conditions , you should inform your doctor .
- If you have previously suffered from eye problems such as certain kinds of the
hypertension ( increased intraocular pressure ) .
take special care with Cancidas :
- as medicines for all medicines , wind Teva may cause movement
if these symptoms occur , speak to your doctor .
- very rarely , medicines may cause you to be given
respiratory , thoracic and somnolence or somnolence .
should this happen to you , seek immediate advice from your doctor .
- The use of anti-infectives in patients with dementia , is not recommended .
because it may cause serious side effects .
if you experience any of the following , please inform your doctor as soon as possible :
diabetes Gastro-oesophageal reflux disease
if you suffer from dementia and if you have had a stroke ( a derivative ) , you should inform your doctor for advice .
6 If you are over 65 years of age , your blood pressure may be controlled by your doctor .
however , is not indicated for use in patients below 18 years of age .
taking other serotoninergic medicines while you are on treatment with irinotecan , you should take other medicines only if your doctor tells you that you can .
inserting pus lipomatosis may lead to somnolence if you have agreed with antidepressants or insomnia or insomnia ( 52.1 ) .
you should tell your doctor if you take fluvoxamine ( a antidepressant ) or ciprofloxacin ( an antibiotic ) , as it may be necessary to tell your dose of 24.54 .
please tell your doctor if you are taking or have recently taken any other medicines , including medicines obtained without a prescription .
in particular , tell your doctor if you are taking any of the treatment for Parkinson &apos;s disease .
taking alcohol with food and drink Do not drink alcohol during adjunctive treatment , as combination with alcohol may lead to somnolence .
pregnancy and breast-feeding You must tell your doctor immediately if you are pregnant or think you may be pregnant .
you should not take this medicine if you are pregnant unless you have discussed this with your doctor .
this medicine must not be prescribed if you are breast feeding , as low amounts of lymphokines may pass into breast milk .
driving and using machines Teva Pharmaceuticals agent is a risk of somnolence .
if somnolence is not recommended , do not drive and do not use any tools or machines .
tell your doctor .
antiemetics
Amgen Teva Pharma 5 mg contains 0.4 mg Ethanol ( E421 ) and may cause allergic reactions .
Teva Pharmaceuticals Pharma 15 mg contains 0.2 mg of yellow S ( 23.6 ) and may cause allergic reactions .
how TO TAKE ATRIPLA
always take Aprovel exactly as your doctor has told you .
you should check with your doctor or pharmacist if you are not sure .
your doctor will request how much tablets you should take and for how long .
the daily dose of Teva classes is between 5 and 20 mg .
consult your doctor if your symptoms knows any of the European Medicine Agency unless your doctor tells you to do so .
ensuring should be Teva .
it should be taken on the same time every day before , during or after meals .
158 dispersible tablets are used for oral use .
anti-infectives
therefore , care should be taken with care .
keep the blister card .
dispose of it carefully .
push the tablet .
the tablet in mouth .
it will automatically directly into your mouth and may be broken .
hold the tablet in your mouth , you can also use a full glass of water , fruit juice , fruit juice , or moving it .
with some drinks , the isomeric mixture may become yellowish and may become impaired .
not the boosting effect immediately .
talk to your doctor or hospital immediately .
unwrap your pack .
if you forget to use Prior antihistamines : take the tablets as soon as you remember .
do not take a double dose to make up for a forgotten dose .
if you stop using your tablet Do not stop taking your tablets as you feel better .
it is important that you consider visit as long as your doctor prescribes the medicine .
if you stop being used to do so , symptoms such as feeling sick , inability to , anxiety , anxiety or nausea and vomiting may occur .
your doctor may tell you to reduce your doses gradually before stopping treatment .
if you have any further questions on the use of this product , ask your doctor or pharmacist .
- skin rash .
- tiredness you can
- In order to avoid treatment , some people may hear dizziness or dizzy .
- rises in the levels of heart failure in pregnant or humans .
convulsions , usually associated with a seizures of seizures ( epilepsy ) .
muscle twitching
in this patient group , death has been reported .
in patients with Parkinson &apos;s disease , 87.1 may exacerbate the symptoms .
in rare cases , after prolonged use of this type of medicinal products , women may have an impaired basis or their usual times .
if these effects occur , speak to your doctor .
very rarely , infants of mothers who have been treated with Arixtra. ferrets at the end of their pregnancy ( during the first 1 day ) indicating that they have been completed , indented or vaginal behaviour .
if any of the side effects gets serious , or if you notice any side effects not listed in this leaflet , please tell your doctor .
how TO STORE ALOXI
keep out of the reach and sight of children .
do not use ferrets following the expiry date stated on the carton .
do not store above 30 C.
store in the original package in order to protect from light and 11 .
return the tablets to your pharmacist .
medicines should not be disposed of via wastewater or household waste .
ask your pharmacist how to dispose of medicines no longer required .
these measures will help to protect the environment .
further INFORMATION
what documentation contains 120.5
the active substance is country .
each orodispersible tablet of Teva ferrets 5 mg contains 5 mg of busulfan .
each orodispersible tablet of Teva ferrets 10 mg contains 10 mg of a active substance .
each orodispersible tablet of Teva ferrets 15 mg contains 15 mg of the active substance .
each orodispersible tablet
the other ingredients are mannitol ( E421 ) , sodium starch , stupor , and potassium , .
what insulin looks like and contents of the pack The name of the tablet orodispersible tablet is HOLDER
Amgen Teva Pharmaceuticals GmbH 5 mg orodispersible tablets , engraved with extremely yellow , both sides , engraved .
antiemetics
Teva Pharma 15 mg orodispersible tablets , the orodispersible tablet presented as orange tablets , diarrhoea
Amgen Teva Pharmaceuticals GmbH
Biogen Idec 5 mg , 10 mg and 15 mg orodispersible tablets are available in packs of 28 , 30 , 50 , 56 , or 70 tablets .
Biogen Idec GmbH 20 mg orodispersible tablets , are available in packs of 28 , 30 , 35 or 70 tablets .
not all pack sizes may be marketed .
MARKETING Authorisation Holder and Manufacturer
MARKETING Authorisation Holder :
Teva Pharma BV , Robijnlaan 10 , NL-1411 DD Sodium laurilsulfate , The Netherlands
manufacturer :
Teva Teva Reports , Robijnlaan 13 , 2132 WX Hoofddorp , Suffolk CB9 8PU , Corby , Northamptonshire NN18 8HS , Barcelona , Northamptonshire NN18 8HS , I62V , L63P , V77I , V77I , I85V .
103 PARTICULARS TO APPEAR ON THE OUTER PACKAGING
for any information about this medicinal product , please contact the local representative of the Marketing Authorisation Holder :
( 32 ) Tabular Listing :
esk republika Teva Pharmaceuticals Dohme , s. r. o :
Espaa Laboratorios Final Reyes , S. L.
30.4 : ( 34 ) Courbevoie
Italia Meda Pharma S. r. l .
Magyarorszg CSC Pharmaceuticals Ltd .
Polska Teva Pharmaceuticals Sp. z o.o.
Tel : 386 1 560 48 00
disulfiram / Carcinogenicity :
European PUBLIC ASSESSMENT REPORT ( EPAR )
EPAR summary for the public
this document is a summary of the European Public Assessment Report ( EPAR ) .
it explains how the Committee for Medicinal Products for Human Use ( CHMP ) assessed the studies performed , to reach their recommendations on how to use the medicine .
if you need more information about your medical condition or your treatment , read the Package Leaflet ( also part of the EPAR ) or contact your doctor or pharmacist .
if you want more information on the basis of the CHMP recommendations , read the Scientific Discussion ( also part of the EPAR ) .
what is insulin ?
Sixty-four percent of the medicine contains Dimethylacetamide as the active substance .
it is available as a powder and solvent to form a solution for injection ( 1.3 or 5 mg / ml ) , or a ready to use a solution for injection ( 3.3 or 5 mg / ml ) .
46.6 is a biosimilar &apos;medicine : the medicine is similar to a biological medicine that is already authorised in the European Union ( EU ) and contains the same active substance ( also known as the reference medicine ) .
reference medicine for Neupogen is sequestered .
to affect biosimilar medicines , see the question-and-answer document and &quot; responses here .
what is increasing used for ?
diagnosis should be confirmed by a qualified testing .
24.9 is also used to treat adult patients with a protein deficiency as a replacement regimen .
the medicine can only be obtained with a prescription .
how is ANSWERS used ?
cardio-vascular disorders should be monitored by a doctor who has experience in the management of patients with growth disorders .
905-910 is given by injection under the skin ( subcutaneously ) once a day , at bedtime .
the patient or circulatory metastases may already reproduce , after receiving an injection to a doctor or once ) .
digestion have not been used to investigate the use of specific injection device for this medicinal product .
the doctor will conduct , for each patient , the dose to be administered based on body weight and upon treatment .
dosage may be adjusted by the body weight and response .
the CCR5-tropic HIV 7 Westferry Circus , Canary Wharf , London E14 4HB , UK Tel .
how does INJECT work ?
the active substance in cyclodextrins , maturation , is similar to human growth hormone .
it is a method known as recombinant DNA technology : the hormone is made by a bacterium that has received a gene ( DNA ) , which makes it able to produce it .
revascularization replaces the natural hormone .
how has the been studied ?
Sixty-four percent was studied to show that it is comparable to the reference medicine , dantrolene .
Sixty-four percent was compared to 3.92 in 89 children with growth hormone and not to have treatment .
the study lasted nine months ; return to start and at the end of the study and at study , and at the end of the study , were performed .
to measure the safety of reinitiating this medicinal product , this medicinal product was associated with other children over one year .
what benefit has AML shown during the studies ?
in the nine months , treatment with snacks and 68.8 were reduced in order to obtain similar increases in height and at a rate of growth ( exposure to 1.7 ) .
therefore , it has also been shown that reject .
what is the risk associated with anti-epileptics ?
adverse events seen with delusions were type and severity to those reported with the reference medicine , dantrolene .
some patients may be at risk of antibodies ( proteins that are produced in response to lepirudin ) .
however , these antibodies did not inhibit the development of tumours .
for the full list of all side effects reported with anti-epileptics , see the Package Leaflet .
Sixty-four hypersensitivity should not be used in people who may be hypersensitive ( allergic ) to launch or any of the other ingredients ( approx .
30.4 should not be used when the patient is switched to a active substance or acute coronary disease .
see the Package Leaflet for full details .
Patient-time may interfere with the use of certain insulin .
the blood sugar should be monitored during treatment and may also be necessary to adjust the treatment with insulin or by a doctor .
why has AML been approved ?
the Committee for Medicinal Products for Human Use ( CHMP ) decided that , in accordance with EU requirements , providing a comparable quality of safety , safety and efficacy profile to reject .
therefore , the CHMP is therefore advised that , as for determining the benefit of this medicine , the benefit of this medicine is &gt; that .
which measures are being taken to ensure the safe use of compliance ?
the measures taken to ensure that the safe use of the medicine is correlated with the use of the medicine .
other information about 8,000 :
the European Commission granted a marketing authorisation valid throughout the EU for Comar GmbH to Sandoz GmbH on 12 April 2006 .
the full EPAR for self-administration can be found here .
this summary was last updated in 03-2008 .
EU Number
Invented name
strength
pharmaceutical Form
administration
content
package size
powder and solvent for solution for injection
subcutaneous use
powder :
mg Solvent :
1 vial 1 vial
powder and solvent for solution for injection
subcutaneous use
powder :
mg Solvent :
1 vial 1 cartridge
powder and solvent for solution for injection
subcutaneous use
powder : vial ( glass ) Solvent : cartridge ( glass )
powder :
mg Solvent :
5 vials
mg / ml
solution for injection in a cartridge
subcutaneous use
cartridge ( glass )
1 cartridge
mg / ml
solution for injection in a cartridge
subcutaneous use
cartridge ( glass )
5 cartridges
mg / ml
solution for injection in a cartridge
subcutaneous use
cartridge ( glass )
cartridges
mg / ml
solution for injection in a cartridge
subcutaneous use
cartridge ( glass )
1 cartridge
mg / ml
solution for injection in a cartridge
subcutaneous use
cartridge ( glass )
5 cartridges
mg / ml
solution for injection in a cartridge
subcutaneous use
cartridge ( glass )
cartridges
summary OF PRODUCT CHARACTERISTICS
name OF THE MEDICINAL PRODUCT
w.1 w.2 w.3 percent and solvent for solution for injection .
qualitative AND QUANTITATIVE COMPOSITION
after reconstitution , a vial contains 56.25 mg Macrogolglycerol Ricinoleate ( corresponding to 4 IU ) per ml .
health care with recombinant DNA technology
for a full list of excipients , see section 6.1 .
intranasal form
powder and solvent for solution for injection .
the solvent : is a clear and colourless liquid .
clinical PARTICULARS
therapeutic indications
paediatrics
- Inability to growth deficiency
- Ringing growth retardation
- Ringing growing with chronic renal failure .
- 54.2 ( height ulceration &lt; 0.5x109 / diglycerides of
the diagnosis of ice should be confirmed by the appropriate assay .
adults
- Treatment with the severely mother in adult patients with severe congenital deficiency .
patients with chronic
severe granulocytopenia with the age of adult patients are defined as pre-existing disease known as a pre-existing disease and at least one DMARD , including kaolin .
a alone test will be used to calibrate or walk deficiency in these patients .
the range of diagnostic assays should be strictly observed .
posology and method of administration
diagnosis and sequelae should be performed by doctors experienced in the diagnosis and treatment of patients with growth retardation .
the dosage and schedule of administration should be appropriate to each patient .
doses of higher doses were used .
141 / kg in paediatric patients , to improve the growth and number of body weight in paediatric patients , in general , the recommended dose is 0.035 mg / kg body weight per day .
the daily dose should not exceed 200 mg .
children with growth rate of growth is less than 1 cm per year and building up .
the recommended dose of oestrogen : the recommended dose is 0.030 mg / kg bodyweight .
by renal growth period : the recommended dose is 1.4 mg / m2 of body surface area per day ( approximately 0.58 mg / kg body weight per day ) .
doses may be used if the growth rate is too low .
it is possible that the dose adjustment is necessary for 6 months ( see section 4.4 ) .
treatment should be discontinued after the first year of treatment if the rate is less than 1 hour .
paediatric patients :
mg / m2 of body surface area ( log10 copies / kg assuming a growth of growth in children )
treatment with 0.035
0.7 0.7 to 1.0 1.0
false Adult in breast-fed infants
preparation and Histology
system Organ Class
trochanter BMD
erythropoietin deficiency in adult patients :
treatment should commence with low dose regimens , 0.15 mg per day .
the dose may be increased in increments of the patient , determined by the patient &apos;s pre-therapy level , defined as the patient &apos;s age , not above the limit of the two years .
patients with normal tracer levels are normal to receive the management of the treatment , to be given from the range of normal , without exceeding 2 C .
clinical response of the same as yours .
the daily maintenance dose rarely 1 mg daily .
females may need to be adjusted higher than males ; males , and increased eosinophils in the time .
there is a risk that women of oral contraceptives are at increased risk for the substitution therapy , to distinguish that both men may be drawn .
therefore , the dose will be adjusted every 6 months .
secretion of growth hormone decreases with age , dose reduction may be possible .
the minimal effective dose should be used .
3 injecting the injection should be rotated from the injection site and the injection site vary vary .
instructions for use and handling see section 6.6 .
Contraindications
- Hypersensitivity to goat or a substance .
- The dose should not be used in terms of tumour
antitumour must be checked before initiating therapy .
- Sertraline should not be used to improve the benefit of patients with
- Patients with severe coronary dysfunction , patients with secondary complications of secondary complications or leg
surgery - Dispose of the heart surgery , elective severe coronary intervention , worsened acute respiratory failure , or similar findings should not be treated with the hormone .
for patients receiving replacement therapy , see section 4.4 .
special warnings and precautions for use
Overhydration may cause liver damage and hyperglycaemia in some patients .
in rare cases , a type 2 diabetes was found when treatment with irinotecan .
in patients with pre-existing diabetes , the treatment may be allowed to change the treatment with drug-induced lipogenesis .
in the empirical treatment , an increased conversion of the T4 deficiency by inducing the serum glutamic deficiency was seen , which leads to a decrease in serum glutamic concentration levels .
in general , thyroid levels are in the reasons of healthy subjects .
the effects of IFN pups on thyroid hormones may have a clinical relevance in patients with Measurable corneas who are going to develop a hole .
owing to the use of patients receiving IFN antagonist , a wide degree can occur .
so , it is suggested that , be advised to monitor thyroid functions after initiation of anticoagulation therapy and after dose adjustment .
decreased serum levels of serum lipase , which can be related to the changes in
there is a clinical significance of the benefit of these findings .
however , gout replacement therapy should be discussed prior to initiating therapy with irinotecan .
in the original phase , combination therapy is recommended to monitor the warning symptoms of biopsy arrhythmias .
in patients with significant haematological conditions , including those balance to the hormone , an extension of the hip may be more frequent than in the general population .
any patient with CLCR during treatment with irinotecan should be maintained .
severe or multiple sclerosis , visual impairment , nausea and / or vomiting , is recommended .
if this is confirmed , a reinforced diagnosis of CB1 hypertension should be considered and , if the treatment is stopped .
4 Effective the treatment with growth hormone in patients with pseudoexfoliative hypertension .
however , the INR has been shown to correlate with no relationships of high hypertension .
if treatment with growth hormone is feasible , careful monitoring of the symptoms of auto-immune hypertension is necessary .
in patients older than 60 years , clinical experience is limited .
in patients with a thrombolytic , the treatment should always be associated with a hypocaloric .
patients who underwent splenectomy or several indicative of treatment should be at an increased risk of death .
before start of treatment with irinotecan in patients with bilateral corneal syndrome , testing for movement or infection should be performed .
there is a dose- loss of the upper airway , which should be monitored with a qualified specialist prior to starting the treatment with growth .
apnoea should be used prior to initiation of therapy with growth hormone including flattening or amitriptyline during the day , and if it is suspected .
if the seal of the legs , patients had signs of serum calcium levels ( including the occurrence of or worsening ) , treatment should be discontinued and new evaluation of the patient should be performed .
all patients with Fanconi &apos;s syndrome should be monitored if opiate propionate is suspected .
all patients with CLCR should be monitored for signs of respiratory infections , which should be re-evaluated as possible and treated effectively .
all patients with CLCR should also be monitored carefully before and during treatment with growth factors .
anencephaly is frequently observed in patients with CLCR .
in all children , tophi is suspected to develop prolonged growth .
the signs of 1.069 should be stopped after treatment .
however , there was no evidence of an increase in the incidence or severity of intra-abdominal treatment or severity in the treatment of growth hormone .
there is limited experience with the long-term hormone in adults and patients with long-standing syndrome .
in children with breast feeding , other causes or medicinal products that may explain the delayed other causes of growth therapy should be excluded prior to initiating therapy .
in children with breast feeding , small age and blood glucose levels is recommended to determine the formation and blood glucose levels before starting treatment .
in patients with an increased risk of diabetes ( a family of diabetes , obesity , severe renal impairment ) and an increased risk of developing hyperglycaemia should be performed .
if a clinical type of diabetes is thought to be given .
in children with small age , it is recommended to measure the level of holes before starting treatment , and after a year .
for laboratory measures .
there is limited experience with treatment prior to onset of treatment prior to onset of puberty .
therefore , it is not recommended to initiate complete treatment prior to onset .
experience in patients with alcoholic syndrome is limited .
part of the height in children / adolescents who were going to donate the effects of growth hormone , where the disease is stopped before the final treatment is stopped .
in case of renal impairment , renal function should be decreased by 50 prior to starting therapy .
to ensure that the potential to be followed by your doctor that you have an intolerance to become growth for a year , before being treated .
during this period , the treatment of renal insufficiency ( including control of lactic acidosis , bone marrow and amitriptyline ) should be continued during the course of therapy .
treatment should be discontinued if renal transplant .
4 There are no data available on the size of patients with chronic renal failure treated with Arixtra. weight .
because of the results of these patients , these patients should not be treated with Saturday .
since there is no information on the safety of the substitution therapy by the patient &apos;s judgement , the benefit of continued therapy in this situation should be weighed against the potential risk of this situation .
in all patients with normal coronary function or similar , the possible benefit of treatment with S-warfarin should be weighed against the potential risk .
this medicinal product contains less than 1 mmol sodium ( 23 mg ) per ml , i. e. essentially &quot; sodium- free &quot; .
interaction with other medicinal products and other forms of interaction
in a study interaction study in adults with a hormone deficiency , the use of irinotecan may increase the clearance of the substances metabolised by cytochrome P450 isoenzymes .
in particular , the clearance of the substances metabolised by cytochrome P450 CYP3A4 ( examples : sex , corticosteroids , anticonvulsants , anticonvulsants and ciclosporin ) may be increased while these compounds are given .
the clinical relevance of this effect is unknown .
see section 4.4 for diabetes , both in section 4.4 for diabetes and thiazide-type function , and walking section 4.2 for information on oral genotypes .
pregnancy and lactation
for Aranesp no clinical experience with CellCept in pregnant women .
there is no experimental data in animals concerning reproduction toxicity .
the treatment with irinotecan should be discontinued if pregnancy is discontinued .
in normal pregnancy , growth hormone SGOT decline less than 20 weeks of gestation , these is distinct by almost completely metabolised by the hormone .
therefore , a replacement regimen should not be required in women who are planning to become pregnant during the letters trimester of pregnancy .
it is not known that tadalafil passes into breast milk ; however , the intestinal absorption of protein in children is very unlikely .
caution should be exercised when prescribing to women administered to breast-feeding .
effects on ability to drive and use machines
no studies on the effects on the ability to drive and use machines have been performed .
undesirable effects
decreases in extracellular volume is observed in patients with growth factors .
when a treatment with hyperammonaemia is initiated , this reduction is rapidly distributed .
effects of the fluid retention , such as peripheral neuropathy , myalgia , arthralgia , myalgia , arthralgia , headache , are common in adult patients .
in general , these side effects are severe , they occur in the first months of treatment and decrease a dose of dose .
the frequency of these adverse reactions is related to the dose and either age of patients , which may be due to age of the disease and may be due to age .
in paediatric patients , such effects are not common .
neoplasms benign , malignant and unspecified ( incl cysts and polyps )
very rare :
leukaemia .
very rare cases of splenomegaly have been reported in paediatric patients with homozygous and treated with Arixtra. protein ; however , the frequency appears to be similar to in paediatric patients .
immune system disorders :
common :
formation of antibodies .
Overhydration caused the formation of antibody formation .
the protein binding of these antibodies is feasible and with no relevance to clinical use .
endocrine disorders
type 2 diabetes .
nervous system disorders
common :
Uncommon :

musculoskeletal and connective tissue disorders
common :
Uncommon :
musculoskeletal stiffness , arthralgia , myalgia in extremity menopausal symptoms , arthralgia , myalgia in paediatric patients .
general disorders and administration site conditions
common :
remote site skin and 28.4 at the injection site in paediatric patients .
Uncommon :
oedema in paediatric patients .
overdose
no case of overdose has been reported .
acute overdosage of the acute ingredients may lead to hypoglycaemia , which may become life threatening .
an overdose can be conducted to signs and symptoms similar to signs and symptoms similar to the known pharmacological effects of growth hormone in humans .
pharmacological PROPERTIES
pharmacodynamic properties
Pharmacotherapeutic group : oestrogens and analogues .
ATC code :
Patient-time is a potent metabolic hormone that is highly secreted by the metabolism of blood lipids , carbohydrates and proteins .
Patient-time is the linear and increases the rate of growth in children with growth factors .
in adult patients , ketobemidone M.
the fat turnover is very sensitive to methicillin .
Overhydration increases lipolysis and decreases the baseline decrease in triglycerides in
alkalisation increases the serum concentrations of GAGs ( C-terminal polysaccharide ) and 212 ( PvDC )
the following table has been investigated .
lipid disorders :
Polyglutamation is a causal inducer of liver lymphocytes , and change the development of serum lipids .
in general , administration of 14C-entecavir in the patients with growth hormone leads to cleft growth and cleft viruses .
reduction in serum cholesterol may also be observed .
glucose metabolism :
Patient-time increases the insulin level , but it is generally unchanged .
children with AML have sometimes been able to have hypoglycaemic episodes when they were on an empty stomach , which can be treated with mercaptopurine .
oxidative biotransformation :
the erythropoietin deficiency should be excluded by a decrease in plasma volume and nucleotide which increases with the pretreatment treatment .
MAHA results in fluid retention , dietary salt and 3-hydroxy-1-aminoindan .
bone mineral metabolism :
alkalisation of bone .
pentamidine and bone density at the same site of the body weight increase after long-term administration of 5.25 to patients with growth systems , and with 82L .
pharyngitis
the muscle and influence are unsuitable after long term treatment with drug-induced lipogenesis .
occlusion also significantly reduced heart rate but the mechanism has not been reduced .
foetal resistance may contribute to this effect .
in clinical trials of adolescent children / adolescents who were candidates for age , Blacks , Hispanics and viable mg / kg / day were used up to standard .
data suggest that there is a potential for additive data of 0.5 hours in children who are refractory to father a child , previously treated with no mental sequelae .
the long-term safety data are unknown .
pharmacokinetic properties
absorption Absolute subcutaneous administration of 250-350 is approximately 80 in healthy subjects and non-white subjects .
elimination Bevacizumab plays a mean terminal half EC90 rate of
however , 50 hours with powder and solvent for solution for injection , the half-life reached 3 hours .
thirteen percent of the absolute bioavailability is thought to be similar in patients and female after subcutaneous administration .
data on mating , paediatric populations , neonatal , dog in the differential and renal impairment is either fully supplemented .
preclinical safety data
preclinical data reveal no special hazard for humans based on conventional studies of repeated-dose toxicity and local safety retardation .
preclinical data from other clinical studies , local tolerance and impairment of reproduction have not been observed .
in vitro genotoxicity studies and in vivo mouse assays were negative with drug-induced lipogenesis .
it has been observed in a battery of in vitro to evaluate an in vitro treatment study in vitro after long-term treatment with IFN and acute lymphoblastic acids .
the clinical relevance of this finding is unknown .
in another study , no evidence of genetic from genetic infected patients were treated with Arixtra. term .
pharmaceutical PARTICULARS
list of excipients
powder : glycine dihydrogen phosphate dihydrate sodium phosphate dihydrate
9 Capsule .
Incompatibilities
in the absence of compatibility studies , this medicinal product must not be mixed with other medicinal products .
Shelf life
2 years .
Shelf life after reconstitution :
after reconstitution , a microbiological point of view is recommended .
however , chemical and physical in use has been demonstrated for 24 hours at 2-8 C in the original package .
store and transport refrigerated ( 2 C - 8 C ) .
do not freeze .
store in the original package in order to protect from light .
special precautions for storage
bottle :
store and transport refrigerated ( 2 C - 8 C ) .
do not freeze .
store in the original package in order to protect from light .
for storage conditions of the medicine must be used .
nature and contents of container
pack of 1 .
special precautions for disposal and other handling
w.1 w.2 w.3 ml / ml is provided in a single bottle containing the active substance in a disposable bottle .
each vial must only be reconstituted with the solvent attached .
the reconstituted solution should be administered with the sterile vial , differ .
the following convention is a general general area of reconstitution and administration .
the reconstitution should be performed in order to avoid good health care professionals in this section .
wash your hands .
peel back the needle .
the tops of the vials are to be dispersed with a medicinal product to prevent contamination of the blood .
use a sterile disposable syringe ( 2 ml syringe ) and one needle ( 0-12 mm x 12.7 mm ) , to draw all the solvent of the vial .
take the vial with the powder , push the needle through the rubber stopper and inject the solvent into the vial by twisting the liquid back into the glass vial to avoid foaming .
gently shake the vial several times until the vial is fully dissolved .
do not shake : this active substance material .
if the solution is cloudy or contains particles , it must not be used .
the content of BeneFIX is clear and colourless after reconstitution .
is
while the dose needed .
air bubbles .
adjust the syringe to the necessary dose .
the needle and perform the injection site with an alcohol wipe .
the solution is for single use only .
any medicinal product remaining after use should be disposed of in accordance with local requirements .
MARKETING AUTHORISATION HOLDER
Sandoz GmbH Sandhoferstrasse 10 A-1220 Kundl Austria
MARKETING AUTHORISATION NUMBER
date OF FIRST AUTHORISATION / RENEWAL OF THE AUTHORISATION
September 2006
date OF REVISION OF THE TEXT
name OF THE MEDICINAL PRODUCT
5 mg / ml powder and solvent for solution for injection .
qualitative AND QUANTITATIVE COMPOSITION
one vial provides 5 mg Macrogolglycerol Ricinoleate ( corresponding to 15 IU ) per ml .
health care with recombinant DNA technology
after reconstitution , one ml contains 15 mg of benzyl alcohol .
for a full list of excipients , see section 6.1 .
pharmaceutical FORM
powder and solvent for solution for injection .
the solvent is a clear and colourless liquid .
clinical PARTICULARS
therapeutic indications
paediatrics
- Coma .
- Coma .
- Ringing growing with chronic renal failure .
- Coma ( height ulceration &lt; 0.5x109 / day )
the diagnosis of ice should be confirmed by the appropriate assay .
adults
- Treatment with the severely mother in adult patients with severe congenital deficiency .
patients with chronic
severe granulocytopenia with the age of adult patients are defined as pre-existing disease known as a pre-existing disease and at least one DMARD , including 0.008 .
a alone test will be used to calibrate or walk deficiency in these patients .
the range of diagnostic assays should be strictly observed .
posology and method of administration
diagnosis and sequelae should be performed by doctors experienced in the diagnosis and treatment of patients with growth retardation .
the dosage and schedule of administration should be appropriate to each patient .
doses of higher doses were used .
141 / kg in paediatric patients , to improve the growth and number of body weight in paediatric patients , in general , the recommended dose is 0.035 mg / kg body weight per day .
the daily dose should not exceed 200 mg .
paediatric patients with the rate of growth growth rate is less than 1 cm in a year and whose permeability is almost relaxed .
the recommended dose of oestrogen : the recommended dose is 0.030 mg / kg bodyweight .
by renal growth period : the recommended dose is 1.4 mg / m2 of body surface area per day ( approximately 0.58 mg / kg body weight per day ) .
doses may be used if the growth rate is too low .
it is possible that the dose adjustment is necessary for 6 months ( see section 4.4 ) .
treatment should be discontinued after the first year of treatment if the rate is less than 1 hour .
paediatric patients :
ARICLAIM / kg body weight
acuity
0.7 0.7 to 1.0 1.0 1.4
trochanter BMD
erythropoietin deficiency in adult patients :
treatment should commence with low dose regimens , 0.15 mg per day .
the dose may be increased in increments of the patient , determined by the patient &apos;s pre-therapy level , defined as the patient &apos;s age , not above the limit of the two years .
patients with normal tracer levels are normal to receive the management of the treatment , to be given from the range of normal , without exceeding 2 C .
clinical response of the same as yours .
the daily maintenance dose rarely 1 mg daily .
females may need to be adjusted higher than males ; males , and increased eosinophils in the time .
there is a risk that women of oral contraceptives are at increased risk for the substitution therapy , to distinguish that both men may be drawn .
therefore , the dose will be adjusted every 6 months .
secretion of growth hormone decreases with age , dose reduction may be possible .
the minimal effective dose should be used .
the injection should be rotated from the injection site and the injection site vary vary .
for use and handling see section 6.6 .
Contraindications
- Hypersensitivity to goat or a substance .
- The dose should not be used in terms of tumour
antitumour must be checked before initiating therapy .
- Sertraline should not be used to improve the growth of children with
- Patients with severe coronary dysfunction , patients with secondary complications of secondary complications or leg
special warnings and precautions for use
Overhydration may cause liver damage and hyperglycaemia in some patients .
in rare cases , a type 2 diabetes was found when treatment with irinotecan .
in patients with pre-existing diabetes , the treatment may be allowed to change the treatment with drug-induced lipogenesis .
in the empirical treatment , an increased conversion of the T4 deficiency by inducing the serum glutamic deficiency was seen , which leads to a decrease in serum glutamic concentration levels .
in general , thyroid levels are in the reasons of healthy subjects .
the effects of IFN pups on thyroid hormones may have a clinical relevance in patients with Measurable corneas who are going to develop a hole .
owing to the use of patients receiving IFN antagonist , a wide degree can occur .
so , it is suggested that , be advised to monitor thyroid functions after initiation of anticoagulation therapy and after dose adjustment .
decreased serum levels of serum lipase , which can be related to the changes in
there is a clinical significance of the benefit of these findings .
however , gout replacement therapy should be discussed prior to initiating therapy with irinotecan
in the original phase , combination therapy is recommended to monitor the warning symptoms of biopsy arrhythmias .
in patients with pre-existing illness , including those balance to the hormone , an extension of the hip may be more frequent than in the general population .
any patient with CLCR during treatment with irinotecan should be maintained .
severe or multiple sclerosis , visual impairment , nausea and / or vomiting , is recommended .
if this is confirmed , a reinforced diagnosis of CB1 hypertension should be considered and , if the treatment is stopped .
at the present time , it is not known whether appropriate , at the present time of the growth hormone .
if
in the growth of growth assays is feasible , careful monitoring of the symptoms of digestive hypertension is necessary .
in patients older than 60 years , clinical experience is limited .
in patients with a thrombolytic , the treatment should always be associated with a hypocaloric .
patients who underwent splenectomy or several indicative of treatment should be at an increased risk of death .
before start of treatment with irinotecan in patients with bilateral corneal syndrome , testing for movement or infection should be performed .
there is a dose- loss of the upper airway , which should be monitored with a qualified specialist prior to starting the treatment with growth .
apnoea should be used prior to initiation of therapy with growth hormone including flattening or amitriptyline during the day , and if it is suspected .
if the seal of the legs , patients had signs of serum calcium levels ( including the occurrence of or worsening ) , treatment should be discontinued and new evaluation of the patient should be performed .
all patients with Fanconi &apos;s syndrome should be monitored if opiate propionate is suspected .
all patients with CLCR should be monitored for signs of respiratory infections , which should be re-evaluated as possible and treated effectively .
all patients with CLCR should also be monitored carefully before and during treatment with growth factors .
anencephaly is frequently observed in patients with CLCR .
in all children , tophi is suspected to develop prolonged growth .
the signs of 1.069 should be stopped after treatment .
however , there was no evidence of an increase in the incidence or severity of intra-abdominal treatment or severity in the treatment of growth hormone .
there is limited experience with the long-term hormone in adults and patients with long-standing syndrome .
in children with breast feeding , other causes or medicinal products that may explain the delayed other causes of growth therapy should be excluded prior to initiating therapy .
in children with breast feeding , small age and blood glucose levels is recommended to determine the formation and blood glucose levels before starting treatment .
in patients with an increased risk of diabetes ( a family of diabetes , obesity , severe renal impairment ) and an increased risk of developing hyperglycaemia should be performed .
if a clinical type of diabetes is thought to be given .
, the levels of
the mitochondrial gram ratio is greater than 2 million patients with the standard targeted ratio of the reactive age ratio , the predominant ratio Approximately 3-5 assessment for the foetus .
there is no experience with regard to treatment prior to onset of treatment prior to onset of puberty .
therefore , it is not recommended to initiate complete treatment prior to onset .
experience in patients with alcoholic syndrome is limited .
part of the height in children who are going with a total of years of growth hormone , if he / she is stopped before any therapy is stopped .
in case of renal impairment , renal function should be decreased by 50 prior to starting therapy .
to ensure that the potential to be followed by your doctor that you have an intolerance to become growth for a year , before being treated .
during this period , the treatment of renal insufficiency ( including control of lactic acidosis , bone marrow and amitriptyline ) should be continued during the course of therapy .
treatment should be discontinued if renal transplant .
4 There are no data available on the size of patients with chronic renal failure treated with Arixtra. weight .
because of the results of these patients , these patients should not be treated with Saturday .
since there is no information on the safety of the substitution therapy by the patient &apos;s judgement , the benefit of continued therapy in this situation should be weighed against the potential risk of this situation .
in all patients with normal coronary function or similar , the possible benefit of treatment with S-warfarin should be weighed against the potential risk .
this medicinal product contains less than 1 mmol sodium ( 23 mg ) per ml , i. e. essentially &quot; sodium- free &quot; .
due to the rare occurrence of benzyl alcohol , this medicinal product must not be used in patients with deteriorating renal function .
and Prior adverse reactions in infants and children less than 3 years of age or less than 3 years .
interaction with other medicinal products and other forms of interaction
in a study interaction study in adults with a hormone deficiency , the use of irinotecan may increase the clearance of the substances metabolised by cytochrome P450 isoenzymes .
in particular , the clearance of the substances metabolised by cytochrome P450 CYP3A4 ( examples : sex , corticosteroids , anticonvulsants , anticonvulsants and ciclosporin ) may be increased while these compounds are given .
the clinical relevance of this effect is unknown .
see section 4.4 for diabetes , both in section 4.4 for diabetes and thiazide-type function , and walking section 4.2 for information on oral genotypes .
pregnancy and lactation
for Aranesp no clinical experience with CellCept in pregnant women .
there is no experimental data in animals concerning reproduction toxicity .
the treatment with irinotecan should be discontinued if pregnancy is discontinued .
in normal pregnancy , growth levels of experimental growth levels decline less than 20 weeks of gestation , these is sent to approximately 30 weeks .
therefore , a replacement regimen should not be required in women who are planning to become pregnant during the letters trimester of pregnancy .
it is not known whether sleeping passes into breast milk ; however the gastrointestinal absorption of protein in children is very unlikely .
particular attention should be paid to the use of lactating women .
effects on ability to drive and use machines
no studies on the effects on the ability to drive and use machines have been performed .
undesirable effects
decreases in extracellular volume is observed in patients with growth factors .
when a treatment with hyperammonaemia is initiated , this reduction is rapidly distributed .
effects of the fluid retention , such as peripheral neuropathy , myalgia , arthralgia , myalgia , arthralgia , headache , are common in adult patients .
in general , these side effects are severe , they occur in the first months of treatment and decrease a dose of dose .
the frequency of these adverse reactions is related to the dose and either age of patients , which may be due to age of the disease and may be due to age .
in paediatric patients , such effects are not common .
neoplasms benign , malignant and unspecified ( incl cysts and polyps )
very rare :
leukaemia .
very rare cases
immune system disorders :
common :
formation of antibodies .
Overhydration caused the formation of antibody formation .
the protein binding of these antibodies is feasible and with no relevance to clinical use .
endocrine disorders
type 2 diabetes .
nervous system disorders
common :
Uncommon :

musculoskeletal and connective tissue disorders
common :
arthralgia , myalgia , myalgia in adults .
musculoskeletal and connective tissue disorders :
general disorders and administration site conditions
common :
remote site skin and 28.4 at the injection site in paediatric patients .
Uncommon :
oedema in paediatric patients .
overdose
no case of overdose has been reported .
acute overdosage of the acute ingredients may lead to hypoglycaemia , which may become life threatening .
an overdose can be conducted to signs and symptoms similar to signs and symptoms similar to the known pharmacological effects of growth hormone in humans .
pharmacological PROPERTIES
pharmacodynamic properties
Pharmacotherapeutic group : oestrogens and analogues .
ATC code :
Patient-time is a potent metabolic hormone that is highly secreted by the metabolism of blood lipids , carbohydrates and proteins .
Patient-time is the linear and increases the rate of growth in children with growth factors .
in adult patients , ketobemidone M.
the fat turnover is very sensitive to methicillin .
alkalisation increases the serum concentrations of GAGs ( C-terminal polysaccharide ) and 212 ( PvDC )
the following table has been investigated .
lipid disorders :
Polyglutamation is a causal inducer of liver lymphocytes , and change the development of serum lipids .
in general , administration of 14C-entecavir in the patients with growth hormone leads to cleft growth and cleft viruses .
reduction in serum cholesterol may also be observed .
glucose metabolism :
Patient-time increases the insulin level , but it is generally unchanged .
children with AML have sometimes been able to have hypoglycaemic episodes when they were on an empty stomach , which can be treated with mercaptopurine .
oxidative biotransformation :
the erythropoietin deficiency should be excluded by a decrease in plasma volume and nucleotide which increases with the pretreatment treatment .
MAHA results in fluid retention , dietary salt and 3-hydroxy-1-aminoindan .
bone mineral metabolism :
alkalisation of bone .
pentamidine and bone density at the same site of the body weight increase after long-term administration of 5.25 to patients with growth systems , and with 82L .
rotation Cycle 2
the muscle and influence are unsuitable after long term treatment with drug-induced lipogenesis .
Overhydration also significantly reduced heart rate , but the mechanism has not been elucidated .
foetal resistance may contribute to this effect .
in clinical trials of adolescent children / adolescents who were candidates for age , Blacks , Hispanics and viable mg / kg / day were used up to standard .
data suggest that there is a potential for additive data of 0.5 hours in children who are refractory to father a child , previously treated with no mental sequelae .
the long-term safety data are unknown .
pharmacokinetic properties
absorption Absolute subcutaneous administration of 250-350 is approximately 80 in healthy subjects and non-white subjects .
elimination The mean terminal half-life of S-warfarin is approximately 1.4 hours following both insulin and 78.4 , respectively .
however , in subcutaneous administration of 14C-entecavir , the half-life reached 3 hours .
thirteen Absorption Absolute bioavailability of cytidine appears in patients and female patients after subcutaneous administration .
data on mating , paediatric populations , neonatal , dog in the differential and renal impairment is either fully supplemented .
preclinical safety data
preclinical data reveal no special hazard for humans based on conventional studies of repeated-dose toxicity and local safety retardation .
preclinical data from other clinical studies , local tolerance and impairment of reproduction have not been observed .
in vitro genotoxicity studies and in vivo mouse assays were negative with drug-induced lipogenesis .
it has been observed in a battery of in vitro to evaluate an in vitro treatment study in vitro after long-term treatment with IFN and acute lymphoblastic acids .
the clinical relevance of this finding is unknown .
in another study , no evidence of genetic from genetic infected patients were treated with Arixtra. term .
pharmaceutical PARTICULARS
list of excipients
glycine sodium dihydrogen phosphate dihydrate
solvent : water for injections
Incompatibilities
in the absence of compatibility studies , this medicinal product must not be mixed with other medicinal products .
Shelf life
3 years .
Shelf life after reconstitution :
after reconstitution and first injection , the cartridge must be kept in the pen and store in a refrigerator ( 2 C - 8 C ) for up to 21 days .
store and transport refrigerated ( 2 C - 8 C ) .
do not freeze .
store in the original package in order to protect from light .
special precautions for storage
bottle :
store and transport refrigerated ( 2 C - 8 C ) .
do not freeze .
store in the original package in order to protect from light .
for storage conditions of the medicine must be used , see section 6.3 .
nature and contents of container
pack of 1 and 5 .
not all pack sizes may be marketed .
special precautions for disposal and other handling
thirteen percent of the 10 mg / ml is packed in a vial containing the active substance and solvent in a cartridge .
the recommended volume of transfer should be reconstituted in the Package Leaflet of the transfer .
this pack is a single use .
it should only be administered with great serial recycling , a particular dial-a-dose disposable pen 5 mg / ml , reconstituted solution for injection .
it should be given with the sterile pens for particulate matter .
the patients and forced diuresis should receive adequate training and appropriate instructions on the use of goats , cartridges with solvent , and the pen or qualified trained .
9 Figure an general area of the reconstitution and administration time .
wash your hands .
pull the needle cap from the vial .
the top of the vial should be dispersed with saline solution to prevent contamination of the blood .
use the transfer contents of the cartridge into the vial .
gently shake the vial several times until the vial is fully dissolved .
do not shake : this active substance material .
if the solution is cloudy or contains particles , it must not be used .
the content of BeneFIX is clear and colourless after reconstitution .
aseptically transfer the solution into the cartridge by using the transfer spike .
Thursday the pen instructions for use .
discard the air bubbles if necessary .
clean the injection site with an alcohol wipe .
administer the appropriate dose by subcutaneous injection under the skin to a needle .
remove the pen from the pen , and discard as well .
MARKETING AUTHORISATION HOLDER
Sandoz GmbH Sandhoferstrasse 10 A-1220 Kundl Austria
MARKETING AUTHORISATION NUMBER ( S )
date OF FIRST AUTHORISATION / RENEWAL OF THE AUTHORISATION
September 2006
date OF REVISION OF THE TEXT
name OF THE MEDICINAL PRODUCT
w.1 mg / ml solution for injection .
qualitative AND QUANTITATIVE COMPOSITION
3.18 mg ( corresponding to 10 IU ) / ml .
one cartridge contains 1.5 ml of 2-17 ( 15 IU ) .
health care with recombinant DNA technology
one ml contains 9 mg of benzyl alcohol
for a full list of excipients , see section 6.1 .
pharmaceutical FORM
solution for injection The solution for injection The solution is clear and colourless .
clinical PARTICULARS
therapeutic indications
paediatrics
- Inability to growth deficiency
- Ringing growth retardation
- Ringing growing with chronic renal failure .
- 54.2 ( height ulceration &lt; 0.5x109 / diglycerides ) and / or
the diagnosis of ice should be confirmed by the appropriate assay .
adults
- Treatment with the severely mother in adult patients with severe congenital deficiency .
patients with severe congenital deficiency of age are defined as a pre-existing disease known as a pre-existing disease and at least one DMARD , including 0.008 .
a alone test will be used to calibrate or walk deficiency in these patients .
the range of diagnostic assays should be strictly observed .
posology and method of administration
diagnosis and sequelae should be performed by doctors experienced in the diagnosis and treatment of patients with growth retardation .
the dosage and schedule of administration should be appropriate to each patient .
doses of higher doses were used .
141 / kg in general , to improve the growth and number of body drug in paediatric patients was
the daily dose should not exceed 200 mg .
paediatric patients with the rate of growth growth rate is less than 1 cm in a year and whose permeability is almost relaxed .
the recommended dose of oestrogen : the recommended dose is 0.030 mg / kg bodyweight .
by renal growth period : the recommended dose is 1.4 mg / m2 of body surface area per day ( approximately 0.58 mg / kg body weight per day ) .
doses may be used if the growth rate is too low .
it is possible that the dose adjustment is necessary for 6 months ( see section 4.4 ) .
treatment should be discontinued after the first year of treatment if the rate is less than 1 hour .
paediatric patients :
2 / kg body weight of the body surface area ( BSA )
acuity
0.7 0.7 to 1.0 1.0 1.4
trochanter BMD
erythropoietin deficiency in adult patients :
treatment should commence with low dose regimens , 0.15 mg per day .
the dose may be increased in increments of the patient , determined by the patient &apos;s pre-therapy level , defined as the patient &apos;s age , not above the limit of the two years .
patients with normal tracer levels are normal to receive the management of the treatment , to be given from the range of normal , without exceeding 2 C .
clinical response of the same as yours .
the daily maintenance dose rarely 1.0 mg per day .
females may need to be adjusted higher than males ; males , and increased eosinophils in the time .
there is a risk that women of oral contraceptives are at increased risk that the substitution therapy with oestrogens , have been conclusive .
therefore , the dose will be adjusted every 6 months .
secretion of growth hormone decreases with age , dose reduction may be possible .
the minimal effective dose should be used .
the injection should be administered and the injection sites for avoid self-administration .
instructions for use and handling : see section 6.6 .
Contraindications
- Hypersensitivity to goat or a substance .
- The dose should not be used in terms of tumour
antitumour must be checked before initiating therapy .
- Sertraline should not be used to improve the benefit of patients with
- Patients with severe coronary dysfunction , patients with secondary complications of secondary complications or leg
special warnings and precautions for use
Overhydration may cause liver damage and hyperglycaemia in some patients .
in rare cases , a type 2 diabetes was found when treatment with irinotecan .
in patients with pre-existing diabetes , the treatment may be allowed to change the treatment with drug-induced lipogenesis .
in the empirical treatment , an increased conversion of the T4 deficiency by inducing the serum glutamic deficiency was seen , which leads to a decrease in serum glutamic concentration levels .
in general , thyroid levels are in the reasons of healthy subjects .
the effects of IFN pups on thyroid hormones may have a clinical relevance in patients with Measurable corneas who are going to develop a hole .
owing to the use of patients receiving IFN antagonist , a wide degree can occur .
so , it is suggested that , be advised to monitor thyroid functions after initiation of anticoagulation therapy and after dose adjustment .
decreased serum levels of serum lipase , which can be related to the changes in
there is a clinical significance of the benefit of these findings .
however , gout replacement therapy should be discussed prior to initiating therapy with irinotecan .
in the original phase , combination therapy is recommended to monitor the warning symptoms of biopsy arrhythmias .
in patients with pre-existing illness , including those balance to the hormone , an extension of the hip may be more frequent than in the general population .
any patient with CLCR during treatment with irinotecan should be maintained .
severe or multiple sclerosis , visual disturbance , nausea and / or vomiting , is recommended .
if this is confirmed , a reinforced diagnosis of CB1 hypertension should be considered and , if the treatment is stopped .
24 Paclitaxel of the long-term hormone in patients with stenosing hypertension .
however , the INR has been shown to correlate with no relationships of high hypertension .
if treatment with growth hormone is feasible , careful monitoring of the symptoms of auto-immune hypertension is necessary .
in patients older than 60 years , clinical experience is limited .
in patients with a thrombolytic , the treatment should always be associated with a hypocaloric .
patients who underwent splenectomy or several indicative of treatment should be at an increased risk of death .
before start of treatment with irinotecan in patients with bilateral corneal syndrome , testing for movement or infection should be performed .
there is a dose- loss of the upper airway , which should be monitored with a qualified specialist prior to starting the treatment with growth .
apnoea should be used prior to initiation of therapy with growth hormone including flattening or amitriptyline during the day , and if it is suspected .
if the seal of the legs , patients had signs of serum calcium levels ( including the occurrence of or worsening ) , treatment should be discontinued and new evaluation of the patient should be performed .
all patients with Fanconi &apos;s syndrome should be monitored if opiate propionate is suspected .
all patients with CLCR should be monitored for signs of respiratory infections , which should be re-evaluated as possible and treated effectively .
all patients with CLCR should also be monitored carefully before and during treatment with growth factors .
anencephaly is frequently observed in patients with CLCR .
in all children , tophi is suspected to develop prolonged growth .
the signs of 1.069 should be stopped after treatment .
however , there was no evidence of an increase in the incidence or severity of intra-abdominal treatment or severity in the treatment of growth hormone .
there is limited experience with the long-term hormone in adults and patients with long-standing syndrome .
in children with breast feeding , other causes or medicinal products that may explain the delayed other causes of growth therapy should be excluded prior to initiating therapy .
in children with breast feeding , small age and blood glucose levels is recommended to determine the formation and blood glucose levels before starting treatment .
in patients with an increased risk of diabetes ( a family of diabetes , obesity , severe renal impairment ) and an increased risk of developing hyperglycaemia should be performed .
if a clinical type of diabetes is thought to be given .
for children with small age , it is recommended that the level of S-warfarin before initiating therapy , and after a year .
for laboratory measures .
there is limited experience with treatment prior to onset of treatment prior to onset of puberty .
therefore , it is not recommended to initiate complete treatment prior to onset .
experience in patients with alcoholic syndrome is limited .
part of the height in children / adolescents who were going to donate the effects of growth hormone , where the disease is stopped before the final treatment is stopped .
in the case of renal impairment , renal function should be decreased by 50 in the normal case .
before initiating therapy , to ensure the delayed benefit of growth , to be followed by your doctor for a year before being treated .
during this period , the treatment of renal insufficiency ( including control of lactic acidosis , bone marrow and amitriptyline ) should be continued during the course of therapy .
treatment should be discontinued if renal transplant .
4 There are no data available on the size of patients with chronic renal failure treated with Arixtra. weight .
because of the results of these patients , these patients should not be treated with Saturday .
since there is no information on the safety of the substitution therapy by the patient &apos;s judgement , the benefit of continued therapy in this situation should be weighed against the potential risk of this situation .
in all patients with normal coronary function or similar , the possible benefit of treatment with S-warfarin should be weighed against the potential risk .
this medicinal product contains less than 1 mmol sodium ( 23 mg ) per ml , i. e. essentially &quot; sodium- free &quot; .
due to the rare occurrence of benzyl alcohol , this medicinal product must not be used in patients with deteriorating renal function .
and Prior adverse reactions in infants and children less than 3 years of age or less than 3 years .
interaction with other medicinal products and other forms of interaction
in a study interaction study in adults with a hormone deficiency , the use of irinotecan may increase the clearance of the substances metabolised by cytochrome P450 isoenzymes .
in particular , the clearance of the substances metabolised by cytochrome P450 CYP3A4 ( examples : sex , corticosteroids , anticonvulsants , anticonvulsants and ciclosporin ) may be increased while these compounds are given .
the clinical relevance of this effect is unknown .
refer to section 4.4 for the diabetes , and thiazide-type function , and thiazide-type function , and in section 4.2 for information on oral therapy .
pregnancy and lactation
for Aranesp no clinical data on exposed pregnancies are available .
there is no experimental data in animals concerning reproduction toxicity .
the treatment with irinotecan should be discontinued if pregnancy is discontinued .
in normal , growth levels of experimental growth levels decline less than 20 weeks of gestation , these is sent to approximately 30 weeks .
therefore , a replacement regimen should not be required in women who are planning to become pregnant during the letters trimester of pregnancy .
it is not known whether sleeping passes into breast milk ; however the gastrointestinal absorption of protein in children is very unlikely .
however , caution should be exercised when breast-feeding is breast-feeding .
effects on ability to drive and use machines
no studies on the effects on the ability to drive and use machines have been performed .
undesirable effects
decreases in extracellular volume is observed in patients with growth factors .
when a treatment with hyperammonaemia is initiated , this reduction is rapidly distributed .
effects of the fluid retention , such as peripheral edema , myalgia , myalgia , arthralgia , headache , are common in adult patients .
in general , these side effects are severe , they occur in the first months of treatment and decrease a dose of dose .
the frequency of these adverse reactions is related to the dose and either age of patients , which may be due to age of the disease and may be due to age .
in paediatric patients , such effects are not common .
neoplasms benign , malignant and unspecified ( incl cysts and polyps )
very rare :
leukaemia .

immune system disorders :
common :
formation of antibodies .
Patient-time was given to the formation of antibodies in approximately 1 of patients .
the protein binding of these antibodies is feasible and with no relevance to clinical use .
endocrine disorders
type 2 diabetes .
nervous system disorders
common :
Uncommon :
renovascular hypertension .
musculoskeletal and connective tissue disorders
common :
Uncommon :
musculoskeletal stiffness , arthralgia , myalgia in extremity menopausal symptoms , arthralgia , myalgia in paediatric patients .
general disorders and administration site conditions
common :

Uncommon :
oedema in paediatric patients .
overdose
no case of overdose has been reported .
acute overdosage of the acute ingredients may lead to hypoglycaemia , which may become life threatening .
an overdose can be conducted to signs and symptoms similar to signs and symptoms similar to the known pharmacological effects of growth hormone in humans .
pharmacological PROPERTIES
pharmacodynamic properties
Pharmacotherapeutic group : oestrogens and analogues .
ATC code :
Patient-time is a potent metabolic hormone that is highly secreted by the metabolism of blood lipids , carbohydrates and proteins .
Patient-time is the linear and increases the rate of growth in children with growth factors .
in adult patients , ketobemidone M.
the fat turnover is very sensitive to methicillin .
alkalisation increases the serum concentrations of GAGs ( C-terminal polysaccharide ) and 212 ( PvDC )
the following table has been investigated .
lipid disorders :
Polyglutamation is a causal inducer of liver lymphocytes , and change the development of serum lipids .
in general , administration of 14C-entecavir in the patients with growth hormone leads to cleft growth and cleft viruses .
reduction in serum cholesterol may also be observed .
glucose metabolism :
Patient-time increases the insulin level , but it is generally unchanged .
children with AML have sometimes been able to have hypoglycaemic episodes when they were on an empty stomach , which can be treated with mercaptopurine .
oxidative biotransformation :
the erythropoietin deficiency should be excluded by a decrease in plasma volume and nucleotide which increases with the pretreatment treatment .
MAHA results in fluid retention , dietary salt and 3-hydroxy-1-aminoindan .
bone mineral :
alkalisation of bone .
pentamidine and bone density at the same site of the body weight increase after long-term administration of 5.25 to patients with growth systems , and with 82L .
pharyngitis
the muscle and influence are unsuitable after long term treatment with drug-induced lipogenesis .
Overhydration also significantly reduced heart rate , but the mechanism has not been elucidated .
foetal resistance may contribute to this effect .
in clinical trials of adolescent children / adolescents who were candidates for age , Blacks , Hispanics and viable mg / kg / day were used up to standard .
data suggest that there is a potential for additive data of 0.5 hours in children who are refractory to father a child , previously treated with no mental sequelae .
the long-term safety data are unknown .
pharmacokinetic properties
absorption Absolute subcutaneous administration of 250-350 is approximately 80 in healthy subjects and non-white subjects .
following subcutaneous administration of a 5 mg dose of 5 mg Ethanol .
elimination Bevacizumab plays a mean terminal half EC90 rate of
however , subcutaneous administration of 14C-entecavir 10 mg / ml solution for injection , the half-life reached 3 hours .
thirteen Absorption Absolute bioavailability of cytidine appears in patients and female patients after subcutaneous administration .
data on mating , paediatric populations , neonatal , dog in the differential and renal impairment is either fully supplemented .
preclinical safety data
preclinical data reveal no special hazard for humans based on conventional studies of repeated-dose toxicity and local safety retardation .
preclinical data from other clinical studies , local tolerance and impairment of reproduction have not been observed .
in vitro genotoxicity studies and in vivo mouse assays were negative with drug-induced lipogenesis .
it has been observed in a battery of in vitro to evaluate an in vitro treatment study in vitro after long-term treatment with IFN and acute lymphoblastic acids .
the clinical relevance of this finding is unknown .
in another study , no evidence of genetic from genetic infected patients were treated with Arixtra. term .
pharmaceutical PARTICULARS
list of excipients
disodium phosphate dihydrate Sodium dihydrogen phosphate dihydrate disodium phosphate dodecahydrate Water for injections
Incompatibilities
in the absence of compatibility studies , this medicinal product must not be mixed with other medicinal products .
Shelf life
2 years .
Shelf life after first use :
after first use , the cartridge must be kept in the pen and store in a refrigerator ( 2 C - 8 C ) for up to 28 days .
store and transport refrigerated ( 2 C - 8 C ) .
do not freeze .
store in the original package in order to protect from light .
special precautions for storage
anti cartridge :
store and transport refrigerated ( 2 C - 8 C ) .
do not freeze .
store in the original package in order to protect from light .
for storage conditions of the medicine must be used , see section 6.3 .
nature and contents of container
ml solution in a cartridge ( type I colourless glass ) with a bromobutyl rubber stopper ( a bromobutyl rubber ) and a seal ( aluminium ) of the other side wall .
packs of 1 , 5 and 10 .
not all pack sizes may be marketed .
special precautions for disposal and other handling
6-23 mg / ml solution for injection is a sterile , ready to use
this pack is a single use .
it should be given only with great 5 , a injection device designed to be used with peel-off stickers for Injection .
this medicinal product must be administered for the sterile disposable pen .
the patients and leukaemias should receive adequate training and are subject to adhere to the anti-HIV use of germinal cartridges , and the use performed .
is in Figure 1 .
the manufacturer &apos;s instructions for each pen must be followed for leaving the cartridge , and the instructions of administering the needle , and administering it .
wash your hands .
if the solution is cloudy or contains particles , it must not be used .
the product should be clear and colourless .
disinfect the rubber membrane with an alcohol wipe .
insert the cartridge in the reusable pen without squeezing the pen .
clean the injection site with an alcohol wipe .
administer the appropriate dose by subcutaneous injection under the skin to a needle .
remove the pen from the pen and discard it as well .
MARKETING AUTHORISATION HOLDER
Sandoz GmbH Sandhoferstrasse 10 A-1220 Kundl Austria
MARKETING AUTHORISATION NUMBER ( S )
date OF FIRST AUTHORISATION / RENEWAL OF THE AUTHORISATION
September 2006
date OF REVISION OF THE TEXT
name OF THE MEDICINAL PRODUCT
3.18 mg / ml solution for injection .
qualitative AND QUANTITATIVE COMPOSITION
3.18 Red Cell Count ( corresponding to 20 IU / ml . )
one cartridge contains 1.5 ml of beer ( 30 IU ) .
health care with recombinant DNA technology
for a full list of excipients , see section 6.1 .
pharmaceutical FORM
solution for injection The solution for injection The solution is clear and colourless .
clinical PARTICULARS
therapeutic indications
paediatrics
- Inability to growth deficiency
- Ringing growth retardation
- Ringing growing with chronic renal failure .
- 54.2 ( height ulceration &lt; 0.5x109 / diglycerides ) and / or
the diagnosis of ice should be confirmed by the appropriate assay .
adults
- Treatment with the severely mother in adult patients with severe congenital deficiency .
patients with severe congenital deficiency of age are defined as a pre-existing disease known as a pre-existing disease and at least one DMARD , including 0.008 .
a alone test will be used to calibrate or walk deficiency in these patients .
the range of diagnostic assays should be strictly observed .
posology and method of administration
diagnosis and sequelae should be performed by doctors experienced in the diagnosis and treatment of patients with growth retardation .
the dosage and schedule of administration should be appropriate to each patient .
doses of higher doses were used .
141 / kg in general , to improve the growth and number of body drug in paediatric patients was
the daily dose should not exceed 200 mg .
paediatric patients with the rate of growth growth rate is less than 1 cm in a year and whose permeability is almost relaxed .
the recommended dose of oestrogen : the recommended dose is 0.030 mg / kg bodyweight .
by renal growth period : the recommended dose is 1.4 mg / m2 of body surface area per day ( approximately 0.58 mg / kg body weight per day ) .
doses may be used if the growth rate is too low .
it is possible that the dose adjustment is necessary for 6 months ( see section 4.4 ) .
treatment should be discontinued after the first year of treatment if the rate is less than 1 hour .
paediatric patients :
2 / kg body weight of the body surface area ( BSA )
acuity
0.7 0.7 to 1.0 1.0 1.4
erythropoietin deficiency in adult patients :
treatment should commence with low dose regimens , 0.15 mg per day .
the dose may be increased in increments of the patient , determined by the patient &apos;s pre-therapy level , defined as the patient &apos;s age , not above the limit of the two years .
patients with normal tracer levels are normal to receive the management of the treatment , to be given from the range of normal , without exceeding 2 C .
clinical response of the same as yours .
the daily maintenance dose rarely 1.0 mg per day .
females may need to be adjusted higher than males ; males , and increased eosinophils in the time .
there is a risk that women of oral contraceptives are at increased risk that the substitution therapy with oestrogens , have been conclusive .
therefore , the dose will be adjusted every 6 months .
secretion of growth hormone decreases with age , dose reduction may be possible .
the minimal effective dose should be used .
the injection should be administered and the injection sites for avoid self-administration .
for information on the handling and handling : see section 6.6 .
Contraindications
- Hypersensitivity to goat or a substance .
- The dose should not be used in terms of tumour
antitumour must be checked before initiating therapy .
- Sertraline should not be used to improve the benefit of patients with
- Patients with severe coronary dysfunction , patients with secondary complications of secondary complications or leg
special warnings and precautions for use
Overhydration may cause liver damage and hyperglycaemia in some patients .
in rare cases , a type 2 diabetes was found when treatment with irinotecan .
in patients with pre-existing diabetes , the treatment may be allowed to change the treatment with drug-induced lipogenesis .
in the empirical treatment , an increased conversion of the T4 deficiency by inducing the serum glutamic deficiency was seen , which leads to a decrease in serum glutamic concentration levels .
in general , thyroid levels are in the reasons of healthy subjects .
the effects of IFN pups on thyroid hormones may have a clinical relevance in patients with Measurable corneas who are going to develop a hole .
owing to the use of patients receiving IFN antagonist , a wide degree can occur .
so , it is suggested that , be advised to monitor thyroid functions after initiation of anticoagulation therapy and after dose adjustment .
decreased serum levels of serum lipase , which can be related to the changes in
there is a clinical significance of the benefit of these findings .
however , gout replacement therapy should be discussed prior to initiating therapy with irinotecan .
in the original phase , combination therapy is recommended to monitor the warning symptoms of biopsy arrhythmias .
in patients with pre-existing illness , including those balance to the hormone , an extension of the hip may be more frequent than in the general population .
any patient with CLCR during treatment with irinotecan should be maintained .
severe or multiple sclerosis , visual disturbance , nausea and / or vomiting , is recommended .
if this is confirmed , a reinforced diagnosis of CB1 hypertension should be considered and , if the treatment is stopped .
at the present time , it is not known whether appropriate , at the present time of the growth hormone .
if
in the growth hormone is feasible , careful monitoring of the symptoms of autoimmune hypertension is necessary .
in patients older than 60 years , clinical experience is limited .
in patients with a thrombolytic , the treatment should always be associated with a hypocaloric .
patients who underwent splenectomy or several indicative of treatment should be at an increased risk of death .
before start of treatment with irinotecan in patients with bilateral corneal syndrome , testing for movement or infection should be performed .
there is a dose- loss of the upper airway , which should be monitored with a qualified specialist prior to starting the treatment with growth .
apnoea should be used prior to initiation of therapy with growth hormone including flattening or amitriptyline during the day , and if it is suspected .
if the seal of the legs , patients had signs of serum calcium levels ( including the occurrence of or worsening ) , treatment should be discontinued and new evaluation of the patient should be performed .
all patients with Fanconi &apos;s syndrome should be monitored if opiate propionate is suspected .
all patients with CLCR should be monitored for signs of respiratory infections , which should be re-evaluated as possible and treated effectively .
all patients with CLCR should also be monitored carefully before and during treatment with growth factors .
anencephaly is frequently observed in patients with CLCR .
in all children , tophi is suspected to develop prolonged growth .
the signs of 1.069 should be stopped after treatment .
however , there was no evidence of an increase in the incidence or severity of intra-abdominal treatment or severity in the treatment of growth hormone .
there is limited experience with the long-term hormone in adults and patients with long-standing syndrome .
in children with breast feeding , other causes or medicinal products that may explain the delayed other causes of growth therapy should be excluded prior to initiating therapy .
in children with breast feeding , small age and blood glucose levels is recommended to determine the formation and blood glucose levels before starting treatment .
in patients with an increased risk of diabetes ( a family of diabetes , obesity , severe renal impairment ) and an increased risk of developing hyperglycaemia should be performed .
if a clinical type of diabetes is thought to be given .
, the levels of
the mitochondrial gram ratio is greater than 2 authorised with the standard terminal half-life for both age and hepatically accidents , the predominant ratio of neurons should be considered for the adjustment of dose adjustment .
there is limited experience with treatment prior to onset of treatment prior to onset of puberty .
therefore , it is not recommended to initiate complete treatment prior to onset .
experience in patients with alcoholic syndrome is limited .
part of the height in children / adolescents who were going to donate the effects of growth hormone , where the disease is stopped before the final treatment is stopped .
in the case of renal impairment , renal function should be decreased by 50 in the normal case .
before initiating therapy , to ensure the delayed benefit of growth , to be followed by your doctor for a year before being treated .
during this period , the treatment of renal insufficiency ( including control of lactic acidosis , bone marrow and amitriptyline ) should be continued during the course of therapy .
treatment should be discontinued if renal transplant .
4 There are no data available on the size of patients with chronic renal failure treated with Arixtra. weight .
because of the results of these patients , these patients should not be treated with Saturday .
due to the lack of limited information on the safety of substitution therapy in patients with impaired mental conditions , the benefit of continued therapy with irinotecan should be weighed against the potential risk of this situation .
in all patients with normal coronary function or similar , the possible benefit of treatment with S-warfarin should be weighed against the potential risk .
this medicinal product contains less than 1 mmol sodium ( 23 mg ) per ml , i. e. essentially &quot; sodium- free &quot; .
interaction with other medicinal products and other forms of interaction
in a study interaction study in adults with a hormone deficiency , the use of irinotecan may increase the clearance of the substances metabolised by cytochrome P450 isoenzymes .
in particular , the clearance of the substances metabolised by cytochrome P450 CYP3A4 ( examples : sex , corticosteroids , anticonvulsants , anticonvulsants and ciclosporin ) may be increased while these compounds are given .
the clinical relevance of this effect is unknown .
refer to section 4.4 for the diabetes , and thiazide-type function , and thiazide-type function , and in section 4.2 for information on oral therapy .
pregnancy and lactation
for Aranesp no clinical data on exposed pregnancies are available .
there is no experimental data in animals concerning reproduction toxicity .
the treatment with irinotecan should be discontinued if pregnancy is discontinued .
therefore a change in the EC90 state
do not be used in the treatment of growth hormone in women who are breastfeeding .
it is not known whether sleeping passes into breast milk ; however the gastrointestinal absorption of protein in children is very unlikely .
however , caution should be exercised when breast-feeding is breast-feeding .
effects on ability to drive and use machines
no studies on the effects on the ability to drive and use machines have been performed .
undesirable effects
decreases in extracellular volume is observed in patients with growth factors .
when a treatment with hyperammonaemia is initiated , this reduction is rapidly distributed .
effects of the fluid retention , such as peripheral edema , myalgia , myalgia , arthralgia , headache , are common in adult patients .
in general , these side effects are severe , they occur in the first months of treatment and decrease a dose of dose .
the frequency of these adverse reactions is related to the dose and either age of patients , which may be due to age of the disease and may be due to age .
in paediatric patients , such effects are not common .
neoplasms benign , malignant and unspecified ( incl cysts and polyps )
very rare :
leukaemia .

immune system disorders :
common :
formation of antibodies .
Patient-time was given to the formation of antibodies in approximately 1 of patients .
the protein binding of these antibodies is feasible and with no relevance to clinical use .
endocrine disorders
type 2 diabetes .
nervous system disorders
common :
Uncommon :

musculoskeletal and connective tissue disorders
common :
Uncommon :
musculoskeletal stiffness , arthralgia , myalgia in extremity menopausal symptoms , arthralgia , myalgia in paediatric patients .
general disorders and administration site conditions
common :

Uncommon :
oedema in paediatric patients .
overdose
no case of overdose has been reported .
acute overdosage of the acute ingredients may lead to hypoglycaemia , which may become life threatening .
an overdose can be conducted to signs and symptoms similar to signs and symptoms similar to the known pharmacological effects of growth hormone in humans .
pharmacological PROPERTIES
pharmacodynamic properties
Pharmacotherapeutic group : oestrogens and analogues .
ATC code :
Patient-time is a potent metabolic hormone that is highly secreted by the metabolism of blood lipids , carbohydrates and proteins .
Patient-time is the linear and increases the rate of growth in children with growth factors .
in adult patients , ketobemidone M.
the fat turnover is very sensitive to methicillin .
Overhydration increases lipolysis and decreases the baseline decrease in triglycerides in
alkalisation increases the serum concentrations of GAGs ( C-terminal polysaccharide ) and 212 ( PvDC )
the following table has been investigated .
lipid disorders :
Polyglutamation is a causal inducer of liver lymphocytes , and change the development of serum lipids .
in general , administration of 14C-entecavir in the patients with growth hormone leads to cleft growth and cleft viruses .
reduction in serum cholesterol may also be observed .
glucose metabolism :
Patient-time increases the insulin level , but it is generally unchanged .
children with AML have sometimes been able to have hypoglycaemic episodes when they were on an empty stomach , which can be treated with mercaptopurine .
oxidative biotransformation :
the erythropoietin deficiency should be excluded by a decrease in plasma volume and nucleotide which increases with the pretreatment treatment .
MAHA results in fluid retention , dietary salt and 3-hydroxy-1-aminoindan .
bone mineral metabolism :
alkalisation of bone .
pentamidine and bone density at the same site of the body weight increase after long-term administration of 5.25 to patients with growth systems , and with 82L .
pharyngitis
the muscle and influence are unsuitable after long term treatment with drug-induced lipogenesis .
occlusion also significantly reduced heart rate , but the mechanism was
foetal resistance may contribute to this effect .
in clinical trials of adolescent children / adolescents who were candidates for age , Blacks , Hispanics and viable mg / kg / day were used up to standard .
data suggest that there is a potential for additive data of 0.5 hours in children who are refractory to father a child , previously treated with no mental sequelae .
the long-term safety data are unknown .
pharmacokinetic properties
absorption Absolute subcutaneous administration of 250-350 is approximately 80 in healthy subjects and non-white subjects .
following subcutaneous administration of a 5 mg dose of 5 mg / ml solution for injection in healthy adult patients with normal renal function and tmax were 74 respectively , respectively .
elimination Bevacizumab plays a mean terminal half EC90 rate of
however , following subcutaneous administration of iodinated contrast mg / ml solution for injection , the half-life reached 3 hours .
thirteen Absorption Absolute bioavailability of cytidine appears in patients and female patients after subcutaneous administration .
data on mating , paediatric populations , neonatal , dog in the differential and renal impairment is either fully supplemented .
preclinical safety data
preclinical data reveal no special hazard for humans based on conventional studies of repeated-dose toxicity and local safety retardation .
preclinical data from other clinical studies , local tolerance and impairment of reproduction have not been observed .
in vitro genotoxicity studies and in vivo mouse assays were negative with drug-induced lipogenesis .
it has been observed in a battery of in vitro to evaluate an in vitro treatment study in vitro after long-term treatment with IFN and acute lymphoblastic acids .
the clinical relevance of this finding is unknown .
in another study , no evidence of genetic from genetic infected patients were treated with Arixtra. term .
pharmaceutical PARTICULARS
list of excipients
disodium phosphate dihydrate Sodium dihydrogen phosphate dihydrate
Incompatibilities
in the absence of compatibility studies , this medicinal product must not be mixed with other medicinal products .
Shelf life
months .
Shelf life after first use :
after first use , the cartridge must be kept in the pen and stored at refrigerated temperature ( between 2 C and 8 C ) for up to 28 days .
store and transport refrigerated ( 2 C - 8 C ) .
do not freeze .
store in the original package in order to protect from light .
special precautions for storage
anti cartridge :
store and transport refrigerated ( 2 C - 8 C ) .
do not freeze .
store in the original package in order to protect from light .
for storage conditions of the medicine must be used , see section 6.3 .
nature and contents of container
ml solution in a cartridge ( type I colourless glass ) with a bromobutyl rubber stopper ( a bromobutyl rubber ) and a seal ( aluminium ) of the other side wall .
packs of 1 , 5 and 10 cartridges .
not all pack sizes may be marketed .
special precautions for disposal and other handling
6-23 mg / ml solution for injection is a sterile , ready to use
this pack is a single use .
it should be given only with peel-off stickers 10 , a injection device designed to be used with peel-off stickers for Injection .
this medicinal product must be administered for the sterile disposable pen .
the patients and leukaemias should receive adequate training and are subject to adhere to the anti-HIV use of germinal cartridges , and the use performed .
is in Figure 1 .
the manufacturer &apos;s instructions for each pen must be followed for leaving the cartridge , and the instructions of administering the needle , and administering it .
wash your hands .
if the solution is cloudy or contains particles , it must not be used .
the product should be clear and colourless .
disinfect the rubber membrane with an alcohol wipe .
insert the cartridge in the reusable pen with the full instructions for use with the pen .
clean the injection site with an alcohol wipe .
administer the appropriate dose by subcutaneous injection under the skin to a needle .
remove the pen from the pen and discard it as well .
MARKETING AUTHORISATION HOLDER
Sandoz GmbH Sandhoferstrasse 10 A-1220 Kundl Austria
MARKETING AUTHORISATION NUMBER ( S )
date OF FIRST AUTHORISATION / RENEWAL OF THE AUTHORISATION
September 2006
date OF REVISION OF THE TEXT
manufacturer OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE
conditions OF THE MARKETING AUTHORISATION
manufacturer OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE
name and address of the manufacturer of the biological active substance
Sandoz GmbH Sandhoferstrasse 10 A-1220 Kundl Austria
name and address of the manufacturer responsible for batch release
Sandoz GmbH Sandhoferstrasse 10 A-1220 Kundl Austria
conditions OF THE MARKETING AUTHORISATION
conditions OR RESTRICTIONS REGARDING SUPPLY AND USE IMPOSED ON THE MARKETING AUTHORISATION HOLDER
medicinal product subject to restricted medical prescription ( See Annex I :
summary of Product Characteristics , section 4.2 ) .
conditions OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT
not applicable .
other CONDITIONS
pharmacovigilance system
risk Management plan
as per the CHMP Guideline on Risk Management Systems for medicinal products for human use , the updated RMP should be submitted at the same time as the next Periodic Safety Update Report ( PSUR ) .
in addition , an updated RMP should be submitted
- When new information is received that may have the current Safety Specification ,
an updated Risk Management Plan or risk minimisation activities ;
- in 60 days if a stream is withdrawn ( pharmacovigilance or risk minimisation ) ,
- on the request of the EMEA
labelling AND PACKAGE LEAFLET
labelling
PARTICULARS TO APPEAR ON THE OUTER PACKAGING
OUTER CARTON
name OF THE MEDICINAL PRODUCT
statement OF ACTIVE SUBSTANCE
one vial with 650 mg ( 4 IU ) / ml .
after reconstitution , a vial provides 1.3 mg ( corresponding to 4 IU ) per ml .
list OF EXCIPIENTS
other ingredients :
solvent : water for injections
pharmaceutical FORM AND CONTENTS
powder and solvent for solution for injection ( 1.3 mg ) in a vial ( 1.3 mg )
pack of 1 .
method AND ROUTE OF ADMINISTRATION
for subcutaneous use after reconstitution .
single use only .
read the package leaflet before use .
special WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN
keep out of the reach and sight of children .
other SPECIAL WARNING ( S ) , IF NECESSARY
only a clear and solution should be used .
after reconstitution use , use only 24 hours .
special STORAGE CONDITIONS
store and transport refrigerated ( 2 C - 8 C ) .
do not freeze .
store in the original package in order to protect from light .
special PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS , IF APPROPRIATE
name AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
A-6250 Kundl Austria
MARKETING AUTHORISATION NUMBER
general CLASSIFICATION FOR SUPPLY
medicinal product subject to medical prescription .
instructions ON USE
information IN BRAILLE
0.5mg / ml
minimum PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
EU-Number
name OF THE MEDICINAL PRODUCT AND ROUTE OF ADMINISTRATION
116a
method OF ADMINISTRATION
read the package leaflet before use .
single use only .
after reconstitution use , use only 24 hours .
contents BY WEIGHT , BY VOLUME OR BY UNIT
mg Ethanol
other
minimum PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
OUTER CARTON / sodium chloride
name OF THE MEDICINAL PRODUCT AND ROUTE OF ADMINISTRATION
intraarterial use .
method OF ADMINISTRATION
read the package leaflet before use .
single use only .
EXP / During reconstitution use
contents BY WEIGHT , BY VOLUME OR BY UNIT
1 ml of water for injections .
other
PARTICULARS TO APPEAR ON THE OUTER PACKAGING
OUTER BOX
name OF THE MEDICINAL PRODUCT
statement OF ACTIVE SUBSTANCE
thirteen percent of the 5 mg vial .
after reconstitution , a cartridge contains 5 mg wine ( corresponding to 15 IU / ml ) .
list OF EXCIPIENTS
other ingredients :
powder : exanthem sodium dihydrogen phosphate dihydrate , sodium phosphate monobasic .

pharmaceutical FORM AND CONTENTS
powder and solvent for solution for injection ( 5 mg ) solution for injection ( 5 mg ) and solvent in a cartridge ( 1 ml ) .
packs of 1 and 5 .
method AND ROUTE OF ADMINISTRATION
for subcutaneous use after reconstitution .
read the package leaflet before use .
special WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN
keep out of the reach and sight of children .
other SPECIAL WARNING ( S ) , IF NECESSARY
only a clear and solution should be used .
after reconstitution use within 21 days .
special STORAGE CONDITIONS
store and transport refrigerated ( 2 C - 8 C ) .
do not freeze .
store in the original package in order to protect from light .
special PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS , IF APPROPRIATE
name AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
A-6250 Kundl Austria
MARKETING AUTHORISATION NUMBER ( S )
general CLASSIFICATION FOR SUPPLY
medicinal product subject to medical prescription .
instructions ON USE
use only
information IN BRAILLE
minimum PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
EU-Number
name OF THE MEDICINAL PRODUCT AND ROUTE OF ADMINISTRATION
intraarterial use .
method OF ADMINISTRATION
read the package leaflet before use .
after reconstitution use , use only 21 days .
contents BY WEIGHT , BY VOLUME OR BY UNIT
5 mg Macrogolglycerol oncology
other
minimum PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
OUTER CARTON / sodium chloride
name OF THE MEDICINAL PRODUCT AND ROUTE OF ADMINISTRATION
thirteen 5 mg / ml powder and solvent for solution for injection Imiglucerase
method OF ADMINISTRATION
read the package leaflet before use .
after reconstitution use , use only 21 days .
contents BY WEIGHT , BY VOLUME OR BY UNIT
Tel in water for injections .
other
PARTICULARS TO APPEAR ON THE OUTER PACKAGING
OUTER BOX
name OF THE MEDICINAL PRODUCT
116a
statement OF ACTIVE SUBSTANCE
30.4 ( 10 IU ) / ml .
one cartridge contains 1.5 ml of 2-17 ( 15 IU ) .
list OF EXCIPIENTS
other ingredients : disodium phosphate dihydrate , sodium phosphate dihydrate , mannitol , carbomer 188 , stearyl alcohol , water for injections .
contains benzyl alcohol , see the Package Leaflet for further information .
pharmaceutical FORM AND CONTENTS
solution for injection in a cartridge ( 1.5 ml ) .
packs of 1 , 5 and 10 .
method AND ROUTE ( S ) OF ADMINISTRATION
for subcutaneous use .
read the package leaflet before use .
special WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN
keep out of the reach and sight of children .
other SPECIAL WARNING ( S ) , IF NECESSARY
use only a clear solution .
EXP After first opening , use within 28 days .
special STORAGE CONDITIONS
store and transport refrigerated ( 2 C - 8 C ) .
do not freeze .
store in the original package in order to protect from light .
special PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS , IF APPROPRIATE
name AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
A-6250 Kundl Austria
MARKETING AUTHORISATION NUMBER ( S )
general CLASSIFICATION FOR SUPPLY
medicinal product subject to medical prescription .
instructions ON USE
use only 5 .
information IN BRAILLE
3.18 mg / ml
minimum PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
EU / 1 / 01 / 190 / 009
name OF THE MEDICINAL PRODUCT AND ROUTE OF ADMINISTRATION
subcutaneous use .
method OF ADMINISTRATION
read the package leaflet before use .
EXP After first opening , use within 28 days .
contents BY WEIGHT , BY VOLUME OR BY UNIT
5 mg Macrogolglycerol oncology
other
PARTICULARS TO APPEAR ON THE OUTER PACKAGING
OUTER BOX
name OF THE MEDICINAL PRODUCT
116a
statement OF ACTIVE SUBSTANCE
0.5mg / ml ( 20 IU ) / ml .
one cartridge contains 1.5 ml of 10 mg Macrogolglycerol ( 30 IU ) .
list OF EXCIPIENTS
other ingredients : disodium phosphate dihydrate , sodium phosphate dihydrate , sodium phosphate dihydrate , tyloxapol , water for injections .
pharmaceutical FORM AND CONTENTS
solution for injection in a cartridge ( 1.5 ml ) affixed of 1.5 and 10 .
method AND ROUTE ( S ) OF ADMINISTRATION
for subcutaneous use .
read the package leaflet before use .
special WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN
keep out of the reach and sight of children .
other SPECIAL WARNING ( S ) , IF NECESSARY
use only a clear solution .
EXP After first opening , use within 28 days .
special STORAGE CONDITIONS
store and transport refrigerated ( 2 C - 8 C ) .
do not freeze .
store in the original package in order to protect from light .
special PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS , IF APPROPRIATE
name AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
A-6250 Kundl Austria
MARKETING AUTHORISATION NUMBER ( S )
general CLASSIFICATION FOR SUPPLY
medicinal product subject to medical prescription .
instructions ON USE
use only 10 .
information IN BRAILLE
0.5mg / ml
minimum PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
EU / 1 / 01 / 190 / 009
name OF THE MEDICINAL PRODUCT AND ROUTE OF ADMINISTRATION
subcutaneous use .
method OF ADMINISTRATION
read the package leaflet before use .
EXP After first opening , use within 28 days .
contents BY WEIGHT , BY VOLUME OR BY UNIT
mg Ethanol in 1.5 ml
other
package LEAFLET
package LEAFLET :
information FOR THE USER
Danmark 1 mg / ml powder and solvent for solution for injection
gynaecomastia
read all of this leaflet carefully before you start taking this medicine .
- Keep this leaflet .
you may need to read it again .
- If you have any further questions , ask your doctor or pharmacist .
- This medicine has been prescribed for you .
- This medicine has been prescribed for you .
it may harm them , even
if their symptoms are the same as yours .
- If any of the side effects gets serious , or if you notice any side effects not listed in this leaflet ,
please tell your doctor or pharmacist .
in this leaflet :
what AERINAZE is and what it is used to reject it .
before you are given 3 .
how to use insulin 4 .
possible side effects 5 .
possible side effects 5 How to store ATryn 6 .
further information
what ABSEAMED IS AND WHAT IT IS USED FOR
30.4 is the human hormone produced by a method known as recombinant DNA technology :
metoclopramide is similar to the human body .
thirteen percent of the 10 mg / ml is intended for single use only .
30.4 is used in the following case .
treatment of paediatric patients and adolescents :
- with growth factors have been associated with growth factors .
- with growth retardation has been associated with growth retardation .
- with growth renal disease ( CRF ) .
- with reduced growth retardation in children / adolescents infants
no testicular growth effects are available with regard to 4 years of age or older .
diagnosis of ice should be confirmed by the appropriate assay .
before YOU TAKE ABSEAMED
diagnosis and consolidation should be performed and supervised by a physician experienced in the diagnosis and treatment of patients with growth retardation .
do not use reused
- if you are allergic ( hypersensitive ) to launch or any of the other ingredients of
polyvinylchloride .
- if you have discussed this with you , she should be checked prior to treatment .
this summary was last updated in 11-2007 .
- to increase foetal growth if it proceeds ( FVC ) .
- if you have previously suffered from acute complications associated with surgery
6
take special care with Cancidas
- The OBR may interfere with your insulin needs .
your blood sugar should be checked .
17 controlled treatment with capecitabine .
- If you have diabetes or a family history of diabetes treatment , treatment with insulin
this dosage adjustment may be necessary when initiating treatment with AML .
- Redistribution ( a thyroid gland activity ) may develop during the
treatment with amiodarone .
a symptom may reduce the response to the hydrophilic .
therefore , thyroid hormones should be checked periodically during therapy .
- an adequate high blood pressure ( high pressure in the brain ) ensures a
HVOD .
if symptoms such as headaches , visual disturbance , nausea , vomiting or vomiting , ask your doctor for advice .
you may need to have an eye test to achieve an abnormal increase in intrauterine pressure .
depending on the outcome , treatment with irinotecan may be stopped .
- Patients with pre-existing neurologic disorder ( OI ) may leak
if you develop digitalis or pain for the hip , ask your doctor .
- The seal of Life ( a para-hydroxy-sulphate ) can occur during treatment with the spine .
there is a potential for additive benefit .
therefore , signs of hyperthyroidism should be monitored during treatment with Saturday .
however , there was no evidence of an increase or severity of mineralisation .
- If you have any process , you will have a regular basis of your signs of
recurrence of contamination .
- No information on the safety of the substitution therapy by the growth of growth
experience in patients with acute coronary syndromes .
if you have acute Coronary positive , your doctor will assess the safety of continuing therapy .
- The clinical experience is limited in patients &gt; 60 years of age .
treatment with rectal coronary function ( CRF )
- In patients with an autologous heart disease treatment cannot complete their
renal function is less than 50 for the normal range .
to ensure that the potential to be followed by your doctor that you have an intolerance to become growth for a year , before being treated .
adjuvant treatment with renal insufficiency should be evaluated for the iliac .
in kidney transplant patients , the treatment should be discontinued .
patients with long-standing syndrome ( mCRC )
- In patients with splenectomy , treatment with AML should always be associated with a hole in the esophagus and / or
a hypocaloric revasc .
- experience in patients with hyperuricemia
- There have been reports of death associated with the use of growth hormone
a severe Coronary Syndrome and / or several risk factors : severe angina , a history of respiratory failure , severe respiratory failure , or lung infection or benign .
patients with a gastrostomy or more indicative of these factors is greater than those .
in patients receiving this medicine , you should consider an alternative for problems with their doctor .
- If infection is
recovered before start of treatment with AML .
there is a possibility of any signs of pulmonary infection should be explained .
- Acute respiratory distress during sleeping , keratosis contributing to sleep disorder , then
before treatment , you should start to monitor treatment accordingly during the day .
if a patient wishes to respond , the monitoring of your sleep should be continued .
- If you have any of the questions , you may have any problems with their liver .
the treatment must be discontinued and your doctor should closely discontinue the treatment for the injury .
effective CONDITIONS and Administration Site Conditions
small patients
- In children undergoing small infants , other causes or treatments that may require
pregnant growth of growth should be excluded prior to initiating therapy .
- experience in this patient group
therefore , treatment should not be started in patients with a venous relaxation .
- There is limited experience in patients with long-standing syndrome .
- Select your height &apos;s height in children / nursing infants
these may disappear if the treatment is stopped before treatment is discontinued .
- blood levels of sugar and insulin should be checked before the start of treatment and insulin .
FAS PP during treatment with growth hormone .
taking other medicines
- if you are taking or have recently taken any other medicines , including medicines obtained
please tell your doctor or pharmacist .
it is especially important that you inform your doctor if you are taking medicines for diabetes , thyroid disorder , thyroid disorder or diuretics such as oestrogen , loratadine or corticosteroids .
dosage adjustment of these medicinal products may be necessary .
pregnancy and lactation
cardio-vascular treatment with irinotecan should be discontinued during pregnancy .
if you are breast-feeding , ask your doctor for advice before taking this medicine .
ask your doctor or pharmacist for advice before taking any medicine .
driving and using machines
no studies on the effects on the ability to drive and use machines have been performed .
important information about some of the ingredients of digitalis
this medicinal product contains less than 1 mmol sodium ( 23 mg ) per ml , i. e. essentially &quot; sodium- free &quot; .
how TO USE ALTARGO
thirteen percent of the subcutaneous route is required .
this means that it is injected with a small needle in the tissue just before the injection .
you will receive appropriate training and should be trained appropriately .
for keeping the injection site , see section 5.3 .
the treatment with amiodarone is a long-term treatment .
please tell your doctor if you are planning to become pregnant .
do not use
your doctor should prescribe your own dose technique and your schedule for the dosage regimen .
understanding is comprised of each nostril .
please note the dose recommendations or the schedule without consulting your doctor .
dosage adjustments may be necessary according to your weight gain and your treatment response .
if you use more digitalis than you should
acute overdose may lead to hypoglycaemia ( a decrease in the blood sugar level ) and then in feeling removed ( increase in blood sugar levels ) .
if you forget to take digitalis
do not take a double dose to make up for a forgotten dose .
continue taking the prescribed dose by your doctor .
if you forget to breastfeed , ask your doctor for advice .
how to inject 14C-entecavir
the following instructions are to inject highlighted - 0.30 mg / ml , even .
read all of the carefully defined by step .
your doctor or other medical advice will show you how to inject yourself .
do not try to inject a double dose to make up for a forgotten dose .
- After reconstitution .
- Limit the solution carefully before injection and re-insert it only if it is clear or
- Measure sites to lower risk of myopathy
changes under the skin ) .
preparation of the components required before instituting :
- a vial containing 3 mg / ml powder for solution for injection .
- one vial with solvent for reconstitution
- a sterile disposable syringe ( e. g. one 2 ml syringe ) and a
mm mm mm ) to draw the solvent of the vial ( not supplied in the carton ) .
- a sterile glass syringe with appropriate single use only ( e. g. a
syringe with bandages ) and injection needle ( e. g.
29 mm ) For subcutaneous injection .
- 2 alcohol wipes ( not supplied in the pack ) .
wash your hands prior to any other steps .
reconstitution
- Remove the capsules from the two carton of the carton .
with cleaning educational the rubber membranes of powder and solvent vials , respectively .
- Take the solvent vial and the pre-filled syringe ( e.g. a one pre-filled pen ) ,
syringe ( 2 ml ) and needle ( e. g.
mm mm ) .
insert the needle into the rubber membrane .
- Measure the solvent vial and remove all the solvent
- Take the vial with powder and insert the needle into the powder
rubber membrane .
inject the liquid into a vein by gently , the liquid under the glass of the glass wall .
remove the syringe and the needle .
- Measure the reconstituted solution without delay
if it is intended for you .
do not shake .
-
insulin should not be used if particulate matter is visible .
it must be a clear and colourless liquid .
- use the solution immediately
for the dose titration .
- Take the sterile packed cell syringe ( e. g. a
syringe 1 ml ) and injection needle ( e. g. 3 ml )
mm ) .
- Measure the needle in the vial
reconstituted solution .
- Measure the vial and syringe in one hand
- Check that the needle tip is on in the ina
saturable transfer .
your other hand will be available to calibrate the plunger .
- holding the syringe in your outer needle upwards
7a of the vial .
- Reduced the plunger and withdraw into the syringe just immediately
if your doctor has told you to .
- Collection of air in the syringe .
if you get these blood , pull out
tap the syringe gently , the needle pointing upwards .
push the plunger slowly until the correct dose is dissolved .
- Limit of the reconstituted platelet solution prior to conception
do not use the solution if the solution is cloudy or with particles .
you now now inject the dose .
injection site
- Firmly increase the site of injection .
the best places to inject yourself are :
the damage with prolonged layer between the skin and muscle , such as the thigh and legs ) .
- you are injecting to at least 1 cm of the Marketing Authorisation :
inject and you change the injection site as you may have been trained .
- just wipe while you are on an alcohol wipe .
wait until the area is dry .
- you are gaining one sore skin fold .
with other hand , do not refrigerate the abdomen ,
pre-filled syringe you get a concern .
action the syringe in the skin that has been punctured with a 45 angle to 90 .
once the needle is in place , remove the hand in the hand and rest out of the syringe .
push the plunger on the plunger with one hand .
syringe , the needle is in a blood vessel .
do not inject this clean , remove the needle and repeat the procedure .
inject the solution by pushing the plunger slowly .
- Remove the needle out of the skin .
after injection
- After injection , press the site with a small amount of injection in patients
this summary was a thin layer for a few seconds .
do not rub the injection site .
- The final solution , and for single use only .
to be disposed of via wastewater or household waste .
discard any unused syringes in a puncture-resistant container .
if you stop taking your medicine
an interruption of or discontinuation of treatment with capecitabine treatment may involve attacking this latter .
talk to your doctor before stopping .
possible SIDE EFFECTS
like all medicines , myelitis can cause side effects , although not everybody gets them .
you should seek help for one of the following symptoms described below .
in adults ; mild
musculoskeletal and connective tissue disorders
in adults :
in infants / infants
nervous system
4.9 Overdose
adolescents
in adults : oesophageal oestradiol syndrome
endocrine disorders
development of antibodies
diabetes mellitus
neoplasms benign , malignant neoplasms
leukaemia
general Disorders and Administration Site Conditions
- local skin reactions - injection site reactions , as left , redness , redness and redness
many people are common side effects .
in rare cases , subcutaneous administration of 250-350 may result in a decrease in body weight to injection site .
- swollen , oedema ( high water in the tissue ) were observed .
this side effect
due to metformin consumption and occurs only at the beginning of treatment with colchicine and is dependent on treatment with drug-induced lipogenesis .
it is common in adults but are in adults but children and adolescents .
musculoskeletal and connective tissue disorders
- joint pain ( particularly at the hip or knee ) , hyperuricaemia of limbs
were observed .
adverse reactions that occur with drug-induced treatment and are dose-related .
they are very common in adults but uncommon in children , children and adolescents .
nervous system disorders
- a few sensory period such as numbness and tingling have been observed .
they occur .
general disorders and administration site conditions .
they are very common in adults but uncommon in children , children and adolescents .

the fingers and the gemcitabine of the hand are common side effects which were common side effects .
the pharmacokinetics of oesophageal oestradiol ( to the breakdown of the hand ) , which has been shown to be especially in adults .
- visual disturbance , headache , and vomiting have been observed .
these these reactions these are
symptoms could be considerably hypertension ( increased intraocular pressure ) that is a rare neurological event of treatment with drug-induced lipogenesis .
endocrine disorders
- There have been rare reports of diabetes have been observed .
immune system disorders :
- as medication , a few patients developed antibodies to the
however , these findings have not been shown to have an effect on tumour growth .
therefore , a common side effect .
neoplasms benign , malignant neoplasms
- Hypersensitivity reactions have been reported in children with a hormone
growth and treated by CSII .
a causal relationship has been unlikely .
if any of the side effects gets serious , or if you notice any side effects not listed in this leaflet , please tell your doctor or pharmacist .
how TO STORE ABSEAMED
keep out of the reach and sight of children .
do not use after the expiry date stated on the label and carton .
the expiry date refers to the last day of that month .
- Store and transport refrigerated ( 2 C - 8 C ) .
- Do not freeze
- Store in the original package in order to protect from light .
- After reconstitution , an infusion site pain , the Netherlands
- The medicine should be used immediately .
means up to 24 hours for the original package .
- For single use only .
do not use if you notice that the solution has been frozen or exposed to existing crises .
do not use if you notice that the solution is cloudy .
further INFORMATION
what AERINAZE contains
the active substance in radioactive is visit ( 1,3 mg ) in a vial .
1 vial contains 1.3 mg ( corresponding to 4 IU ) of wine after reconstitution with 1 ml of solvent .
the other ingredients are :
powder : glycine dihydrogen phosphate dihydrate sodium phosphate dihydrate
solvent : water for injections .
195 What looks like and contents of the pack
powder and solvent for solution for injection ( 1.3 mg ) , solvent in one vial ( 1.3 mg ) :
single use only .
the powder is white and the solvent solution is a clear , colourless liquid .
MARKETING Authorisation Holder and Manufacturer
Sandoz GmbH Sandhoferstrasse 10 A-1220 Kundl Austria
for any information about this medicinal product , please contact the local representative of the Marketing Authorisation Holder :
184 Deutschland GmbH Kandelstrasse Kirchzarten Germany .
Eesti Sandoz GmbH Sandoz GmbH Biochemiestr .
Eesti Eesti .
R01AD12
J02AX04
J02AX04 MediNet u . .
these 15
Danmark
- : 1.13 12 80
Slovenija Produkt Zdrovit Sp. z o. o .
J farmacevtska druba d.o.o.
United Kingdom Sandoz Limited Sandoz d. d .
Jevany Bohumil 37 , Dr. Way
this leaflet was last approved in { MM / YYYY } .
package LEAFLET :
information FOR THE USER
5 mg / ml powder and solvent for solution for injection
gynaecomastia
read all of this leaflet carefully before you start taking this medicine .
- Keep this leaflet .
you may need to read it again .
- If you have any further questions , ask your doctor or pharmacist .
- This medicine has been prescribed for you .
- This medicine has been prescribed for you .
it may harm them , even
if their symptoms are the same as yours .
- If any of the side effects gets serious , or if you notice any side effects not listed in this leaflet ,
please tell your doctor or pharmacist .
in this leaflet :
what AERINAZE is and what it is used to reject it .
before you are given 3 .
how to use insulin 4 .
possible side effects 5 .
possible side effects 5 How to store ATryn 6 .
further information
what ABSEAMED IS AND WHAT IT IS USED FOR
30.4 is the human hormone produced by a method known as recombinant DNA technology :
metoclopramide is similar to the human body .
30.4 is used in the following case .
treatment of infants and adolescents
- with growth factors have been associated with growth factors .
- with growth retardation has been associated with growth retardation .
- with growth renal disease ( CRF ) .
- with reduced growth retardation in children / adolescents infants
no testicular growth effects are available with regard to 4 years of age or older .
diagnosis of ice should be confirmed by the appropriate assay .
before YOU TAKE ABSEAMED
diagnosis and sequelae should be performed by doctors experienced in the diagnosis and treatment of patients with growth retardation .
do not use reused
- if you are allergic ( hypersensitive ) to launch or any of the other ingredients of
polyvinylchloride .
- if you have discussed this with you , she should be checked prior to treatment .
this summary was last updated in 11-2007 .
- to increase foetal growth if it proceeds ( FVC ) .
- if you have previously suffered from acute complications associated with surgery
6
take special care with Cancidas
- The OBR may interfere with your insulin needs .
your blood sugar should be checked .
17 controlled treatment with capecitabine .
- If you have diabetes or a family history of diabetes treatment , treatment with insulin
this dosage adjustment may be necessary when initiating treatment with AML .
- Redistribution ( a thyroid gland activity ) may develop during the
treatment with amiodarone .
a symptom may reduce the response to the hydrophilic .
therefore , thyroid hormones should be checked periodically during therapy .
- an adequate high blood pressure ( high pressure in the brain ) ensures a
HVOD .
if symptoms such as headaches , visual disturbance , nausea , vomiting or vomiting , ask your doctor for advice .
you may need to have an eye test to achieve an abnormal increase in intrauterine pressure .
depending on the outcome of treatment with irinotecan may be stopped .
- Patients with pre-existing neurologic disorder ( OI ) may leak
if you develop digitalis or pain for the hip , ask your doctor .
- The seal of Life ( a para-hydroxy-sulphate ) can occur during treatment with the spine .
there is a potential for additive benefit .
therefore , signs of hyperthyroidism should be monitored during treatment with Saturday .
however , there was no evidence of an increase or severity of mineralisation .
- If you have any process , you will have a regular basis of your signs of
recurrence of contamination .
- No information on the safety of the substitution therapy by the growth of growth
experience in patients with acute coronary syndromes .
if you have acute Coronary positive , your doctor will assess the safety of continuing therapy .
- The clinical experience is limited in patients &gt; 60 years of age .
patients with chronic renal failure ( CRF )
- In patients with an autologous heart disease treatment cannot complete their
renal function is less than 50 for the normal range .
to ensure that the potential to be followed by your doctor that you have an intolerance to become growth for a year , before being treated .
adjuvant treatment with renal insufficiency should be evaluated for the iliac .
in kidney transplant patients , the treatment should be discontinued .
patients with long-standing syndrome ( mCRC )
- In patients with CLCR , the treatment with L-dopa should always be associated with a hole .
a hypocaloric revasc .
- experience in patients with hyperuricemia
- There have been reports of death associated with the use of growth hormone
a severe Coronary Syndrome and / or several risk factors : severe angina , a history of respiratory failure , severe respiratory failure , or lung infection or benign .
patients with a gastrostomy or more indicative of these factors is greater than those .
in patients receiving this medicine , you should consider an alternative for problems with their doctor .
- If infection is
recovered before start of treatment with AML .
there is a possibility of any signs of pulmonary infection should be explained .
- Acute respiratory distress during sleeping , keratosis contributing to sleep disorder , then
before treatment , you should start to monitor treatment accordingly during the day .
if a patient wishes to respond , the monitoring of your sleep should be continued .
- If you have any of the questions , you may have any problems with their liver .
the treatment must be discontinued and your doctor should closely discontinue the treatment for the injury .
-
prior to and during treatment with growth hormone .
small patients
- In children undergoing small infants , other causes or treatments that may require
pregnant growth of growth should be excluded prior to initiating therapy .
- experience in this patient group
therefore , treatment should not be started in patients with a venous relaxation .
- There is limited experience in patients with long-standing syndrome .
- Select your height &apos;s height in children / nursing infants
these may disappear if the treatment is stopped before treatment is discontinued .
- blood levels of sugar and insulin should be checked before the start of treatment and insulin .
FAS PP during treatment with growth hormone .
taking other medicines
- if you are taking or have recently taken any other medicines , including medicines obtained
please tell your doctor or pharmacist .
it is especially important that you inform your doctor if you are taking medicines for diabetes , thyroid disorder , thyroid disorder or diuretics such as oestrogen , loratadine or corticosteroids .
dosage adjustment of these medicinal products may be necessary .
pregnancy and lactation
cardio-vascular treatment with irinotecan should be discontinued during pregnancy .
if you are breast-feeding , ask your doctor for advice before taking this medicine .
ask your doctor or pharmacist for advice before taking any medicine .
driving and using machines
no studies on the effects on the ability to drive and use machines have been performed .
important information about some of the ingredients of digitalis
this medicinal product contains less than 1 mmol sodium ( 23 mg ) per ml , i. e. essentially &quot; sodium- free &quot; .
after reconstitution , one ml contains 15 mg of benzyl alcohol .
due to the rare occurrence of benzyl alcohol , this medicinal product must not be used in patients with deteriorating renal function .
there may be some reactions and children less than 3 years of age and children less than 3 years of age .
how TO USE ALTARGO
5 mg / ml is expected to be used for single use only .
it must only be given with the re-usable pen injector , a specific injection device for specific injection and solvent for solution for injection .
J is injected with a small needle in the tissue just , just within the tissue just .
you will receive appropriate training and should be trained appropriately .
for keeping the injection site , see section 5.3 .
the treatment with amiodarone is a long-term treatment .
please tell your doctor if you are planning to become pregnant .
( , 95 CI ) In
your doctor should prescribe your own dose technique and your schedule for the dosage regimen .
understanding is comprised of each nostril .
please note the dose recommendations or the schedule without consulting your doctor .
dosage adjustments may be necessary according to your weight gain and your treatment response .
if you use more digitalis than you should
acute overdose may lead to hypoglycaemia ( a decrease in the blood sugar level ) and then in feeling removed ( increase in blood sugar levels ) .
if you forget to take digitalis
do not take a double dose to make up for a forgotten dose .
continue on the prescribed dose .
if you forget to breastfeed , ask your doctor for advice .
how to inject 14C-entecavir 5 mg / ml
the following instructions are to inject highlighted 5 mg to allow the following instructions .
read all of the carefully defined by step .
your doctor or other medical advice will give you how to inject noticeably different .
do not try to inject a double dose to make up for a forgotten dose .
- After reconstitution .
- Limit the solution carefully before injection and use only if it is clear or only the
- Measure sites to lower risk of myopathy
changes under the skin ) .
preparation of the components required before instituting :
- a bottle containing 5 mg / ml powder for solution for injection .
- one cartridge of solvent to measure 5 mg / ml
- an transfer bag for transfer and transfer
reconstituted in the cartridge ( see instructions for using the pen injector ) .
- The pen injector Cardiomegaly ADMINISTERED to be degraded .
used with AML 5.0 mg / ml
- For subcutaneous injection .
- 2 alcohol wipes ( not supplied in the pack ) .
wash your hands prior to any other steps .
reconstitution
- Remove the protective cap from the vial .
with the wipe of the
cleaning tapping the rubber membranes of the powder and rubber device .
- .
cartridge in the vial .
follow the transfer instructions for transfer .
special care with the reconstituted solution should be discarded
until all .
do not shake .
-
insulin should not be used if particulate matter is visible .
it must be a clear and colourless liquid .
- Measure the dose dissolved in the cartridge with the
transfer transfer .
injection site
- Lead the cartridge in the reusable pen .
follow the instructions for using the pen injector .
now set the dose .
- Dispose of the air bubble .
- Firmly increase the site of injection .
the best places to inject yourself are :
the damage with prolonged layer between the skin and muscle , such as the thigh and legs ) .
- you are injecting to at least 1 cm of the Marketing Authorisation :
inject and you change the injection site as you may have been trained .
- just wipe while you are on an alcohol wipe .
wait until the area is dry .
- Inability to the needle in the skin as well as
doctor .
after injection
- After injection , press the site with a small amount of injection in patients
this summary was a thin layer for a few seconds .
do not rub the injection site .
- Remove the needle from the pen with protection cap and needle cap
dispose of it .
this modulates the sterile filter matrix .
this will also air bubbles in the pen and all of the needle .
do not force your needles or the pen .
- Let the cartridge in the pen , put the pen cap back on , then the pen cap
Shelf life
do not use the solution if the solution is cloudy or contains particles .
if you stop taking digitalis
an interruption of or discontinuation of treatment with capecitabine treatment may involve attacking this latter .
talk to your doctor before stopping .
possible SIDE EFFECTS
like all medicines , myelitis can cause side effects , although not everybody gets them .
consult your doctor for advice when you get any of the following symptoms described below .
common ( at least 1 in 100 patients but less than 1 in 10 patients )
there is
Uncommon ( at least 1 in 10,000 patients but less than 1 in 10,000 patients but less than 1 in every 1,000 patients )
very rare ( occurring in less than 1 in 10,000 patients )
/ the child / child / child
mild
musculoskeletal and connective tissue disorders
in adults ; oedema in adults with mild limbs , joint pain and muscle pain
in infants / the child / breast stiffness , neuropathic pain , joint pain and muscle stiffness
nervous system
hallucinations
/ the child / child / child
gemcitabine Cisplatin
CTCa 2005
6 .
immune system disorders
development of antibodies
diabetes mellitus
neoplasms benign , malignant neoplasms
general Disorders and Administration Site Conditions
- local reactions - injection site reactions , as left , pain , redness , redness , and redness
many people are common side effects .
in rare cases , subcutaneous administration of 250-350 may result in a decrease in body weight to injection site .
- swollen , oedema ( high water in the tissue ) were observed .
this side effect
due to metformin consumption and occurs only at the beginning of treatment with colchicine and is dependent on treatment with drug-induced lipogenesis .
it is common in adults but are in adults but children and adolescents .
musculoskeletal and connective tissue disorders
- joint pain ( particularly at the hip or knee ) , hyperuricaemia of limbs
exacerbation of and repeated doses were observed .
adverse reactions that occur with drug-induced treatment and are dose-related .
they are very common in adults but uncommon in children , children and adolescents .
nervous system disorders
- a few sensory period such as numbness and tingling have been observed .
they occur .
general disorders and administration site conditions .
they are very common in adults but uncommon in children , children and adolescents .

the fingers and the gemcitabine of the hand are common side effects which were common side effects .
the pharmacokinetics of oesophageal oestradiol ( to the breakdown of the hand ) , which has been shown to be especially in adults .
- visual disturbance , headache , and vomiting have been observed .
these these reactions these are
symptoms could be considerably hypertension ( increased intraocular pressure ) that is a rare neurological event of treatment with drug-induced lipogenesis .
endocrine disorders
- There have been rare reports of diabetes have been observed .
immune system disorders :
- as medication , a few patients developed antibodies to the
however , these findings have not been shown to have an effect on tumour growth .
therefore , a common side effect .
neoplasms benign , malignant neoplasms
- Hypersensitivity reactions have been reported in children with a hormone
growth and treated by CSII .
a causal relationship has been unlikely .
if any of the side effects gets serious , or if you notice any side effects not listed in this leaflet , please tell your doctor or pharmacist .
how TO STORE ABSEAMED
keep out of the reach and sight of children .
do not use after the expiry date stated on the label and carton .
the expiry date refers to the last day of that month .
- Store and transport refrigerated ( 2 C - 8 C ) .
- Do not freeze .
- Store in the original package in order to protect from light .
- After first injection , the cartridge must remain in the pen injector and stored at refrigerated temperature
42 C ( 2 C - 8 C ) and only used for up to 21 days .
do not use if you notice that the solution has been frozen or exposed to existing crises .
do not use if you notice that the solution is cloudy .
further INFORMATION
what AERINAZE contains
the active substance in radioactive is visit in a vial .
one cartridge contains 5 mg ( corresponding to 15 IU ) of wine after reconstitution with 1 ml of solvent .
the other ingredients are :
powder : glycine dihydrogen phosphate dihydrate sodium phosphate dihydrate
solvent : water for injections
what differs and contents of the pack
MARKETING Authorisation Holder and Manufacturer
Sandoz GmbH Sandhoferstrasse 10 A-1220 Kundl Austria
for any information about this medicinal product , please contact the local representative of the Marketing Authorisation Holder :
Sandoz A / S Hallas All
Norge Biovitrum Production Sandoz GmbH Kandelstrasse 4 D-80336 Mnchen Germany .
Eesti Sandoz d. d .
Danmark
- : 1.13 12 80
Italia Sandoz S. p . A.
haematemesis Avastinb
Latvija Sandoz d. d .
52 Consistent Sandoz Tl .
this leaflet was last approved in { MM / YYYY } .
package LEAFLET :
information FOR THE USER
w.1 mg / ml solution for injection
gynaecomastia
read all of this leaflet carefully before you start using this medicine .
you may need to read it again .
- If you have any further questions , ask your doctor or pharmacist .
- This medicine has been prescribed for you .
- This medicine has been prescribed for you .
it may harm them , even
if their symptoms are the same as yours .
- If any of the side effects gets serious , or if you notice any side effects not listed in this leaflet ,
please tell your doctor or pharmacist .
in this leaflet :
- You are aware of the operation and in passing it to unlock
before YOU use tools or machines
- How to use reused
- 5 Possible side effects
- storing Apidra-
- further information
what ABSEAMED IS AND WHAT IT IS USED FOR
30.4 is the human hormone produced by recombinant DNA technology as recombinant DNA technology :
metoclopramide is similar to the human body .
30.4 is used in the following case .
treatment of infants and adolescents :
- with growth factors have been associated with growth factors .
- with growth retardation has been associated with growth retardation .
- with growth renal disease ( CRF ) .
- with reduced growth retardation in children / adolescents infants
no investigations were affected by looking at the age of 4 years or older .
diagnosis of ice should be confirmed by the appropriate assay .
before YOU USE ALTARGO
diagnosis should be comprehensively and supervised by a physician experienced in the diagnosis and treatment of patients with growth retardation and to receive appropriate precautions .
do not use reused
- if you are allergic ( hypersensitive ) to launch or any of the other ingredients of
polyvinylchloride .
- if you have discussed this with you , she should be checked prior to treatment .
this summary was last updated in 11-2007 .
- to increase foetal growth if it proceeds ( FVC ) .
- if you have previously suffered from acute complications associated with surgery

take special care with Cancidas
- The OBR may interfere with your insulin needs .
your blood sugar should be checked .
17 controlled treatment with capecitabine .
- If you have diabetes or a family history of diabetes treatment , treatment with insulin
this dosage adjustment may be necessary when initiating treatment with AML .
- Redistribution ( a thyroid gland activity ) may develop during the
treatment with amiodarone .
a symptom may reduce the response to the hydrophilic .
therefore , thyroid hormones should be checked periodically during therapy .
- an adequate high blood pressure ( high pressure in the brain ) ensures a
HVOD .
if symptoms such as headaches , visual disturbance , nausea , vomiting or vomiting , ask your doctor for advice .
you may need to have an eye test to achieve an abnormal increase in intrauterine pressure .
depending on the outcome of treatment with irinotecan may be stopped .
- Patients with pre-existing neurologic disorder ( OI ) may leak
if you develop digitalis or pain for the hip , ask your doctor .
- The seal of Life ( a para-hydroxy-sulphate ) can occur during treatment with the spine .
there is a potential for additive benefit .
therefore , signs of hyperthyroidism should be monitored during treatment with Saturday .
however , there was no evidence of an increase or severity of mineralisation .
- If you have any process , you will have a regular basis of your signs of
recurrence of contamination .
- No information on the safety of the substitution therapy by the growth of growth
experience in patients with acute coronary syndromes .
if you have acute Coronary positive , your doctor will assess the safety of continuing therapy .
- The clinical experience is limited in patients &gt; 60 years of age .
patients with an autologous renal function ( congestive heart failure )
- In patients with an autologous heart disease treatment cannot complete their
renal function is less than 50 than normal .
to ensure that the potential to be followed by your doctor that you have an intolerance to become growth for a year , before being treated .
adjuvant treatment with renal insufficiency should be evaluated for the iliac .
in kidney transplant patients , the treatment should be discontinued .
patients with splenectomy ( seminiferous capillary )
- In patients with splenectomy , treatment with AML should always be associated with a hole in the esophagus and / or
a hypocaloric revasc .
- experience in patients with hyperuricemia
- There have been reports of death associated with the use of growth hormone
a severe Coronary Syndrome and / or several risk factors : severe angina , a history of respiratory failure , severe respiratory failure , or lung infection or benign .
patients with a gastrostomy or more indicative of these factors is greater than those .
in patients receiving this medicine , you should consider an alternative for problems with their doctor .
- If infection is
recovered before start of treatment with AML .
there is a possibility of any signs of pulmonary infection should be explained .
- Acute respiratory distress during sleeping , keratosis contributing to sleep disorder , then
before treatment , you should start to monitor treatment accordingly during the day .
if a patient wishes to respond , the monitoring of your sleep should be continued .
- If you have any of the questions , you may have any problems with their liver .
the treatment must be discontinued and your doctor should closely discontinue the treatment for the injury .
-
prior to and during treatment with growth hormone .
small patients
- In children undergoing small infants , other causes or treatments that may require
pregnant growth of growth should be excluded prior to initiating therapy .
- experience in this patient group
therefore , treatment should not be started in patients with a venous relaxation .
- There is limited experience in patients with long-standing syndrome .
- Select your height &apos;s height in children / nursing infants
these may disappear if the treatment is stopped before treatment is discontinued .
- blood levels of sugar and insulin should be checked before the start of treatment and insulin .
FAS PP during treatment with growth hormone .
taking other medicines
- if you are taking or have recently taken any other medicines , including medicines obtained
please tell your doctor or pharmacist .
it is especially important to tell your doctor if you are taking medicines to treat diabetes or thyroid problems , anticonvulsant agents , cyclosporin or corticosteroids such as hypothyroidism , fertility or corticosteroids .
dosage adjustment of these medicinal products may be necessary .
pregnancy and lactation
the treatment with irinotecan should be discontinued if pregnancy is discontinued .
if you are breast-feeding , ask your doctor for advice before taking this medicine .
ask your doctor or pharmacist for advice before taking any medicine .
driving and using machines
no studies on the effects on the ability to drive and use machines have been performed .
important information about some of the ingredients of digitalis
this medicinal product contains less than 1 mmol sodium ( 23 mg ) per ml , i. e. essentially &quot; sodium- free &quot; .
one ml contains 9 mg of benzyl alcohol .
due to the rare occurrence of benzyl alcohol , this medicinal product must not be used in patients with deteriorating renal function .
there may be some reactions and children less than 3 years of age and children less than 3 years of age .
how TO USE ALTARGO
Danmark .
it must only be given with the reusable pen disrupting 5 , a device designed to be used with peel-off stickers for solution for injection .
J is injected with a small needle in the tissue just , just within the tissue just .
you will receive appropriate training and should be trained appropriately .
for keeping the injection site , see section 5.3 .
the treatment with amiodarone is a long-term treatment .
please tell your doctor if you are planning to become pregnant .
at
your doctor should prescribe your own dose technique and your schedule for the dosage regimen .
understanding is comprised of each nostril .
please note the dose recommendations or the schedule without consulting your doctor .
dosage adjustments may be necessary according to your weight gain and your treatment response .
if you use more digitalis than you should
acute overdose may lead to hypoglycaemia ( a decrease in the blood sugar level ) and then in feeling removed ( increase in blood sugar levels ) .
an ongoing long-term overdose may result in signs and symptoms of ROS or tilting ( enlargement of the ears , nose , lips , tongue , tongue and jaw ) .
if you have used a dose of 5.25 too high , ask your doctor .
if you forget to use tools or machines
do not take a double dose to make up for a forgotten dose .
continue on the prescribed dose .
if you forget to breastfeed , ask your doctor for advice .
how AMBIRIX IS / ml are
the following instructions are intended to explain 144 mg / ml , even .
read all of the carefully defined by step .
your doctor or other medical advice will give you how to inject noticeably different .
do not try to inject a double dose to make up for a forgotten dose .
- Measure is given by injection under the skin ( subcutaneously ) .
- Limit the solution carefully before injection and use only if it is clear or only the
- Measure sites to lower risk of myopathy
changes under the skin ) .
preparation of the components required before instituting :
- a cartridge containing specially mg / ml solution for injection .
- Obstruction of the monovalent 5 , a device of injection device
occasionally Hyponatremia is designed to be used with talking mg / ml solution for injection ( not supplied in the carton ; see the instructions for compassionate use ) .
- For subcutaneous injection .
- 2 alcohol wipes ( not supplied in the pack ) .
wash your hands prior to any food .
injection site
- Are you are aware of the
rubber stopper .
- The liquid should be clear and colourless .
- Measure the cartridge in the disposable pen injector .
follow the instructions
use of the pen injector .
to decide the pen .
- Firmly increase the site of injection .
the best places to inject yourself are :
the damage with prolonged layer between the skin and muscle , such as the thigh and legs ) .
- you are injecting to at least 1 cm of the Marketing Authorisation :
inject and you change the injection site as you may have been trained .
- just wipe while you are on an alcohol wipe .
wait until the area is dry .
- Inability to the needle in the skin as well as
doctor .
after injection
- After injection , press the site with a small amount of injection in patients
this summary was a thin layer for a few seconds .
do not rub the injection site .
- Remove the needle from the pen with protection cap and needle cap
dispose of it .
this will assure the sterile bandage and method of visible precipitates .
this will also air bubbles in the pen and all of the needle .
do not force your needles or the pen .
- Clean the cartridge in the pen , put the cap back on the pen
and keep them .
do not use the solution if the solution is cloudy or contains particles .
if you stop taking your medicine
an interruption of or discontinuation of treatment with capecitabine treatment may involve attacking this latter .
talk to your doctor before stopping .
possible SIDE EFFECTS
like all medicines , myelitis can cause side effects , although not everybody gets them .
consult your doctor for advice when you experience symptoms described below .
adult patients In an autologous blood predonation :
nervous system disorders
in adults :
in infants / the child / child infection : ILP ILP :
hypertension
in adults : oesophageal oestradiol syndrome
endocrine disorders
development of antibodies
diabetes mellitus
neoplasms benign , malignant neoplasms
leukaemia
general Disorders and Administration Site Conditions
- local reactions - injection site reactions , as left , pain , redness , redness , and redness
many people are common side effects .
in rare cases , subcutaneous administration of 250-350 may result in a decrease in body weight to injection site .
- swollen , oedema ( high water in the tissue ) were observed .
this side effect
due to metformin consumption and occurs only at the beginning of treatment with colchicine and is dependent on treatment with drug-induced lipogenesis .
it is common in adults but Uncommon in infants and adolescents .
musculoskeletal and connective tissue disorders
- joint pain ( particularly at the hip or knee ) , hyperuricaemia of limbs
exacerbation of and repeated doses were observed .
adverse reactions that occur with drug-induced treatment and are dose-related .
they are very common in adults but uncommon in children , children and adolescents .
nervous system disorders
- a few sensory period such as numbness and tingling have been observed .
they occur .
general disorders and administration site conditions .
they are very common in adults but uncommon in children , children and adolescents .
- Thrombotic ( reduced fat tissue )
find on the finger and the design of the hand are uncommon side effects .
the pharmacokinetics of oesophageal oestradiol ( to the breakdown of the hand ) , which has been shown to be especially in adults .
- visual disturbance , headache , and vomiting have been observed .
these these reactions these are
symptoms could be considerably hypertension ( increased intraocular pressure ) that is a rare neurological event of treatment with drug-induced lipogenesis .
endocrine disorders
- There have been rare reports of diabetes have been observed .
immune system disorders :
- as medication , a few patients developed antibodies to the
however , these findings have not been shown to have an effect on tumour growth .
therefore , a common side effect .
neoplasms benign , malignant neoplasms
- Hypersensitivity reactions have been reported in children with a hormone
growth and treated by CSII .
a causal relationship has been unlikely .
if any of the side effects gets serious , or if you notice any side effects not listed in this leaflet , please tell your doctor or pharmacist .
how TO STORE ABSEAMED
keep out of the reach and sight of children .
do not use after the expiry date stated on the label and carton .
the expiry date refers to the last day of that month .
- Store and transport refrigerated ( 2 C - 8 C ) .
- Do not freeze .
- Store in the original package in order to protect from light .
- After first injection , the cartridge must be kept in the reusable pen injector and stored in stored
in a refrigerator ( 2 C - 8 C ) and only used for up to 28 days .
do not use if the medicine has been frozen or exposed to existing crises .
do not use if you notice that the solution is cloudy .
further INFORMATION
what AERINAZE contains
the active substance in radioactive is visit .
one cartridge contains 5 mg ( corresponding to 15 IU ) of wine in 1.5 ml .
the other ingredients are : disodium phosphate sodium dihydrogen phosphate dihydrate
cetyl alcohol 188 water for injections
195 What looks like and contents of the pack
w.1 it is presented as a solution for injection .
packs of 1 , 5 or 10 .
905-910 is a clear and colourless solution for injection .
not all pack sizes may be marketed .
MARKETING Authorisation Holder and Manufacturer
Sandoz GmbH Sandhoferstrasse 10 A-1220 Kundl Austria
for any information about this medicinal product , please contact the local representative of the Marketing Authorisation Holder :
Eesti Sandoz GmbH Biochemiestr .
Eesti Eesti .
R01AD12
J02AX04
Thursday Index .
Cellulose .
Espaa Sandoz A , Ariclaim .
Danmark
Portugal Sandoz SAS
United Kingdom Sandoz Limited Sandoz d. d .
Jevany Bohumil 37 , Dr. Way
this leaflet was last approved in { MM / YYYY } .
package LEAFLET :
information FOR THE USER
3.18 mg / ml solution for injection
gynaecomastia
read all of this leaflet carefully before you start using this medicine .
you may need to read it again .
- If you have any further questions , ask your doctor or pharmacist .
- This medicine has been prescribed for you .
- This medicine has been prescribed for you .
it may harm them , even
if their symptoms are the same as yours .
- If any of the side effects gets serious , or if you notice any side effects not listed in this leaflet ,
please tell your doctor or pharmacist .
in this leaflet :
what AERINAZE is and what it is used to reject it .
before you use tools or machines .
how to use insulin 4 .
possible side effects 5 .
possible side effects 5 How to store ATryn 6 .
further information
what ABSEAMED IS AND WHAT IT IS USED FOR
30.4 is the human hormone produced by recombinant DNA technology as recombinant DNA technology :
metoclopramide is similar to the human body .
30.4 is used in the following case .
treatment of infants and adolescents :
- with growth factors due to the lack of growth hormone production .
- with growth retardation has been associated with growth retardation .
- with growth renal disease ( CRF ) .
- with reduced growth retardation in children / adolescents infants
no investigations were affected by looking at the age of 4 years or older .
diagnosis of ice should be confirmed by the appropriate assay .
before YOU USE ALTARGO
diagnosis should be comprehensively and supervised by a physician experienced in the diagnosis and treatment of patients with growth retardation and to receive appropriate precautions .
do not use reused
- if you are allergic ( hypersensitive ) to launch or any of the other ingredients of
polyvinylchloride .
- if you have discussed this with you , she should be checked prior to treatment .
this summary was last updated in 11-2007 .
- to increase foetal growth if it proceeds ( FVC ) .
- if you have previously suffered from acute complications associated with surgery

take special care with Cancidas
- The OBR may interfere with your insulin needs .
your blood sugar should be checked .
17 controlled treatment with capecitabine .
- If you have diabetes or a family history of diabetes treatment , treatment with insulin
this dosage adjustment may be necessary when initiating treatment with AML .
- Redistribution ( a thyroid gland activity ) may develop during the
treatment with amiodarone .
a symptom may reduce the response to the hydrophilic .
therefore , thyroid hormones should be checked periodically during therapy .
- an adequate high blood pressure ( high pressure in the brain ) ensures a
HVOD .
if symptoms such as headaches , visual disturbance , nausea , vomiting or vomiting , ask your doctor for advice .
you may need to have an eye test to achieve an abnormal increase in intrauterine pressure .
depending on the outcome of treatment with irinotecan may be stopped .
- Patients with pre-existing neurologic disorder ( OI ) may leak
if you develop digitalis or pain for the hip , ask your doctor .
- The seal of Life ( a para-hydroxy-sulphate ) can occur during treatment with the spine .
there is a potential for additive benefit .
therefore , signs of hyperthyroidism should be monitored during treatment with Saturday .
however , there was no evidence of an increase or severity of mineralisation .
- If you have any process , you will have a regular basis of your signs of
recurrence of contamination .
- No information on the safety of the substitution therapy by the growth of growth
experience in patients with acute coronary syndromes .
if you have acute Coronary positive , your doctor will assess the safety of continuing therapy .
- The experience in patients &gt; 60 years is limited .
patients with an autologous renal function ( congestive heart failure )
- In patients with an autologous heart disease treatment cannot complete their
renal function is less than 50 than normal .
to ensure that the potential to be followed by your doctor that you have an intolerance to become growth for a year , before being treated .
adjuvant treatment with renal insufficiency should be evaluated for the iliac .
in kidney transplant patients , the treatment should be discontinued .
patients with splenectomy ( seminiferous capillary )
- In patients with splenectomy , treatment with AML should always be associated with a hole in the esophagus and / or
a hypocaloric revasc .
- experience in patients with hyperuricemia
- There have been reports of death associated with the use of growth hormone
a severe Coronary Syndrome and / or several risk factors : severe angina , a history of respiratory failure , severe respiratory failure , or lung infection or benign .
patients with a gastrostomy or more indicative of these factors is greater than those .
in patients receiving this medicine , you should consider an alternative for problems with their doctor .
- If infection is
recovered before start of treatment with AML .
during your treatment with the signs of pulmonary infection should be difficult .
- Acute respiratory distress during sleeping , keratosis contributing to sleep disorder , then
before treatment , you should start to monitor treatment accordingly during the day .
if a patient wishes to respond , the monitoring of your sleep should be continued .
- If you have any of the questions , you may have any problems with their liver .
the treatment must be discontinued and your doctor should closely discontinue the treatment for the injury .
-
prior to and during treatment with growth hormone .
small patients
- In children undergoing small infants , other causes or treatments that may require
pregnant growth of growth should be excluded prior to initiating therapy .
- experience in this patient group
therefore , treatment should not be started in patients with a venous relaxation .
- There is limited experience in patients with long-standing syndrome .
- Select your height &apos;s height in children / nursing infants
these may disappear if the treatment is stopped before treatment is discontinued .
- blood levels of sugar and insulin should be checked before the start of treatment and insulin .
FAS PP during treatment with growth hormone .
taking other medicines
- if you are taking or have recently taken any other medicines , including medicines obtained
please tell your doctor or pharmacist .
it is especially important to tell your doctor if you are taking medicines to treat diabetes or thyroid problems , anticonvulsant agents , cyclosporin or corticosteroids such as hypothyroidism , fertility or corticosteroids .
dosage adjustment of these medicinal products may be necessary .
pregnancy and lactation
the treatment with irinotecan should be discontinued if pregnancy is discontinued .
if you are breast-feeding , ask your doctor for advice before taking this medicine .
ask your doctor or pharmacist for advice before taking any medicine .
driving and using machines
no studies on the effects on the ability to drive and use machines have been performed .
important information about some of the ingredients of digitalis
this medicinal product contains less than 1 mmol sodium ( 23 mg ) per ml , i. e. essentially &quot; sodium- free &quot; .
how TO USE ALTARGO
gently pinch 48 mg / ml is intended for use .
it should only be given with the reusable pen GTC 10 , an injection device designed to be used with peel-off stickers for Injection .
J is injected with a small needle in the tissue just , just within the tissue just .
you will receive appropriate training and should receive appropriate training for of your doctor or in giving yourself .
for keeping the injection site , see section 5.3 .
the treatment with amiodarone is a long-term treatment .
please tell your doctor if you are planning to become pregnant .
at
your doctor should prescribe your own dose technique and your schedule for the dosage regimen .
understanding is comprised of each nostril .
please note the dose recommendations or the schedule without consulting your doctor .
dosage adjustments may be necessary according to your weight gain and your treatment response .
if you use more digitalis than you should
acute overdose may lead to hypoglycaemia ( a decrease in the blood sugar level ) and then in feeling removed ( increase in blood sugar levels ) .
an ongoing long-term overdose may result in signs and symptoms of ROS or tilting ( enlargement of the ears , nose , lips , tongue , tongue and jaw ) .
if you have used a dose of 5.25 too high , ask your doctor .
if you forget to use tools or machines
do not take a double dose to make up for a forgotten dose .
continue on the prescribed dose .
if you forget to breastfeed , ask your doctor for advice .
how to inject 50-150 mg / ml
subsequent dosing instructions are provided to inject Betaferon correctly / ml , even .
read all of the carefully defined by step .
your doctor or other medical advice will show you how to inject yourself .
do not try to inject a double dose to make up for a forgotten dose .
- Measure is given by injection under the skin ( subcutaneously ) .
- Limit the solution carefully before injection and re-insert it only if it is clear or
- Measure sites to lower risk of myopathy
changes under the skin ) .
preparation of the components required before instituting :
- a cartridge of 250-350 mg / ml solution for injection .
- Paclitaxel GTC 10 , a injection device 10 , an injection device
tremor ) .
- For subcutaneous injection .
- 2 alcohol wipes ( not supplied in the pack ) .
wash your hands prior to any other steps .
select an injection site
- Are you are aware of the
rubber stopper .
- The liquid should be clear and colourless .
- Measure the cartridge in the disposable pen injector .
follow the instructions
use of the pen injector .
to decide the pen .
- Firmly increase the site of injection .
the best places to inject yourself are :
the damage with prolonged layer between the skin and muscle , such as the thigh and legs ) .
- you are injecting to at least 1 cm of the Marketing Authorisation :
inject and you change the injection site as you may have been trained .
- just wipe while you are on an alcohol wipe .
wait until the area is dry .
- Inability to the needle in the skin as well as
doctor .
after injection
- After injection , press the site with a small amount of injection in patients
this summary was a thin layer for a few seconds .
do not rub the injection site .
- Remove the needle from the pen with protection cap and needle cap
dispose of it .
this will assure the sterile bandage and method of visible precipitates .
this will also air bubbles in the pen and all of the needle .
do not force your needles or the pen .
- Clean the cartridge in the pen , put the cap back on the pen
and keep them .
do not use the solution if the solution is cloudy or contains particles .
if you stop taking your medicine
an interruption of or discontinuation of treatment with capecitabine treatment may involve attacking this latter .
talk to your doctor before stopping .
possible SIDE EFFECTS
like all medicines , myelitis can cause side effects , although not everybody gets them .
consult your doctor for advice when you experience symptoms described below .
adult patients In an autologous blood predonation :
nervous system disorders
in adults :
in infants / the child / child infection : ILP ILP :
hypertension
in adults : oesophageal oestradiol syndrome
endocrine disorders
development of antibodies
diabetes mellitus
neoplasms benign , malignant neoplasms
leukaemia
general Disorders and Administration Site Conditions
- local reactions - injection site reactions , as left , pain , redness , redness , and redness
many people are common side effects .
in rare cases , subcutaneous administration of 250-350 may result in a decrease in body weight to injection site .
- swollen , oedema ( high water in the tissue ) were observed .
this side effect
due to metformin consumption and occurs only at the beginning of treatment with colchicine and is dependent on treatment with drug-induced lipogenesis .
it is
musculoskeletal and connective tissue disorders
- joint pain ( particularly at the hip or knee ) , hyperuricaemia of limbs
exacerbation of and repeated doses were observed .
adverse reactions that occur with drug-induced treatment and are dose-related .
they are very common in adults but uncommon in children , children and adolescents .
nervous system disorders
- a few sensory period such as numbness and tingling have been observed .
they occur .
general disorders and administration site conditions .
they are very common in adults but uncommon in children , children and adolescents .
- Thrombotic ( reduced fat tissue )
find on the finger and the design of the hand are uncommon side effects .
the pharmacokinetics of oesophageal oestradiol ( to the breakdown of the hand ) , which has been shown to be especially in adults .
- visual disturbance , headache , and vomiting have been observed .
these these reactions these are
symptoms could be considerably hypertension ( increased intraocular pressure ) that is a rare neurological event of treatment with drug-induced lipogenesis .
endocrine disorders
- There have been rare reports of diabetes have been observed .
immune system disorders :
- as medication , a few patients developed antibodies to the
however , these findings have not been shown to have an effect on tumour growth .
therefore , a common side effect .
neoplasms benign , malignant neoplasms
- Hypersensitivity reactions have been reported in children with a hormone
growth and treated by CSII .
a causal relationship has been unlikely .
if any of the side effects gets serious , or if you notice any side effects not listed in this leaflet , please tell your doctor or pharmacist .
how TO STORE ABSEAMED
keep out of the reach and sight of children .
do not use after the expiry date stated on the label and carton .
the expiry date refers to the last day of that month .
- Store and transport refrigerated ( 2 C - 8 C ) .
- Do not freeze .
- Store in the original package in order to protect from light .
- After first injection , the cartridge must be kept in the reusable pen injector and stored in stored
in a refrigerator ( 2 C - 8 C ) and only used for up to 28 days .
do not use if the medicine has been frozen or exposed to existing crises .
do not use if you notice that the solution is cloudy .
further INFORMATION
what AERINAZE contains
the active substance in radioactive is visit .
one cartridge contains 35.7 mg ( corresponding to 30 IU ) of beer in 1.5 ml .
the other ingredients are : disodium phosphate dihydrate sodium dihydrogen phosphate dihydrate
116a
what TO looks like and contents of the pack
w.1 it is presented as a solution for injection .
packs of 1 , 5 or 10 .
905-910 is a clear and colourless solution for injection .
not all pack sizes may be marketed .
MARKETING Authorisation Holder and Manufacturer
Sandoz GmbH Sandhoferstrasse 10 A-1220 Kundl Austria
for any information about this medicinal product , please contact the local representative of the Marketing Authorisation Holder :
Eesti Sandoz d. d .
R01AD12
J02AX04
7a .
this may be .
Danmark
Latvija Sandoz d. d .
Lietuva Sandoz France Tl .
this leaflet was last approved in { MM / YYYY } .
European PUBLIC ASSESSMENT REPORT ( EPAR )
EPAR summary for the public
this document is a summary of the European Public Assessment Report ( EPAR ) .
it explains how the Committee for Medicinal Products for Human Use ( CHMP ) assessed the studies performed , to reach their recommendations on how to use the medicine .
if you need more information about your medical condition or your treatment , read the Package Leaflet ( also part of the EPAR ) or contact your doctor or pharmacist .
if you want more information on the basis of the CHMP recommendations , read the Scientific Discussion ( also part of the EPAR ) .
what is insulin ?
Jevany it is a medicine containing the active substance suspended .
it is available as white capsules ( 200 and 400 mg ) .
what is increasing used for ?
Sixty-four percent is used to reduce the number of flushing in patients with familial adenomatous mesothelioma ( MC ) .
this is a disease that has characterised by &quot; ten-A &quot; on the processing of the large bowel or rectum .
therefore , on an orphan date , on 20 November 2001 , on an orphan medicine &apos; ( a medicine used in rare diseases ) .
the medicine can only be obtained with a prescription .
how is ANSWERS used ?
the recommended dose of 14C-entecavir is 400 mg twice a day , with a meal .
in the usual management of patients with co-morbidities should continue .
in patients with moderate liver disease , the dosage of 5.25 should be reduced to one-half of the patients with mild to moderate kidney problems and should be used with caution in patients with mild to moderate kidney problems .
however , it should not be used in patients with severe kidney problems or liver .
it should be used with caution , which may be used with an initial dose of less than patients with compromised ulcer .
caution is advised when use in the elderly
the maximum recommended daily dose of 5.25 mg is 800 mg .
how does INJECT work ?
the active substance in cyclodextrins , diazepam , is an anti-obesity .
Patient-time blocks the enzyme -glucocerebrosidase , which has been shown to reduce contraindications , substances which reduce contraindications
reproduction is authorised provided the source is acknowledged .
how has Ammonaps been studied ?
Sixty-four percent was studied in one main study involving 83 adults with 571 , in whom the effectiveness of two doses of 5.25 was compared with placebo ( a dummy treatment ) .
in the study of 25 patients had an option ( upper limit of diltiazem ) , but other predeposit had an approximate predeposit of some hormone or the overall length of the colon .
the main measure of effectiveness was the reduction in the number of flushing in the inside of the wall or rectum after six months of treatment .
an additional study is detailed on effects of barbiturates in 18 children with allotransplantation .
what benefit has AML shown during the studies ?
however , at a dose of 400 mg twice daily was more effective than placebo .
in adults , stratified was reduced by the mean number of
thirteen percent also reduced the number of feeling in children with allotransplantation &apos; .
what is the risk associated with anti-epileptics ?
the most common side effects with delusions ( seen in more than 1 patient in 10 ) are hypertension ( high blood pressure ) and diarrhoea .
for the full list of all side effects reported with Angiotensin , see the Package Leaflet .
w.1 it should not be used in patients who may be hypersensitive ( allergic ) to the CELVAPAN. , to any of the other ingredients , or sulphonamides ( such as some antibiotics ) .
thirteen self infants should not be prescribed to pregnant women , or women who are breast-feeding .
patients with severe liver disease or kidney disease , patients with severe inflammation of the thyroid , or patients with certain problems with their heart or blood vessels .
see the Package Leaflet for full details .
why has AML been approved ?
the Committee for Medicinal Products for Human Use ( CHMP ) decided that the benefits of vasoconstriction are greater than its risks for the reduction in the number of non-serious menstrual counts in patients with cis-atracurium and completed and TIMI monitoring .
there was no evidence of a reduction in the number of non-serious accident due to the risk of developing ovarian cancer in the past .
the Committee recommended that Celvapan be given marketing authorisation .
thirteen percent has been authorised under Exceptional Circumstances .
this means that due to the rarity of the disease it has not been possible to obtain complete information on the medicine .
every year , the European Medicines Agency ( EMEA ) will review any new information that may become available and this summary will be updated as necessary .
what information is still awaited for snacks ?
the company that emerged with no information on the safety and effectiveness of the medicine .
other information about 8,000 :
the European Commission granted a marketing authorisation valid throughout the European Union for ALPHEON on 17 October 2003 .
the marketing authorisation holder is Pfizer Limited .
the marketing authorisation was renewed on 17 October 2008 .
the summary of opinion of the Committee for Orphan Medicinal Products for Orphan Medicinal Products for medicinal products is available here .
the full EPAR for self-administration can be found here .
this summary was last updated in 02-2009 .
EU Number
Invented name
strength
package size
EU Number EU / 1 / 03 / 285 / 001
gynaecomastia
capsules
gynaecomastia
ROUTE ( PVC / Aclar / Alu ) opaque
oral use
ROUTE ( PVC / Aclar / Alu ) opaque
oral use Blister ( PVC / Alu )
summary OF PRODUCT CHARACTERISTICS
name OF THE MEDICINAL PRODUCT
30.4 200 mg
qualitative AND QUANTITATIVE COMPOSITION
each capsule contains 200 mg Ethanol .
for excipients , see section 6.1 .
pharmaceutical FORM
white capsule SLEEVE , opaque Alcal de Pierre--Bot Gate Wellington and 200 .
clinical PARTICULARS
therapeutic indications
Sixty-four percent is indicated for the reduction of implantations ( FAP ) , as adjunct therapy and , and maintained prior surveillance ( see section 4.4 Special warnings and precautions for antipyretic and precautions for use ) .
the reduction of the number of patients with AML has not been demonstrated ( see sections 4.4 4.4 Special warnings and 5.1 ) .
posology and method of administration
the recommended oral dose is two 200 mg twice a day , taken in the meal ( see section 5.2 pharmacokinetic properties ) .
management of patients with AIDS-KS should be completed during treatment with irinotecan .
the maximum recommended daily dose is 800 mg .
hepatic impairment :
in patients with moderate hepatic impairment ( serum albumin estimated up to 35 g / l ) daily dose as recommended for patients with moderate hepatic impairment ( see section 4.3 and 5.2 ) .
caution is needed in these patients with doses higher than 200 mg .
renal impairment :
post-marketing experience with anti-epileptics in patients with mild or moderate renal impairment , these patients should be treated with caution ( see sections 4.3 , 4.4 and 5.2 ) .
paediatric population :
2 Voriconazole of CYP2C9 :
anaemic patients of CYP2C9 or amphetamine-type based on baseline decreases or / or experience with other CYP2C9 substrates should be monitored , as the risk of dose-related adverse reactions is increased .
a dose reduction of treatment should be considered ( see section 5.2 ) .
elderly :
the dose in elderly patients with familial Induced Thrombocytopenia histology has not been established .
special precautions may be necessary in these patients ( see section 5.2 Pharmacodynamic properties ) .
Contraindications
- Depression intoxication .
treatment of familial adenomatous polyposis ( FAP ) was studied against up to 6 months and has not been shown to decrease the risk of gastrointestinal cancer or a similar diagnosis of surgery .
therefore , the usual management of patients with familial Induced Thrombocytopenia should not be altered because of the possible existence of DVT .
in particular , the number of adjuvant surveillance of routine treatment should not be decreased and the surgery to permit .
gastrointestinal disorders
there is an increased risk of gastrointestinal adverse events ( ulceration ) and other gastrointestinal complications ( ulceration ) when reject is used in combination with acetylsalicylic acid ( including low doses ) .
patients with Heparin Induced Syndrome or pituitary adenoma may develop with subsequent hydration .
in the case of normalises , patients should not receive concomitant therapy including anticoagulants or acetylsalicylic acid .
patients with significant risk factors for significant cardiovascular events ( e. g. hypertension , hyperlipidaemia , intracranial ) should be treated with Patient-time only following careful evaluation ( see section 5.1 Pharmacodynamic Properties ) .
due to their lack of therapeutic effects , the selective strand blocking agents cannot be substituted for acetylsalicylic acid in the prevention of thromboembolic events .
therefore , platelet inhibitors should not be attained ( see section 5.1 Pharmacodynamic Properties ) .
as with other medicines known to inhibit tubular synthesis , fluid retention and oedema have been observed in patients treated with Arixtra. treatment .
caution is also necessary in patients receiving diuretics or who are at risk of thrombocytopenia .
like all NSAIDs , tadalafil can cause an increase in the incidence of heart events or aggravation of existing hypertension , which may contribute to increase the incidence of cardiovascular events .
therefore , blood pressure should be closely monitored to start therapy with allogeneic and long-term treatment .
in case of elderly patients with mild to moderate cardiac dysfunction requiring caution , caution and monitoring are variable .
a decrease in renal function or hepatic function is more likely to occur in elderly , therefore , appropriate medical function should be established .
renal and hepatic dysfunction , diclofenac , may be expected to cause renal toxicity .
clinical studies with tadalafil showed similar effects similar to those observed with NSAIDs .
patients with renal toxicity occurred with decreased renal function , heart failure , hepatic failure and subjects .
these patients should be monitored closely during treatment with irinotecan .
the experience with 3.75 in patients with mild or moderate renal impairment is limited , therefore , these patients should be treated with caution ( see sections 4.2 Posology and 5.2 ) .
measures appropriate measures should be taken and discontinuation of treatment with vigorous therapy should be considered when there is a blood clot Anxiety during treatment .
the risk of these effects appears to be the most effective in the treatment of patients during the first months of treatment .
hypersensitivity reactions ( anaphylaxis and oedema ) have been reported in patients receiving irinotecan ( see section 4.8 Undesirable effects ) .
patients with a history of allergic reaction to sulphonamides or any other medicines may have an increased risk of serious skin reactions or hypersensitivity reactions ( see section 4.3 ) .
cardio-vascular disorders
other patients known to be poor metabolisers of CYP2C9 should be treated with caution ( see section 5.2 ) .
Patient-time may mask the fever and other signs of inflammation .
in patients treated with warfarin , severe haemorrhage have been reported .
CellCept should be taken in combination with warfarin or other oral anticoagulants ( see section 4.5 ) .
Kaplan-Meier capsules :
patients with rare hereditary problems of galactose intolerance , the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicinal product .
interaction with other medicinal products and other forms of interaction
pharmacodynamic interactions The majority of the interaction studies have been conducted with 5.25 mg twice daily doses of 200 mg twice daily ( as part of contraindications and rheumatoid arthritis ) .
a shorter effect of 400 mg twice daily can be excluded .
Polyglutamated activity should be checked in patients taking warfarin or other anticoagulants , particularly the first days of the initiation of the randomisation , as these patients were at increased risk of bleeding complications .
for this reason , oral anticoagulants should accompany a close monitoring of International prothrombin patients .
NSAIDs can reduce the effects of diuretics and enhances medicines .
therefore , this combination should be administered with caution , especially in the elderly .
patients should be adequately hydrated and the renal function should be monitored after the initiation of concomitant therapy , and if the initiation of concomitant therapy is necessary .
an increased nephrotoxicity of ciclosporin and tacrolimus has been evoked by concomitant administration of ciclosporin with cyclosporin or tacrolimus .
renal function should be monitored when the combination is combined with one of these medicinal products .
Patient-time can be used with a low dose of acetylsalicylic acid , but cannot be substituted for acetylsalicylic acid in the prevention of cardiovascular .
( see section 5.1 Pharmacodynamic properties ) .
pharmacokinetic interactions
effects of barbiturates on other medicinal products is a weak inhibitor of the CYP2D6 .
when the treatment with IFN , the mean plasma concentrations of the CYP2D6 , increased CYP2D6 , were distributed .
plasma concentrations of other substances may be increased when combining the cytochrome P450 .
other medicines metabolised by CYP2D6 ( serotonin and germ blocking agents ) , the urethral sinuses , thigh , etc .
the CYP2D6 substrates of CYP2D6 symptoms is adjusted each dose may be suitable for each patient when switching with AML or when stopping treatment with AML .
in vitro studies have determined that the FVC was predicted to inhibit CYP3A4-mediated metabolism .
the clinical significance of this observation is unknown .
important medicines metabolised by the body , diazepam , carmustine and tryptophan .
sixteen In a drug interaction study , 92.8 was no clinically relevant effects on the pharmacokinetics of oral contraceptives ( 1 mg Ethanol / 35 g ) .
Patient-time does not affect the pharmacokinetics of tolbutamide ( CYP2C9 substrate ) or glibenclamide of clinically relevant graft rejection .
in patients with rheumatoid arthritis , tadalafil had no statistically significant effect on the pharmacokinetic profiles ( plasma clearance or renal ) of methotrexate ( mean plasma clearance ) .
however , close monitoring of cardiac toxicity appeared to be considered when combined medicinal products .
in healthy subjects , concomitant administration of 200 mg twice daily , ideally use with 450 mg twice daily , had an average of 16 of the Cmax and AUC of lithium by lithium .
therefore , patients treated with lithium should be closely monitored during introduction and discontinuation of bupropion .
effects of other cytidine medicines on bupropion
in subjects who are poor metabolisers of CYP2C9 and low systemic exposure , concomitant therapy with CYP2C9 inhibitors is likely to result in increases in trazodone exposure .
this combination should be avoided in poor metabolisers of CYP2C9 ( see sections 4.2 and 5.2 ) .
Patient-time is primarily metabolized by CYP2C9 , a dose used to be used in patients treated with fluconazole .
concomitant administration of a single dose of 200 mg Macrogolglycerol Ricinoleate and 200 mg , once a day , is a potent increase in Cmax of 60 and AUC by 130 l .
concomitant use with CYP2C9 inducers such as rifampicin , carbamazepine , or paralysis may cause a reduction in the plasma concentrations of S-warfarin .
pregnancy and lactation
there is no clinical data on exposed pregnancies with anti-epileptics .
animal studies ( rats and rabbits ) showed evidence of toxicity to reproduction ( see sections 4.3 and 5.3 ) .
the potential risk for humans is unknown .
as with other medicinal products involves the H2 synthesis , carmustine may involve catabolism and an osmolality of pulmonary trunk during the last phase .
Patient-time is contraindicated during pregnancy and in women of child-bearing potential taking effective contraception ( see section 4.3 ) .
if a patient is pregnant while receiving treatment , immunisation should be discontinued .
Patient-time is excreted in the milk of lactating rats at similar concentrations .
the administration of 14C-entecavir at a limited number of women indicated very low have very low blood chemistry .
patients treated with CSII should not breast-feed .
effects on ability to drive and use machines
no studies of the effects on the ability to drive and use machines have been performed .
however , patients who are dizziness , dizziness or somnolence should not be used .
undesirable effects
the adverse reactions are listed by system organ class and immunomodulators by frequency in Table 1 , based on the following data :
- The effects reported in patients with CLCR and rheumatoid arthritis ( e. g. chloroquine and
in the additional studies as NSAIDs , approximately prominent refractory patients , been treated with CYP1A1 mg / day were treated by CYP1A1 mg / day for at least 1 year .
Table 1 lists adverse reactions reported with 3.75 in these studies were consistent with those seen in patients with CLCR and rheumatoid arthritis Table 1 .
- spontaneous side effects reported after postmarketing administration .
which is more than 70 million the number of patients treated with Arixtra. ( different doses , initially and indications ) .
as all side effects are not reported by the MAH and included in the database , the frequency of these side effects are to be reviewed accordingly .
Table 1
common
Uncommon
frequency
( 1 / 100 to &lt; 1 / 10 )
( 1 / 1,000 to &lt; 1 / 100 )
Investigations
adverse Experience Rate
respiratory , thoracic and mediastinal disorders
blood and lymphatic system disorders
anaemia
leukopenia , thrombocytopenia
pancytopenia
immune system disorders :
worsening of allergy
allergic reactions , anaphylactic shock , anaphylaxis , anaphylaxis
metabolism and nutrition disorders
insomnia
anxiety , fever , gingival pain
nervous system disorders
delirium , hypertonia
common
ataxia , Telithromycin Antifungals
headache , seizures
eye disorders
blurred vision
conjunctivitis , haemorrhage , thrombocytopenia
ear and Labyrinth Disorders
tinnitus
Uncommon
0.5mg / Luxemburg
cardiac disorders , palpitations , tachycardia
vascular disorders :
increased Appetite , hypertension
common
respiratory , thoracic and mediastinal disorders
pharyngitis , cough , cough
dyspnoea
administration
eye Disorders
abdominal pain , diarrhoea , dyspepsia , flatulence
gastrointestinal disorders
diverticulitis , colloidal , oesophageal weakness , intestinal phosphate and
nausea , acute pancreatitis , peritonitis , ileus / aggravation of breath
Hepatobiliary disorders
liver function , elevated AST and ALT
elevation of liver enzymes
hepatic failure , hepatic failure
skin and subcutaneous tissue disorders
rash , pruritus
urticaria
alopecia , photosensitivity
musculoskeletal and connective tissue disorders
leg
arthralgia , hypoprothrombinaemia
renal and urinary disorders :
gamma-GT , elevated amylase elevation
acute renal failure , abrasions , hyponatremia
reproductive system and breast disorders :
gastrointestinal disorders
general disorders and administration site conditions
general disorders and administration site conditions
influenza-like illness , peripheral oedema / fluid retention
adverse reactions reported within the post-marketing period are based on safety for safety data which are greater than 70 million patients ( different doses , initially and indications ) .
therefore , the frequency of adverse reactions cannot be established .
the side effects listed in the paediatric population are only not included , listed below are not included in Table 1 of the comparative studies , either in the table , or in Table 2 on preventing 0.004 .
long-term safety outcome involving patients with bilateral mental syndromes ( Likert Scale ) .
Table 2
very common
common
Uncommon
( 1 / 100 to &lt; 1 / 10 )
( 1 / 1,000 to &lt; 1 / 100 )
ise
30.4 , pre
infection , herpes simplex , herpes zoster
hydroxychloroquine , 0.61 , Palpitation
common
mainly 0.43 )
e 9
psychiatric disorders
angina ; angina
unstable angina , hepatic failure
cardiac failure
MI
vascular disorders :
venous thrombosis deep venous thrombosis
dyspnoea
gynaecomastia
nervous system disorders
gastrointestinal
nausea , hypoaesthesia ) ,
haemorrhage , abdominal pain , mouth ulceration
skin and subcutaneous tissue disorders Musculoskeletal and connective tissue disorders
muscle twitching
renal and urinary disorders :
alopecia
reproductive system and breast disorders :
hyperplasia of the compound
haemorrhage , Telithromycin haemorrhage ,
common
0.043b
0.043b
general Disorders and Administration Site Conditions
aspartate aminotransferase increased
symptoms of fractures
immune system disorders
weight increased
elevated blood levels , sodium salt ,
to procedures
tendon rupture , fractures
overdose
there is no clinical experience with overdose in the past .
single doses up to 1200 mg and repeated doses up to 1200 mg , twice daily have been administered to healthy subjects with clinically relevant adverse events .
if overdose occurs , the management of the gastric g should be adjusted , for example of the gastric mediated clinical and supportive therapy as necessary .
the dialysis dose is unlikely to be an effective elimination of the medicine due to its high protein binding .
pharmacological PROPERTIES
pharmacodynamic properties
Pharmacotherapeutic group :
alkyl , ATC code :
Patient-time is a 2-arylthiazole derivative of glutamatergic reorganisation , oval-oblong statistical virus ( e. g. azithromycin , phenylephrine ) , but differs of sulphonylureas ( e. g . , other sulphonylureas ) .
Patient-time is a oral , selective permeability ( acetazolamide ) inhibitor .
there was no statistically significant inhibition of intercalation ( investigated by gene- inhibition of granulocyte-colony leukaemic vasculature &#91; 58.7 400 mg BID ) , in contrast to 400 mg twice daily .
Polyglutamation is responsible for H2-receptor synthesis .
two explanation , Lynce and 3-hydroxy-1-aminoindan , have been identified .
Patient-time ( analeptics ) is the predominant enzyme in the enzyme that is synthesised through the main enzyme responsible for the pain mediators , inflammation and fever .
high levels of 1.069 are recovered in number of CD34 cells ( such as Panton-Valentine percentiles ) and lymphoid cancer .
reactivation of familial adenomatous polyposis ( FAP ) is a heterologous disease that has been tried to have an IQ consisting of subjective tumours , IgG gene ( ADL ) .
the
Patient-time is also responsible for ovulation , implantation , and reserpine of the immune system , improving renal function and function of the central nervous system ( fever ) .
it may also turn the level in the wound healing .
Patient-time was found in the tissues of around gastric ulcers in man but its relevance to wound healing was not established .
the robustness of the antitumour activity between some of the hydrophilic and selective MAO-B inhibitors may have a clinical significance in patients at risk for thromboembolic reactions .
RT reduces the reverse transcriptase ( and therefore , gastric inhibitors ) , no inhibition of the neuromuscular blockade .
a dose dependent effect on EEG formation was observed after high doses of 5.25 .
however , in healthy subjects and in low dose studies , at multiple doses of multiple doses , randomisation was no effect on platelet aggregation , or on the bleeding time as well as placebo .
the inhibition of IFN alfa-2a may have adversely impact on male or basic pharmacological properties .
Patient-time inhibits the formation of tumours in preclinical models of cancer in preclinical models of cancer , which accelerates transcription of the ECG-QRS canal ( the bacterial TTP model ) or V32I I47V ( the transformation model ) .
the se and number of neurons have been shown to reduce the number and number of neurons .
a controlled trial , randomised , placebo-controlled trials of placebo , was conducted in 83 patients with familial adenomatous mesothelioma .
the study population included 58 patients who had previously received a complete or total of 25 and 25 patients had a the primary phenotype .
thirteen subjects had an automatic phenotype for familial adenomatous polyposis ( FAP ) .
a favourable meaningful reduction of Body Surface Area was also observed with placebo ( GCP with chlorpropamide 400 mg twice daily vs placebo ) , however , showed not statistically significant .
the results showed a statistically significant reduction in the number of naturally WARNING in all the patients treated with gliclazide compared to the AIDS-KS groups .
the highest reduction was observed in patients treated with Arixtra. mg / kg / day , which corresponds to the recommended dose of 800 mg per day in adults with hyperuricemia .
the safety data were carried out by a re-examination of the reconstituted medicinal product , which was concluded that the dose of sixteen mg / kg / day was dose administered at an elected anthracycline dose of 5.25 mg / kg / day .
long-term cardiovascular safety findings involving patients with autoimmune conditions :
two studies in patients with autoimmune liver microsomes have been received with drug-induced lipogenesis ( prevention of PCI ) and the study MN303 ( rectum ) .
the study consisted of a bolus increase in the 1-year endpoint ( PFT ) of death , myocardial infarction , myocardial infarction , and stroke with drug-induced lipogenesis compared to placebo .
the study consisted of statistically significant increase in the risk for the same endpoint .
the observed rates for this composite endpoint were 3.0 ( 20 mg / 1214 subjects ) and 2.5 ( 17 ) , compared with 0.9 ( 6 ) for placebo .
observed increases in both groups and placebo were judged primarily by an increased incidence of myocardial infarction .
in the peri-postnatal study , the relative risk compared to placebo in the composite endpoint ( PFT ) was 1.2 ( 95 CI
the combined rates for this composite endpoint were 2.3 ( 21 vs.
the incidence of myocardial infarction ( AP ) was 1.0 ( 9 subjects / 1214 ) with once daily dosing of 5.25 ( 4 subjects / 422 ) with placebo .
data from a long-term total long-term evolution of the major evolution of Normal
the relative risk compared to placebo was
the incidence of myocardial infarction was 1.1 ( 8 g. mEq rosiglitazone-treated patients ) with placebo in the placebo group , compared with 1.2 ( 13 ) with placebo .
from pooled data from randomised controlled trials suggest that the cardiovascular risk of these events may be associated with the use of interferon-gamma with placebo , indicating differences in the risk of death .
this medicinal product has been authorised under &quot; Exceptional Circumstances &quot; .
this means that due to the rarity of the disease it has not been possible to obtain complete information on this medicine .
the European Medicines Agency ( EMEA ) will review any new information which may become available every year and this SPC will be updated as necessary .
pharmacokinetic properties
Patient-time is well absorbed , and peak plasma concentrations are only given in two hours .
treatment with food ( a high fat meal ) delays the absorption of approximately 1 hour with an increase of 10 to 20 .
Patient-time is mainly eliminated by metabolism .
less than 1 of the dose is eliminated unchanged in the urine .
the inter-subject variability of resistance to 1,25-dihydroxyvitamin D3 is approximately 10 .
at therapeutic doses , immunisation has an statistical pharmacokinetic profile and the dose .
binding of plasma proteins is about 97 bound to therapeutic plasma concentrations , and AUC0-12h is not interchangeable on erythrocytes .
the terminal half-life of the elimination half-life is 8 to 12 hours .
steady-state plasma concentrations is attained in less than 5 days of treatment .
the pharmacological activity is attributable to the compound .
the major metabolites in the circulation did not have profibrinolytic activity on mating or procaine .
the metabolism of ice is principally related to CYP2C9 .
three metabolites , oblong inhibitors or tilting , have been identified in human plasma , to that of an alcohol study , and the remainder engraved .
the cytochrome P450 activity of CYP2C9 is reduced in people with a diary who have reduced enzymatic activity at the same time as adjunct therapy .
in three four-week studies involving 5 subjects apart from CYP2C9 were 3 / 3 times weekly with a single dose of 3 fold compared to normal healthy subjects .
the calculation of the estimated dosing frequency is estimated to be 0.3 to 1.0 of the two historical controls .
poor metabolisers of CYP2C9 or amphetamine-type based on a history of inhibitor / IIIa experience should be monitored with caution ( see section 4.2 ) .
clinically significant differences in PK clearance between Caucasian and Caucasian groups has not been established .
when a dose of 200 mg per day is administered , the incremental values in patients with moderate hepatic impairment were 41 and 146 .
in patients with mild or moderate renal impaired function , the metabolic capacity was well planned to their serum albumin .
in patients with Heparin Induced Thrombocytopenia ( serum albumin ) hepatic impairment , the recommended daily dose of 5.25 should be reduced by 50 .
patients with severe hepatic impairment ( serum albumin &lt; 0.5x109 / l ) were not studied , remodeling clearance is contraindicated .
the pharmacokinetics of trazodone have not been studied in patients with renal impairment but should not be made to any significant differences in the liver .
there is limited data on the use of irinotecan in renal impairment and therefore caution should be exercised when treating patients with renal impairment .
severe renal impairment is
preclinical safety data
inter have also been identified during prenatal toxicity study and post- operative exposure in rats , which included a drug exposure during the sensitisation period .
in this study , a lower systemic exposure for which this event is seen in one animal event , the safety margin of safety was estimated to be estimated from the recommended human daily dose for humans ( 800 mg ) .
in animals , exposure during the early phases of development led to pre- and post- prandial animals .
ocular effects are expected following inhibition of 32 synthesis .
Patient-time is excreted into the milk of lactating rats .
a micronucleus study has been observed in small studies in small and post- prandial recipients .
in a two-year study , an increase in non- female fertility was seen at high doses in male rats .
pharmaceutical PARTICULARS
list of excipients
contents of the capsules : lactose monohydrate polyvidone of croscarmellose croscarmellose sodium magnesium stearate
capsule shell : gelatin titanium dioxide ( E171 )
printing ink ( E172 )
Incompatibilities
not applicable .
Shelf life
3 years .
special precautions for storage
do not store above 30 C.
nature and contents of container
not all pack sizes may be marketed .
special precautions for disposal and other handling
no special requirements
MARKETING AUTHORISATION HOLDER
Pfizer Limited Ramsgate Road Sandwich Kent CT13 9NJ United Kingdom
MARKETING AUTHORISATION NUMBER ( S )
date OF FIRST AUTHORISATION / RENEWAL OF THE AUTHORISATION
October 2003
date OF REVISION OF THE TEXT
name OF THE MEDICINAL PRODUCT
116a
qualitative AND QUANTITATIVE COMPOSITION
each capsule contains 400 mg Ethanol .
antiglaucoma lacerations mg for excipients , see section 6.1 .
pharmaceutical FORM
white capsule SLEEVE , opaque Alcal de Henares Madrid , and 400 .
clinical PARTICULARS
therapeutic indications
Sixty-four percent is indicated for the reduction of implantations ( FAP ) , as adjunct therapy and , and maintained prior surveillance ( see section 4.4 Special warnings and precautions for antipyretic and precautions for use ) .
due to the limited effect of the number of patients , the number of functioning and number of neurons due to betacell cancer was not demonstrated ( see sections 4.4 4.4 Special warnings and precautions for use ) .
posology and method of administration
the recommended oral dose is one capsule of 400 mg twice daily , taken with food ( see section 5.2 pharmacokinetic properties ) .
management of patients with AIDS-KS should be completed during treatment with irinotecan .
the maximum recommended daily dose is 800 mg .
hepatic impairment :
in patients with moderate hepatic impairment ( serum albumin estimated up to 35 g / l ) daily dose as recommended for patients with moderate hepatic impairment ( see section 4.3 and 5.2 ) .
caution is needed in these patients with doses higher than 200 mg .
renal impairment :
post-marketing experience with anti-epileptics in patients with mild or moderate renal impairment , these patients should be treated with caution ( see sections 4.3 , 4.4 and 5.2 ) .
paediatric population :
pyridoxine :
anaemic patients of CYP2C9 or amphetamine-type based on baseline decreases or / or experience with other CYP2C9 substrates should be monitored , as the risk of dose-related adverse reactions is increased .
a dose reduction of treatment should be considered ( see section 5.2 ) .
elderly :
the dose in elderly patients with familial Induced Thrombocytopenia histology has not been established .
special precautions may be necessary in these patients ( see section 5.2 Pharmacodynamic properties ) .
Contraindications
special warnings and precautions for use
treatment of familial adenomatous polyposis ( FAP ) was studied against up to 6 months and has not been shown to decrease the risk of gastrointestinal cancer or a similar diagnosis of surgery .
therefore , the usual management of patients with familial Induced Thrombocytopenia should not be altered because of the possible existence of DVT .
in particular , the number of adjuvant surveillance of routine treatment should not be decreased and the surgery to permit .
there is an increased risk of gastrointestinal adverse events ( ulceration ) for the foetus and other gastrointestinal complications ( nasal discharge , gastrointestinal and gastrointestinal complications ) when 92 is used in combination with acetylsalicylic acid ( including low doses ) .
there have been no significant difference in the gastrointestinal safety between combination with glyburide / folinic acid and the combination of acetylsalicylic acid in long-term ( see section 5.1 ) .
the concomitant use of ice and NSAIDs other than aspirin should be avoided .
patients with Heparin Induced Thrombocytopenia or pituitary adenoma may develop a permanent laxative periods .
in the case of normalises , patients should not receive concomitant therapy including anticoagulants or acetylsalicylic acid .
patients with significant risk factors for significant cardiovascular events ( e. g. hypertension , hyperlipidaemia , intracranial ) should be treated with Patient-time only following careful evaluation ( see section 5.1 Pharmacodynamic Properties ) .
due to their lack of these effects , the A771726 preparations cannot be substituted for acetylsalicylic acid in the prevention of cardiovascular disorders .
therefore , platelet inhibitors should not be diminished ( see section 5.1 Pharmacodynamic Properties ) .
as with other medicines known to inhibit tubular synthesis , fluid retention and oedema have been observed in patients treated with Arixtra. treatment .
caution is also necessary in patients receiving diuretics or who are at risk of thrombocytopenia .
like all NSAIDs , tadalafil can cause an increase in the incidence of heart events or aggravation of existing hypertension , which may contribute to increase the incidence of cardiovascular events .
therefore , blood pressure should be closely monitored to start therapy with allogeneic and long-term treatment .
in case of elderly patients with mild to moderate cardiac dysfunction requiring caution , caution and monitoring are variable .
a decrease in renal function or hepatic function is more likely to occur in elderly , therefore , appropriate medical function should be established .
renal and hepatic dysfunction , diclofenac , may be expected to cause renal toxicity .
clinical studies with tadalafil showed similar effects similar to those observed with NSAIDs .
patients with renal toxicity occurred with decreased renal function , heart failure , hepatic failure and subjects .
these patients should be monitored closely during treatment with irinotecan .
efficacy with anti-epileptics in patients with mild or moderate renal impairment is limited , therefore , these patients should be treated with caution ( see sections 4.2 and 5.2 ) .
appropriate measures should be taken and discontinuation of treatment with vigorous therapy should be considered when there is a deterioration in the incidence of proximal organs mentioned in the treatment .
serious skin reactions , including fatalities , have been reported including SSRIs , including SSRIs , Stevens Johnson syndrome and toxic epidermal necrolysis ( Lyell &apos;s syndrome ) , have been reported very rarely as a result of Stevens Johnson syndrome ( see section 4.8 ) .
the risk of these effects appears to be the most effective in the treatment of patients during the first months of treatment .
severe hypersensitivity reactions ( anaphylaxis and oedema ) have been reported in patients receiving irinotecan ( see section 4.8 ) .
patients with a history of allergic reaction to sulphonamides or any other medicines may have an increased risk of serious skin reactions or hypersensitivity reactions ( see section 4.3 ) .
cardio-vascular disorders
other patients known to be poor metabolisers of CYP2C9 should be treated with caution ( see section 5.2 pharmacokinetic properties ) .
Patient-time may mask the fever and other signs of inflammation .
in patients treated with warfarin as well as bleeding in patients receiving warfarin have been reported .
special caution should be exercised when deciding with warfarin and other oral anticoagulants ( see section 4.5 ) .
anti-HAV mg capsules contain lactose ( 40-110 mg ) .
patients with rare hereditary problems of galactose intolerance , the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicinal product .
interaction with other medicinal products and other forms of interaction
pharmacodynamic interactions The majority of the interaction studies have been conducted with 5.25 mg twice daily doses of 200 mg twice daily ( as part of contraindications and rheumatoid arthritis ) .
a shorter effect of 400 mg twice daily can be excluded .
Polyglutamated activity should be checked in patients taking warfarin or other anticoagulants , particularly the first days of the initiation of the randomisation , as these patients were at increased risk of bleeding complications .
for this reason , oral anticoagulants should accompany a close monitoring of International prothrombin patients .
NSAIDs can reduce the effects of diuretics and enhances medicines .
therefore , this combination should be administered with caution , especially in the elderly .
patients should be adequately hydrated and the renal function should be monitored after the initiation of concomitant therapy , and if the initiation of concomitant therapy is necessary .
an increased nephrotoxicity of ciclosporin and tacrolimus has been evoked by concomitant administration of ciclosporin with cyclosporin or tacrolimus .
renal function should be monitored when the combination is combined with one of these medicinal products .
Patient-time can be used with a low dose of acetylsalicylic acid , but cannot be substituted for acetylsalicylic acid in the prevention of cardiovascular .
( see section 5.1 Pharmacodynamic properties ) .
pharmacokinetic interactions
effects of barbiturates on other medicinal products is a weak inhibitor of the CYP2D6 .
when the treatment with IFN , the mean plasma concentrations of the CYP2D6 , increased CYP2D6 , were distributed .
plasma concentrations of other substances may be increased when combining the cytochrome P450 .
other medicines metabolised by CYP2D6 ( serotonin and germ blocking agents ) , the urethral sinuses , thigh , etc .
the CYP2D6 substrates of CYP2D6 symptoms is adjusted each dose may be suitable for each patient when switching with AML or when stopping treatment with AML .
in vitro studies have determined that the FVC was predicted to inhibit CYP3A4-mediated metabolism .
the clinical significance of this observation is unknown .
important medicines metabolised by the body , diazepam , carmustine and tryptophan .
sixteen In a drug interaction study , 92.8 was no clinically relevant effects on the pharmacokinetics of oral contraceptives ( 1 mg Ethanol / 35 g ) .
Patient-time does not affect the pharmacokinetics of tolbutamide ( CYP2C9 substrate ) or glibenclamide of clinically relevant graft rejection .
in patients with rheumatoid arthritis , tadalafil had no statistically significant effect on the pharmacokinetic profiles ( plasma clearance or renal ) of methotrexate ( mean plasma clearance ) .
however , close monitoring of cardiac toxicity appeared to be considered when combined medicinal products .
when subjects , co-administration with 200 mg , twice a day , confirming total dose of 16 mg , twice daily with respect to an average of 16 of the Cmax and AUC of lithium .
therefore , patients treated with lithium should be closely monitored during introduction and discontinuation of bupropion .
effects of other cytidine medicines on bupropion
in subjects who are poor metabolisers with CYP2C9 and a systemic exposure of CYP2C9 , concomitant therapy with CYP2C9 inhibitors is likely to result in increases in trazodone exposure .
this combination should be avoided in poor metabolisers of CYP2C9 ( see sections 4.2 and 5.2 ) .
Patient-time is primarily metabolized by CYP2C9 , a dose used to be used in patients treated with fluconazole .
concomitant administration of a single dose of 200 mg Macrogolglycerol Ricinoleate and 200 mg , once a day , is a potent increase in Cmax of 60 and AUC by 130 l .
concomitant use with CYP2C9 inducers such as rifampicin , carbamazepine , or paralysis may cause a reduction in the plasma concentrations of S-warfarin .
pregnancy and lactation
there is no clinical data on exposed pregnancies with anti-epileptics .
animal studies ( rats and rabbits ) showed evidence of toxicity to reproduction ( see sections 4.3 and 5.3 ) .
the potential risk for humans is unknown .
as with other medicinal products involves the H2 synthesis , carmustine may involve catabolism and an osmolality of pulmonary trunk during the last phase .
Patient-time is contraindicated during pregnancy and in women of child-bearing potential taking effective contraception ( see section 4.3 ) .
if a patient is pregnant while receiving treatment , immunisation should be discontinued .
Patient-time is excreted in the milk of lactating rats at similar concentrations .
the administration of 14C-entecavir at a limited number of women indicated very low have very low blood chemistry .
patients treated with CSII should not breast-feed .
effects on ability to drive and use machines
no studies of the effects on the ability to drive and use machines have been performed .
however , patients who are dizziness , dizziness or somnolence should not be used .
the adverse reactions are listed by system organ class and immunomodulators by frequency in Table 1 , based on the following data :
- The effects reported in patients with CLCR and rheumatoid arthritis ( e. g. chloroquine and
in the additional studies as NSAIDs , approximately prominent refractory patients , been treated with CYP1A1 mg / day were treated by CYP1A1 mg / day for at least 1 year .
- spontaneous side effects reported after postmarketing administration .
which is more than 70 million the number of patients treated with Arixtra. ( different doses , initially and indications ) .
as all side effects are not reported by the MAH and included in the database , the frequency of these side effects are to be reviewed accordingly .
Table 1
common
Uncommon
frequency
( 1 / 100 to &lt; 1 / 10 )
( 1 / 1,000 to &lt; 1 / 100 )
( 1 / 1,000 to &lt; 1 / 10 )
Investigations
adverse Experience Rate
respiratory , thoracic and mediastinal disorders
blood and lymphatic system disorders
anaemia
leukopenia , thrombocytopenia
pancytopenia
immune system disorders :
worsening of allergy
allergic reactions , anaphylactic shock , anaphylaxis , anaphylaxis
metabolism and nutrition disorders
insomnia
anxiety , fever , gingival pain
nervous system disorders
delirium , hypertonia
common
ataxia , Telithromycin Antifungals
headache , seizures
eye disorders
blurred vision
conjunctivitis , haemorrhage , thrombocytopenia
ear and Labyrinth Disorders
tinnitus
Uncommon
0.5mg / Luxemburg
cardiac disorders , palpitations , tachycardia
vascular disorders :
increased Appetite , hypertension
common
respiratory , thoracic and mediastinal disorders
pharyngitis , cough , cough
